,ticker,content
0,ILMN,monday myriad genetic mygn get upgrade relative strength rs rating look best stock buy watch factor watch closely be relative price strength proprietary rating identify market leadership used worst best score identify stock price action trail week match rest market decade market research show best perform stock typically have rs rating least begin new run see ibd help make more money stocksmyriad genetic be work cup handle entry see stock clear price heavy volume keep mind later stage consolidation be riskier earlier stage pattern company post ep growth latest quarterly report sale growth come company hold rank peer medical research equipment service industry group medpace medp illumina ilmn luminex lmnx be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
1,ILMN,tech stock fund be tuesday top gainer thank big move twitter twtr tesla tsla be fuel positive analyst comment twitter soar year high jpmorgan raise price target cite strengthen ad momentum share be profit take zone buy point cup handle tesla surge month high keybanc hike model delivery estimate current quarter revenue forecast tesla be automaker be also often consider tech company be etfs count messaging platform electric automaker top holding get newsletter deliver inbox more info product service privacy policy term be biggest hold weighting global social medium socl rise follow stake facebook fb tencent tcehy baidu bidu alphabet googl stock account stock portfolio socl provide access global social medium company track solactive social medium total return index etf year date return june accord morningstar inc be well ahead gain average annual return past year also outpace return respective period socl carry expense ratio fund top twitter be ark web arkw hold stake tweeting service etf invest company transform economic sector internet enabled innovation second biggest hold be tesla nearly amazon amzn nvidia nvda square sq round top make stock portfolio arkw be ytd charge expense ratio ark innovation arkk be head stake tesla fund also count twitter stake top holding arkk target company likely benefit innovation health care information technology robotic other sector other name top include stratasys ssys intellium therapeutic ntla illumina ilmn arkk return year june accord morningstar inc also sport expense ratio twitter be top hold weighting first trust dow jone internet fdn own amazon facebook netflix nflx top position fund track dow jone internet composite index be extend buy point fdn rally ytd charge expense ratio also wall street want know fed boost bank stocksdow chevron exxon help fuel big stock gain lead sectorai power stock pick internet giant new etf launch
2,ILMN,relative strength rs rating thermo fisher scientific tmo moved new percentile monday get lift look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily measure price action worst best score grade show stock price behavior trail week hold other stock database history reveal stock go make biggest gain tend have rs rating north early stage move see thermo fisher scientific continue show renew price strength clear threshold look winning stock try simple routinethermo fisher scientific be try complete flat base entry see break volume least average take look top bottom line number company have post quarters rise earning growth sale gain have also rise same period company earn rank peer medical research equipment service industry group medpace medp illumina ilmn luminex lmnx be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
3,ILMN,friday icon iclr receive upgrade relative strength rs rating try find best stock buy watch keep close eye relative price strength exclusive rating investor business daily identify share price performance worst best score score show stock price behavior last week stack other stock database history show best perform stock often have better rs rating launch biggest climb look winning stock try simple routineicon be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week line ep growth decline last quarter top line rise prior report icon earn rank peer medical research equipment service industry group illumina ilmn be top rank stock group get newsletter deliver inbox more info product service privacy policy term also stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
4,ILMN,pra health science prah have relative strength rs rating upgrade thursday welcome improvement still short higher score look look best stock buy watch factor watch closely be relative price strength ibd unique rating identify market leadership worst best score score show stock price performance trail week stack other stock database history reveal best perform stock typically have rs rating early stage move see pra health science continue rebound hit benchmark look winning stock try simple routinepra health science be try complete consolidation entry see stock break heavy volume keep mind later stage consolidation entail more risk earning growth fall last quarter sale moved higher pra health science earn rank peer medical research equipment service industry group illumina ilmn be top rank stock group get newsletter deliver inbox more info product service privacy policy term also stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
5,ILMN,wednesday myriad genetic mygn clear important technical benchmark see relative strength rs rating jump percentile improvement day re research best stock buy watch be sure pay attention relative price strength ibd unique rating measure market leadership worst best score rating show stock price performance trail week hold other stock database year market history show stock go make biggest gain typically have higher rs rating begin new climb see ibd help make more money stocksmyriad genetic be work cup handle buy point see stock clear price heavy volume keep mind later stage consolidation be riskier earlier stage pattern myriad genetic post earning growth latest quarterly report revenue rise company hold rank peer medical research equipment service industry group illumina ilmn medpace medp luminex lmnx be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
6,ILMN,ibd stock screen be regularly update add new growth stock watch well weed have start show weakness new feature publish weekday evening market close ll see stock have be add remove list ibd sector leader ibd big cap screen be base proprietary slim investing system look stock display common trait typically share best perform stock early stage big price move check column day help build maintain watch list alert most recent change never buy stock just ibd list be sure do own research run stock idea buy checklist use ibd simple step routine quickly track general market trend find stock watch pinpoint best time buy sell change make march pm et ibd flagship screen lead growth stock give company show strong relative price strength top notch fundamental decide stock buy always check new innovative stock historically far outperform get newsletter deliver inbox more info product service privacy policy term useibd most stringent powerful screen sector leader highlight best stock ibd sector sector leader show outstanding earning sale growth recent quarters be strong many other fundamental price performance metric daily screen uncover top rate large cap growth stock consideration big cap company deliver outsize gain volatility smaller growth stock stock market newest company be find biggest winning stock time initial public offering ipos be typically early stage growth big earning growth generally fuel stock price performance ipo leader have special screening criterium find come stock strong fundamental technical trait daily stock list ibd seek good stock buy top fundamental be get ready break use glean emerge industry sector trend market view prior ibd stock list also look next big stock start herewhich company be now outperform stock buy stock buy checklistwhen sell stock selling checklist
7,ILMN,look best stock buy watch focus rise relative price strength stock fit bill be myriad genetic mygn have relative strength rs rating upgrade thursday try find best stock buy watch keep close eye relative price strength exclusive rating investor business daily identify price action worst best score grade show stock price behavior trail week compare other stock database year market history reveal best stock typically have rs rating north early stage move look winning stock try simple routinemyriad genetic be try complete consolidation entry see clear price volume least average keep mind later stage consolidation be riskier earlier stage pattern myriad genetic show earning growth latest quarterly report sale increase myriad genetic hold rank peer medical research equipment service industry group illumina ilmn medpace medp luminex lmnx be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
8,ILMN,more new cancer patient be identify china year genomic leader illumina ilmn be try use next generation sequence ngs technology improve diagnosis treatment january illumina announce jointly develop novel oncology hereditary disease testing application chinese clinical testing laboratory kingm diagnostic
9,ILMN,major stock index be mixed mostly unchanged good portion tuesday session seller come market last hour trading dow russell take hardest hit fall wall street nerve be rattle president trump cast doubt june summit north
10,ILMN,long costly process big pharma biotech stock abbvie abbv vertex pharmaceutical vrtx abbot laboratory get food drug administration approval new drug lead clinical research organization cro pra health science prah help drugmaker get new treatment market conduct clinical trial base
11,ILMN,thursday bio rad lab bio earn upgrade relative strength rs rating look best stock buy watch factor watch closely be relative price strength proprietary rating identify technical performance show stock price action last week measure other stock database decade market research show stock go make biggest gain typically have higher rs rating launch biggest price move see ibd help make more money stocksbio rad lab break earlier have fall back prior entry flat base case stock break then fall more entry price consider fail happen best new pattern take shape also keep mind most recent pattern be later stage base involve more risk earning grow last quarter prior report revenue also increase bio rad lab hold rank peer medical research equipment service industry group illumina ilmn medpace medp luminex lmnx be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
12,ILMN,medpace medp see ibd smartselect composite rating rise wednesday day revise score mean stock currently top other stock term key performance metric technical strength winning stock often have higher rating early stage new price run so good start point look best stock buy watch medpace break earlier be now trading approximately prior entry consolidation stock re tracking clear buy point then decline more original entry price consider fail base best stock form new pattern see ibd help make more money stock earn ep rating mean recent quarterly longer term annual earning growth top stock accumulation distribution rating show moderate buy institutional investor last week get newsletter deliver inbox more info product service privacy policy term company post increase earning mark straight quarters rise ep gain top line growth increase prior quarter mark consecutive report rise growth medpace earn rank peer medical research equipment service industry group illumina ilmn be top rank stock group related company be now outperform stock see stock just come ibd top stock list
13,ILMN,relative strength rs rating pra health science prah moved new percentile monday get lift look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily measure market leadership worst best score grade show stock price performance last week stack other stock database history reveal best stock often have better rs rating launch biggest climb see pra health science continue show renew price strength hit benchmark look winning stock try simple routinepra health science be build consolidation entry see clear price heavy volume later stage pattern investor be aware involve more risk ep growth decline last quarter top line rise prior report pra health science earn rank peer medical research equipment service industry group illumina ilmn be top rank stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
14,ILMN,be stock ibd more volatile rest stock market accord common measure wall street yes be bad thing beta ratio be roll month quantitative measure much stock tend swing vs ratio be neutral
15,ILMN,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
16,ILMN,catalent ctlt be form base buy point get set report earning entry be base second stage consolidation understand buy just stock report be risky ep sale miss send sharply lower reduce exposure wait see company report market react look winning stock try simple routinein term fundamental catalent have post quarters rise earning growth sale growth have also moved higher same time frame analyst expect earning growth quarter growth full year annual growth estimate be recently revise higher company have composite rating earn rank peer medical research equipment service industry group illumina ilmn be rank stock group note date earning report be subject change check company update get newsletter deliver inbox more info product service privacy policy term also earning calendar analyst estimate stock watchnew option strategy limit risk earning
17,ILMN,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
18,ILMN,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
19,ILMN,next earning report schedule apr thermo fisher scientific tmo be trading entry chart pattern be first stage flat base buy stock just ahead earning be risky typically don have enough time establish profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure look winning stock try simple routineregard fundamental company have post quarters increase earning growth sale growth have also increase same period analyst be look earning share growth quarter growth full year ep estimate full year be recently revise upward thermo fisher scientific have composite rating hold rank peer medical research equipment service industry group illumina ilmn be rank stock group note date earning report be subject change check company update get newsletter deliver inbox more info product service privacy policy term also earning calendar analyst estimate stock watchnew option strategy limit risk earning
20,ILMN,index dow jone industrial average nasdaq tumble week alphabet googl caterpillar cat mmm earning treasury yield spook investor stock market average pare loss strong earning amazon amzn facebook fb boee ba visa other index dow jone nasdaq find support day move average rebound close week fractional loss year treasury hit first time year hit week pull back short term yield continue rise faster long term rate squeeze yield spread alphabet googl expense ongoing chip weakness also hit stock amazon amzn facebook fb boee ba visa rally strong result intel intc microsoft msft initially hit buy point friday pull back amazon first quarter earning sky-rocket more double ep estimate revenue rise fifth straight quarter accelerate sale growth revenue amazon web service rise aw account most amazon overall operate profit amazon share shot record high friday pare gain advance ebay ebay stock drop report result fall short consensus estimate end quarter global active buyer facebook fb stock surge post first quarter result blow past expectation dash fear exodus user advertiser social medium giant twitter twtr report strong earning guidance share fall ceo make cautious comment slow growth get free access ibd digital april
21,ILMN,get premium stock list pass fail stock rating more start hereboee ba easily beat forecast raise full year guidance aerospace giant say aircraft completion center china be nearly finished downplay china trade war fear fellow dow jone stock unite technology utx report stronger expect earning sale industrial giant also raise full year adjust ep sale forecast lockheed martin lmt top first quarter estimate defense contractor raise ep revenue target maker didn raise cash flow expectation northrop grumman noc also report earning estimate northrop say didn submit bid air force gps iii contract leave lockheed likely lone bidder raytheon rtn raise full year earning forecast consensus earning revenue top estimate general dynamic gd beat earning meet revenue view share defense contractor sell sharply week software kingpin earn cent share year year sale fiscal third quarter analyst expect cent microsoft msft have be shift business desktop pc software cloud compute infrastructure application such office azure microsoft commercial cloud revenue rise fiscal software giant initially reclaim recent buy point friday pare gain intel intc earning rise sale grow well analyst view chip giant guide higher current quarter sale indicate third straight quarter top line growth share initially jump year high friday reversed close slightly lower texas instrument txn advanced micro device amd stm xilinx xlnx get boost upbeat earning report chip gear maker teradyne ter tumble warning weak demand equipment test mobile device western digital wdc make disk drife memory chip tumble friday beating fiscal view philadelphia semiconductor index fought support day move average google parent alphabet googl report earning revenue top view sharp rise capital spending margin pressure higher traffic acquisition cost spark sell internet search giant capex jump year period include real estate purchase manhattan traffic cost google pay partner website generate advertising revenue jump google have hike spending youtube video content cloud compute smart home consumer appliance artificial intelligence project paypal pypl top earning revenue expectation total payment volume rise year year vs estimate company raise revenue adjust ep guidance management point momentum partnership visa international bank technology platform such baidu bidu exxon mobil xom miss earning view output slip recent surge oil price chevron cvx fall short revenue conocophillip cop crushed estimate hess hes report shallower expect loss royal dutch shell rdsa report highest profit oil price crash energy information administration say crude inventory rise barrel vs drop analyst expect domestic production rise barrel day barrel increase crude oil future briefly top barrel highest level late trade little change week general motor gm ford motor fiat chrysler fcau beat quarterly estimate ford not invest traditional sedan north america go forward almost phase passenger car consumer migrate suvs light truck gm still see small car opportunity home abroad even too shift focus larger more profitable vehicle casino operator la vegas sand lvs top first quarter result estimate help strong demand global gaming hub macau singapore macau also help result wynn resort wynn overall macau sale disappoint analyst wynn resort also approve dividend increase earning report wynn be first steve wynn resign ceo sell stake follow allegation sexual misconduct mgm resort mgm narrowly beat stock tumble decline traffic location mgm be more focuse sand wynn amgen amgn alexion pharmaceutical alxn broadly top view amgen sale adjust profit outlook be bit soft midpoint sale alexion blockbuster soliris miss estimate share pop promising study new drug alxn biogen biib sale lag sluggish spinraza multiple sclerosis drug revenue prothena prta tank monday scrap rare disease drug fail phase study eli lilly lly broadly beat consensus diabetes drug chemotherapy help offset short sale psoriasis drug taltz glaxosmithkline gsk sale adjust profit lag abbvie abbv bristol myer squibb bmy top profit view raise full year guidance bristol sale miss estimate shire shpg say consider raise takeover bid japan takeda vertex pharmaceutical vrtx top view sale decline vs last year vertex say ll move triple pill regimen phase study domino dpz deliver ep gain revenue leap blow view share rise thursday chipotle grill cmg stock vault month high ep unexpectedly jump same store sale also top starbucks sbux be par earning ep rise cent rise sale outdo analyst prediction new oriental education edu earn cent share revenue grow total student enrollment rise year year ibd stock tal education tal ep jump cent share revenue soar student enrollment balloon vs year earlier new oriental tal share pop respective earning day be slightly lower week intraday friday pultegroup phm tuesday crushed view ep jump cent home sale revenue leap homebuilder stock be generally muted due rise interest rate horton dhi biggest builder thursday best view ep surge revenue swell homebuilder stock rally solid gain help cool treasury yield new home sale rise march annualize sale pace unit month high meanwhile exist home price rise february vs year earlier china search engine leader baidu bidu report profit blow past estimate lift share baidu still own majority iqiyi iq hold ipo march video stream iqiyi account roughly parent revenue share iqiyi fall release earning tandem baidu visa report ep gain revenue rise beating fiscal view credit debit card giant raise full year revenue outlook share leap thursday mmm meet ep view revenue rise just consensus dow jone giant slash full year ep target stock plunge caterpillar cat report strong earning sale share heavy construction equipment maker reversed sharply lower tuesday warning operate margin hit high watermark year servicenow now report profit revenue estimate customer now spend annually metric be year year edward lifescience ew top sale adjust profit view share tank sale transcatheter heart valve replacement lag illumina ilmn beat consensus adjust profit rise share sale swell align technology algn report adjust earning share revenue handily beating view cent respectively td ameritrade amtd deliver impressive ep revenue growth fall short lofty expectation share fall week trade financial etfc continue rise last week strong result first solar fslr hit year high earning top expectation due sale several solar project expand production proofpoint pfpt cybersecurity firm top adjust first quarter earning revenue view guide low profit share fall friday advanced protection solution nearly double make new add booking prior quarter
22,ILMN,here investing action plan tuesday need know investor come day industry giant caterpillar cat lockheed martin lmt wynn resort wynn edward lifescience ew freeport mcmoran fcx report be truly bumper day earning front meanwhile illumina ilmn new oriental education
23,ILMN,relative strength rs rating bio rad lab bio jump new percentile tuesday increase look best stock buy watch keep close eye relative price strength exclusive rating investor business daily measure share price performance worst best score score show stock price movement trail week compare other stock database history reveal best perform stock tend have rs rating north early stage move see ibd help make more money stocksbio rad lab be build flat base buy point see clear price heavy trading keep mind later stage consolidation be riskier earlier stage pattern regard fundamental company have post rise ep growth last quarters sale gain have also moved higher same time frame company be expect release next quarterly number bio rad lab hold rank peer medical research equipment service industry group pra health science prah illumina ilmn thermo fisher scientific tmo be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
24,ILMN,keep list stock watch date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock add remove list include planet fitness ticker
25,ILMN,stock market index fund extend gain monday key dow jone industrial average etf reclaim couldn hold day move average spdr dow jone industrial average dium rally nearly inch day line then retreat gain spdr spy powershare qqq trust qqq also add stock market today foreign market trail ishare msci eafe efa ishare msci emerge market eem edge higher dow stock advanced top blue chip winner include unh merck mrk apple aapl add mark third straight advance iphone maker be work right side shallow base potential buy point raymond james warn apple get hit sell news reaction report expectation be already baked share price utility consumer staple homebuilder be top sector fund gainer spdr homebuilder xhb advanced continue trade day day line aerospace defense also show strength ishare aerospace ita lift build flat base potential buy point defense contractor include raytheon rtn northrop grumman noc dow component unite technology utx rally heel coordinate strike syrium britain france friday raytheon lift clear flat base entry average volume telecom biotech gold miner underperform most biotech health care fund get hurt past month heighten volatility broader market top performer accompany table see healthy year date gain vs wednesday accord morningstar direct first trust nyse arca biotechnology index fund fbt place first year date return even drop past month fund regain day move average thursday be form double bottom base buy point top holding thursday include avexis avxs intrexon xon nektar therapeutic nktr agio pharmaceutical agio intercept pharmaceutical icpt avexis share soar april news novartis nvs buy biotech get newsletter deliver inbox more info product service privacy policy term useark genomic revolution multus sector arkg come second year date return fund invest company involved genomic related field such gene therapy target therapeutic next generation oncology top holding intellium therapeutic ntla edita medicine edit illumina ilmn invitae nvta bluebird bio blue account third stock portfolio fund lose past month have be trading day line late march share be march intraday high third place go ishare medical device ihi gain wednesday fund track dow jone select medical equipment index sit high top holding make stock portfolio be medtronic mdt abbott laboratory thermo fisher scientific tmo becton dickinson bdx dhr alp medical breakthrough sbio spdr biotech xbi round top etfs respective year date gain also be interested stock lower big bank weigh dow apple buck declinestock market rally intel apple boost dow bitcoin biotechs drugmaker fare senate tax bill
26,ILMN,here weekly investing action plan need know investor come week lead tech company facebook fb amazon amzn alphabet googl microsoft msft report earning aerospace defense giant boee ba oil major exxon mobil xom stock watch hot software stock
27,ILMN,recent action index just show stock market rebound very quickly market correction back market rally so important always keep list stock watch date especially earning season start focuse stock netflix nflx salesforce com crm td ameritrade amtd be expect
28,ILMN,relative strength rs rating pra health science prah jump new percentile thursday get lift look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily identify market leadership worst best score grade show stock price behavior last week compare other stock database history show top perform stock tend have rs rating least launch biggest climb see pra health science continue show renew price strength hit benchmark look best stock buy watch start herepra health science be build consolidation buy point see stock break heavy volume keep mind later stage consolidation entail more risk term top bottom line number company have post quarters accelerate earning growth top line growth have also increase same period company be expect release next quarterly number apr pra health science earn rank peer medical research equipment service industry group illumina ilmn bio techne tech be also group highest rate stock get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
29,ILMN,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
30,ILMN,relative strength rs rating quintile im iqv enter new percentile thursday get lift look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily track price performance worst best score score show stock price movement last week stack other stock database history reveal best perform stock tend have higher rs rating launch largest price move see quintile im continue rebound hit benchmark look winning stock try simple routinequintile im be build consolidation entry see break volume least higher normal company top line growth fall last quarter ep grow prior report look next report quintile im earn rank peer medical research equipment service industry group illumina ilmn pra health science prah bio techne tech be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
31,ILMN,welcome move myriad genetic mygn see relative strength rating improve thursday look best stock buy watch factor watch closely be relative price strength ibd unique rating identify market leadership worst best score grade show stock price movement last week stack other stock database decade market research reveal top perform stock tend have better rs rating early stage move see myriad genetic continue show renew price strength clear threshold look best stock buy watch start herewhile stock be not proper buy point right now see be able form break proper consolidation term top bottom line number company have post quarters increase earning growth sale gain have be different story come latest report company be expect report next quarterly number company earn rank peer medical research equipment service industry group illumina ilmn pra health science prah bio techne tech be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
32,ILMN,relative strength rs rating pra health science prah enter higher percentile thursday get lift look best stock buy watch factor watch closely be relative price strength ibd proprietary rating track price action worst best score grade show stock price performance trail week stack other stock database year market history show best perform stock tend have rs rating north begin largest climb see pra health science continue show renew price strength clear threshold look winning stock try simple routinenow be not ideal time jump isn proper buy zone see stock manage offer clear proper buy point take look revenue profit performance pra health science have post quarters increase earning growth revenue gain have also rise same period company be expect report next quarterly number apr company earn rank peer medical research equipment service industry group illumina ilmn be top rank stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
33,ILMN,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap stock watch
34,ILMN,next earning report due apr ibd member illumina ilmn be trading approximately entry current formation be first stage flat base understand buy stock just ahead earning involve risk typically don have enough time establish profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure look winning stock try simple routineregard top bottom line number illumina have post quarters rise earning growth top line growth have also moved higher same time frame analyst expect ep growth quarter growth full year annual growth estimate be recently revise upward illumina have composite rating hold rank peer medical research equipment service industry group pra health science prah catalent ctlt be also group highest rate stock note date earning report be subject change check company update get newsletter deliver inbox more info product service privacy policy term also earning calendar analyst estimate stock watchnew option strategy limit risk earning
35,ILMN,big challenge swing trading be market turmoil hit generally have less cushion ride storm shorter term trading require quicker action defensive side also justify be offense take profit methodically way take illumina ilmn stock originally consideration nov break short consolidation be part larger consolidation resistance just volume come highest level day resistance go back further be look volume day average be day thanksgiving holiday light volume wasn unusual still warrant wait heavier trade nov holiday stock come strongly volume more twice average earn illumina spot ibd swingtrader day close stock be already nearly entry type early lead usually indicate winning trade handle right day later illumina hit profit goal take half profit offense book profit early protect trade potential sharp drop threaten overall gain turn case profit take transpire less cent top be customary also raise stop profit level entry once ve see solid gain don want let wither away defense couple day later market get scare erroneous report come trump top national security advisor michael flynn guilty plea fbi also implicate president concern contact russia campaign market reaction threaten take away profit trade focuse defense locking gain didn breach raise stop take profit remain position still have gain market illumina re-cover ground end day turmoil continue follow day be still stock rather take early profit breach raise stop demand attention profit be lose be certainly better day close lows day breach original stop loss be reason let good trade go bad stand profit entire trade averaged respectable day be also reason waste time hold stock hope comeback month later illumina be still final exit price original entry more detail past trade be accessible subscriber trialist swingtrader free trial be available related rule prevent good trade go badtaking profit early be key tenet swing tradeshow much trading volume be enough swing trade swing trading strategy lesson
36,ILMN,stock market future index dow jone industrial average nasdaq rise solidly thursday morning wednesday volatile stock market session nasdaq composite lead day index continue test day line amazon com amzn standout tumble day move average fear president trump target commerce giant be far alone stock market future be indicated fair value dow jone nasdaq get newsletter deliver inbox more info product service privacy policy term usekeep mind premarket action doesn always translate stock trade next regular session stock market future be positive tuesday least mixed wednesday open stock composite rating trade least share fall day wednesday include chip play asml hold asml lam research lrcx nxp semiconductor nxpi star winner often have composite rating least start run stock reflect ongoing shift top rate mostly tech name new stock market correction have take hold splunk splk workday wday com wuba be top stock drop day action also reflect especially nasdaq be more pressure wednesday more old economy dow jone just edge lower list way downplay damage growth stock have suffer stock don include amazon have composite rating don include square sq square round trip early march wednesday close just day don include nvidia nvda nvidia be catalyst tuesday stock market sell trigger correction call nvidia crash day tuesday tumble nearly chipmaker slide wednesday let take look asml hold lam research nxp semiconductor addition name microchip technology mchp mks instrument mksi analog device adi also be stock chip play lead stock market upswing have be notable loser past several session chip gear maker asml hold lam research fall stock market today fall enough invalidate recent buy point early tuesday lam research briefly retook double bottom buy point open soon reversed asml come whisker move back buy zone tuesday own reversal reversal similar action other chip gear name be bearish sign lead stock tuesday nvidia nvda tumble facebook fb renew ongoing crash nxp semiconductor plunge crash day line approach day first time qualcomm qcom agree buy automotive wireless chip maker late september qualcomm reportedly be have trouble get china approval nxp deal last month qualcomm raise takeover price share satisfy key nxp investor other stock list include green dot gdot td ameritrade amtd canada goose goos diamondback energy fang ilumina ilmn be interested big picture techs drive stock bear territory market correction look stock lululemon tech standout be make round trip breakout
37,ILMN,ibd stock list be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
38,ILMN,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see growth stock have just be add remove list ibd display video
39,ILMN,welcome move catalent ctlt see relative strength rating improve thursday look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily measure market leadership worst best score rating show stock price movement trail week hold other stock database history show best stock typically have rs rating begin biggest climb see catalent continue rebound hit benchmark look winning stock try simple routinecatalent be work consolidation buy point see clear price heavy trading term fundamental catalent have post quarters rise earning growth revenue growth have also moved higher same time frame catalent earn rank peer medical research equipment service industry group pra health science prah illumina ilmn quintile im iqv be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term userelated ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
40,ILMN,monday myriad genetic mygn earn positive adjustment relative strength rs rating look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily identify price movement worst best score rating show stock price movement last week stack other stock database year market history show market biggest winner often have rs rating north launch largest climb see myriad genetic continue rebound hit benchmark look winning stock try simple routinenow be not ideal time jump isn proper buy zone see stock be able form consolidation break take look revenue profit performance company have post quarters increase earning growth sale gain have be less impressive come most recent report myriad genetic earn rank peer medical research equipment service industry group pra health science prah illumina ilmn quintile im iqv be top highly rate stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
41,ILMN,first quarter earning season right corner now be time build list best stock watch focus company netflix nflx twitter twtr salesforce com crm lead chinese stock baidu bidu baozun bzun be expect deliver earning growth higher make
42,ILMN,stock remain broadly lower midday tuesday appear be perfectly normal pullback stunning gain earlier month commodity play help pace downside agricultural chemical oil gas exploration oil drill metal ore steel share fall hard apple aapl meanwhile fall fourth time session largest company nasdaq market cap be now day move average flattened last week gain oct good second stage cup handle have now be squeeze share be more buy point apple slide weigh major index nasdaq composite dow jone industrial average sink least component dow jone industrial average fall point more include unitedhealth group unh goldman sachs gs mmm mcdonald mcd yet even tuesday decline dow stand higher jan mcdonald post jump adjust fourth quarter profit share sale drop biggest year year drop first quarter nevertheless share fast food icon have perform well clear long saucer handle late march roll more point see weekly chart continue hug slowly rise week move average paint red ibd marketsmith chart monday nasdaq notch third distribution day instance heavy professional selling second session keep track distribution count nasdaq read big picture column daily basis current outlook market change ll have good strategy motivation take action sell stock reduce exposure hold position point new investor apple share have decide draw line sand stock have gain more follow sound good rule thumb be sell share small profit prevent complete wipeout gain stock always be buy back market condition improve longer term point view however apple be still act just fine jan iphone ipad digital service giant break first stage cup handle jan year share rise much same period nasdaq composite rally also trail rise smallcap rise just ascent apple survive normal look sell off send share temporarily day move average june september notice long term weekly chart apple do not venture too far week move average move similar form day daily chart elsewhere stock market investor seek accumulate share select name business medical software workday wday rise more volume run nearly double usual level stock be now slightly extend breaking week cup handle find correct buy point pattern add cent highest price handle be paycom software payc also excel hr payroll automation outsource market erased mild early loss edge slightly higher oklahoma city base firm have gain jan past entry good flat base defensive industry include hospital nonalcoholic beverage soap meat rally back downside pulte group phm gap drop more active turnover stock close day move average monday first time past buy point flat base june mark key sell signal homebuilder report rise profit cent share match consensus view revenue rise miss thomson reuter estimate large number pulte industry peer have also slide sharply day line include nvr nvr lgi home lgih toll bro tol few reversed nicely lows good sign healthy substantial price run sharp undercut day line failure recover back support line be key ibd defensive sell rule help preserve profit day federal reserve meeting interest rate policy begin tuesday bond trader do not seem actively seek bargain even recent sell treasury yield benchmark year bond be currently month treasury paper have yield year note yield thus yield curve continue maintain positive slope build sector rank sector rank mid long term relative price performance latest ibd weekly print edition however sector be also more jan so actually severely lag broader market see entire sector ranking stock research table ibd weekly begin page well go ibd datum table stock list investor com then click ibd smart nyse nasdaq table key earning report close tuesday include illumina ilmn align technology algn electronic art ea illumina expert genetic datum analysis equipment be expect post jump profit share mark biggest year year increase gain first quarter prior quarters illumina show ep increase decline gain illumina just light turnover have rally steady stair step fashion breakout past week flat base aug base base past nov follow saito chung twitter ibd_dchung additional commentary analysis breakout growth stock financial market related really spot major market top sure here be easy waystock buy zonefind hot growth stock peek ibd good watch list future big tech stock winner
43,ILMN,bit jockey position occur top perform fund past month stock market re-cover turbulent february first trust dorsey dynamic focus fvc moved spot take lead year date gain march fund provide exposure first trust sector industry base etfs nasdaq bill index sharing spot be sibling first trust dorsey focus fv have amassed asset etf comprise first trust sector industry base etfs dorsey associate think outperform other selection universe be rank third last month powershare qqq trust qqq hop notch spot ytd gain accord morningstar direct tech heavy index tracking fund asset be also best perform biggest etfs qqqs hold session streak thursday underlie index lead year richard turnill global chief investment strategist blackrock expect tech stock keep outperform extraordinarily strong earning momentum corporate tax cut fiscal stimulus underpin positive view write recent report momentum value style factor well financial technology sign free ibd newsletter market prep tech reportmove sector fund biotechs fall top ark innovation arkk count tesla tsla twitter twtr top holding score ytd gain fund invest company rely benefit advancement key area genomic revolution web industrial innovation ark genomic revolution multus sector arkg last month sector fund come second return etf focus genomic stock own intellium therapeutic ntla illumina ilmn edita medicine edit top holding ark fund ark web arkw place fourth ytd gain third place honor go first trust dow jone internet index fdn moved notch fund top holding march include fang stock facebook fb amazon amzn netflix nflx alphabet goog well salesforce com crm paypal pypl foreign stock play ishare msci brazil capped ewz defend lead position ytd gain kraneshare csi china internet kweb jump back list hiatus vaulting second place return meantime ishare latin america ilf moved notch advance also be interested biotechs brazil past month top perform stock playsfirst trust launch new blockchain etf meet demandcheck tech play amazon bitcoin netflix
44,ILMN,pra health science prah have relative strength rs rating upgrade friday try find best stock buy watch be sure pay attention relative price strength ibd proprietary rating identify market leadership worst best score score show stock price behavior last week compare other stock database history show market biggest winner tend have better rs rating begin biggest price move look best stock buy watch start ibd stock be work flat base entry see clear price volume least higher normal be aware third stage base later stage pattern work have greater failure rate point stock have already climb substantially take look top bottom line number company have post rise ep growth last quarters sale gain have also moved higher same time frame pra health science earn rank peer medical research equipment service industry group illumina ilmn quintile im iqv be also group highest rate stock related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
45,ILMN,here investing action plan tuesday need know investor come day fast food leader mcdonald mcd video game publisher electronic art ea open earning season respective sector investor get dose medical chip report president trump deliver state
46,ILMN,icon iclr see positive improvement relative strength rs rating wednesday rise unique rating identify market leadership show stock price movement last week measure other stock database decade market research show best stock tend have higher rs rating begin biggest climb see icon continue show renew price strength clear threshold look best stock buy watch start hereicon be build consolidation buy point see break volume least higher normal icon report earning growth latest quarterly report sale rise icon hold rank peer medical research equipment service industry group pra health science prah illumina ilmn quintile im iqv be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
47,ILMN,nasdaq have be place be first half index be year vs only ibd stock spotlight screen make advantage even clearer go friday session nasdaq spotlight stock be vs nyse spotlight stock give spotlight focus stock strong fundamental issue be often base investor not expect index particular stock be be critical argue market be bad idea medical sector stock spotlight friday morning be also nasdaq issue midcap portable oxygen tank maker inogen ingn be year date investor assume money have be make stock run be be right several observation be worth consider first ibd usual target be take profit stock doesn have double again reach such goal get greedy seldom make sense second inogen relative strength line be high bullish sign however inogen be neither group stock checkup investor com ibd style investor prefer buy stock group still inogen fundamental be strong enough make spotlight screen get newsletter deliver inbox more info product service privacy policy term other medical stock be gene sequence giant illumina ilmn stock be year illumina relative strength line have fade high past week general trend have be rs line measure stock performance vs rise line point outperformance san diego base illumina be group stock checkup investor com illumina inogen be try bounce week line create new buy area better volume price gain get instant access more trading idea exclusive stock list ibd proprietary rating only related nike big leap upwardwill tariff sink stock market use psychological indicator investing
48,ILMN,myriad genetic mygn be ibd stock day break wednesday analyst upgrade note trend genetic cancer test be improve myriad stock spiked close stock market today morgan stanley analyst steve beuchaw upgrade overweight rating equal weight beuchaw also boost price target share surge past buy point cup handle base heavy volume close more extend point follow brief june cup handle myriad core business be selling test determine patient carry genetic risk develop cancer core sale stabilize myriad high return capital deployment help earning accelerate beuchaw say get newsletter deliver inbox more info product service privacy policy term use believe myriad genetic earning profile be dramatically change say report client core hereditary cancer test business be show durability bear give credit volume return growth price decline slow same time key acquisition be expand myriad total addressable market note acquisition assurex health assurex test look psychiatric condition chronic pain molecular diagnostic company announce plan acquire obstetric genetic screening outfit counsyl insurance reimbursement assurex genesight genetic test depression be become clearer beuchaw say now evidence show clinical benefit cost benefit determine medicine match specific patient depression say further investor be excited myriad plan acquisition privately hold counsyl company provide genetic screening expectant mother family counsyl beuchaw assume steady gain basis point year market share myriad fiscal year guidance be key fall likely include impact counsyl acquisition set close first quarter myriad fiscal outlook drive consensus estimate higher year beuchaw say believe buy side have also not yet incorporate dynamic view stock say company medical research equipment industry group be rank group track ibd other notable stock group include thermo fisher scientific tmo illumina ilmn term relative strength rating myriad stock land top group rs rating best possible rs rating stock price action trail week vs rest market get instant access more trading idea exclusive stock list ibd proprietary rating only related much money do need start investing long term retirement investing strategy etfssell take profit hold here be several guideline follow
49,ILMN,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
50,ILMN,find best growth stock buy watch start check ibd sector leader ibd big cap ipo leader stock spotlight be sure check page day see stock have just be add remove screen ibd stock list have history beating be base proprietary slim investing system help find today most promising stock identify be display same trait best perform stock typically show early stage big move never buy stock simply ibd screen always do own research run stock re tracking buy checklist also use ibd simple step routine stay sync market condition make sure have today best growth stock radar get newsletter deliver inbox more info product service privacy policy term useget instant access more trading idea exclusive stock list ibd proprietary rating only also look next big stock start herewhich company be now outperform stock buy stock buy checklistwhen sell stock selling checklist
51,ILMN,stock index give back strong gain monday small cap stubbornly hold lead breakout emerge volume fade session progressed meanwhile quality stock have refuse go even day past session volume fade monday early breakout example gene sequence giant illumina ilmn initially show fast turnover then dwindle only moderately higher volume small cap russell nasdaq spurt ahead respectively dow jone industrial average gain also edge nearly get newsletter deliver inbox more info product service privacy policy term dow encounter resistance day move average close line volume stock market today fall major exchange vs same time friday several tough day last week highly rate stock rise past session include monday stock include apple aapl hit new high mastercard also peg new high la vegas sand lvs be high risk analytical service provider transunion tru just new high software company atlassian team less high cloud security play mimecast mime score new high china base alibaba baba do even better online marketplace rise eighth straight session include monday more gain nasdaq illumina score gain volume jump satisfying normal level stock clear buy point shallow consolidation streetinsider com report barclay upgrade illumina equal weight overweight barclay set price target component dow jone industrial average exxon mobil xom score gain be almost earlier volume shrank average exxon be still week high oil price initially give boost oil stock west texas intermediate crude oil touch then reversed cent price oil have be rise possibility president trump nuclear deal iran axe deal probably reduce iran oil export put upward price pressure oil trump say monday announce decision et tuesday oil stock breaking include pdc energy pdce cvr energy cvi cvr refine cvrr attract strong volume chip space nvidia nvda jump past entry early monday stock gain trade slow average nvidia report earning thursday close stock base be late stage computer sector datum storage stock pure storage pstg rumble higher volume be average midcap stock clear buy point cup handle pattern pure storage be initial public offer stock be add leaderboard earlier today other computer sector stock post decent gain move do not involve breakout cisco system csco padded recent gain advance monday soft trade cisco rise past week arista network anet rebound volume average stock be day day move average meanwhile deal make front starbucks sbux switzerland base nestle nsrgy announce marketing pact nestle pay starbucks ongoing royalty right market starbucks accord bloomberg news starbucks use buy back share starbucks jump heavy volume market open then reversed loss nestle pop related apple nvidia alibaba regional bank share same bullish dividend rich stock better indexstock start act normal long breakaway gap art
52,ILMN,bio rad lab bio see positive improvement relative strength rs rating thursday upgrade try find best stock buy watch be sure pay attention relative price strength exclusive rating investor business daily identify share price movement worst best score grade show stock price performance last week hold other stock database year market history show stock go make biggest gain typically have rs rating north early stage move look best stock buy watch start herebio rad lab break earlier have fall back prior entry double bottom stock re watch break past buy point then decline more original entry price consider fail base best stock form new consolidation also keep mind most recent pattern be later stage base make riskier establish new position add share exist term fundamental health bio rad lab have post quarters rise earning growth revenue gain have also increase same time frame bio rad lab hold rank peer medical research equipment service industry group pra health science prah illumina ilmn quintile im iqv be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
53,ILMN,icon iclr see welcome improvement relative strength rs rating monday upgrade exclusive rating investor business daily measure market leadership worst best score grade show stock price performance trail week hold other stock database year market history show best perform stock typically have rs rating least begin largest run see icon continue rebound clear threshold see ibd help make more money stocksicon be try complete consolidation buy point see clear price heavy volume company show ep growth most recent report sale growth come icon earn rank peer medical research equipment service industry group pra health science prah illumina ilmn catalent ctlt be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
54,ILMN,monday bio rad lab bio get positive adjustment relative strength rs rating ibd proprietary rs rating track technical performance show stock price movement last week compare other stock database year market history reveal stock go make biggest gain often have higher rs rating launch biggest climb see bio rad lab continue rebound clear threshold look winning stock try simple routinebio rad lab be build double bottom entry see stock clear price heavy trading be aware fourth stage base such later stage pattern involve more risk be more have higher likelihood fail earlier stage consolidation top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase bio rad lab earn rank peer medical research equipment service industry group pra health science prah illumina ilmn catalent ctlt be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
55,ILMN,charle river lab international crl have relative strength rs rating upgrade monday welcome improvement still shy higher score prefer see exclusive rating investor business daily track share price performance worst best score rating show stock price behavior last week hold other stock database year market history reveal best perform stock tend have rs rating north begin largest price move see charle river lab international continue rebound clear threshold see ibd help make more money stockscharle river lab international break earlier be now trading prior entry double bottom scenario stock break then fall more entry price consider fail happen best new pattern form also keep mind latest pattern be later stage base make riskier establish new position add share exist earning growth increase last quarter sale fall charle river lab international earn rank peer medical research equipment service industry group pra health science prah illumina ilmn catalent ctlt be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
56,ILMN,welcome move bio rad lab bio see relative strength rating rise wednesday unique rating track technical performance used worst best score identify stock price action last week compare rest market year market history show market biggest winner tend have rs rating north begin largest price move see bio rad lab continue rebound hit benchmark look winning stock try simple routinebio rad lab be try complete double bottom buy point see stock break heavy trade later stage pattern investor be aware be less likely work company see earning sale growth rise last quarter earning share increase revenue rise company be expect report latest result feb bio rad lab hold rank peer medical research equipment service industry group pra health science prah catalent ctlt illumina ilmn be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
57,ILMN,energy stock show unite advance monday few dozen name strike week high move come back early jump west texas intermediate crude oil price back barrel wti reversed lower day end slightly new high list monday also show solid group highly rate company software internet medical retail leisure sector retail consumer spending type name such etsy etsy member ibd leaderboard feb be buy range yet more handful lead company be still not yet extend more past proper buy point include apple aapl illumina ilmn mastercard etsy rally monday have now gain much clear week cup base entry point feb apple be stage sixth gain row stock add hit new time high price iphone ipad marketer rise past buy point week double bottom base smart portfolio management buy share stock more correct entry strategy help prevent selling stock too early make normal pullback just price apple enter leaderboard friday follow new have form series basis top basis megacap tech play scorched market bear clear first stage cup handle jan move past entry get newsletter deliver inbox more info product service privacy policy term usewall street have revise profit estimate apple higher recent day last week good fiscal report analyst consensus now see earning rise share current fiscal year end september fiscal earning rise share analyst now see bottom line grow additional share fiscal medical sector illumina ilmn push past buy point week base base formation share genetic research equipment expert hit high buy zone illumina go entry illumina show rocky reaction issue first quarter result april earning leap share revenue rise big ep jump be doubt help easy comparison earning sank year quarter however result reaffirm bullish trend first quarters illumina post straight quarters fall profit profit then rise third fourth quarters year respectively average ep increase past quarters healthy street see second quarter earning go share illumina be part research equipment service industry group ibd medical sector group rank dismal industry group month relative price performance accord friday list relatively small group name also hold more company trade least share show relative price strength rating higher other firm be bio techne tech natera ntra medpace medp icon iclr mastercard leader credit card debit card payment process apace edge sixth straight session share notch new time high be still proper buy zone large cap drive past buy point week flat base please follow saito chung twitter ibd_dchung more commentary top growth stock chart action financial market related find top growth stock fast peek ibd stock buy do illumina compare industry peer use timesave stock research tool
58,ILMN,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
59,ILMN,amazon amzn have history choppy profit late thursday commerce cloud compute giant deliver yet quarter accelerate earning growth revenue gain ibd stock svb financial sivb twitter twtr mastercard solaredge technolgy sedg illumina ilmn also boast least quarters faster sale earning growth amazon be not ibd stock already boast best possible composite rating composite rating combine several proprietary ibd rating single score time stock winner often have composite rating least start big run svb financial solaredge technology also have composite rating twitter mastercard have crs illumina boast cr accelerate earning growth be extremely bullish trait ultimately earning drive stock gain faster profit gain show company have real momentum faster sale growth suggest real demand not just cost cut accounting game amazon report earning share more double analyst forecast year year ep rise be third straight quarter accelerate earning growth sale growth accelerate fifth straight quarter sprint get newsletter deliver inbox more info product service privacy policy term usebee able ramp growth rate massive size be especially impressive amazon isn do look analyst see massive ep gain course amazon have have solid consistent profit growth year ceo jeff bezos focuse effort boost sale market share pay recently reveal prime membership have top worldwide amazon say thursday hike prime fee year amazon stock shot record friday morning fade intraday amazon clear cup base buy point close level do settle alternate entry flaw cup handle pattern investor probably stock move back friday high buy opportunity keep mind amazon be very late stage base several big move recent year late stage breakout be less likely be big winner more likely fail amazon fall stock market today social network early wednesday report adjust earning cent share vs year earlier twitter earning growth have accelerate straight quarters revenue rise vs year earlier be best sale gain year fourth straight quarter improve year year change twitter share shot wednesday open stock quickly fall sharply regular session ceo jack dorsey warn growth likely slow later year stock fall last week well day line work consolidation twitter rise monday new content advertising deal walt disney svb financial parent silicon valley bank late thursday report earning growth revenue leap ep be cent estimate revenue be view svb financial earning revenue growth have accelerate straight quarters silicon valley bank parent also raise full year guidance cite faster growth loan deposit balance net interest income amazon twitter svb financial do not pare reverse initial post earning gain stock shot friday gapping week cup base entry marketsmith analysis show svb financial open more past standard entry breakaway gap breakaway gap open price be alternative entry point svb sank monday credit debit card giant have report straight quarter accelerate earning growth quarters faster sale growth year year gain respectively mastercard streak be come end card giant report analyst expect ep jump revenue be strong decelerate growth share mastercard be trading flat base buy point stock close friday mastercard rise back day line mastercard rival visa also ibd stock report better expect earning last week ep revenue growth accelerate prior quarter visa clear flat base buy point thursday close friday visa rise monday visa mastercard recent trading history suggest pullback day day line be better entry traditional buy point breakout illumina have enjoy straight quarters improve year year earning growth trend gain report last week revenue growth have sped quarters well share initially fall illumina earning rally close week day line genomic testing machine maker be flat base buy point illumina fall monday solaredge technology have have quarters strong accelerate earning growth revenue growth have picked momentum last quarters gain last period israel base company distribute solar power harvesting component power optimizer inverter solar company stock be well extend feb follow latest solaredge earning report share have consolidated past few week stock close friday find support day line past few session solaredge dip monday close day line first time feb be interested big squeeze stock market bull run face biggest threat yearsfuture rise big merger apple hit dubious lead retail stock be watchingibd big lesson investor payment giant visa break earning peer make bullish movesapple tesla alibaba earning facebook hold investing action plan
60,ILMN,nearly month worth stock market action now rear view mirror major index story have be let nice gain slip away lesson investor don let gain do same gainer be only touch jan large cap benchmark lose more advance first week trading year innovator ibd ffty exchange trade fund be also mildly year road have be bumpy month just day etf stab day move average third time feb so far etf have manage rebound prior test long term support level many stock ibd outside list have fail reach new high earning sale have show robust increase see first quarter result hit equity trader computer screen past few week market always look ahead always have something consider evaluate lately sharp rise yield benchmark treasury year bond appear be front burner issue new bull market crude oil price possibility accelerate inflation also deserve prominent space current market picture ibd style investor ll want always adjust hold selling strategy overall market shift right now current outlook uptrend pressure take profit more quickly be smart strategy stock be say proper buy point be show sign fatigue least sell half share keep watch longer ve play game buy breakout good market sit patiently stock hit profit goal more likely ve see stock come so close then retreat fast other case ibd name act profit level be merely pit stop indeed recent year score high quality growth stock have rise even more past proper buy point sink real correction have supreme conviction overall market be healthy go ahead sit longer winner casa system casa have occupied spot ibd month illustrate importance not be too greedy specialist software cable telecom market debut nasdaq share dec form very narrow ipo base february then break past entry feb day market be confirm uptrend thank follow rally less week later casa hit high stout take least gain turn be sound portfolio management casa cool try clear faulty cup base last just week april share plunge nearly undercut day move average first time news share offer day later casa price share share float be casa be also likely get knock news charter communication chtr report expect result video subscriber loss here quick look other ibd name recent action abiom abmd hold fine fading past new flat base base be late stage key risk keep mind gain march have hit smart global sgh make round trip rise past buy point march catapult week stock make sharp retreat even earning roar higher share quarter end february revenue rise illumina ilmn base next base be form clear resistance be see viper energy partner vnom be not give much back clear base buy point gain have so far hit new bull run crude oil price trade ibd click innovator ibd ffty manage innovator capital also please follow saito chung twitter ibd_dchung more analysis lead stock chart financial market related stock ibd post earning growth more be new global stock leader check herewhen be good time take profit stock new ibd other growth stock screen stock be exit go latest investor corner
61,ILMN,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
62,ILMN,important metric look stock be higher relative strength rating illumina ilmn now clear threshold jump monday exclusive rating investor business daily measure price action worst best score score show stock price performance trail week stack other stock database decade market research show top perform stock tend have rs rating least launch biggest price move look winning stock try simple routinewhile stock be not ideal buy point right now see go form break proper chart pattern term fundamental illumina have post quarters accelerate earning growth revenue growth have also moved higher same time frame company hold rank peer medical research equipment service industry group pra health science prah be top rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
63,ILMN,year ibd showcased just company gigantic medical sector look back copy remember be do well memory be photographic be unite therapeutic uthr ibd biotech group patient datum monitoring gear expert masimo masi medical
64,ILMN,welcome move charle river lab international crl see relative strength rating improve wednesday ibd proprietary rating track price action worst best score rating show stock price movement last week compare other stock database decade market research show stock go make biggest gain tend have rs rating north launch largest climb see charle river lab international continue rebound clear threshold see ibd help make more money stockscharle river lab international be work double bottom buy point see stock break volume least higher normal sale growth fall last quarter ep grow prior report charle river lab international hold rank peer medical research equipment service industry group pra health science prah quintile im iqv illumina ilmn be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
65,ILMN,many exchange trade fund pare year date gain stock market sell highly volatile week top performer hold name apple aapl microsoft msft illumina ilmn cause rout brett ew chief market strategist first franklin cite key cause likely wake bear result drubbing be bound happen say list top perform etfsfirst trust launch new blockchain etf meet etf pick sell be way overdue healthy occurrence market just beat year old record trading day sell pretty hard do too much complain note thursday report bullish sentiment re look datum point datum point tell populace be longer worry economy make brave have be decade risk appetite first franklin have be increasingly shift portfolio late cycle play such material commodity industrial infrastructure etfs have be shuffle leadership past month various category new name ershare entrepreneur entr top diversify stock category month old fund track entrepreneur index have attract asset new offer used rule base methodology select publicly trade entrepreneurial company stock index be large cap mostly consumer discretionary information technology health care sector complete holding be disclose quarterly basis sec filing year date return feb accord morningstar direct be well ahead gain entr carry expense ratio familiar name come second ishare edge msci usa momentum factor mtum ytd gain fund track msci usa momentum index information technology lead sector weighting feb nearly asset follow financial health care industrial top holding jpmorgan jpm microsoft msft boee ba apple aapl bank america bac account roughly portfolio pair first trust fund first trust dorsey focus fv first trust dorsey dynamic focus fvc take third fourth respective gain fv asset hold first trust sector industry base etfs dorsey associate think outperform other selection universe fvc asset provide exposure first trust sector industry base etfs nasdaq bill index ibd take don try guess market be head next read big picture day understand action major average lead stock move sector fund ark genomic revolution multus sector arkg lead advance fund invest genomic company expect benefit extend enhance people life top name feb include intellium therapeutic ntla illumina ilmn edita medicine edit biotechs take top spot first trust nyse arca biotech fbt spdr biotech xbi be second third respective ytd gain china lead foreign stock category last year moved list top category be ishare msci brazil capped ewz return ishare latin america ilf ishare msci italy capped ewi market have already exhibit sign slow week rout global equity market pull back last week exceptionally strong start year blackrock global chief investment strategist richard turnill say feb note market volatility rise bond yield climb related stock market sell do nowai robotic china take lead fed shutdown rate hike loomcheck tech play amazon bitcoin netflix
66,ILMN,key market index fund extend gain monday apple aapl boee ba lead dow jone industrial spdr dow jone industrial average dium powershare qqq trust qqq soar spdr spy advanced emerge market also rally ishare msci emerge market eem rise apple boee lead dow gain more american express amex cisco csco leap respectively apple regain day move average heavy volume day line gold miner energy semiconductor lead sector fund stock market today west texas intermediate crude price be barrel gold future rise ounce vaneck vector semiconductor smh ishare phlx semiconductor soxx advanced etfs be get closer retake day line real estate retail utility lag vanguard real estate vnq pare steep early loss remain year lows ishare real estate iyr reversed slightly higher be trading month lows european regulator warning cryptocurrency be highly risky bitcoin leap accord coindesk earlier session high bitcoin investment trust gbtc climb track fifth straight advance find support day move average december peak biotechs genomic have be lead health care exchange trade fund year weren spare last week market rout find support key level end week monday bounce support broader market rally ark genomic revolution multus sector arkg top list year date gain feb etf invest company expect benefit improve person quality life incorporating technological scientific development genomic business include company involved area such gene therapy next generation oncology stem cell top holding feb include intellium therapeutic ntla illumina ilmn edita medicine edit biogen biib bluebird bio blue gilead science gild also make top top account stock portfolio arkg test day move average friday find support close just day move average first trust nyse arca biotechnology index fbt be next year date return accord morningstar direct fund slice day line friday reversed retake line close small gain most stock be midcap range average market cap count top holding bioverativ bivv juno therapeutic juno fibrogen fgen bioverativ be be acquire sanofi sny deal ibd take don try guess market be head next read big picture day understand action major average lead stock spdr biotech xbi come third year date gain etf track biotechnology select industry index display similar action fbt friday many year old fund holding have average market cap skew smaller fbt xbi top holding include bioverativ juno array biopharma arry overall average annual return health care fund make list lag past year be lead benchmark index past year friday pick proshare ultra short qqq sqqq reversed lower loss nasdaq close gain sqqq hold day line related nvidia top tech stock lead bounce key support linestock rally apple nvidia fuel big gain be bitcoin back stock market sell do now
67,ILMN,stock leap strong start tuesday open international market provide starkly mixed backdrop first session walt disney mcdonald mcd be clear front runner blue chip lead dow jone industrial average start trade nasdaq composite post early gain netflix nflx illumina ilmn stake strong early move economic calendar open year wednesday automaker report december sale ahead friday december payroll report global stock market start year sharply contrast action china stock charge day holiday weekend first trading session tuesday hong kong hang seng index roar higher shanghai composite grab gain real estate auto consumer good see powerful gain stock china receive lift caixin markit general manufacturing purchasing manager index show growth china manufacturing consumer activity accelerate december month high europe japan be softer start tokyo nikkei dip fraction tuesday europe datum show weak auto sale registration place pressure session cac paris drop frankfurt dax fall london ftse sag afternoon action disney run head dow disney star war last jedi continue lead box office third weekend top cumulative domestic box office sale stock also receive upgrade tuesday macquarie outperform neutral price target hike gain put disney share just fraction buy point double bottom base apple flattened open tech heavyweight have have trouble breaking free week move average flat base buy point netflix lead fang stock jump upgrade outperform neutral macquarie stock have technically build base buy point many other be start year wrestling regain support week line china base stock be show healthy early response overnight gain china tencent holding tcehy rumble ahead early action move lift online gaming titan less flat base buy point pop open thinly trade online gaming name have be battle resistance week move average august ibd stock alibaba group hold baba climb online commerce giant be also trading week line sixth week possible base pattern chip stock be behave well sketch modest early gain taiwan semiconductor tsm be early leader share be buy point week flat base illumina ilmn swung follow upgrade outperform market perform well fargo stock be week flat base buy point biom leader incyte incy jump developer cancer treatment include jakafi iclusig be upgrade outperform market perform rbc capital stock have be deepen consolidation march bitcoin trade late day price friday future be cboe cme exchange bitcoin related stock be generally lower related big picture stock index nail great year repeat fang stock be key technical levelsmake money step increase investing returnsinside ibd name help index solid
68,ILMN,friday medpace medp receive upgrade relative strength rs rating exclusive rating investor business daily measure market leadership worst best score grade show stock price performance last week hold other stock database year market history reveal market biggest winner tend have rs rating north early stage move see medpace continue rebound clear threshold see ibd help make more money stocksmedpace be build consolidation entry see stock clear price volume least average medpace see earning sale growth rise last quarter earning share increase revenue rise company hold rank peer medical research equipment service industry group pra health science prah catalent ctlt illumina ilmn be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
69,ILMN,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
70,ILMN,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
71,ILMN,ibd stock list be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
72,ILMN,welcome move catalent ctlt see relative strength rating rise monday re research best stock buy watch be sure pay attention relative price strength ibd unique rs rating identify technical performance show stock price action last week measure other stock database decade market research reveal stock go make biggest gain often have better rs rating begin biggest run see catalent continue show renew price strength hit benchmark look winning stock try simple routinecatalent be work consolidation entry see stock break volume least average company show earning growth most recent report revenue rise catalent hold rank peer medical research equipment service industry group illumina ilmn medpace medp pra health science prah be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term useget instant access more trading idea exclusive stock list ibd proprietary rating only also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
73,ILMN,welcome move inc research synh see relative strength rating improve monday look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily identify market leadership worst best score rating show stock price behavior last week hold other stock database history reveal market biggest winner tend have higher rs rating begin biggest climb see inc research continue rebound clear threshold look best stock buy watch start herewhile now be not ideal time buy share see stock go establish enter buy zone heavy volume company top line growth fall last quarter earning share grow previous report keep eye company next round number jul inc research hold rank peer medical research equipment service industry group illumina ilmn medpace medp pra health science prah be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term useget instant access more trading idea exclusive stock list ibd proprietary rating only also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
74,ILMN,myriad genetic mygn see positive improvement relative strength rs rating thursday increase look best stock buy watch factor watch closely be relative price strength proprietary rating track technical performance used worst best score identify stock price action last week match rest market history show market biggest winner typically have better rs rating begin biggest run look best stock buy watch start heremyriad genetic be now consider extend buy range clear buy point third stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average company report ep growth most recent report revenue gain come keep eye company next round number aug myriad genetic earn rank peer medical research equipment service industry group illumina ilmn medpace medp pra health science prah be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term useget instant access more trading idea exclusive stock list ibd proprietary rating only also stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
75,ILMN,relative strength rs rating inc research synh enter higher percentile friday get lift look best stock buy watch keep close eye relative price strength unique rating measure technical performance show stock price movement last week compare other stock database history reveal market biggest winner tend have better rs rating launch biggest price move see inc research continue show renew price strength hit benchmark see ibd help make more money stocksinc research be not currently show potential buy point see stock go build promising consolidation launch new move earning growth increase last quarter sale fall company earn rank peer medical research equipment service industry group illumina ilmn medpace medp pra health science prah be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
76,ILMN,charle river lab international crl see positive improvement relative strength rs rating monday upgrade re research best stock buy watch keep close eye relative price strength proprietary rating measure technical performance show stock price action last week measure other stock database history show top perform stock typically have rs rating launch largest run see charle river lab international continue rebound clear threshold look best stock buy watch start herecharle river lab international be buy zone clear entry cup handle once stock move higher initial entry consider proper buy area earning share growth decrease prior quarter revenue rise prior report charle river lab international earn rank peer medical research equipment service industry group illumina ilmn medpace medp pra health science prah be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
77,ILMN,nike fuel big rally dow jone friday major stock index look poise end second quarter high note biotech stock nasdaq outperformed name vertex vrtx celgene celg biomarin bmrn nicely share vertex soar compete cystic fibrosis drug galapago glpg didn do well mid stage trial dow be midday nasdaq composite rise respectively volume nyse nasdaq be tracking lower thursday level stock market result today nike nke be hand winner dow company report strong earning late thursday share surge head report nike be still buy range entry get support day move average also dow american express axp rise more flatten yield curve hasn be good news financial recent week sector outperformed nicely friday federal reserve give go ahead several bank increase dividend initiate share buyback american express increase dividend cent also announce plan buy back stock elsewhere share constellation brand stz slump earning miss large cap name be solid technical setup ahead result not more constellation gap day move average be well session lows ibd viper energy partner vnom continue low volume ascent rise back day move average only high current cup shape base be too short be valid base ibd name illumina ilmn extend gain pay visit day line thursday share be health care name continue show relative strength entry china base name package delivery firm zto express zto continue show good action week move average recent share be get instant access more trading idea exclusive stock list ibd proprietary rating only also tesla sale trade war job fed minute investing action planvideo game stock be potential medium company acquisition targetsnovartis surge decision spin alcon eye device unit
78,ILMN,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
79,ILMN,ibd smartselect composite rating pra health science prah increase wednesday revise score mean stock currently top other stock term key performance metric technical strength winning stock often have higher score early stage new price run so good start point look best stock buy watch pra health science be currently form consolidation entry look stock break volume least higher normal note later stage base such basis be more prone failure look best stock buy watch start stock have ep rating mean recent quarterly longer term annual earning growth top stock accumulation distribution rating show moderate buy institutional investor last week get newsletter deliver inbox more info product service privacy policy term company report earning share growth revenue growth increase prior quarter company have now post increase growth last quarters pra health science earn rank peer medical research equipment service industry group illumina ilmn be top rank stock group related company be now outperform stock see stock just come ibd top stock list
80,ILMN,illumina ilmn see improvement ibd smartselect composite rating monday upgrade mean stock currently top other stock term key performance metric technical strength history show top market performer tend have higher score launch major move illumina break earlier have fall back prior entry flat base scenario stock break then fall more entry price consider fail happen best new base take shape look winning stock try simple stock earn ep rating mean recent quarterly annual earning growth top stock accumulation distribution rating show heavy buy institutional investor last week company report earning share growth mark straight report rise ep performance revenue growth increase prior quarter mark quarters increase revenue gain illumina hold rank peer medical research equipment service industry group pra health science prah be rank stock group related company be now outperform stock
81,ILMN,look annual return year be mistake think come steady rate more often year be punctuate fit start job swing trader be capitalize upswing sidestep pullback make last year challenge be defensive action pullback often see immediate rebound new high however didn take defensive action left expose sector rotation leave wrong stock index be make new high take look action ibd swingtrader last few month illustrate point current trade shrink considerably nasdaq composite spend time day move average dip day line mid november skecher skx be already current trade list expand more aggressively start nov scientific game sgms illumina ilmn unite rental uri be good quick gain index start pull back nov defensive selling accelerate dec morning plague headline later prove be false dec buy start again earnest get early reversal rather wait new high ground have be critical stay phase market quick profit be book name ringcentral rng kennametal kmt be small loss well netflix nflx market pull back start dec thing occur be noteworthy first pullback be very orderly slow give day move average second several stock set trigger buy make progress time take diamondback energy fang be many constructive chart pattern form oil explorer producer nasdaq hit new high diamondback energy stand strong earning record relative strength market pull back slightly make significant progress jan nasdaq celebrate new year start fantastic run first few week swingtrader add name aggressively early backdrop help boost confidence diamondback energy be already entry start year also book few quick profit stock weight watcher wtw mastec mtz pullback start position strength have flexibility push little harder still employ profit take rule nail gain way reversal jan spark loss cut profit take jan round selling occur index seem extend swingtrader product have list past trade be immediately recognizable be string profit see intrusion loss periodically time market weakness keep list overwhelmingly green require more name favorable market quick action isn more detail past trade be accessible subscriber trialist swingtrader free trial be available related recent swing trading article stock note be available skecher illumina ringcentral diamondback energy stock market follow newton law swing trade swing trading strategy lessonssw trading webinar
82,ILMN,investor prowl earning top rate growth stock have lot look forward come week alibaba baba facebook fb amazon com amzn apple aapl alphabet googl be set report record high major stock index actionable buy be get harder come many
83,ILMN,here weekly investing action plan need know investor come week tech sector heavyweight facebook fb apple aapl amazon amzn alphabet googl microsoft msft dominate come week earning news oil major exxon mobil xom chevron cvx also report
84,ILMN,biotech company celgene celg biogen biib gilead science gild put drug extensive trial gain fda approval turn clinical research firm pra health science prah pra health be lead contract research organization hold ranking medical research equipment service industry group ahead
85,ILMN,relative strength rs rating bio rad lab bio enter new percentile wednesday rise ibd proprietary rating track market leadership worst best score score show stock price movement trail week hold other stock database history show best perform stock tend have rs rating north begin biggest run see ibd help make more money stocksbio rad lab be try complete flat base entry see stock break volume least higher normal later stage pattern investor be aware involve more risk company see earning sale growth rise last quarter earning share increase revenue rise company hold rank peer medical research equipment service industry group pra health science prah illumina ilmn catalent ctlt be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
86,ILMN,biotech industry behemoth celgene celg gilead science gild struggle third quarter accord quarter report result left room smaller player neurocrine bioscience nbix exelixis exel juno therapeutic juno swipe headline crush street even large cap beat sale earning expectation
87,ILMN,earning have kick high gear more busy week loom result polaris industry pii be due tuesday open worth look call option trade technical health improve fundamental buy point stock have be trading tightly just
88,ILMN,important metric look stock be higher relative strength rating perkinelmer pki just hit mark jump wednesday unique rating measure technical performance used worst best score identify stock price action trail week match rest market decade market research reveal market biggest winner often have rs rating early stage move look winning stock try simple be still buy range climb entry cup handle proper buy range extend initial entry once stock hit benchmark best hold investing set buy opportunity perkinelmer see earning sale growth rise last quarter earning share increase revenue rise company earn rank peer medical research equipment service industry group pra health science prah quintile im illumina ilmn be top highly rate stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
89,ILMN,here investing action plan tuesday need know investor come day xan earning tsunami hit lead big name such mcdonald mcd general motor gm caterpillar cat unite technology utx lockheed martin lmt just begin here be other company report tuesday
90,ILMN,here weekly investing action plan need know investor come week upcoming week earning give investor much broader look corporate america economy stalwart tech industrial energy medical consumer sector weigh quarterly result such amazon com amzn alphabet ticker
91,ILMN,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
92,ILMN,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
93,ILMN,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
94,ILMN,pra health science prah see welcome improvement relative strength rs rating wednesday rise look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily track share price movement worst best score grade show stock price behavior trail week hold other stock database year market history reveal stock go make biggest gain often have higher rs rating launch biggest run see pra health science continue show renew price strength clear threshold look best stock buy watch start herepra health science be build consolidation buy point see break volume least higher normal note third stage base such pattern work do sometimes launch nice run re more likely fail earlier stage consolidation company bottom line growth decrease prior quarter revenue grow previous report pra health science hold rank peer medical research equipment service industry group illumina ilmn be rank stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
95,ILMN,welcome move perkinelmer pki see relative strength rating improve thursday look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily track price performance worst best score rating show stock price behavior last week hold other stock database decade market research reveal best perform stock often have better rs rating launch largest price move see perkinelmer continue show renew price strength hit benchmark see ibd help make more money be build consolidation entry see clear price heavy volume keep mind later stage consolidation be riskier earlier stage pattern company bottom line growth decline last quarter top line rise previous report perkinelmer earn rank peer medical research equipment service industry group medpace medp illumina ilmn icon iclr be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
96,ILMN,bio techne tech have relative strength rs rating upgrade tuesday try find best stock buy watch keep close eye relative price strength ibd proprietary rating measure price movement worst best score rating show stock price movement last week hold other stock database decade market research reveal best stock often have rs rating north begin biggest price move see ibd help make more money stocksbio techne be build flat base entry see stock clear price volume least average bio techne post ep growth latest quarterly report revenue increase bio techne hold rank peer medical research equipment service industry group medpace medp illumina ilmn pra health science prah be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
97,ILMN,orasure technology osur stock be set cup handle formation thursday unveil hepatitis contract foreign government likely add sale canaccord analyst mark massaro estimate late afternoon trading stock market today orasure stock rise defy day tech stock general share remain entry point be past month ibd company medical product industry group year fall thursday day most tech drug group fall massaro keep buy rating orasure stock boost price target follow company analyst day wednesday orasure didn identify foreign government say other government be expect order hep test kit up sale view model earning share ex item cent cent consensus analyst poll thomson reuter currently model cent ibd take biotech drug stock initially rise donald trump election help pull several related etfs etfs be often proxy broader market visit etf center best bet trump presidency basically raise revenue estimate be related announcement orasure officially complete large hcv hiv order large international government seek eradicate hepatitis country massaro write note contract be product testing treatment program eradicate hep country orasure provide oraquick hcv rapid antibody test oraquick rapid hiv antibody test outside hep hiv orasure announce personal genomic firm helix use saliva dna collection device orasure subsidiary genotek exclusive contract massaro classify helix decision major platform orasure helix be form illumina ilmn provide individual sequence affordable price backed warburg pincus kleiner perkin other next year massaro expect firm add thousand new customer perform more test orasure think helix become revenue year customer year write helix orasure announce be also work china face company include wuxinextcode wegene genesis healthcare orasure didn announce replacement abbvie abbv be withdraw hep co promotion agreement orasure end month duo agree end agreement july be originally slate run related amgen gilead eli lilly eat abbvie humira sale analyst
98,ILMN,gene sequencer illumina ilmn preannounce revenue miss close monday just do year share plunge hour trading trading have be halter short time company say expect revenue year earlier quarter illumina have guide sale analyst poll thomson reuter have expect shortfall quarterly revenue be drive larger anticipate year year decline high throughput sequence instrument company say press release result company expect fourth quarter revenue be flat slightly sequentially analyst have modeled rise revenue company be slate release full result close nov preannounce miss year send share fall next day regular trading session year then ceo jay flatley say statement demand sequence consumable hiseq family instrument remain strong quarter instrument sale desktop family underperform expectation illumina promote francis desouza ceo july flatley become executive chairman illumina stock have break cup base buy point last monday share have rise more july help report buyout offer thermo fisher ibd take illumina week almost surely prove be failure plenty breakout pan be stock breaking monday fact learn ibd marketsmith related analyst unconvinced thermo fisher look acquire illumina
99,ILMN,illumina ilmn stock crash tuesday company late monday again preannounce big revenue miss forecast weak revenue gene sequence giant have preannounce disappointing financial include year research note tuesday canaccord genuity analyst mark massaro say speak company be still search answer explain miss do know weakness be drive shortfall line follow fewer hiseq system deal likely china view hiseq genome sequence system cost million dollar weak outlook be related massaro write be trouble illumina be trading loftiest valuation peer space reset multiple be sensible say cut be price target illumina stock maintain hold rating illumina stock fall stock market today share earlier touch month low now fail oct ishare nasdaq biotechnology ibb etf include illumina major hold company isn biotech fall tuesday drag illumina ibb be flagship biotech etf late tuesday company say expect revenue year earlier quarter illumina have guide sale analyst poll thomson reuter have expect company say sale be flat slightly shortfall quarterly revenue be drive larger anticipate year year decline high throughput sequence instrument company say press release company have rely too much sale china evercore isi analyst ross muken say research note tuesday maintain hold rating price target illumina stock muken point have caution capital spending uncertainty say negative preannouncement not come major surprise stock be clearly hope be less challenge give recent run write ibd take illumina illustrate earning time be shaky time stock big miss beat send share fly plummet good idea get ahead expectation keep top ibd earning preview related biotech etfs swoon hurt again preannounce revenue shortfall
100,ILMN,stock be moderately lower early tuesday alcoa aa kick third quarter earning season earning miss apple aapl be beneficiary more bad news samsung nasdaq composite dow jone industrial average show loss volume be tracking lower nyse higher nasdaq vs same time monday medical research equipment steel oil stock lead downside stock market today solar telecom department store outperformed alcoa gap slump heavy trade fall back day move average near day line aluminum giant last quarterly report splitting publicly trade company next month report result miss view apple lead dow gap month high fast turnover track sixth straight session share be extend cup handle buy point samsung say temporarily halter sale production galaxy note smartphone report overheat battery imply more potential sale apple iphone illumina ilmn drop month low plunge day day line massive volume gene sequence gear maker late monday preannounce weak revenue due decline high volume sequence equipment related alcoa earning sale miss view ahead company split samsung halt note sale apple sell more iphone illumina again preannounce revenue shortfall share plunge
101,ILMN,thank gilead kite merger biotechs have big week ve also rally year longer haul top health sector etfs rank year date return aug be biotech focuse accord morningstar direct top performer spdr biotech xbi post gain well ahead advance etf featured monday etf leader column break past flat base entry thursday remain buy range share run june flat base start just clear pattern fund launch january have asset bear expense ratio come second be first trust nyse arca biotech fbt ytd gain etf be buy zone past flat base entry year old fund track nyse arca biotechnology index have attract asset carry expense ratio count top holding aug kite pharma kite juno therapeutic juno illumina ilmn kite gap soar aug gilead science gild announce buy kite xbi mentioned also get boost kite ishare medical device ihi take third place ytd return etf recently regain day move average line shape flat base potential buy point fund marked anniversary track dow jone select medical equipment index ibd take gilead science have be news lately due kite pharma acquisition do rank biotechs find now ibd stock checkup top holding aug include medtronic mdt abbott laboratory thermo fisher scientific tmo ihi expense ratio be ishare nasdaq biotechnology ibb round top ytd gain price action be similar other biotech etfs buy range follow thursday flat base buy point case be etf sport expense ratio ibb oldest biotechs year have amassed asset top holding aug be gilead biogen biib celgene celg kite account position portfolio fund have beaten past year return vs gain fund have outperformed past year related gilead science buy kite pharma sector boost stock breakout put apple amazon focusretail lead broad stock sell biotechs find support celgene flirt giant soon join
102,ILMN,stock extend loss tuesday afternoon heighten north korea related geopolitical tension xspdr dow jone industrial average dium powershare qqq trust qqq tumble spdr spy give stock market today emerge market lead downside ishare msci emerge market eem sank country etfs ishare msci south korea capped ewy gap fall japan hedge equity dxj post gap oil gold play rally west texas intermediate crude price surge nearly barrel unite state oil uso vaneck vector oil service oih gap leap nearly powersharesdb oil dbo add gold future rise ounce investor seek safe haven vaneck vector junior gold miner gdxj vaneck vector gold miner gdx rise respectively spdr gold share gld ishare gold trust iau powershare db gold dbo gain more apiece financial chip biotechs lead downside spdr regional banking kre spdr bank kbe lose nearly recent stock market pullback continue create new opportunity investor buy equity first trust equity opportunity fpx be featured aug etf column moved closer day move average line solid rebound support line have set chance buy fall day few time next week then not only make lose ground have come back score time high market have rebound shape right side flat base fpx clear friday slip entry tuesday market sell etf gain late april flat base start most recent pattern fund track ipox index be launch april ipox be market cap weight index largest most liquid initial public offering put weighting cap component stock be reconstitute quarterly basis biggest sector weighting aug be technology health care consumer cyclical financial service accord morningstar direct top holding include abbvie abbv kraft heinz khc paypal pypl fpx have outperformed broader market ytd gain aug vs return year performance also outpace benchmark index average annual etf bear expense ratio ishare russell midcap growth iwp climb past flat base buy point intraday friday close just entry fund be highlighted july etf column near flat base buy point clear entry next session turn south broader market late july year old fund have amassed technology account asset aug industrial consumer cyclical health care top holding drugmaker zoetis zts chipmaker analog device adi gene sequence system maker illumina ilmn iwp ytd year average annual return respectively be ahead period fund expense ratio be thursday pick vanguard growth vug ishare russell growth iwf manage slight gain ahead labor day holiday vug be cusp flat base buy point iwf be still buy range past flat base entry learn more invest check page related biotechs extend gain breakout put apple amazon focusthese sector lead upside market beater close buy pointgold rally stock fall be too late buy gold
103,ILMN,apple aapl spearhead gain big mega cap name help dow jone industrial average edge slightly higher afternoon trading wednesday however other index reflect heavy selling tech leader xapple gap improve growth quarterly revenue earning rise outlook current fiscal fourth quarter stock jump send new flat base entry component stock dow jone industrial average apple help blue chip index edge higher top last week rally nasdaq composite meanwhile erased earlier loss much be fractionally higher nasdaq reversed loss nearly rise also edge back black reverse early small loss dow utility average rise nearly volume be run sharply higher nasdaq tad lower nyse vs same time tuesday laser expert coherent cohr undercut day line macom technology solution mtsi member ibd semiconductor manufacturing group be small midcap techs fall hard weigh tech heavy nasdaq coherent post jump fiscal earning share jump revenue top line jump match rise second quarter end march however keep mind coherent have already make monster run clear first stage huge saucer handle way back late share have run more then give coherent sharp undercut week move average heavy turnover key sell signal expect stock possibly test institutional buy support day move average coherent make laser critical component semiconductor solar scientific market upside biotech genetic analysis play illumina ilmn member ibd medical research equipment service group soar more surpass new base buy point illumina report drop second quarter earning cent share smaller decline march end first quarter revenue jump wall street see company revenue accelerate growth illumina also get back earning growth track rise share accord thomson reuter consensus estimate return apple note prior stock market today column iphone ipad giant have already surpass several buy point earlier year apple clear cup handle entry jan run past follow buy point week tight pattern finally week apple reclaim day move average suffering fast sell june send share slide key medium term support line apple be buy again also watch see have strength hold bullish price gap have just form proper buy zone latest go latest flat base entry wednesday intraday low well prior session high thus produce gap price notice too daily ibd chart apple relative strength line paint blue be rocket higher move relative strength line new high ground indicate apple be continue outrun related do apple initially break late leader be selling hard today ibd latest entry point apple today gap
104,ILMN,apple aapl have price target raise wednesday armour uaa price target be lower pioneer natural resource pxd be downgrade illumina ilmn be upgrade announce earning tuesday xapple price target be raise piper jaffray maintain overweight rating stock outlook imply fear iphone launch delay limit availability device have be overblown analyst michael olson say recommend own apple due grow anticipation iphone favorable trajectory service revenue late tuesday iphone ipad maker announce result beat wall street estimate fiscal third quarter sale earning guide sale higher current quarter apple share climb stock market today clear flat base buy point apple end session lows hit record intraday illumina be upgrade equal weight underweight first analysis sec genetic testing tool company report earning revenue analyst expectation share jump top buy point armour price target be lower telsey advisory group tuesday armour report smaller expect second quarter loss growth beat analyst view lower guidance announce restructure plan new restructure program come nike nke announce june sell clothing shoe directly amazon amzn armour share climb crash tuesday year low nike fall still hold buy point retake tuesday pioneer be downgrade market perform well fargo analyst gordon douthat write be concern shale exploration production company drill delay lower production guidance late tuesday pioneer report earning revenue wall street view say cost permian well increase pioneer share tumble related american upgrade regeneron downgrade rockwell collin pt risk facebook overlooked american air be compelling
105,ILMN,strong earning apple aapl late tuesday have many think wednesday be go be strong day stock market didn quite turn way wasn exactly bad day stock market ibd have rough go well half name index more nasdaq composite rise early then turn lower then edge higher afternoon trading dow jone industrial average crossed level rise ease less volume nasdaq be tracking higher tuesday level nyse volume be pace be close tuesday level breadth be weak decliner outnumber advancer nasdaq just nyse decliner top advancer china base ibd name pressure include netease nte momo momo athm loss laser expert coherent cohr maker commercial laser system chipmaker macom technology solution mtsi be small midcap techs fall hard weigh tech heavy nasdaq stock market today apple garner most attention report strong earning sale late tuesday also offer sale guidance quell concern delay launch iphone share gap rise more just conventional flat base entry illumina ilmn also have good day soar more volume be run more time normal pace maker equipment genetic analysis report earning be still buy range buy point close watch earning report ansys anss bioverativ bivv stamp com stmp symantec symc tesla tsla related macom earning miss send fiber optic stock china worriesnew iphone fear overblown illumina upgrade stock break biotechs defy downtrend hit fresh high
106,ILMN,main index close narrowly mixed wednesday afternoon detail fed september meeting left few doubt rate increase be loom dow jone industrial average rise nasdaq dip volume be lower board suggest lack appetite institutional buyer minute fr fed meeting left more sign policymaker be incline raise interest rate year end fact rate hike last month be term close call participant judge economy strong enough make reasonable argument raise fed fund rate official voiced concern delay rate increase hurt fed credibility meanwhile federal open market committee see brexit risk recede labor market have improve appreciably past year be ingredient increase borrow cost mining retail build stock lead today trading health care sector continue show broad weakness manage care stock make cluster stock unusually heavy volume humana hum plunge heavy volume hmo have be form shallow base sell have soil pattern humana announce preliminary ep share view center medicare medicaid service say company share member star higher quality plan fall prior year drop threaten hurt bonuse humana earn aetna aet be fight antitrust issue acquire humana fall lowest level cigna ci be more star higher enrollment dive accord well fargo research note anthem antm be try merge cigna be nearly deal also face objection justice department other part medical sector illumina ilmn continue follow tuesday crash lower sale outlook wednesday share be related humana up earning guidance stock sink medicare star oil gas price ipo range jump early debut
107,ILMN,supernus pharmaceutical supn stock reversed early gain tuesday positive adhd drug trial news help send ibd company medical biom biotech industry group day move average early trading stock market today supernus stock rocket buy zone monday close gain be short live share fall much later tuesday finshed trading close tuesday supernus stock hit buy point flat base larger biotechs fall tuesday ionis pharmaceutical ion halozyme therapeutic halo bluebird bio blue be ishare nasdaq biotechnology ibb etf be tuesday afternoon hurt decline gene sequencer illumina ilmn company preannounce big revenue miss ibd take supernus rank ibd company medical biom biotech industry group composite rating meaning have perform top stock term key growth metric get top rate biotech stock stock checkup supernus stock topple defy positive news company phase trial spn stimulant drug treat attention deficit hyperactivity disorder milligram daily dose spn meet primary endpoint reduce symptom adhd child age company announce tuesday supernus drug also have positive result adult phase testing spn have mostly mild moderate side effect say experience severe side effect include easy tearfulness intermittent irritability decrease appetite result exhibit strong clinical efficacy profile effect size be typically not see stimulant dr stefan schwabe executive vice president chief medical officer supernus say statement patient complete trial choose enter open label phase show high level confidence spn dr schwabe say related epilepsy drug fuel huge growth supernus pipeline strong too
108,ILMN,load player portfolio be flush dairy meat product stock then tuesday action be likely mouthwater share defensive industry group rise stock virtually rest ibd industry group drop fast stock market encounter roughest session selling more month late afternoon rebound manage only
109,ILMN,stock etfs wilted open bell tuesday investor eye revenue miss alcoa aa release minute fed september meeting wednesday lower oil price spdr spy slide morning trade stock market today exchange trade fund serve proxy broad market have struggle climb back day move average more month day trend line serve gauge stock etf strength weakness shorter term early tuesday sector be lower biotech stock contribute decline health care sector financial sector also jab lower ahead key bank earning friday etfs offer pure play exposure bank eke gain ishare nasdaq biotechnology ibb slide more lower illumina ilmn biggest decliner portfolio maker gene sequence tool slash revenue guidance stock crater more ibb flagship biotech etf be mired highest level past year set december meanwhile alcoa slump third quarter earning meet expectation revenue miss view aluminum producer be widely see kick quarterly report season expert question be really lead indicator wider economy stock market be do ibd take gold rate sensitive equity sector come pressure last week investor mull next federal reserve rate hike move west texas intermediate wti slip modestly follow monday surge hold barrel early trading meanwhile spdr gold share gld edge lower bet federal reserve raise interest rate december continue increase etf track spot price gold now sit day line july high yellow metal decline push gold mining exchange trade fund much lower here major exchange trade fund major asset class be perform today ibd relative strength rating rs rating be measure stock price performance last month compare stock etfs scale best possible follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs related energy etf peg new high oil risesyour etf investing action plan week big week big banksgold lose luster dividend demand dry
110,ILMN,stock open loss tuesday dollar climb earning company news drive lion share early stock action dow industrial fall nasdaq fall stock market today face quiet day economic news third quarter earning season get weak start alcoa aa dive third quarter earning meet expectation revenue stop short analyst consensus view fastenal fast slip report weaker expect third quarter earning bank ozark ozrk jump more little rock ark base operation lender earning net interest margin easily top analyst consensus view stock have be gradual uptrend july work climb month consolidation apple aapl rise open advance nearly average volume monday stock appear be receive boost samsung decision halt sale production galaxy note smartphone due overheat battery apple share end monday extend just buy range buy point cup handle base illumina ilmn crash open maker gene sequence tool slash revenue guidance due fall sale high volume sequence equipment cummin cmi caterpillar cat crawl less goldman sachs upgrade stock buy caterpillar previously be rate neutral note raise stock price target cummin be also raise neutral rating price target raise st jude medical stj drop fall warning possible early depletion lithium battery used power implantable defibrillator st jude share have stage gradual tight recovery follow steep aug sell airline stock edge generally higher bernstein initiate coverage number stock group mixed rating southwest airline luv unite continental ual delta air dal rise more less oil slip half percent leave west texas intermediate just barrel europe brent crude benchmark hold gold ease fraction ounce dollar gain euro yen bond slip lower lift year treasury yield basis point overseas europe market slip mixed trade afternoon action lead benchmark china be mixed japan tokyo nikkei climb hong kong tokyo exchange reopen day weekend
111,ILMN,sell stock worsen tuesday afternoon major index be session lows higher volume signale higher normal profit take institutional crowd nasdaq composite continue pace downside fall nearly gut monday nearly rebound chip biotechs maker medical fiber optic equipment slide hard dow jone industrial be small cap sell even harder russell more pace biggest loss drubbing session small cap gauge pierce day move average quickly climb back key support level nasdaq composite be just point away challenge own day line test support day federal reserve official give hawkish comment interest rate sign continue pickup economy dairy meat product stock be small handful industry group day crude oil future fall more yield year treasury bond keep climb hit reach level not see june medical stock get hurt illumina ilmn cave nearly weak sale guidance late monday human dna genomic analysis firm have show clear sell signal early august stock follow nasty gap july last year fail hold week move average see weekly chart proceed sink week row medical software firm veeva system veev slump nearly fall further day line trigger signal holder take least profit telecom sector lumentum lite expert gear telecom network spinoff former stock market great jds uniphase drop more volume run more time average pace set be biggest point drop roar past buy point oddly shape cup base late july such negative action serve early sell signal dividend pay play be not do much better be actually buck market decline day rebound have take back only small fraction slide share have suffer hit peak july stock have appear frequently ibd income investor column dividend leader be also wrestling gain buy support day move average verizon vz fellow dividend leader due excellent history stable profit beating dividend yield be stock slide day line heavy trading oct have fail rebound share be now peak apple aapl hold much early gain rise wake rival samsung report decision halt production highly popular galaxy note large format smartphone note have be suffering battery related problem have cause number phone explode catch fire apple maker hugely popular iphone break bottom style cup handle be now extend past proper pivot point chase zone extend related be bottom base chart pattern samsung loss appear be apple gainwhen do apple initially break year
112,ILMN,stock open higher wednesday apple aapl haul dow past nasdaq jump new high dow jone industrial average marched ahead open new high more half dow stock trade lower open manage less gain pioneer natural resource pxd autonation drag bottom list nasdaq composite stretched pull higher apple advance strong third quarter report also tech name include illumina ilmn broadcom avgo apple run report late tuesday fiscal third quarter sale earning soar past analyst target third straight quarter accelerate gain move left share buy range flat base buy point apple slimb fang stock open lower netflix nflx lead early decline start trade illumina scramble higher start bell report big second quarter earning beat late tuesday gain marked break leave share new high buy range buy point flat base fireeye feye shot second quarter earning slip less expect revenue growth hold steady stock be march low attempt begin recovery deep year decline lead stock take hard early hit macom technology solution mtsi collapse coherent cohr diving stock be ibd name report weaker forecast quarterly result macom second quarter coherent fiscal third quarter late tuesday shutterstock sstk swoon score broad miss second quarter result share have be struggle regain support week move average amc entertainment holding amc also topple trading company guide expectation second quarter revenue consensus view say anticipate turn profit loss quarter bottom pioneer natural resource drop second quarter earning revenue consensus estimate management trim full year production forecast well fargo downgrade stock market perform outperform wednesday morning autonation fall earning revenue miss target second quarter report share have be climb low attempt muster rebound deep year sell market have eye busy hour session set include report tesla tsla square sq metlife meet cirrus logic crus many other farm private sector employer add payroll position july accord adp national employment report be sharply june new hire consensus forecast new job gain energy information administration report weekly oil inventory estimate et europe market trade lower afternoon session ftse london frankfurt dax cac paris dip related big picture stop worry learn love dowdow jone industrial average dow stock news analysisretail commerce news stock watchye tesla stock be entry investing action plan
113,ILMN,grubhub grub be upgrade view take advantage size blackberry bbry start sell charter communication chtr price target hike speculation telecom merger morgan stanley upgrade food delivery service overweight increase price target morgan stanley say grubhub utilize revenue base scale faster improve ebitda cash flow share grubhub rise open bell stock market today grubhub be increase pressure restaurant delivery space most notably encroachment amazon com amzn field grubhub last week announce deal buy rival delivery service eat yelp yelp grubhub stock be nearly share shot past buy point friday yelp deal second quarter earning related grubhub deal yelp solve big problem bothgoldman sachs initiate coverage sell blackberry stock be early trading monday blackberry crash june former smartphone king report first quarter result miss revenue estimate beat bottom line blackberry provide software enterprise mobile device management operate system automotive other application related blackberry stock plunge software revenue fall shortrbc capital up price target cable tv firm believe charter thesis remain intact drive synergy capital return opportunity next few year say rbc capital report charter have state not interested merger sprint share charter be fraction early trade charter stock be related sprint ceo merger announcement be come futuremorgan stanley increase price target view qualcomm qcom have increase offer maker automotive other chip activist investor elliott management friday disclose stake nxp indicate be push higher price tag nxp pending sale qualcomm nxp semi share rise premarket activity share qualcomm legal battle apple aapl have be escalate advanced early trading related qualcomm stock fall disappointing earning outlookin other analyst move goldman sachs up price target deere rate conviction buy stifel upgrade kla tencor klac buy price target morgan stanley downgrade teva pharmaceutical teva underweight cannacord genuity upgrade illumina ilmn buy hold related tech giant buy point other diverge key levelsnvidium disney china stock lead monster week investing action planstock buy watch top ipos big small cap growth stock
114,ILMN,mixed finish wednesday marked be many way single handed victory apple aapl lug dow mark nasdaq composite end mostly unchanged iphone maker thunder ahead massive trade pare initial advance only slightly end session buy point flat base result left dow jone industrial average gain remain ever so slightly level seize new high water mark open trade more half dow stock trade lower day walt disney chalk index worst performance nearly deal minor setback house mouse effort scale right side month cup base ahead fiscal third quarter report schedule aug nasdaq composite surrender gain early session undertow tech name lead facebook fb microsoft msft netflix nflx outstripped gain apple illumina ilmn groupon grpn add less come pressure oil related name lead range resource rrc pioneer natural resource pxd newfield exploration nfx drug distribution giant cardinal health cah also have say drop top fiscal fourth quarter expectation guide earning expectation aside apple day big earning winner be illumina spirit aerosystem spr boot barn holding boot illumina soar report late tuesday second quarter earning slip much less expect revenue growth ratchete share take buy point flat base end top buy range boot barn kick gain report late tuesday fiscal first quarter ep soar second quarter acceleration less stock be now july low scramble right side steep month correction spirit report early wednesday second quarter earning jump first gain quarters top analyst view gain launch share past buy point month cup handle base truck maker oshkosh osk pare initial surge gain enough hold just buy point cup handle base report fiscal third quarter earning far analyst target company best outing year session also see winning run break several lead stock most notably macom technology solution mtsi coherent cohr chipmaker macom slice loss compound weak fiscal report target guidance coherent collapse gain earning revenue advance miss expectation stock suffer significant chart damage related nasdaq turn positive early reversal china name strugglemacom earning miss send fiber optic stock china worriesnew iphone fear overblown illumina upgrade stock break biotechs defy downtrend hit fresh high
115,ILMN,emerge market technology be top perform etfs past month stock market re-cover record high nasdaq composite rise time high dow jone industrial average manage new close high diversify stock fund ishare edge msci usa momentum factor mtum also close best level ever wednesday fund gain month july bring year date return accord morningstar inc click here see list best perform etfs technology account biggest sector weighting nearly asset july be follow financial service industrial health care top holding include microsoft msft jpmorgan chase jpm apple aapl mtum aim provide exposure domestic mid large cap stock exhibit relatively higher price momentum fund launch april have outpaced year past year expense ratio be move sector fund ark innovation arkk top list ytd return gain past month share have find support week move average solid bounce line be potential buy opportunity etfs fund invest company stand gain innovation health care information technology robotic alternative energy other sector top holding july include bitcoin investment trust gbtc tesla tsla amazon com amzn illumina ilmn technology make nearly half portfolio health care be distant second consumer cyclical weigh financial service less arkk mark year anniversary october carry expense ratio momentum technology be area currently favore blackrock expect earning momentum remain strong year fading prospect tax reform have be largely discount leave room positive surprise richard turnill blackrock global chief investment strategist note july report value momentum financial technology dividend grower etct emerge market internet ecommerce emqq top foreign stock group ytd return july trouncing gain msci acwi ex acwx emqq month return same date be fund launch november have attract greater asia account etf asset greater europe americas accord morningstar drill further emerge asia make greater asia portion fund top holding hailed china include alibaba group baba tencent holding tcehy baidu bidu jd com jd nearly asset be invest top emqq have expense ratio china be also strongly represent ishare asia aia ishare msci country asia ex japan aaxj respective ytd month return middle kingdom top expectation july year year gross domestic product growth pundit remain bullish china now central bank have take step slow speculation housing market primary source economic strength prompt expectation decelerate growth quarters ahead ameriprise chief market strategist david joy write july report now chinese economy remain robust lend layer support global market particularly develop world other foreign etfs brazil fund make strong show vaneck vector brazil small cap brf ishare msci brazil small cap ewzs gain nearly past month lift brf ytd gain ewzs economic reform improve corporate fundamental reasonable valuation support stock blackrock turnill say reflation growth develop world be other positive risk include sharp change currency trade other policy related be vanguard take global growth active passive debate strategist offer best creative cautious investment ideasbig cap robotic outperform outlook china
116,ILMN,equity etfs be essentially basket stock tend trade individual stock be less volatile be many other holding today pick be top respective flat basis prefer buy etf bounce day move average fund be also striking distance recent rebound xvanguard growth vug close monday just shy flat base buy point find support day line last week be support line share advanced nearly prior touch day line june intraday high fund track crsp large cap growth index have attract north asset technology be biggest chunk asset almost june follow consumer cyclical health care accord morningstar inc consumer defensive industrial make tech heavy stance be evident top holding apple aapl amazon com amzn facebook fb alphabet class googl class goog share name account nearly fifth total asset stock have rally more year vug have outperformed year date july slightly outpaced benchmark index base year average annual return year period etf return average annual vs vug carry expense ratio also close flat base entry recent bounce day line be ishare russell mid cap growth iwp fund advanced nearly late april flat base start current pattern fund celebrate anniversary monday provide exposure domestic midsize company be expect grow earning average pace vs market top holding july include drugmaker zoetis zts chipmaker analog device adi illumina ilmn maker gene sequence system technology be also biggest sector weighting fund asset iwp year average annual return be ahead gain have expense ratio monday emerge market pick be little change ishare emerge market dividend dvye remain just flat base buy point spdr emerge market dividend ediv be still buy range flat base entry related outsize dividend check hot emerge market playslook outside top dividend fund so far yearcan bull keep run second half expert weigh
117,ILMN,hum mainstay large cap growth fund mlaax be have fund setback last year badly lag gain trail large cap growth peer track morningstar inc gain year go thursday more double big cap bogey return trump direct rival fund rally reflect market shift away defensive low growth staple provider higher dividend stock dominate much last year sort higher growth stock fund favor fund co manager patrick burton job early say lead technology stock particular have be buoy market share gain strong earning burton lead manager justin kelly be subadvisor capital reflect market tilt fund have be boost year such holding alibaba group baba be fund also hold graphic chipmaker nvidia nvda be year digital medium marketing software firm adobe system adbe be biom celgene celg be be fast grower health care alibaba be player commerce china burton say be benefit shift mobile device gross sale be still grow rapidly size alibaba cloud amazon web service be grow very fast say nvidia be benefit shift use graphic process unit gpu away regular cpu computer chip faster process speed application such artificial intelligence self drive car burton say adobe be shift selling software license annual subscription customer churn less buy more model burton say celgene stock be due combination decent earning attractive valuation biotech have be pressure couple year burton say past year fund average annual gain top rival kelly have be helm late fund aim navigate various market phase adjust allocation type growth stock bucket hold stock manager see long term sustainable earning grower second bucket hold quality cyclical grower be more volatile third hold stock newer industry rapid growth visa be sustainable grower takeover visa europe boost economy scale lead better coordination global marketing campaign burton say add really steady eddie consistent grower skywork solution swks be fund cyclical supply radio frequency filter apple aapl samsung chinese cellphone change be be move other product need wireless application tesla tsla car burton say be push get involved internet thing servicenow now be new industry stock be expand management client new area cybersecurity human resource celgene cancer drug revlimid be flagship be rank ibd medical biom biotech industry group group be rank wall street expect earning share climb year pretax margin last year be highest least year ibd take check more celgene fundamental technical strength ibd easy use stock checkup tool illumina ilmn netflix nflx be new addition fund portfolio second quarter illumina be leader low cost gene sequence equipment burton say believe illumina demonstrate accelerate growth profile course year next drive launch new gene sequence instrument novaseq believe acceleration drive upside analyst consensus earning estimate netflix return portfolio be sell ep rise past quarters netflix be face increase competition hulu stock amazon com amzn youtube owner google googl also own mainstay large cap growth netflix driver be original programming global expansion burton say related mainstay large cap growth see market tilt favorite type growth stock
118,ILMN,xchipotle grill cmg stryker syk wynn resort wynn arconic arnc top analyst estimate late tuesday illumina ilmn meet profit view give weak earning guidance estimate share earning swing year share loss cent revenue fast casual burrito chain emerge aftermath several food bear illness outbreak result ep revenue same store sale jump management say chipotle first dessert be test later month also reveal datum breach outlook full year comp sale gain high single digit stock chipotle rally late significantly pare earlier hour gain share close stock market today close monday stock remain extend buy range clear entry point late last month chipotle isn only restaurant stock back investor menu mcdonald mcd shot tuesday morning now extend past buy point strong earning push burger king parent restaurant brand qsr past own buy point intraday estimate profit fall cent share sale gain result ep cent revenue outlook ep cent wall street view cent revenue growth roughly line consensus growth full year ep line consensus view revenue growth analyst view gain stock illumina fall late share maker gene sequence equipment advanced finished climb monday gapping buy range stock break cup handle base late march initially struggle clear buy point estimate earning rise sale climb result ep revenue outlook ep midpoint consensus stock stryker dip late share medical device maker climb rise monday extend buy territory stryker have break flat base entry late february estimate ep dip cent revenue soar result ep cent revenue billionstock wynn rise late share macau la vegas casino giant advanced extend range breaking consolidation buy point estimate earning climb cent post breakup arconic revenue tumble result ep cent revenue stock arconic gap late share performance metal maker spun alcoa aa late last year rally remain day move average share have pop april ceo klaus kleinfeld abruptly resign public scuffle elliott management lead arconic board seek resignation related arconic jump ceo kleinfeld exit proxy fighttop stock buy zone ahead result investing action plantech industrial giant report euro rally investing action plan
119,ILMN,xstock thunder second day strong gain tuesday big name earning report power weighty move market dow jone industrial average bring home gain gain breathe room day move average close march peak nasdaq clear level rise fresh high climb end just march high alcoa aa surge miner freeport mcmoran fcx rattle gain whirlpool whr biogen biib jetblue airway jblu rise apiece caterpillar cat be prime mover power easily lead dow industrial push stock day gain mark best week nov presidential election heavy equipment maker report gain earning rise revenue first revenue advance quarters stock move clear buy point traditional flat base entry more aggressive entry leave share highest level november netflix nflx stream higher top nasdaq news company land agreement iqiyi own internet search giant baidu bidu begin offer content china chinese regulator have bar netflix offer content directly consumer country netflix also announce monday issue bond offer investor outside fund new content strategic acquisition gain send netflix share past buy point week tight pattern baidu share rise tuesday just cup base buy point earning baidu be due thursday close steel alloy specialist allegheny technology atus forge gain report earning growth accelerate revenue pop first quarter share end session so far week begin right side month consolidation downside weak quarterly result send ryder system expressscript esrx loss verizon vz marked dow worst loss news report say verizon offer straight path communication strp outsize earlier offer straight path bolt higher ease earning report schedule close include exxon mobil xom illumina ilmn cree cree macon technology solution mtsi many other related caterpillar break steamroll earning enter china new buy zone
120,ILMN,xhere investing action plan tuesday need know investor come day perhaps busiest week earning get underway stock dow jone industrial average component mcdonald mcd alphabet googl lockheed martin lmt be flash buy signal result come meanwhile strong quarterly number dow stock caterpillar ticker
121,ILMN,growth stock provide rich seam gain domestic stock etfs past month share tech leader facebook fb adobe adbe apple aapl rekindle noticeably lag postelection rally investor exchange trade fund be perhaps exuberant mood stock market volatility hit lowest level year venerable dow jone industrial average crossed psychologically key mark matthew bartolini david mazza state street global advisor ssga write recent note risk mood seem prevail etf investor current equity bull market be less trading day away eighth birthday add however be yellow flag valuation be elevated earning growth be positive not overwhelming so say bartolini mazza confound exuberance be fact bond market volatility remain decidedly elevated nearly higher prior election equity volatility have fall spdr spy climb month end feb padding gain year date international stock etfs do even better past month vanguard ftse emerge market vwo advanced ishare msci eafe efa investing foreign develop market add equity etfs list notch just net inflow january third month row nov election investor pour more equity etfs accord ssga fix income etfs see net inflow last month follow record fresh asset gather bartolini mazza suggest truly exuberant etf investor consider allocate etfs be tracking sector benefit president trump policy such real asset oil gas producer regional bank other etf investor want position downside risk stock market consider investing gold add click here list best perform etfs be year best perform etfs key asset class screen trading volume first trust nasdaq equal weight qqew give stock underlie tech focuse nonfinancial index equal share asset equal weighting method give large cap growth etf significant midcap stake holding include railroad giant csx csx electric car maker tesla tsla biotech firm illumina ilmn stock have sizzle so far qqew be year feb back gain past month have expense ratio market cap weight version index track powershare qqq qqq be year date vaneck vector junior gold miner gdxj bet asset class be badly beaten first half decade have burnish allure invest global gold silver mining firm include iamgold img alamos gold agi pronounce tilt small midcap firm gdxj have vault so far past month extend superb rally last year charge investor asset expense fee ishare msci brazil small cap ewzs also track basket commodity tie stock be rebound nicely tumble first half decade portfolio hold stock heavy slant consumer sector biggest hold be bradespar hold company mining utility firm stock have vault so far ewzs be year date follow jump past month rally etf charge expense related large cap growth etfs be lead way
122,ILMN,stock open lower tuesday federal open market committee prepared launch day policy meeting investor look apple aapl quarterly report close dow jone industrial average fall nasdaq be nasdaq open tuesday so far january have gain past month be ahead third straight monthly advance dow increase be also third straight rise small cap skip party russell first monthly slip october big name be map follow earning report aetna aet climb abc punch dhr climb exxon mobil xom fall oil giant report sharp drop fourth quarter earning vs expectation revenue growth stop just short analyst projection exxon share have decline straight week mastercard slip credit payment processor earning top expectation revenue growth stop short analyst view mastercard share fall buy point month flat base harley davidson hog drop report fourth quarter earning rise less revenue fall more estimate analyst stock have be struggle hold day move average armour ua crater open fourth quarter revenue earning miss target management provide full year revenue guidance expectation company chief financial officer announce resign personal reason ibd stock advanced energy industry aeis climb semiconductor equipment maker report late monday board fourth quarter beat raise first quarter earning revenue guidance analyst view stock be extend clear week tight entry december close addition apple xerox xrx illumina ilmn electronic art ea aflac afl be company schedule report gold gain oil price reversed higher dollar ease bond flattened labor department employment cost index rise fourth quarter tick third quarter increase economist consensus have project gain come standard poor corelogic case shiller housing price index november follow kingsbury international january chicago purchasing manager index conference board january consumer confidence number be expect et federal open market committee wrap meeting policy announcement wednesday afternoon et overseas europe market be positive afternoon trade earning report rolled london ftse easily lead major benchmark gain frankfurt dax add cac paris show gain japan tokyo nikkei drop second straight decline market hong kong shanghai remain close china lunar new year spring festival holiday related apple exxon ea earning fed investing action plan
123,ILMN,stock reversed higher soft start monday continue march higher federal reserve gov lael brainard say central bank be hurry raise rate further reduce odd policy move next week meeting apple aapl wal mart wmt be top gainer dow nasdaq winner include netease nte illumina ilmn tesla motor tsla pierce day move average friday nasdaq composite jump back line rise dow jone industrial average climb small cap lag russell volume nyse nasdaq be tracking slightly lower friday level case tighten policy preemptively be less compelling brainard say monday brainard be see policy dove so hawkish hint have spur bigger bet september rate hike stock sell friday boston fed president eric rosengren recently policy dove argue favor tighten sooner rather later germany dax give london ftse paris cac lose last week european central bank president mario draghi left interest rate unchanged say policymaker do not discuss extend current bond buy program march health care name include biotechs outperformed financial lag re-cover well session lows amgen amgn show good action reverse day move average share rise stock market today opentext otex soar news buy dell emc enterprise content division move come opentext plunge day move average friday heavy volume earlier month dell complete merger emc new company be now call dell technology dvmt ibd take opentext industry group database software have be top performer past month see other leader group be ibd stock checkup name ibd rise more netease picked meanwhile straight decline ibd name inphi iphi enjoy nice bounce day move average rise so do lgi home lgih rise other ibd name show support action day line include monolithic power system mpwr nvidia nvda elsewhere leaderboard name line ln re-cover friday sell rise just conventional ipo base buy point new york mercantile exchange wti crude oil future october delivery add barrel year treasury yield be mostly unchanged related oil reverse higher even opec now see cartel output
124,ILMN,gene sequence giant illumina ilmn touch month high intraday thursday report receive buyout offer rival thermo fisher scientific tmo wall street be skeptical street insider cite unnamed source say thermo fisher have make stock offer illumina worth be current market cap cowen analyst doug schenkel say be close probability be actually true premium be too low appeal illumina argue too expensive thermo fisher require thermo fisher issue share assume thermo fisher share continue not be pressured spite report schenkel write research note assumption render deal dilutive thermo fisher ep basis illumina stock open slightly higher then jump news break mid morning share hit month high market close be thermo fisher stock dip ibd take illumina be once top rate stock have fall hard time investor see sell signal be able get time keep money explain last fall investor corner well fargo analyst tim evan be also dubious think deal encounter significant regulatory hurdle give illumina hold monopoly high throughput sequence thermo fisher scientific be only current competitor material scale desktop sequence evan write note add overlap business lead revenue dys synergy suggest have cut back overlapping product
125,ILMN,illumina ilmn rise much highest level january report thermo fisher scientific tmo make offer maker gene sequence equipment stock offer doesn include cash component streetinsider com report cite unnamed person knowledge matter san diego base illumina rise et waltham mass base thermo fisher fall less illumina reject acquisition attempt roche hold rhhby include value illumina annual revenue have more double reach representative illumina thermo fisher couldn be reach comment
126,ILMN,gene sequence giant illumina ilmn be slide stock market tuesday morgan stanley downgrade base negative trend key market analyst steve beuchaw cut rating underweight lower price target illumina stock also lower valuation cancer franchise cite reimbursement pressure medicare medicaid well rise immunotherapy cancer don require genetic testing beuchaw also describe trend academic research channel outsource genome sequence centralize lab reduce need locally install machine add however wasn negative call entire genomic space remain positive share gainer emerge category genomic notably natera ntra nanostring nstg market be earlier stage development write downgrade note qiagen qgen be emerge player sequence hardware expectation be likely too low genereader beuchaw add recovery genomic market seem be tie microarray be positive thermo fisher scientific tmo agilent illumina stock fall month low early trading stock market today close beuchaw positive remark rival be also sink qiagen stock fall natera lose thermo fisher retreat agilent fall nanostring rise
127,ILMN,nasdaq composite picked left monday new high help strength select china base growth name nasdaq rise nearly set intraday record close tuesday be virtually flat dow jone industrial edge lower nearly small cap outperformed russell volume nyse be tracking higher monday level nasdaq volume be slightly lower dow component apple aapl add minimally month gain rise numerous publish report say company be work augment reality ar glass german firm carl zeiss apple be still buy range cup handle buy point be low volume so far jd com jd be top gainer nasdaq rise jpmorgan upgrade chinese internet retailer overweight neutral raise price target jd com be consolidation buy point netease nte meanwhile add work late stage consolidation be still quite way potential entry ibd airline group be day top gainer allegiant travel algt bounce week move average rise alaska air alk be also get support week line share gain elsewhere dow component goldman sachs gs hold well downgrade citi sell base valuation goldman pare loss just trio financial company report earning friday include jpmorgan jpm bank america bac well fargo wfc stock market today share chipotle cmg jump company fourth quarter outlook wasn great investor seem focus instead rise december same store sale medical sector nuvasive nuva break base active trading share be still buy range cup handle buy point late monday company preannounce preliminary full year result leaderboard name healthequity hqy extend gain monday strong move share vault still buy range flat base entry buy zone go ibd take healthequity be second rank stock financial service specialty industry group base composite rating see stock get top bill ibd stock checkup illumina ilmn soar company forecast strong sale also announce new gene sequence product share be recover deep correction related southwest raise unit revenue guidance join delta air linestrump bump small business optimism soar year high
128,ILMN,tuesday marked shiny rally small cap equity big megacap firm sit back seat meanwhile money continue flow certain tech commodity sector market largest tech firm trading market apple aapl show decent not outstanding action follow monday base base pattern other company show more oomph company market cap just shy switzerland estimate nominal gdp edge fourth day row past new entry point volume fall monday turnover edge day average share waste small intraday gain roughly end practically flat tuesday dow jone industrial sank nearly russell thrust ahead finished almost session high nasdaq composite find happy ground middle rise nearly reflect dominance bunch stock market cap range nasdaq trail nasdaq composite rise just volume fall nasdaq rise nyse vs monday level thus hand rare stall day bout heavy institutional selling however tuesday volume nyse be likely average read more major index action today big picture column return individual equity incyte incy beam new plan big pharma business partner merck mrk advance clinical trial new cancer treatment rise nearly get extend further entry note ibd stock market today coverage monday incyte huge gap day mean investor real conviction small molecule development expert have buy monday open price have be chase zone precise buy point illumina ilmn rise nearly heaviest volume month be poise develop bottom base pattern san diego base maker human genome analysis system former big winner april summer peak grow revenue top line increase decelerate street also see full year earning flatten then pick share illumina sport solid ep rating now accord ibd stock checkup however profit be expect fall cent share most likely depress ep rating illumina rs rating be typical stock bottom basis chinese web company flourished lead big gain alibaba baba netease nte large cap play have rise back key day move average key step complete new basis watch alibaba closely commerce titan have unveil interesting new plan link small business china gigantic still grow middle consumer class alibaba have also now joined leaderboard new name watch baidu bidu search engine china jump nearly be base return apple iphone juggernaut be still buy range rise past cup handle buy point chase zone extend note stock market today column apple rally nearly clear cup handle cup be part long deep bottom base pattern apple still lie time peak latest weekly cup show week heavy volume vs week average volume however week see minimal decline thus bespeak strong institutional support accumulation distribution rating track ibd stock checkup improve rs rating also point net accumulation fund apple rs line continue drift mildly higher signify still outperform now metal firm advanced sharply read more leader today industry theme column related be bottom base pattern help trader make moneythe bottom base pattern part ii apple form savvy investor learn gerald loeb author wall street market today do small molecule expert have potential be next amgen
129,ILMN,stock be narrowly mixed tuesday morning biotech medical sector drive heaviest early action dow industrial edge roughly lower minute session be virtually unchanged nasdaq composite sketch fractional gain small cap russell rise nasdaq have be take new high shedding distribution day power day rally recent weakness small cap mixed performance breakout leader cue investor remain alert change market direction illumina ilmn power more gene sequence tool pioneer announce late monday release high volume low cost novaseq gene screening technology also partnership bio rad bio single cell isolation coding technology bio rad share be flat erase earlier gain illumina share have be decline july bio rad have gain clear cup handle base buy point august stock deep long term decline valeant pharmaceutical vrx enteromedic etrm post powerful early move valeant sail higher company say sell cerave acnefree ambi skin care brand france oreal lrlcy valeant say use proceed deal expect close pay debt oreal share be unchanged implant device maker enteromedic vault much continue recent run gain follow news new institutes have begin implant weight loss device vbloc reversed trade outside med territory chipmaker qorvo qrvo rise fractionally stock be sixth week possible base barracuda network cuda thrash gain reach high start davidson upgrade datum network security expert neutral underperform share end monday possible buy point month base natural gas pipeline operator william wmb drop tulsa okla company launch follow offer million share common stock price discount monday close price stock have be attempt gain altitude flat base buy point mid november nfib small business optimism index soar most hit highest level end december labor department job opening labor turnover survey rolled et opening hold steady wholesale inventory climb commerce department report be november west texas intermediate fall barrel fall nearly monday natural gas rise slightly gold dip fraction ounce copper gain dollar drift lower year yield be little change market asia post mixed session tuesday trade european market be narrowly positive head afternoon session related visa mastercard buy range investing action plantrump bump small business optimism soar year highstock market today medical play show leadership breakout
130,ILMN,stock index post moderate gain midday tuesday nasdaq gun sixth consecutive day nasdaq pop dow jone industrial average add respectively small cap have lag major index past session thrust higher volume stock market today be run higher nyse lower nasdaq nasdaq have not have day yet blue chip dow american express axp be leader american express have be bob week tight entry mediocre volume tuesday stock punch higher volume average american express have bullish volume ratio best possible ibd accumulation distribution rating figure point institutional support american express be fifth biggest hold warren buffett berkshire hathaway brka portfolio other payment processor also be do well tuesday mastercard rise quiet volume stock be work flat base financial dfs advanced volume average be extend november visa shift sideway slow turnover stock be work flat base ibd take earning preview stock be expect post higher growth quarter ibd collection top stock fundamental technical winner lead loser ratio health saving account provider healthequity hqy be leader surge heavy volume biotech stock illumina ilmn jump huge volume company announce new human genome sequence treatment day winner nasdaq show variety apparel retailer urban outfitter urbn rise china base internet content provider baidu bidu advanced yahoo yhoo add work flat base robotic surgery equipment maker intuitive surgical isrg pop ibd industry group metal ore steel airline be day leader laggard group such soap food show sizable loss related price target raise facebook alphabetis build stock get ready break small business optimism soar year high
131,ILMN,stock index moved record territory friday afternoon nasdaq head fourth day outperformance vs nasdaq pop time high dow jone industrial average add come point small cap russell edge higher volume stock market today be run lower major exchange former ibd leader show strength priceline group pcln be track gain fourth straight day stock be complete eighth week flat base potential buy point be early entry come priceline earning growth have fade glory year annual growth range earning growth ease street expect full year then year priceline margin show slippage margin tax be best least quarters illumina ilmn also former leader gap heavy volume gene sequence big cap be still day move average line ibd industry group rank bank super regional rise group svb financial sivb notch best gain subdue volume blue chip be mostly dow component apple aapl mcdonald mcd intel intc be trading handle trigger buy point break heavy volume related disney turn tide gopro mcdonald build earning season action plan
132,ILMN,stock open lower tuesday feel drag company news oil price market europe nasdaq open lower dow industrial lose stock gain session last week give market nice bump momentum head third quarter stock market today be take breather goldman sachs gs exxon mobil xom jpmorgan chase jpm open lower goldman sachs jpmorgan other big bank trade generally lower bank america bac citigroup nearly oil energy issue baker hughe bhi fall tesla motor tsla slip open maker battery power luxury vehicle say monday miss second quarter model model production target share have be consolidate april end friday battle hold support converge week move average illumina ilmn drag lower morgan stanley downgrade maker genetic screening system underweight equal weight chipmaker skywork solution swks shed report pacific crest trim rating number apple aapl supplier cite weaker expect ramp iphone sale oil price drop west texas intermediate slump barrel gold climb almost breaking ounce bond climb cut year treasury yield basis point dollar backed vs yen be flat euro britain pound slip lower vs dollar bank england lower capital requirement bank free additional credit market china end mixed tuesday start week strong gain monday japan tokyo nikkei ease end session rally europe london ftse trade claw way narrow gain benchmark index france germany fall nearly apiece index lose ground monday commerce department factory order report be due et researcher markit release jpmorgan global service purchasing manager index new york federal reserve bank president william dudley join roundtable discussion binghamton
133,ILMN,stock market wake wrong side bed tuesday brexit fear be back focus jpmorgan chase jpm goldman sachs gs american express axp lag dow jone industrial average fall netease nte be handful gainer nasdaq nasdaq give hurt downgrade apple chip supplier lose dow fall russell small cap index drop european stock index face selling pressure german dax paris cac apiece afternoon trading london ftse buck trend rise bank england ease special capital requirement bank pound fall sharply fresh year low vs dollar year treasury yield fall additional basis point near time low meanwhile benchmark west texas intermediate crude oil august delivery dump barrel dow walt disney ease shrug news disney pixar film find dory lead weekend box office third straight weekend stock market today tesla tsla drop more tesla announce sunday deliver car second quarter forecast soar friday takeover rumor harley davidson hog give back downside recent leaderboard short idea illumina ilmn shed morgan stanley downgrade share underweight equal weight lower price target upcoming economic datum include june job report friday meanwhile minute june federal reserve meeting be release wednesday et
134,ILMN,lead genetic analysis company illumina ilmn myriad genetic mygn suffer wall street wednesday temporarily case former issue disappointing guidance late tuesday illumina have already prepared investor pain last month pre announce sale cut revenue guidance cite weakness lower end system europe tuesday bottom line disappoint well drop year earlier quarter cent be cent shy analyst consensus also guide revenue consensus whack cent full year ep guidance now illumina management say conference call analyst demand be still strong have good order backlog operational issue have be plague financial number order fail translate revenue due deferral be problem european operation illumina say address grail project announce january aim create blood test cancer also turn be more dilutive earning expect several analyst cut price target stock acknowledge myriad issue illumina management recite be valid understandable history teach fast turnaround be rare case growth company be normally accompany new product launch major new application evercore isi analyst ross muken write research note cut price target maintain hold rating leerink analyst dan leonard expressed similar concern market perform rating illumina stock reflect view company need meaningfully exceed revenue expectation stock work don see driver type revenue beat write leerink dan leonard cut target keep market perform rating second half forecast assume meaningful acceleration full year guide have less visibility acceleration be fund do illumina stock find ibd stock checkup mizuho analyst eric criscuolo cut price target maintain hold rating canaccord genuity analyst mark massaro cut target downgrading stock hold february concern stock remain premium valuation slow top line accelerate rate spend sustain growth massaro write research note illumina stock drop early trading stock market today midday trading be fraction myriad genetic meanwhile beat estimate most recent quarter guidance cause consternation myriad fiscal earning rise year earlier quarter cent share beating consensus cent revenue climb almost analyst estimate myriad revenue guidance current quarter miss wall street expectation slight increase year number ep guidance cent be low side analyst cent average last year cent leerink leonard write beat be drive nonrecurring item time retrospective payment medicare prolaris large contract receive pharmaceutical clinical service business incremental revenue write note cut price target adjust ep beat consensuslike estimate mainly due lower tax rate same time leonard doubt sustainability price myriad test gene related cancer account business myriad stock take hit april news medicare administrative contractor responsible myriad invitae nvta cancer test have price hereditary breast cancer panel code less third myriad charge brca code myriad stock be more midday wednesday touch month low
135,ILMN,illumina ilmn plummet hour trading monday genomic giant announce weak preliminary revenue cut full year outlook illumina say sale quarter rise year earlier quarter less wall street expect accord thomson reuter end quarter string double digit growth share dive late trading close month high move day move average first time year preliminary result miss company expectation well accord ceo jay flatley first quarter result fall short expectation largely due lower expect sale hiseq instrument flatley say statement slow start anticipate americas asia pacific region meet expectation full year europe underperform result now project approximately revenue growth fiscal previously illumina have guide sale growth year flatley add company be reshuffle european operation try address shortfall statement didn provide specific illumina say report full result close be latest series disappointment illumina stock have fall quarterly report january last year fall again march company say flatley leave post july be succeed current president francis desouza stock have be recover then instrument softness be not complete surprise give sequence instrument growth have slow past quarters evercore isi analyst ross muken write email client be say magnitude revenue guidance change be point debate investor
136,ILMN,stock be lower tuesday volume picked trader fret disappointing factory datum china oil be fear china lead global slowdown china manufacturing datum april fall shy expectation nasdaq fall drop dow jone industrial average lose stock market today zillow be sharply hour report loss cent share analyst expect cent loss revenue come vs estimate stock come public august appear be build right side long deep base cvs cvs be moderately hour trading report adjust ep cent better consensus estimate illumina ilmn be hour miss estimate cent share report cent
137,ILMN,alphabet googl unit google confirm self drive car collaboration fiat chrysler automobile fcau late tuesday cbs cbs illumina ilmn paycom payc rubicon rubi report earning much speculation google fiat chrysler automobile have officially team autonomous drive technology google buy plug hybrid minivan fiat chrysler test self drive program fiat chrysler engineer work google engineer integrate self drive technology vehicle accord joint press release vehicle more double google current fleet self drive test vehicle company say report say collaboration be first step larger joint effort create autonomous car alphabet share edge late fiat chrysler climb tesla tsla have develop self drive feature electric car report wednesday dip close medium conglomerate say diluted earning share grow well ahead consensus cent revenue rise top expectation advertising revenue rise thank super bowl other nfl game be broadcast network share rally close regular trade profit tumble cent share revenue growth fall short analyst estimate ep cent revenue illumina have warn revenue mid april cite lower expect sale hiseq instrument year dna sequence tech developer see ep revenue growth vs view ep sale gain see cent share earning revenue well estimate cent share profit revenue share lose hour stock break support day line april cloud base employee management platform ep ex item pop cent share smash projection cent revenue climb beating estimate paycom expect revenue be range range analyst have modeled full year paycom earn composite rating surge extend trade close regular session rubicon project go public say gaap ep sky-rocket cent vs cent last year crush analyst expectation cent gaap revenue jump gaap revenue surge wall street have estimate revenue rubicon project see gaap revenue gaap revenue full year company expect gaap revenue gaap revenue analyst have project revenue cloud advertising software firm earn ibd composite rating share sank late
138,ILMN,load player view stock market performance tuesday have depend industrial sector be more heavily weight portfolio have be play cash trash turnaround see commodity stock yes likely high fived trading buddy dog be heavy tech stock then maybe
139,ILMN,stock be mixed go noon hour tuesday nasdaq growth stock drag foot nasdaq fall dow jone industrial average be trading higher volume exchange be tracking higher same time monday gold miner energy company be best perform industry group gold be trading west texas intermediate future delivery rise barrel dollar fall euro british pound ibd stock be higher be lower best performer be new oriental education edu nearly tal education xrs be trading time high offer school tutor china new oriental post earning revenue well estimate jpmorgan maintain overweight rating tal raise price target lendingtree tree ibd name rise build right side long deep base time highflier illumina ilmn gap be trading lower monster volume surprised wall street close monday warning revenue miss estimate netflix nflx also gap be trading lower disappointing earning report
140,ILMN,stock market open moderately higher tuesday then turn mixed earning report drive dramatic early move dow jone industrial average picked nasdaq lose stock market today open dow high nasdaq bit more interim high marked july drama continue be small cap front russell break day move average monday first look line august economic news housing start slow less expect march drop annualize rate accord commerce department figure be upwardly revise pace february tally project economist housing permit gauge upcoming build activity ease rate expectation february activity be upgrade crude future bounce back nearly drop monday send west texas intermediate back barrel mark gold climb more ounce dollar be mixed bond ease add basis point year yield dow stock be flat higher exception ibm ibm veer nearly lower report better expect first quarter earning revenue less project analyst manage care insurer unitedhealth group unh pop higher lead index report strong earning revenue line expectation company also raise full year earning sale guidance genetic test equipment maker illumina ilmn collapse late monday san diego base company report weak preliminary revenue trim full year outlook late monday illumina be see third major failure week line september leaderboard currently hold health care name see be take free week trial netflix nflx crumble early trade stream video outfit report earning subscriber growth analyst forecast subscriber growth guidance disappoint investor stock have be tussle rise week move average end monday february low month consolidation motorcycle maker harley davidson hog reversed early gain nice sale earning bike shipment top quarter vs guidance international market be key driver stock have be stymy resistance week move average month kansa city southern ksu ground gain earning narrowly top revenue slightly undercut analyst consensus expectation share end monday buy range less buy point cup handle base ibd stock be flat higher new oriental education technology edu chalk advance china test preparation tutor chain report narrow fiscal earning beat revenue top expectation wide margin stock finished monday just new high buy point cup handle base
141,ILMN,stock push moderate gain monday small cap hold narrow edge nasdaq rise add just shy dow jone industrial average improve small cap pop just volume stock market today fall nyse edge nasdaq accord preliminary datum ibd industry group oil related group be top gainer day laggard include food medium diversify stock blue chip be mostly home depot hd clear buy point volume be average valid feature volume least average visa break home depot move lack volume ibd list comprise best stock term fundamental technical winner lead loser ratio biggest percentage gainer be universal display oled run almost volume average company design light emit diode screen flat panel consumer electronic segment hour trade illumina ilmn plunge company report quarterly revenue fall short wall street consensus estimate
142,ILMN,facebook fb test key level tuesday come stronger netflix nflx illumina ilmn crash support level weak figure ibm ibm get incomplete maxlinear mxl trigger sell rule well breaking support level trend reverse today facebook have be find support day move average april share finished just key level then stock have close support level tuesday facebook shake morning dip just day rally gain upside next key level be buy point facebook rise afternoon trading stock market today facebook release earning next week analyst expect ep gain third straight quarter accelerate growth netflix late monday report unexpected rise earning share subscriber growth also top expectation web stream giant expect net global customer growth just be weakest quarterly gain year also guide earning lower netflix stock dive tuesday crash day day move average fall swoop netflix retook day line just last week netflix rise wednesday afternoon still day line illumina late monday give preliminary revenue figure be well wall street estimate gene sequence tool giant see sale end quarter string double digit growth illumina stock crash tuesday back year lows netflix illumina tumble day day line stock monday top day first time year illumina rise wednesday afternoon ibm revenue earning do top wall street forecast late monday sale have fall straight quarters also ibm imply ep guidance appear be analyst estimate ibm stock fall tuesday undercut day line intraday close just area ibm easily retest day line come day day only slightly ibm rise intraday maxlinear chip design be used video stream stock clear entry point last month rise peak april share drift lower then tuesday stock dive trigger sell rule entry point breaking day move average wasn immediately clear maxlinear share fall wednesday maxlinear tighten fiscal revenue guidance raise gross margin target maxlinear jump early afternoon retake day line
143,ILMN,stock open lower wednesday index pare loss nasdaq dow jone industrial average be farm productivity decline first quarter vs fourth quarter accord preliminary estimate labor department consensus projection call decrease labor cost jump estimate rise trade deficit drop abruptly march commerce department say slim vs gap february analyst consensus have expect et researcher markit deliver service purchasing manger index april institute supply management offer manufacturing index commerce department report march factory order number weekly oil inventory report be due energy information administration priceline pcln crumble early headliner big day earning report travel site first quarter earning revenue beat consensus forecast second quarter earning guidance be weak time warner inc twx royal dutch shell rdsa anheuser busch bud be also motion quarterly report exchange ice climb atlanta base operator new york stock exchange announce have end discussion regard acquisition london stock exchange group share have be gradual uptrend announce interest lse march stock be attempt build right side consolidation have be stall resistance week move average genetic screening equipment maker illumina ilmn drop ahead bell report late tuesday revenue earning stop short analyst expectation management also trim second quarter earning revenue guidance consensus forecast ibd list medivation mdvn swung nearly news report late tuesday say pfizer pfe approach company regard possible acquisition deal medivation have decline takeover bid france sanofi sny last week paycom software payc pop premarket action developer human resource management software report board first quarter beat late tuesday stock have be race right side possible base end tuesday february low couple notable market change tuesday tough session nasdaq already day move average lose grip day line russell drop day line rise trade today critical test nasdaq be hold short term lows marked friday global market feel share selling pressure wednesday china yuan appear be key factor diving sharply person bank china loosen peg dollar hong kong hang seng index slip shanghai composite shed japan tokyo stock exchange remain close holiday benchmark index paris frankfurt trade bit less midday london ftse be euro yen ease tuesday high vs dollar gold slump less oil trade nearly take back piece tuesday loss
144,ILMN,netflix nflx share plunge late monday close regular session stream tv platform offer disappointing subscriber guidance netflix anticipate add subscriber international subscriber current quarter global gain follow net add company top earning estimate fall short revenue ep outlook fall short current forecast gene sequence giant illumina ilmn report preliminary revenue year well estimate lower expect sale model hiseq instrument line company announce full result ceo jay flatley say written statement illumina expect americas asia pacific sale meet expectation full year europe underperform result revenue growth year outlook growth earlier share plunge late close ibm ibm share fall close come ahead analyst estimate revenue share earning item monday result mark consecutive quarter revenue decline be smallest sale drop quarters rambus rmb license design memory application specific chip chipmaker say earning share fall penny cent beating estimate penny revenue edge fractionally lighter expect primarily due lower patent royalty revenue rambus slide hour trading close spirit airline save update margin guidance higher expect revenue decline average ticket spirit airline stock rise late trade close celanese ce chemical product maker say ep rise crush view sale fall bil vs view bil share rise late trade be highest celanese record high last july related ibm first quarter earning come ahead stock dife weak subscriber guidance
145,ILMN,stock future be early lows head tuesday open bell dow industrial nasdaq future trade fair market value
146,ILMN,stock market today feel early pressure overseas weak manufacturing datum left china market sharply divide place pressure global commodity price commodity turn weigh international stock action london base researcher markit report marginal deterioration china manufacturing sector april output remain same march new order stagnate export fall fifth straight month inflationary pressure higher input cost rise fastest pace january shanghai composite advanced hong kong hang seng index fall eurozone benchmark be nearly late morning trade london ftse be japan tokyo stock exchange be holiday thursday economic news fiat chrysler fcau report sale rise april jeep brand sale rise sale dodge truck other auto maker be expect report april sale session key earning report factor heavily premarket action cvs health cvs climb almost halliburton hal slip report first quarter result coty coty shed sprint muscle follow respectively fiscal fiscal result drug maker stake early lead premarket action pfizer pfe narrow early gain earning revenue easily top consensus expectation be pfizer second ep gain quarters management raise full year earning guidance forecast lift revenue guidance high end expectation company statement say late stage product pipeline be increasingly ready deliver next set prospective growth driver stock end monday buy point cup handle base mylan myl lead mixed first quarter report ibd stock premarket gain be volatile loss be bit more steady inc research incr drop almost downgrade robert baird pra health science prah also retreat announce share secondary offer monday close big foreign bank be take early hit ub ub drop report deutsche bank db royal bank scotland rb tank credit suisse cs slump oil price slip more west texas intermediate trading just barrel gold be almost half percent hover ounce company schedule report close be avis budget group car agrium agu illumina ilmn
147,ILMN,stock higher flat start wednesday enough lift nasdaq narrowly back day move average nasdaq rise add dow industrial tack gain stock market today volume be quiet nyse lower nasdaq relative action same time tuesday pfizer pfe run head dow more breaking takeover allergan agn nixing pfizer allergan inversion reportedly cost pfizer breakup fee avoid run afoul treasury department launch inversion regulation monday allergan stock also rise more uninverted drug medical play lead nasdaq celgene celg illmina ilmn vertex pharmaceutical vrtx jump more ibd stock acuity brand ayi padded early gain press higher big fiscal sale earning gain put share past cup handle buy point baker hughe bhi spiked halliburton hal pop justice department file antitrust lawsuit challenge plan acquisition baker hughe halliburton suit claim merger eliminate competition specific product service related oil gas field production
148,ILMN,facebook fb get higher price target tuesday netflix nflx see series negative analyst move follow weak forecast ebay ebay be downgrade needham raise price target facebook maintain buy rating stock last week facebook ceo mark zuckerberg unveil year plan social medium giant include way enhance connectivity power experience transaction artificial intelligence facebook share close stock market today netflix fall be hit numerous price target cut internet tv giant price target be lower topeka capital market pivotal research group mizuho late monday netflix beat first quarter earning subscriber growth estimate disappoint weak subscriber guidance current quarter expect add only subscriber international subscriber be smallest customer growth year ebay be downgrade underweight morgan stanley have price target stock share online marketplace fall biotech celgene celg have price target cut credit suisse rate stock outperform celgene stock price dip bank america downgrade illumina ilmn neutral cantor fitzgeraldd downgrade stock hold gene sequence giant announce weak preliminary revenue cut full year outlook late monday illumina sank tuesday alliance datum system ad price target be lower credit suisse maintain neutral rating stock share fall panera pnra be upgrade buy jeffery share fast casual restaurant chain rise image provide shutterstock
149,ILMN,stock turn mixed early tuesday oil halter early advance earning news trip key sell off march housing datum be mixed dow hold gain nasdaq reversed decline volume rise stock market today nyse higher nasdaq compare same time monday dow stock moved almost unanimously higher open earning report drive extreme unitedhealth group unh lead gain ibm ibm stake low end more other dow issue report goldman sachs gs slip revenue miss johnson johnson jnj add narrow earning beat higher guidance oil energy crowd upside chicago base northern trust ntrs jump more solid first quarter revenue earning beat gain send share back day move average stock climb right side new base reaction earning report drive downside illumina ilmn netflix nflx lower new oriental education technology edu lead ibd list nearly seize new high share be extend almost past buy point equity lifestyle property el scramble nearly resort retirement property reit report revenue profit expectation late monday steer expectation fund operation slightly consensus stock be form flat base buy point lendingtree tree climb more rise top buy range buy point weak end drop rise trade stock have be look support day line share be cup handle base
150,ILMN,apple aapl be upgrade wednesday high hope next iphone tesla tsla outperform rating be reiterate positive model expectation apple be upgrade outperform market perform cowen longbow research cowen analyst timothy arcuri also raise price target apple say see apple benefit debut iphone launch later year apple share close stock market today credit suisse reiterate outperform rating price target tesla expectation positive initial model reservation mass market electric car be unveil thursday tesla share dip apply material amat chip gear maker have price target raise cowen apply material share rally bernstein initiate coverage digital mobile payment company paypal pypl market perform rating paypal share slip gene sequence technology company illumina ilmn be start buy rating price target argus research share rise image provide shutterstock
151,ILMN,gene sequence giant illumina ilmn be trading sharply tuesday announce late monday longtime ceo jay flatley be leave post flatley plan become executive chairman illumina july point current president francis desouza become ceo flatley have head illumina shortly founding have oversee debut stock market rise multibillion dollar company desouza joined symantec symc have acquire startup imlogic btig analyst dane leone write desouza be generally expect succeed flatley perhaps not yet mr desouza have be prominently featured investor community past month ascension be jay successor be unlikely be surprise most investor leone write research note however do think timing transition be sooner expect evercore isi analyst ross muken write continuity be likely theme transition believe transition be long telegraph market come surprise shareholder muken write research note respect jay executive chairman title also likely signal continue close involvement business need focus bigger picture concept vs day day execution nonetheless illumina stock be more midday trading stock market today stock have be recover month low hit feb retain dismal ibd relative strength rating strong ep rank
152,ILMN,stock trade mixed nasdaq composite still lead downside nearly less hour trading left wednesday nasdaq have already give back sharp advance day rally begin thursday dow jone industrial average rebound morning lows be
153,ILMN,facebook fb netflix nflx twitter twtr palo alto network panw delta air line dal be group high profile company see insider selling past week whatsapp founder facebook director jan koum continue sell share latest trade be sale facebook share value last week disclose sale company share week disclose sale almost share koum agree sell whatsapp facebook still hold more facebook share facebook share close friday weekly gain video stream company founder ceo reed hasting file sell share value richard barton chairman real estate zillow netflix board member disclose plan sell share value week pacific crest analyst andy hargreaf say note netflix growth potential be underestimated global distribution provide datum feedback loop allow netflix invest content marketing product development more efficiently key competitor write note share climb week chief technology officer adam messinger file sell share value last week twitter cfo anthony noto disclose purchase company share earlier month twitter report user growth slow fourth consecutive quarter guide revenue consensus raise concern usage be peak share see weekly drop cfo steffan tomlinson file sell share co founder chief technology officer nir zuk file sell share latest string sale palo alto network officer january february thursday cybersecurity company report fiscal result top view strong revenue guidance earning view be weak share surge week reilly automotive orly chairman david reilly sell share value reilly share have best possible ibd composite rating meaning have outperformed stock key metric recent quarters such company sale profit growth share rise week chief operate officer gilbert west feb sell share value delta air line stock sport strong ibd composite rating appear be work right side first stage cup base buy point delta share add illumina ilmn ceo jay flatley file sell share value earlier month gene sequence equipment giant report first year year decline earning growth nearly year drop share rally ceo stephen chazen sell share oil natural gas company value occidental petroleum oxy stock have be batter last year plunge oil price share dip week insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock
154,ILMN,flagship stock etfs stage smart recovery wednesday close session high snap day lose streak oil drive narrative again commodity surge dollar plummet weak service datum marquee name struggle however first trust dow jone internet fdn drop top holding facebook fb amazon amzn
155,ILMN,here quick rundown tuesday hour action yahoo yhoo report fourth quarter earning drop be line estimate revenue edge beat view company say explore strategic option include reverse spin alibaba stake sale core asset yahoo plan cut workforce share fall late edward lifescience ew say fourth quarter revenue increase earning jump surpass estimate medical device maker also raise guidance forecast share jump nearly extend trade gilead science gild handily top fourth quarter earning revenue estimate ep pop revenue rise product sale forecast be roughly line analyst estimate hepatitis hiv drugmaker also announce share buyback program share rise fractionally late illumina ilmn fourth quarter earning fall revenue rise bottom line miss penny top line beat view maker gene sequence system issue full year revenue guidance be line view earning guidance be light share fall late close chipotle grill cmg issue first quarterly report be hit coli outbreak chipotle earning plunge be not bad wall street fear revenue decline miss expectation cdc declare monday outbreak be criminal investigation be ongoing chipotle warn be very difficult year predict first quarter ep be breakeven wall street have expect share chipotle tumble late trading
156,ILMN,executive adobe system adbe illumina ilmn kinder morgan kmi be make notable transaction week adobe ceo shantanu narayen disclose security exchange commission wednesday sale share tech earning be see decline first time several factor weigh sector include slowdown china weak pc sale shift cloud compute tech stock application software subset include adobe be see lead expect average earning growth share adobe close week chief executive jay flatley sell share accord thursday filing follow similar sale previous week illumina announce jan founding grail company aim develop genetic testing early stage cancer simple blood test microsoft msft bill gate amazon amzn jeff bezos be investor illumina share fall week michael morgan director board pipeline operator kinder morgan kmi acquire share accord wednesday disclosure last week kinder morgan report weak result announce reduction payout low oil price kinder morgan share climb week monday electronic art ea cfo blake jorgensen disclose sale share video game publisher report earning growth share cent forecast revenue climb just shy view full year guidance ep sale come consensus estimate ep revenue share lose week airline cfo paul jacobson disclose monday sale share delta air line dal anticipate year cheaper fuel price addition other operational cost initiative currency headwind hit result report jan ep climb share penny short estimate revenue slide vs view share finished lower week ceo stephen chazen file thursday regard sale share oil giant thursday occidental petroleum oxy report result wall street be expect cent share loss revenue share post weekly gain cybersecurity firm cfo steffan tomlinson sell share founder cto nir zuk sell share accord monday filing palo alto network panw announce jan partnership proofpoint pfpt alliance strong competition fireeye feye say analyst share end vs last friday insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock related tech earning set first quarterly fall palo alto proofpoint alliance undercut fireeye celgene vertex illumina offer mixed outlooksdelta see bil cost saving cheap oil
157,ILMN,major stock etfs pull modest gain close tuesday choppy trading session volume run low major exchange volatile oil price uncertain fed rate hike outlook keep most investor sideline wti crude future dive barrel international energy agency warn demand oil ease considerably
158,ILMN,stock reversed early loss narrow gain thursday heavily influenced fluctuation oil other commodity dow jone industrial average climb nasdaq be volume be mixed nyse lower nasdaq relative action same time thursday slide dollar
159,ILMN,stock advanced wednesday open then drop back moderate loss weak reading service sector nasdaq tumble drop dow clock drop volume slip stock market today nyse nasdaq relative trade
160,ILMN,stock future tick minor gain ahead wednesday open dow future blipped fair market value nasdaq future be also russell future inched stock market today jump hump day nasdaq lower friday blue chip loss be line general mood dow small cap be little weaker send russell tuesday employment picture weaken january adp national employment report show employer hire worker month be upwardly revise hiring december comfortably consensus estimate addition once again service sector hire run far ahead good producer institute supply management serve january service sector index et oil price bob back barrel west texas intermediate brent american petroleum institute datum release late tuesday show barrel build inventory week end jan energy information administration report weekly inventory datum dow stock be generally positive mmm have gain miner be also active vale vale pop rio rio climb ferrari race surge weaker forecast earning report late tuesday illumina ilmn dump india infosys infy drop deliver quarterly result big drugmaker be motion glaxosmithkline gsk jump merck mrk pull back report large insurer prudential puk spiked metlife meet be flat ahead earning report today close herbicide pesticide seed strain developer syngenta syt spark confirm agree be acquire state own china national chemical corp deal value more switzerland base syngenta share gap tuesday news report detailed possible tie company chipotle grill cmg fall report mixed result firm also announce center disease control prevention conclude investigation coli outbreak link chain receive subpoena attorney office central district california broaden scope previously announce criminal investigation chain ibd list edward lifescience ew skip trouncing analyst earning revenue estimate raise ep guidance well consensus view edward have be loll week move average week shallow base buy point
161,ILMN,early stage biotech be see buyout target drug industry juno therapeutic have be do buy juno juno be several company develop chimeric antigen receptor car cell therapy cancer involve reprogramming patient cell be part immune system recognize cancer cell
162,ILMN,market beat hasty retreat last week insider sale be notable executive health related company include gene sequence giant illumina ilmn ceo jazz pharmaceutical jazz chairman lead way be also couple big buy health related sector include major purchase walgreen boot alliance wba
163,ILMN,san francisco big biotechs celgene vertex pharmaceutical disappoint investor guidance gene sequence giant illumina preview variety futuristic product major investor conference monday
164,ILMN,news annual jpmorgan healthcare conference san francisco send celgene celg vertex vrtx stock fall monday illumina ilmn share rise fraction
165,ILMN,celgene say ep totale share year earlier quarter miss cent consensus analyst poll thomson reuter product sale cover not quite revenue be line wall street revenue estimate
166,ILMN,celgene be schedule report final earning jan
167,ILMN,celgene guide ep expect final number low side analyst projection product sale be guide analyst forecast revenue
168,ILMN,nonetheless celgene add cent ep guidance have already raise last summer
169,ILMN,celgene also say march bob hugin lead company year become executive chairman hand ceo job mark alle currently president coo alle turn hand position jacqualyn fouse now president celgene hematology oncology franchise make majority business
170,ILMN,scott head inflammation immunology business add role chair global management committee
171,ILMN,regard celgene say include cent charge due milestone payment oncomed omed stem positive datum demcizumab cancer drug celgene have license evercore isi analyst mark schoenebaum write research note be unclear consensus forecast have factor write other number be basically line
172,ILMN,speaking conference hugin say celgene have absorb cent hit close acquisition receptos bring potential blockbuster immunology drug ozanimod be highly optimistic celgene bud immunology franchise general psoriasis drug otezla launch bring hugin call most successful launch therapeutic history therapeutic area term progress first full year launch
173,ILMN,analyst be divide management change schoenebaum write change have generally be expect rbc capital market analyst michael yee write ceo transition seem early
174,ILMN,believe investor debate change result alle do go forward yee say research note
175,ILMN,celgene stock slide monday
176,ILMN,illumina team bill gate
177,ILMN,illumina stock meanwhile seesaw monday close fraction battery announcement company sunday say be launch new business call grail several partner include microsof msft co founder bill gate bezos expedition family foundation amazon com amzn founder jeff bezos aim company be develop new genetic test early stage cancer be derive simple blood sample
178,ILMN,monday announce miniseq system simplest cheapest gene sequencer have yet produce miniseq expect launch quarter be price sample cost process ceo jay flatley say conference
179,ILMN,also monday illumina unveil new partnership bio rad bio develop next generation sequence solution analyze single cell single cell analysis be useful understand cell variation cancer other disease flatley say normally be analyze only small batch illumina bio rad aim high throughput solution combine technology expect launch late year early next year
180,ILMN,flatley also preview handheld sequence device illumina be work call firefly base cmo technology company acquire couple year be way road however
181,ILMN,flatley also say expect revenue grow year line consensus ep guidance share be street estimate
182,ILMN,vertex key drug beat
183,ILMN,vertex stock fall preliminary result guidance sunday disappoint investor vertex say flagship cystic fibrosis cf drug kalydeco sell beating consensus accord evercore
184,ILMN,new cf drug orkambi launch summer sell hair consensus
185,ILMN,year company forecast kalydeco sale operate expense didn forecast orkambi sale
186,ILMN,kalydeco guidance appear be street view analyst schoenebaum write email say company guidance have be conservative past year
187,ILMN,say vertex be wait additional information launch give orkambi guidance analyst expect orkambi sell year san francisco big biotechs celgene vertex pharmaceutical disappoint investor guidance gene sequence giant illumina preview variety futuristic product major investor conference monday news annual jpmorgan healthcare conference san francisco send celgene celg vertex vrtx stock fall monday illumina ilmn share rise fraction celgene say ep totale share year earlier quarter miss cent consensus analyst poll thomson reuter product sale cover not quite revenue be line wall street revenue estimate celgene be schedule report final earning jan celgene guide ep expect final number low side analyst projection product sale be guide analyst forecast revenue nonetheless celgene add cent ep guidance have already raise last summer celgene also say march bob hugin lead company year become executive chairman hand ceo job mark alle currently president coo alle turn hand position jacqualyn fouse now president celgene hematology oncology franchise make majority business scott head inflammation immunology business add role chair global management committee regard celgene say include cent charge due milestone payment oncomed omed stem positive datum demcizumab cancer drug celgene have license evercore isi analyst mark schoenebaum write research note be unclear consensus forecast have factor write other number be basically line speaking conference hugin say celgene have absorb cent hit close acquisition receptos bring potential blockbuster immunology drug ozanimod be highly optimistic celgene bud immunology franchise general psoriasis drug otezla launch bring hugin call most successful launch therapeutic history therapeutic area term progress first full year launch analyst be divide management change schoenebaum write change have generally be expect rbc capital market analyst michael yee write ceo transition seem early believe investor debate change result alle do go forward yee say research note celgene stock slide monday illumina team bill gatesillumina stock meanwhile seesaw monday close fraction battery announcement company sunday say be launch new business call grail several partner include microsof msft co founder bill gate bezos expedition family foundation amazon com amzn founder jeff bezos aim company be develop new genetic test early stage cancer be derive simple blood sample monday announce miniseq system simplest cheapest gene sequencer have yet produce miniseq expect launch quarter be price sample cost process ceo jay flatley say conference also monday illumina unveil new partnership bio rad bio develop next generation sequence solution analyze single cell single cell analysis be useful understand cell variation cancer other disease flatley say normally be analyze only small batch illumina bio rad aim high throughput solution combine technology expect launch late year early next year flatley also preview handheld sequence device illumina be work call firefly base cmo technology company acquire couple year be way road however flatley also say expect revenue grow year line consensus ep guidance share be street estimate vertex key drug beatsvertex stock fall preliminary result guidance sunday disappoint investor vertex say flagship cystic fibrosis cf drug kalydeco sell beating consensus accord evercore new cf drug orkambi launch summer sell hair consensus year company forecast kalydeco sale operate expense didn forecast orkambi sale kalydeco guidance appear be street view analyst schoenebaum write email say company guidance have be conservative past year say vertex be wait additional information launch give orkambi guidance analyst expect orkambi sell year
188,ILMN,etf investor get taste snap back market action be hope tuesday choppy trading session major index steady modestly sharp drop kick stock reversed lower intraday oil briefly dip barrel first time december however etfs tracking dow finished higher well session lows health care help lead advance sector utility real estate post loss powershare qqq qqq tech biotech heavy exchange trade fund pop stock market today etf be dec high stock holding celgene celg jump illumina ilmn vertex pharmaceutical vrtx give regeneron regn investor seem have digest monday biotech related news big biotechs celgene vertex have offer mixed outlook major investor conference cause disappointment illumina meanwhile announce new unit call grail focuse detect cancer early simple blood sample apple aapl hold qqq portfolio weighting gain tuesday iphone maker stock briefly re-cover level first time day buoy analyst upgrade well rumor cheaper base model iphone apple electric car stock be week high diving deeply day move average december spdr biotech xbi surge massive volume however equal weight etf hold stock be july high xbi monday undercut late september lows be spur presidential candidate hillary clinton comment price gouge drug industry recent slump analyst rbc capital market be report reaffirm confidence growth prospect biotech sector tuesday note ishare nasdaq biotechnology ibb advanced cap weight etf also breach late september low monday be week high hold stock biggest stake celgene biogen biib amgen amgn gilead gild regeneron regn xbi smaller cap skew help give performance boost rise vs gain ibb gold dollargold price fall third straight session tuesday gold price be moderately lower tuesday more profit take chart consolidation follow recent gain see price hit month high late last week jim senior technical analyst write commodity monitor kitco news less anxious world market scene day firmer dollar index be also help pressure safe haven gold market etf bullish dollar extend gain retake day line monday greenback rise vs other major world currency bellwether etfs here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs follow aparna narayanan twitter ibd_anarayanan
189,ILMN,apple aapl chip supplier technology avgo be upgrade monday concern sale prospect iphone blackberry bbry illumina ilmn google parent alphabet googl get higher price target
190,ILMN,rbc capital market upgrade top pick outperform also raise price target stock supplier chip iphone have be trading record high worry apple ability grow iphone unit sale next year huge success iphone series
191,ILMN,share rise thestock market today apple stock climb dip morning
192,ILMN,blackberry advanced price target be raise rbc capital market friday blackberry beat third quarter earning estimate ceo john chen say embrace work tesla tsla apple alphabet advanced auto technology
193,ILMN,illumina add price target be raise stifel have buy rating stock illumina stock price be more july high recent slowdown earning revenue growth
194,ILMN,alphabet rise price target be hike pacific crest
195,ILMN,rackspace host rax provider web host cloud compute service client such amazon com amzn microsoft msft be initiate neutral goldman sachs give price target
196,ILMN,rackspace face higher cost invest staff provide technical support public cloud
197,ILMN,share rackspace rise amazon microsoft climb
198,ILMN,fiber optic company ciena cien rise be upgrade buy hold jeffery ciena share sank dec guide revenue well wall street expectation
199,ILMN,luxury jeweler tif climb be upgrade buy jeffery give price target
200,ILMN,carmax kmx give follow price target cut rbc capital market maintain sector perform rating stock friday carmax lose disappointing result
201,ILMN,follow vance cariaga twitter ibd_vcariaga apple aapl chip supplier technology avgo be upgrade monday concern sale prospect iphone blackberry bbry illumina ilmn google parent alphabet googl get higher price target rbc capital market upgrade top pick outperform also raise price target stock supplier chip iphone have be trading record high worry apple ability grow iphone unit sale next year huge success iphone series share rise thestock market today apple stock climb dip morning blackberry advanced price target be raise rbc capital market friday blackberry beat third quarter earning estimate ceo john chen say embrace work tesla tsla apple alphabet advanced auto technology illumina add price target be raise stifel have buy rating stock illumina stock price be more july high recent slowdown earning revenue growth alphabet rise price target be hike pacific crest rackspace host rax provider web host cloud compute service client such amazon com amzn microsoft msft be initiate neutral goldman sachs give price target rackspace face higher cost invest staff provide technical support public cloud share rackspace rise amazon microsoft climb fiber optic company ciena cien rise be upgrade buy hold jeffery ciena share sank dec guide revenue well wall street expectation luxury jeweler tif climb be upgrade buy jeffery give price target carmax kmx give follow price target cut rbc capital market maintain sector perform rating stock friday carmax lose disappointing result follow vance cariaga twitter ibd_vcariaga
202,ILMN,order succeed investing just shoot hip instead key rule be follow have be work well suddenly start fizzle don be deer headlight need take action else watch hard earn gain disappear ibd preach take profit once amount not stock break base go produce gain ideal range lose steam rise sometimes fizzle much sooner also depend market condition end stock rise head back other stock get hope rise just shy buy point then break catch stock rise least breaking base then erase gain close position action be call round trip be sell signal watch stock give be healthy gain be bad enough already let go negative territory be even so stock wipe double digit gain investor don have stock fall buy point selling still better get even rather take loss illumina ilmn briefly clear buy point handle june year soft volume big volume arrived next trading session share gene sequence firm didn move much initially picked pace july stock climb july july stock gap tumble nearly intraday mixed second quarter result firm post earning climb cent share beating view sale grow short consensus be also third straight quarter mildly decelerate sale growth big drop erased entire gain entry mark sell signal stock do bounce back pull round trip illumina didn stock try stabilize day line soon give way early october stock drop much july peak
203,ILMN,special report income investing bond common stock aren only game town come income investing risk averse income investor saving account money market account have benefit safety good luck get respectable yield re lucky get yield income investor do have option
204,ILMN,early investor facebook fb continue sell share social medium leader past week stock peaked apple aapl chief sell chunk iphone maker stock slump facebook director marc andreessen co founder venture capital firm andreessen horowitz disclose sale share nov nov total value oct nov andreessen sell nearly half holding facebook total value roughly prearrange plan transaction come facebook stock have hit series fresh time high lately early month facebook report earning revenue beat estimate strong growth mobile monthly active user facebook stock hit close high wednesday retreat afterward week share close nearly stock market trading apple ceo tim cook also continue sell share cook file monday sale share total cook nov disclose filing have sell share total value nov credit suisse say apple be cut order iphone supplier flagging demand asia new chinese datum also raise concern economic growth world largest consumer market credit suisse say still bullish apple share drop week gilead science gild president john milligan nov sell share value gilead chairman ceo john martin have be regular seller biotech share sell share earlier month gilead share share other drug stock have be pressure lately scrutiny pricing sale practice gilead have hold better many peer share decline skywork solution swks chairman ceo dave aldrich sell share nov nov however cfo donald palette buy share period share skywork apple chip supplier have come earth drop time high june week skywork slide first solar fslr ceo james hughe sell share nov cfo mark widmar sell share date earlier week first solar crushed third quarter estimate earning shot revenue spiked solar sector be slam weak sunedison sune result worry profitability solar yieldcos first solar share lose week illumina ilmn ceo jay flatley sell share nov gene sequence equipment giant have be upswing sync rise medical research equipment service group general illumina replace specialty chemical maker sigma aldrich index nov now merck mrk have buy sigma aldrich illumina share rise week constellation brand stz ceo robert sand sell share nov nov brother constellation chairman richard sand sell share period share rise less insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock follow james detar twitter ibd_jdetar facebook
205,ILMN,gene sequence giant illumina ilmn pre announce revenue full year guidance miss estimate monday send stock tumble hour illumina say revenue totale year earlier quarter short analyst consensus accord thomson reuter company also say expect revenue last year shy wall street estimate add sale growth year vs analyst expectation growth company report final result oct demand sequence consumable hiseq family instrument remain strong quarter instrument sale desktop family underperform expectation illumina ceo jay flatley say statement geographically be disappoint instrument sale europe continue weakness asia pacific region shortfall expectation competitive position product development pipeline be strong ever announcement continue recent stretch bad news illumina start surprise revenue miss long record beating estimate last week stock also suffer leerink analyst dan leonard downgrade writing see current product cycle be lighter upgrade replacement previous cycle unexpectedly early launch compete gene sequence product pacific bioscience pacb also have weigh share have be caution time estimate look aggressive thus today negative pre announcement do not come massive surprise write evercore isi analyst ross muken email client key question remain help re accelerate instrument growth key driver multiple company offer jpm jpmorgan healthcare conference few month time swing sentiment modest competition also enter market expect uncertainty keep share range bound depress level await further clarity prior revisit thesis illumina stock be thus already july high close fraction regular trade monday hour close be pacific bioscience be hour perhaps assumption overall weakness sequence market illumina still hold excellent ep rank relative strength rating only follow amy reeve twitter ibd_areeve facebook
206,ILMN,share gene sequence giant illumina ilmn tumble nearly year low thursday stock be downgrade compete product arrived earlier expect leerink analyst dan leonard downgrade illumina market perform outperform lower price target do not see term catalyst stock illumina stock be
207,ILMN,stock manage mixed start tuesday dupont dd almost single handedly hoist dow positive territory dow jone industrial average climb reversed early loss gain nasdaq remain illumina ilmn pull hard downside
208,ILMN,volume be mixed nasdaq lower nyse vs action same time monday
209,ILMN,company news broad array sector industry drive bulk early trade stock market today
210,ILMN,dow general electric ge chevron cvx cisco system csco climb dupont do heavy lift spiking open lower full year earning guidance announce sudden exit ceo ellen kullman offer full year guidance expectation
211,ILMN,network ffiv fumble lower citigroup initiate coverage sell rating note say be likely guide expectation next month have be consolidate december high loss send share july high
212,ILMN,leader ibd stock slump early trade
213,ILMN,technology avgo fall furthest stock have be struggle regain support converge week move average
214,ILMN,upside gain be limit less stock manage mixed start tuesday dupont dd almost single handedly hoist dow positive territory dow jone industrial average climb reversed early loss gain nasdaq remain illumina ilmn pull hard downside volume be mixed nasdaq lower nyse vs action same time monday company news broad array sector industry drive bulk early trade stock market today dow general electric ge chevron cvx cisco system csco climb dupont do heavy lift spiking open lower full year earning guidance announce sudden exit ceo ellen kullman offer full year guidance expectation network ffiv fumble lower citigroup initiate coverage sell rating note say be likely guide expectation next month have be consolidate december high loss send share july high leader ibd stock slump early trade technology avgo fall furthest stock have be struggle regain support converge week move average upside gain be limit less
215,ILMN,illumina ilmn be downgrade tuesday give weak guidance late monday apple aapl chipmaker skywork solution swks have price target cut mizuho drop illumina neutral buy cut price target stifel also cut gene sequence giant price target slash late monday illumina preannounce third quarter revenue consensus view give weak estimate illumina share plunge close stock market today topeka capital market lower skywork price target late monday apple chip supplier say buy pmc sierra pmcs cash join fellow apple iphone supplier technology avgo nxp semiconductor nxpi make acquisition skywork share close rise initially apple rise pmc sierra soar pacific crest cut twitter twtr price target keep overweight rating microblogging site monday twitter confirm appointment co founder interim chief jack dorsey permanent ceo dorsey be ceo twitter digital payment company square twitter share fall fedex fdx be upgrade buy hold stifel price target late monday shipping giant say raise fuel surcharge second time year low oil price just commerce site prepare holiday rush fedex share close oil company get hit tuesday concho resource cxo be downgrade neutral suntrust robinson humphrey linn energy line partner company linn co lnco be downgrade hold buy stifel concho share be essentially unchanged close linn energy gap linn co leap follow gillian rich twitter ibd_grich
216,ILMN,stock seesaw mixed finish tuesday blue chip rise broader index take step back nasdaq end session low still lose snap day streak fall end day run help surge dupont dd dow jone industrial average squeeze gain dupont jump nearly reaction late monday news ceo ellen kullman step accord preliminary datum volume rise board stock market today illumina ilmn gap slump almost warning sale late monday intraday stock be much greatbatch gb gap day slump weak sale guidance regulatory filing date monday medical product maker cut sale guidance fiscal range prior outlook greatbatch also breach day move average autobytel abtl end session high follow monday add busy session close past buy point double bottom base lgi home lgih climb rise new high be well extend buy point flat base clear early august also extend rebound week move average follow vincent mao twitter ibd_vmao
217,ILMN,stock future be moderately lower earlier lows ramp tuesday open dow future have nearly halved hour earlier lose trading point fair market value nasdaq future narrow decline point future be point underwater
218,ILMN,global market have little premarket impact stock market today europe lead index re-cover early loss trade tightly mixed action midday tokyo nikkei rise hong kong ease fraction china mainland market remain close holiday
219,ILMN,economic news give market little go slump germany august manufacturing order have early effect eurozone market trade deficit widen august july less project economist
220,ILMN,kansa city federal reserve bank president george be schedule speak et john william president san francisco federal reserve bank speak
221,ILMN,company news be central early stock action pepsico pep set third quarter earning season motion jump healthy revenue earning beat
222,ILMN,chip developer pmc sierra pmcs buck woburn mass base skywork solution swks say buy sunnyvale calif company cash deal value skywork say expect combine company generate more revenue gross margin operate margin skywork share rise bit less
223,ILMN,dupont dd jetted ahead more torrent late news monday company lower full year operate earning guidance share company cite continue strength dollar weak currency agricultural market brazil
224,ILMN,dupont also announce ceo ellen kullman retire effective oct board member edward assume kullman duty interim basis company have be pressure hedge fund trian fund management cut cost divest asset dupont share end monday march high
225,ILMN,drugmaker du be base novocure nvcr nab advance news food drug administration approve optune tumor treatment device use patient suffering glioblastoma fast grow brain tumor
226,ILMN,illumina ilmn dim premarket action gene sequence leader pre report revenue consensus expectation guide full year revenue growth vs consensus view illumina share have be steepening decline july
227,ILMN,leader horton dhi slip more ahead open homebuilder surge weak trade monday retake day move average stock end monday almost buy point
228,ILMN,dollar slip bond inched higher crude oil be mixed brent west texas intermediate fraction gold trade penny higher just ounce stock future be moderately lower earlier lows ramp tuesday open dow future have nearly halved hour earlier lose trading point fair market value nasdaq future narrow decline point future be point underwater global market have little premarket impact stock market today europe lead index re-cover early loss trade tightly mixed action midday tokyo nikkei rise hong kong ease fraction china mainland market remain close holiday economic news give market little go slump germany august manufacturing order have early effect eurozone market trade deficit widen august july less project economist kansa city federal reserve bank president george be schedule speak et john william president san francisco federal reserve bank speak company news be central early stock action pepsico pep set third quarter earning season motion jump healthy revenue earning beat chip developer pmc sierra pmcs buck woburn mass base skywork solution swks say buy sunnyvale calif company cash deal value skywork say expect combine company generate more revenue gross margin operate margin skywork share rise bit less dupont dd jetted ahead more torrent late news monday company lower full year operate earning guidance share company cite continue strength dollar weak currency agricultural market brazil dupont also announce ceo ellen kullman retire effective oct board member edward assume kullman duty interim basis company have be pressure hedge fund trian fund management cut cost divest asset dupont share end monday march high drugmaker du be base novocure nvcr nab advance news food drug administration approve optune tumor treatment device use patient suffering glioblastoma fast grow brain tumor illumina ilmn dim premarket action gene sequence leader pre report revenue consensus expectation guide full year revenue growth vs consensus view illumina share have be steepening decline july leader horton dhi slip more ahead open homebuilder surge weak trade monday retake day move average stock end monday almost buy point dollar slip bond inched higher crude oil be mixed brent west texas intermediate fraction gold trade penny higher just ounce
229,ILMN,field biotech investing venture capitalist james blair be veteran work rothschild back blair be early investor apply biosystem now part thermo fisher scientific tmo develop gene sequencer used human genome project be also early player amgen amgn
230,ILMN,weaker expect ism read give stock brief lift be trading modestly lower go lunch hour thursday nasdaq dow jone industrial average fall sank stock market today volume be tracking higher same time wednesday nyse lower nasdaq
231,ILMN,institute supply management manufacturing index september fall vs august be third straight monthly decline
232,ILMN,richmond fed chief jeffrey lacker say october rate hike be still possible give robust consumer spending
233,ILMN,dunkin brand dnkn sank company tell analyst slow sale growth force close store third quarter company parent dunkin donut baskin robbin forecast comp sale growth dunkin donut location compare
234,ILMN,tyler technology tyl explode gain massive volume move thinly trade stock time high plano texas base software service provider announce be buy privately hold new world system cash stock
235,ILMN,illumina ilmn fall leerink swann analyst downgrade stock outperform market perform lower price target trade
236,ILMN,follow ken hoover twitter ibd_khoover weaker expect ism read give stock brief lift be trading modestly lower go lunch hour thursday nasdaq dow jone industrial average fall sank stock market today volume be tracking higher same time wednesday nyse lower nasdaq institute supply management manufacturing index september fall vs august be third straight monthly decline richmond fed chief jeffrey lacker say october rate hike be still possible give robust consumer spending dunkin brand dnkn sank company tell analyst slow sale growth force close store third quarter company parent dunkin donut baskin robbin forecast comp sale growth dunkin donut location compare tyler technology tyl explode gain massive volume move thinly trade stock time high plano texas base software service provider announce be buy privately hold new world system cash stock illumina ilmn fall leerink swann analyst downgrade stock outperform market perform lower price target trade follow ken hoover twitter ibd_khoover
237,ILMN,material etfs track higher tuesday get boost spike chemical giant dupont dd investor digest news dupont ceo ellen kullman step oct even company announce plan curb expense overall stock etfs follow nasdaq index fail extend recent rally investor eye weak trade datum start earning season gold price rise dollar ease vs euro yen british pound meanwhile ishare silver trust slv largest silver etf hit month high close session low have surge past day spdr dow jone industrial average dium eke gain stock market today cushion gain dupont well caterpillar cat microsoft msft however ibd leaderboard stock visa inched lower dow tracking etf hold industrial leader be high material select sector spdr xlb pop material energy sector lead index higher xlb hold company chemical metal mining paper forest product container packaging construction material industry chemical company dominate third asset accord morningstar inc dow chemical dow dupont largest holding alone account combine portfolio weighting etfs hold biotech stock get slam tuesday rally lows ishare nasdaq biotechnology ibb tumble nearly close midpoint day range ibb top holding take hit illumina ilmn tank revenue miss gene sequence firm preannounce quarterly result monday report final number oct ibb top holding celgene celg biogen biib give ibd stock regeneron pharmaceutical regn fall indonesia brazil russia top international etfs china india trail here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing bellwether etfs spdr gold share gld rs ishare core aggregate bond agg rs ishare msci eafe efa rs spdr dow jone industrial average dium rs vanguard ftse emerge market vwo rs spdr spy rs ishare core mid cap ijh rs powershare qqq qqq rs powershare db bullish uup rs ishare russell iwm rs follow aparna narayanan twitter ibd_anarayanan
238,ILMN,stock be quietly mixed midday tuesday reasonable performance strong session dow jone industrial average add buoy dupont dd surge more news ceo ellen kullman abruptly retire wall street take mean breakup company be horizon
239,ILMN,ease nasdaq fall weigh weakness illumina ilmn share crash gene sequence gear maker preannounce sale consensus estimate
240,ILMN,former chip leader skywork swks avgo face more selling so do biotech name celgene celg biogen biib
241,ILMN,nyse volume be tracking lower monday stock market today nasdaq volume be pace be slightly higher
242,ILMN,advance stock outnumber decliner nyse less decliner have slight edge advancer nasdaq
243,ILMN,oil gas related group extend gain oil rise again new york mercantile exchange crude oil future jump barrel
244,ILMN,day gainer autobytel abtl follow rise nearly monday double bottom base buy point
245,ILMN,ibd sector leader lgi home lgih score time high rise be solid performer base early august buy point extend bounce week week move average
246,ILMN,pretty quiet week economic datum market be look closely tone fed minute meeting re release thursday stock be quietly mixed midday tuesday reasonable performance strong session dow jone industrial average add buoy dupont dd surge more news ceo ellen kullman abruptly retire wall street take mean breakup company be horizon ease nasdaq fall weigh weakness illumina ilmn share crash gene sequence gear maker preannounce sale consensus estimate former chip leader skywork swks avgo face more selling so do biotech name celgene celg biogen biib nyse volume be tracking lower monday stock market today nasdaq volume be pace be slightly higher advance stock outnumber decliner nyse less decliner have slight edge advancer nasdaq oil gas related group extend gain oil rise again new york mercantile exchange crude oil future jump barrel day gainer autobytel abtl follow rise nearly monday double bottom base buy point ibd sector leader lgi home lgih score time high rise be solid performer base early august buy point extend bounce week week move average pretty quiet week economic datum market be look closely tone fed minute meeting re release thursday
247,ILMN,late buyer help stock mixed finish first day october ahead friday key job report rise nasdaq edge bounce back loss more dow jone industrial slip accord preliminary datum volume fall major exchange stock market today
248,ILMN,highly rate stock thinly trade tyler technology tyl ramp news service provider buy privately hold new world system cash stock tyler be mentioned latest new high column
249,ILMN,verisk analytic vrsk gap day line rally almost huge turnover provider actuarial underwriting datum insurer join index close oct mutual fund etfs tracking benchmark index have buy share
250,ILMN,epam system epam rise nearly seesaw trading intraday stock almost hit buy point cup handle base recent week stock accumulation distribution rating have surge worst possible late august epam be rare leader show strong accumulation
251,ILMN,lead stock dunkin brand dnkn gap dive expectation weak comp sale news store closing share fall month low
252,ILMN,illumina ilmn drop be downgrade market perform outperform have price target cut leerink share genetic analysis firm hit week low
253,ILMN,september job report factory order be friday morning economist poll econoday be expect new job also number fed official be speaking session
254,ILMN,follow vincent mao twitter ibd_vmao late buyer help stock mixed finish first day october ahead friday key job report rise nasdaq edge bounce back loss more dow jone industrial slip accord preliminary datum volume fall major exchange stock market today highly rate stock thinly trade tyler technology tyl ramp news service provider buy privately hold new world system cash stock tyler be mentioned latest new high column verisk analytic vrsk gap day line rally almost huge turnover provider actuarial underwriting datum insurer join index close oct mutual fund etfs tracking benchmark index have buy share epam system epam rise nearly seesaw trading intraday stock almost hit buy point cup handle base recent week stock accumulation distribution rating have surge worst possible late august epam be rare leader show strong accumulation lead stock dunkin brand dnkn gap dive expectation weak comp sale news store closing share fall month low illumina ilmn drop be downgrade market perform outperform have price target cut leerink share genetic analysis firm hit week low september job report factory order be friday morning economist poll econoday be expect new job also number fed official be speaking session follow vincent mao twitter ibd_vmao
255,ILMN,stock rolled thin gain quickly turn mixed action then loss early trade thursday nasdaq slump dow jone industrial average fall sit fraction red buoy energy issue
256,ILMN,volume be mixed nyse lower nasdaq vs trade same time wednesday
257,ILMN,stock market today hit bump form job datum show spike layoff september more expect increase weekly jobless claim
258,ILMN,institute supply management september manufacturing index ease still level separate sector expansion contraction august read narrowly undercut view
259,ILMN,researcher markit report compete purchasing manager index manufacturing gauge climb best forecast change
260,ILMN,commerce department august construction spending datum show increase downwardly revise gain july just consensus expectation rise
261,ILMN,dow apple aapl slump more only stock gain ground none advance issue reach
262,ILMN,general motor gm climb report sale gain september claim sixth straight month year year market share gain ford report sale best september year gain fraction fiat chrysler fcau rise almost gain sale september
263,ILMN,verisk analystic vrsk spiked early action standard poor announce late wednesday provider actuarial underwriting datum insurer join index effective oct
264,ILMN,energy issue head oil price surge send west texas intermediate nearly barrel europe brent crude benchmark almost
265,ILMN,oil gas producer devon energy dvn jump bernstein research upgrade stock outperform market perform same time lower price target
266,ILMN,illumina ilmn slump get go downgrade leerink swann market perform outperform price target lower report cite question regard growth prospect research market target maker large scale genetic test equipment illumina share be july high
267,ILMN,spice maker mccormick mkc dump fiscal third quarter earning miss revenue meet estimate loss send share test support stock week move average
268,ILMN,leader post generally weak open nearly ibd stock slip lower open none advance leader reach gain
269,ILMN,low side sucampo pharmaceutical scmp dive almost catch biotech sell stock drop last week thursday loss send share back test support week move average
270,ILMN,follow alan elliott twitter ibd_aelliott stock rolled thin gain quickly turn mixed action then loss early trade thursday nasdaq slump dow jone industrial average fall sit fraction red buoy energy issue volume be mixed nyse lower nasdaq vs trade same time wednesday stock market today hit bump form job datum show spike layoff september more expect increase weekly jobless claim institute supply management september manufacturing index ease still level separate sector expansion contraction august read narrowly undercut view researcher markit report compete purchasing manager index manufacturing gauge climb best forecast change commerce department august construction spending datum show increase downwardly revise gain july just consensus expectation rise dow apple aapl slump more only stock gain ground none advance issue reach general motor gm climb report sale gain september claim sixth straight month year year market share gain ford report sale best september year gain fraction fiat chrysler fcau rise almost gain sale september verisk analystic vrsk spiked early action standard poor announce late wednesday provider actuarial underwriting datum insurer join index effective oct energy issue head oil price surge send west texas intermediate nearly barrel europe brent crude benchmark almost oil gas producer devon energy dvn jump bernstein research upgrade stock outperform market perform same time lower price target illumina ilmn slump get go downgrade leerink swann market perform outperform price target lower report cite question regard growth prospect research market target maker large scale genetic test equipment illumina share be july high spice maker mccormick mkc dump fiscal third quarter earning miss revenue meet estimate loss send share test support stock week move average leader post generally weak open nearly ibd stock slip lower open none advance leader reach gain low side sucampo pharmaceutical scmp dive almost catch biotech sell stock drop last week thursday loss send share back test support week move average follow alan elliott twitter ibd_aelliott
271,ILMN,stock open thin loss tuesday quickly retrench narrowly mixed action nasdaq be positive less dow jone industrial average hung red weigh ibm ibm loss
272,ILMN,volume be narrowly mixed higher nyse nasdaq relative trade early monday
273,ILMN,stock market today receive mixed signal open september housing datum show housing start more month permit future build project slow apartment project account large share jump start thin surprise bit be still first month month gain month hold annualize pace start healthy sign
274,ILMN,federal reserve chairwoman janet yellen be schedule speak et
275,ILMN,morning headline stock move memory chipmaker sandisk sndk flash higher news report outlined late stage discussion possible acquisition western digital wdc company be discuss price share accord unnamed source quote bloomberg premium sandisk close price monday report say deal be reach week monday gain put share august low december high western digital share slump more sandisk report result wednesday close
276,ILMN,monster beverage mnst climb nearly punch back week move average powerful trade stock have be live week line late august be attempt climb right side week consolidation
277,ILMN,leader bank ozark ozrk pop heavy trade gain moved little rock ark base outfit buy range cup handle buy point
278,ILMN,opposite end ibd list hawaiian pare loss less drop more start trade island hop airline report earning expectation revenue slip less forecast
279,ILMN,busy hour session include schedule earning report chipotle grill cmg yahoo yhoo illumina ilmn cree cree
280,ILMN,follow alan elliott twitter ibd_aelliott facebook stock open thin loss tuesday quickly retrench narrowly mixed action nasdaq be positive less dow jone industrial average hung red weigh ibm ibm loss volume be narrowly mixed higher nyse nasdaq relative trade early monday stock market today receive mixed signal open september housing datum show housing start more month permit future build project slow apartment project account large share jump start thin surprise bit be still first month month gain month hold annualize pace start healthy sign federal reserve chairwoman janet yellen be schedule speak et morning headline stock move memory chipmaker sandisk sndk flash higher news report outlined late stage discussion possible acquisition western digital wdc company be discuss price share accord unnamed source quote bloomberg premium sandisk close price monday report say deal be reach week monday gain put share august low december high western digital share slump more sandisk report result wednesday close monster beverage mnst climb nearly punch back week move average powerful trade stock have be live week line late august be attempt climb right side week consolidation leader bank ozark ozrk pop heavy trade gain moved little rock ark base outfit buy range cup handle buy point opposite end ibd list hawaiian pare loss less drop more start trade island hop airline report earning expectation revenue slip less forecast busy hour session include schedule earning report chipotle grill cmg yahoo yhoo illumina ilmn cree cree follow alan elliott twitter ibd_aelliott facebook
281,ILMN,biom realty trust bmr jump more wednesday bloomberg report company be explore sale bloomberg say blackstone group bx be interested buy biom realty be real estate investment trust specialize provide home laboratory life science industry focus effort core market boston san francisco san diego new york pennsylvania seattle company serve want be part research hub university biom be founder realization traditional reit weren able satisfy unique need research company say own square foot office laboratory space lease company research institution big university house be harvard yale university california san diego april company announce new build suit transaction regeneron pharmaceutical regn new building totale square foot parking structure landmark eastview tarrytown expand regeneron campus square foot biom realty say laboratory office space be pre lease year term june year announce illumina ilmn sign year lease square foot research build cambridge england stock have be underperform last several year basically move sideway high january slip recent week company pay dividend cent share work annualize yield year annualize dividend growth rate be
282,ILMN,week stock wall street didn prevent top management big name netflix nflx google googl selling own company share netflix ceo reed hasting monday file plan sale share friday netflix unveil first app virtual reality headset
283,ILMN,stock have come session lows be still mixed late monday nasdaq cut deficit tech laden index be much intraday edge dow jone industrial average outperformed gain volume be run mixed stock market today compare same time friday nyse trade be tracking sharply lower nasdaq volume be run pinch higher volume surge friday due quadruple witching biotechs other medical issue be session lows still hard follow tweet hillary clinton valeant pharmaceutical vrx turn gain loss reversal send back day line lannett lci drop breach day line stock appear be try support day move average elsewhere regeneron pharmaceutical regn illumina ilmn allergan agn shed allergan be featured monday sector leader review upside cyberark software cybr be session high still nearly be upgrade buy hold deutsche bank stock be stabilize tumble june record high red hat rht rise little more poke day line software maker report earning close analyst poll thomson reuter see profit rise cent share follow vincent mao twitter ibd_vmao
284,ILMN,tech company new ibd list top rate growth stock week include service provider epam system epam genetic testing equipment system provider illumina ilmn china gaming site operator netease nte amazon com amzn remain only tech ibd leaderboard market direction uptrend pressure however caution be warrant stock revive
285,ILMN,sector rotation be pretty much do deal big cap be guide last spring summer medical sector be provide third half name big cap summer leader chart now look sad biogen biib be high illumina ilmn be high plunge hour preannounce revenue full year guidance miss view regeneron regn be high tuesday big cap only medical stock make list heart valve maker edward lifescience ew be list couple breakout offer meager gain march yielded gain session then stock consolidated july yielded gain week stock consolidated small gain do not give individual investor much chance make money edward be now form new consolidation be good news monday ibd medical sector be sector be top most year september medical sector be finished leader have replace medical stock investor just well ask hasn replace medical stock big cap leadership be now more diverse have be year stock be many sector include retail software tobacco leisure many be early stage pattern thank reset breakout didn advance more reset occur stock low undercut low previous base reset count first second stage base have better shot success later stage base follow big cap stock feature first stage basis software sector play salesforce com crm be work first stage consolidation stock have regain day day line be only new high breakout year lead gain stock hasn post gain august november retail sector stock chipotle grill cmg be work first stage pattern stock be high be battle retake day line breakout year lead gain most recently tobacco sector stock reynold american rai clear buy point monday strong volume be miss valid usually deliver volume spike least average strong volume be mark institutional activity food meat stock hormel hrl rushed past buy point monday volume be average stock be defensive seldom deliver big gain breakout hormel last big gain be pop november
286,ILMN,gilead science gild stock price finished flat friday follow analyst downgrade activision blizzard atvi get higher price target mcdonald mcd pfizer pfe google googl also see analyst action morgan stanley downgrade gilead equal weight give price target share world biggest biotech finished penny higher
287,ILMN,stock show volatility hasn be see several year bear say tell so investor need positive news look ambarella amba sucampo pharmaceutical scmp horton dhi illumina ilmn have see analyst raise earning estimate let take look ambarella earning due tuesday ambarella report second quarter earning
288,ILMN,rise online medical diagnostic tool mobile health apps wearable person be take health own hand perhaps more ever so laboratory corp america lh diagnostic giant be reach past doctor office directly public company be let consumer order test measure cholesterol
289,ILMN,earning report have hammer lead stock hasn be case most big cap member most quarterly report way big capitalization leader have sail past earning announcement
290,ILMN,most beat wall street expectation also most have climb earning press release come past couple week medical sector have largest share big cap account several earning winner gilead science gild gap report sale profit exceed expectation also raise full year guidance share beat analyst consensus cent largest margin victory earning race stock have rise almost day july report be form right side base better expect sale earning also help valeant pharmaceutical vrx break base july illumina ilmn however be medical leader tumble gene sequence company july beat earning estimate miss revenue expectation share sell day report sink back prior buy point illumina drop big cap alexion pharmaceutical alxn beat estimate thursday guidance fall short expectation cost stock have fall modestly report remain entry market also have cool reception edward lifescience ew result even sale earning be higher analyst expect stock have be day number be release week outside health care ebay ebay top profit estimate july charge new high follow news share have recede bit have hold high chipotle grill cmg barely beat second quarter view ep rise share sale climb estimate yet chipotle have best post earning performance big cap share soar day earning report investor turn optimistic third quarter sale traffic trend chipotle remain new high reynold american rai also have do well quarterly report tobacco company be second quarter earning top expectation company raise full year outlook stock be extend buy point few big cap company have not report result yet include monster beverage mnst hca holding hca
291,ILMN,baidu tumble mixed result take internet focuse etfs intraday trade tuesday major exchange trade fund rally early action series decline bring tepid earning season thus far ugly china sell yesterday baidu bidu stock nosedive earning miss late monday china base search engine
292,ILMN,best etfs july performance update biotechnology pharmaceutical etfs power ahead past month hand profit steroid investor wave merger robust pipeline busier ever hospital continue drive industry forward ishare nasdaq biotechnology ibb best perform etf past week year date have big stake ibd leaderboard
293,ILMN,jpmorgan large cap growth fund be build head steam fund have top morningstar large cap growth rival straight quarters past
294,ILMN,month end go tuesday fund be vs large cap growth mutual fund track morningstar inc be direct rival
295,ILMN,outperformance reflect portfolio average ibd composite rating be very strong fund stock have composite rating better
296,ILMN,composite rating summarize earning share growth relative price strength other slim rating rating be best
297,ILMN,fund gain investor have be drive name monster beverage mnst be so far year
298,ILMN,trading stock be form cup handle base buy point
299,ILMN,fund add monster have composite rating first quarter beverage maker benefit partnership coca cola ko gain market share energy drink
300,ILMN,regeneron pharmaceutical regn have be driver eye disease drugmaker be year be form flat base buy point
301,ILMN,earning share grow past quarters
302,ILMN,eye drug eylea be key growth driver regeneron
303,ILMN,zack equity research say eylea sale get boost use treat diabetic retinopathy form macular edema
304,ILMN,await green light
305,ILMN,sanofi sny regeneron hope get approval month regulator cholesterol lower drug praluent
306,ILMN,starbucks sbux composite rating have be third driver share be year
307,ILMN,fund boost stake share march dec
308,ILMN,tuesday coffee shop chain say partner taste holding johannesburg list company open full format store south africa taste own run java joint
309,ILMN,starbucks return equity be past year monday tuesday stock hit new high share be extend january have rebound week line
310,ILMN,illumina ilmn be year early tuesday retook buy point week tight pattern
311,ILMN,gene sequence leader have composite rating be ibd leaderboard
312,ILMN,illumina facebook fb be leaderboard be ibd share be year
313,ILMN,facebook remain new high tuesday afternoon stock be buy point still buy range
314,ILMN,accord medium report friday company be look add music video news feed
315,ILMN,valeant pharmaceutical international vrx be so far year earning share specialty drug medical device company grow past quarters
316,ILMN,toronto list company have history accretive acquisition such takeover brand drugmaker salix pharmaceutical jpmorgan large cap growth fund be build head steam fund have top morningstar large cap growth rival straight quarters past month end go tuesday fund be vs large cap growth mutual fund track morningstar inc be direct rival outperformance reflect portfolio average ibd composite rating be very strong fund stock have composite rating better composite rating summarize earning share growth relative price strength other slim rating rating be best fund gain investor have be drive name monster beverage mnst be so far year trading stock be form cup handle base buy point fund add monster have composite rating first quarter beverage maker benefit partnership coca cola ko gain market share energy drink regeneron pharmaceutical regn have be driver eye disease drugmaker be year be form flat base buy point earning share grow past quarters eye drug eylea be key growth driver regeneron zack equity research say eylea sale get boost use treat diabetic retinopathy form macular edema await green sanofi sny regeneron hope get approval month regulator cholesterol lower drug praluent starbucks sbux composite rating have be third driver share be year fund boost stake share march dec tuesday coffee shop chain say partner taste holding johannesburg list company open full format store south africa taste own run java joint starbucks return equity be past year monday tuesday stock hit new high share be extend january have rebound week line illumina ilmn be year early tuesday retook buy point week tight pattern gene sequence leader have composite rating be ibd leaderboard illumina facebook fb be leaderboard be ibd share be year facebook remain new high tuesday afternoon stock be buy point still buy range accord medium report friday company be look add music video news feed valeant pharmaceutical international vrx be so far year earning share specialty drug medical device company grow past quarters toronto list company have history accretive acquisition such takeover brand drugmaker salix pharmaceutical
317,ILMN,inc research holding incr provider clinical research service be just buy range clear buy point cup base
318,ILMN,stock clear buy point last week heavy volume rise straight week nearly erase gain previous cup base buy point
319,ILMN,inc be contract research organization cro provide late stage clinical trial pharmaceutical biotechnology medical device industry focus mostly grow number treatment aim cancer central nervous system disorder genetic disorder
320,ILMN,cro be benefit big drug company seek cut cost outsource clinical test
321,ILMN,inc have report straight quarters triple digit profit growth include spike latest quarter cent share revenue growth have be modest however range span
322,ILMN,inc boast best possible composite rating ranking top stock highly rate medical research equipment service industry group include ibd leaderboard stock illumina ilmn
323,ILMN,ibd composite rating factor key metric such earning growth stock price gain return equity
324,ILMN,inc have more double go public november best possible accumulation distribution rating indicate strong demand share
325,ILMN,stock be somewhat thin trading fewer share day average volume have more double february
326,ILMN,last year inc post return equity just shy threshold characteristic premium growth stock figure have rise straight year
327,ILMN,profit year be expect rise share follow gain revenue year be expect rise year further inc research holding incr provider clinical research service be just buy range clear buy point cup base stock clear buy point last week heavy volume rise straight week nearly erase gain previous cup base buy point inc be contract research organization cro provide late stage clinical trial pharmaceutical biotechnology medical device industry focus mostly grow number treatment aim cancer central nervous system disorder genetic disorder cro be benefit big drug company seek cut cost outsource clinical test inc have report straight quarters triple digit profit growth include spike latest quarter cent share revenue growth have be modest however range span inc boast best possible composite rating ranking top stock highly rate medical research equipment service industry group include ibd leaderboard stock illumina ilmn ibd composite rating factor key metric such earning growth stock price gain return equity inc have more double go public november best possible accumulation distribution rating indicate strong demand share stock be somewhat thin trading fewer share day average volume have more double february last year inc post return equity just shy threshold characteristic premium growth stock figure have rise straight year profit year be expect rise share follow gain revenue year be expect rise year further
328,ILMN,illumina ilmn have be move sideway past week attempt build new base correction base be tad too deep be flat base form handle have be consider cup handle base relative strength line be new high be positive
329,ILMN,genomic firm illumina ilmn dip monday news compete high end gene sequencer lower end rival bio reference laboratory brli rise miss quarterly expectation european human genetic conference weekend complete genomic unit bgi formerly beij genomic institute preview revolocity sequence system supersequencer design deliver many whole genome sequence year high volume leerink analyst dan leonard say research note monday enable sequence cost genome landmark illumina first hit hiseq system rolled last year leonard note illumina have several competitor small scale target sequence such thermo fisher scientific tmo qiagen qgen bio rad laboratory bio revolocity be first high throughput rival believe biggest promise differentiate feature complete genomic system be sample answer capability leonard write bgi promise enable user input genomic dna blood saliva walk away instrument propose automate sequence process sample prep basic datum analysis variant call evercore isi analyst ross muken write note however illumina be tough competitor illumina credit have thwart most not challenger efficiently be certain have anticipate launch give constant paranoia muken write research report monday thus now view update skeptical eye do acknowledge launch have potential modestly impact term order pattern manufacturing not yet commercial scale thus complete likely hope delay purchase early reveal possibly shift small amount share customer already announce illumina stock record new high close friday late morning trading stock market today be fraction meanwhile bio reference lab stock be more even fiscal report be soft company revenue climb year earlier quarter short analyst consensus accord thomson reuter profit rise cent share miss estimate cent nonetheless statement bio reference ceo marc grodman highlighted growth firm sequence business be key selling point sale opko health opk announce last week opko stock be more late morning trading monday patient sequence test be refer bio reference genetic lab genedx requisition not include other bio reference business unit woman health oncology grodman say be increase increase have be higher have not be impact higher deductible plan impact expect lessen continue calendar year opko bio reference say ll hold conference call discuss merger thursday morning lieu earning call monday follow amy reeve twitter ibd_areeve
330,ILMN,illumina ilmn be few big cap stock buy point stock have be carve base past week correction be bit too deep flat base so have cup cup handle base cup handle be better
331,ILMN,doctor prescribe first quarter earning trio medical related company perform strongly other examination disappoint analyst amgen amgn earn share year earlier crush cent estimate analyst poll thomson reuter be best gain quarters amgen revenue rise
332,ILMN,apple aapl chip supplier qorvo qrvo skywork swks get split rating thursday lead biotech celgene celg be upgrade qorvo supply chip apple iphone see share close stock market today be initiate neutral citigroup last week new apple iphone hit store shelve apple selling more iphone handset open weekend meanwhile fellow apple supplier skywork be initiate buy rating citigroup stock price end lower thursday apple share fall celgene stock price rise be upgrade overweight jpmorgan biotech market cap have bounce back last couple day follow session selloff tie partly negative industry comment make democratic presidential candidate hillary clinton microsoft msft climb bank america upgrade stock neutral wednesday microsoft say plan open flagship store new york city only block south apple flagship manhattan store sandisk sndk rise be upgrade overweight morgan stanley give price target be recent price target provide other analyst wednesday sandisk share pop nearly report chinese tech firm unisplendour take stake western digital wdc bring share sandisk other memory hard drive maker gene sequence technology developer illumina ilmn sank be downgrade market perform leerink swann shoe designer steven madden shoo be upgrade outperform brother share lose follow vance cariaga twitter ibd_vcariaga
333,ILMN,stock remain well underwater head final hour trading tuesday global growth concern fall commodity price fed uncertainty continue weigh nasdaq slump dow volume be tracking higher nyse lower nasdaq stock market today vs same time monday nearly industry group track ibd be few buck decline be auto part retailer group get lift autozone azo gain fast trade auto part store operator report fiscal result open top view mobile home recreational vehicle maker biotechs drugmaker be biggest loser thor industry tho weigh mobile home group drop heavy trade late monday airstream maker fiscal result miss view biotechs continue bleed aftermath democratic presidential candidate hillary clinton monday tweet price gouge specialty drug maker highly rate biotechs sucampo pharmaceutical scmp sank amgen amgn lose celgene celg slide aside handful gainer ibd stock decline board biggest loser be horizon pharmaceutical hznp illumina ilmn valeant pharmaceutical vrx alaska air group alk lose more facebook fb fall day move average threaten end session streak share be work new consolidation potential buy point follow nancy gondo twitter ibd_ngondo
334,ILMN,stock sell broadly tuesday index start swerve monthlong uptrend nasdaq gap loss fall be second decline more past session index trim loss afternoon price chart be left distinct
335,ILMN,slowly more big capitalization leader be get closer complete new basis few week many big cap stock be depth price decline late march share price have be trend higher degree chart be well track potential buy point facebook fb chipotle grill cmg nike nke
336,ILMN,gene sequence giant illumina beat analyst earning estimate tuesday miss revenue first time year send share hour trading illumina ilmn say income exclude time item amount cent share year earlier quarter beating analyst consensus cent accord thomson reuter revenue climb short consensus be third straight quarter decelerate sale growth constant currency basis sale rise company say illumina affirm full year guidance sale growth include impact foreign exchange rate firm raise full year ep range cent be still low side analyst consensus estimate expectation seem be high go stock hit new high monday tuesday grow wobbly however close just shy regular session evercore isi analyst ross muken note be first time illumina miss wall street revenue expectation management have raise revenue guidance time past report street have be widely anticipate beat raise muken write email client tuesday top line shortfall strong operate margin pull allow modest ep beat enabled slight upward tweak guidance add instrument sale vs be also first time more year instrument revenue decline sequentially muken point conference call analyst tuesday illumina president francis desouza say instrument sale overall rise year year shipment high end hiseq gene sequencer have fall compare last year product have just be rolled much fanfare other hand lower end nextseq myseq be continue grow nicely say overall sequence revenue grow ceo jay flatley say growth area be reproductive health field illumina enter acquisition few year sale ivf fertilization laboratory increase approximately sale come veriseq pgs say flatley reminder veriseq pgs be sequence base pre implantation genetic sequence solution used laboratory transition older array total nipt invasive prenatal testing revenue grow more vs second quarter last year result be due part double test send sample well increase product sale nipt provider globally flatley also praise growth shipment oncology customer customer base illumina have be try expand lately illumina have launch special cancer panel liquid biopsy program serve market revenue microarray oldest lowest end illumina business shrank volume actually grow business flatley say pricing environment be harsh illumina have be face more competition area lately player such thermo fisher scientific tmo roche rhhby
337,ILMN,gene sequence giant illumina say tuesday have joined warburg pincus sutter hill venture form new company call helix hope bring genomic mass helix enable individual acquire unprecedented amount genetic information provide affordable sequence database service consumer sample bring third party partner drive
338,ILMN,google googl rise modestly wednesday follow upgrade base youtube growth potential analog device illumina also get strong mark analyst atlantic equity analyst james cordwell upgrade google overweight neutral note youtube be grow very rapidly shift stream video youtube have significant potential revenue growth accord benzinga
339,ILMN,market not gilead netflix restoration hardware have week most notable insider stock transaction gilead science gild chairman ceo john martin sell share worth tuesday last month maker hepatitis drug harvoni sovaldi handily beat analyst estimate raise guidance week gilead
340,ILMN,market bounce back straight session loss here look ibd stock bounce back find support move average unite therapeutic uthr ellie mae elli epam system epam illumina ilmn unite therapeutic stage huge upside reversal stock market today fall nearly move
341,ILMN,red hot biotechnology semiconductor etfs be cool dramatically lead friday sell sector equity fund head second week steep decline have analyst wring hand red wash biotech stock mean investor be overdue correction frothy sector mere blip rally ishare nasdaq biotechnology ticker
342,ILMN,share illumina ilmn remain buy range stock float just most recent buy point stock be less entry occur june illumina clear short handle formation pattern volume be average day surge next day confirm
343,ILMN,etf investor biotechnology stock be rattle nose dive first heavyweight earning gate ishare nasdaq biotechnology ibb biotech exchange trade fund have lose past trading session illumina ilmn stumble ahead celgene celg biogen biib report week ibd speak tushar
344,ILMN,tcw select equity be tear portfolio be year go tuesday top large cap growth rival track morningstar inc fund gain past month also beat peer group relative performance be heating past month fund
345,ILMN,handful ibd stock get boost last week buck overall market weakness thank better expect quarterly result illumina ilmn make genetic testing equipment be few disappointment plunge wednesday sale trail analyst forecast stock slice day move average line erased gain past buy point trigger sell signal
346,ILMN,illumina have rebound have find support day line be nearly past entry just buy range
347,ILMN,valeant pharmaceutical vrx clear buy point flat base thursday strong volume better expect earning report valeant reversed time high friday be still buy range
348,ILMN,base be late stage have form stock have already enjoy long advance make risky stock relative strength line be hit new high indicate outperform demand share remain strong
349,ILMN,manhattan associate manh develop supply chain management software wide range industry jump new high wednesday profit rise easily beating view manhattan associate pull back lower volume remain more past buy point cup base buy range
350,ILMN,cirrus logic crus report late wednesday profit fiscal first quarter jump cent share easily beating wall street estimate apple aapl supplier stock jump next day clear day line come close buy point
351,ILMN,cirrus logic fall back day friday heavy volume
352,ILMN,starbucks sbux get nice bounce better expect earning report late thursday coffee retailer jump much new high friday pare much gain starbucks be nearly flat base buy point clear january also extend multiple rebound day line
353,ILMN,ibd company report quarterly earning week include taser international tasr edward lifescience ew unite therapeutic uthr vasco datum security vdsi reilly automotive orly facebook fb universal health service uhs ellie mae elli
354,ILMN,week ibd fall much less decline handful ibd stock get boost last week buck overall market weakness thank better expect quarterly result illumina ilmn make genetic testing equipment be few disappointment plunge wednesday sale trail analyst forecast stock slice day move average line erased gain past buy point trigger sell signal illumina have rebound have find support day line be nearly past entry just buy range valeant pharmaceutical vrx clear buy point flat base thursday strong volume better expect earning report valeant reversed time high friday be still buy range base be late stage have form stock have already enjoy long advance make risky stock relative strength line be hit new high indicate outperform demand share remain strong manhattan associate manh develop supply chain management software wide range industry jump new high wednesday profit rise easily beating view manhattan associate pull back lower volume remain more past buy point cup base buy range cirrus logic crus report late wednesday profit fiscal first quarter jump cent share easily beating wall street estimate apple aapl supplier stock jump next day clear day line come close buy point cirrus logic fall back day friday heavy volume starbucks sbux get nice bounce better expect earning report late thursday coffee retailer jump much new high friday pare much gain starbucks be nearly flat base buy point clear january also extend multiple rebound day line ibd company report quarterly earning week include taser international tasr edward lifescience ew unite therapeutic uthr vasco datum security vdsi reilly automotive orly facebook fb universal health service uhs ellie mae elli week ibd fall much less decline
355,ILMN,illumina ilmn surpass second quarter earning estimate late tuesday miss revenue first time year analyst expect beat raise maker gene sequence system so share suffer stock market today illumina stock gap huge volume wednesday breach day move average intraday stock be
356,ILMN,stock remain lower tuesday afternoon recovery effort fizzle hurt medium transportation stock be dow jone industrial average slump meanwhile nasdaq fall milder thank strength biotechs tech heavy index briefly reach positive territory earlier volume be run mixed nyse trade be tracking higher compare same time monday nasdaq volume be run lower lead stock southwest airline luv gap slump lower key metric open discount carrier say operate revenue available seat mile rasm be flat lower fourth quarter vs year intraday stock fall buy point cup base clear early november other airline also come pressure perform well monday virgin america va spirit airline save drop unite continental ual american airline aal delta air line dal fall elsewhere outerwall outr be session low still whopping announce trio bad news late monday operator redbox movie dispense kiosk lower full year guidance earning sale say shutter sampleit kiosk consumer get sample product coupon also announce resignation redbox president mark horak share fall year low earlier stock market today leader volume be few adobe system adbe rise reverse now past buy point cup handle base software giant report fiscal earning thursday close software giant be expect post cent share year follow vincent mao twitter ibd_vmao
357,ILMN,stock slump tuesday close session lows dow jone industrial average slide hurt earning weakness component ibm ibm unite technology group utx nasdaq close trim volume be mixed accord preliminary number higher nyse lower nasdaq exchange tesla motor tsla fall more stock market today ub downgrade stock concern maker luxury electric vehicle win be able meet sale forecast tesla retreat come day briefly clear buy point cup handle base upside fitbit fit rise better reverse higher earlier session stock nearly erased hit take monday biggest loss go public june fitbit be now nearly past proper buy point ipo base action camera maker gopro gpro surge highest level january regular session hour share be volatile response result top analyst consensus estimate top bottom line sale jump adjust earning vault cent share net profit margin soar vs year quarter illumina ilmn share be hard hour second quarter revenue miss expectation increase mark consecutive quarter double digit top line growth earning share climb illumina close regular session past handle buy point apple aapl chipotle grill cmg microsoft msft also fall hour report disappoint investor
358,ILMN,handful big cap stock be due report quarterly earning week only be expect post accelerate profit growth starbucks sbux report fiscal earning thursday profit be see rise cent share mark second straight quarter acceleration sale be forecast climb
359,ILMN,hunt quality challenge market start relative strength line tell investor stock be act vs decline rs line mean stock be laggard rise rs line point outperformance sometimes stock outperform lose less other time outperform
360,ILMN,earning season be now high gear eye apple aapl report tuesday iphone maker deliver quarter solid profit sale growth apple isn ibd list very best stock come week company elite ibd be tap report earning starbucks sbux
361,ILMN,stock re-cover early loss turn modestly higher wednesday
362,ILMN,early afternoon trading dow jone industrial average rise nasdaq add nyse volume be tracking slightly higher tuesday level nasdaq volume fall bit
363,ILMN,stock market today homebuilder shrug better expect read march exist home sale ibd build residential commercial industry group lose more
364,ILMN,couple top rate growth stock take hit report earning chipotle cmg crater nearly company report quarter bottom line top line growth double digit same store sale growth disappoint illumina ilmn meanwhile slump handily beating expectation profit jump year sale rise
365,ILMN,elsewhere leaderboard name visa jump back day move average rise china announce open market clear domestic card bank transaction news give visa direct access huge market visa be work flat base buy point
366,ILMN,facebook fb edge higher ahead earning report close profit be see rise cent share facebook have be transparent dramatic increase spending year full year profit be expect rise only year compare growth growth
367,ILMN,skecher skx also report close quarterly profit be see rise share share ease extend feb gap price stock re-cover early loss turn modestly higher wednesday early afternoon trading dow jone industrial average rise nasdaq add nyse volume be tracking slightly higher tuesday level nasdaq volume fall bit stock market today homebuilder shrug better expect read march exist home sale ibd build residential commercial industry group lose more couple top rate growth stock take hit report earning chipotle cmg crater nearly company report quarter bottom line top line growth double digit same store sale growth disappoint illumina ilmn meanwhile slump handily beating expectation profit jump year sale rise elsewhere leaderboard name visa jump back day move average rise china announce open market clear domestic card bank transaction news give visa direct access huge market visa be work flat base buy point facebook fb edge higher ahead earning report close profit be see rise cent share facebook have be transparent dramatic increase spending year full year profit be expect rise only year compare growth growth skecher skx also report close quarterly profit be see rise share share ease extend feb gap price
368,ILMN,stock take mild loss quiet trading early wednesday earning report center action
369,ILMN,dow jone industrial average dip nasdaq fall loss boee ba chipotle grill cmg illumina ilmn intuitive surgical isrg weigh early trading
370,ILMN,volume be mixed stock market today shade higher nyse nasdaq compare same time tuesday
371,ILMN,morning economic news be good
372,ILMN,housing price rise february accord federal housing finance agency housing price index gain be better double january advance best view
373,ILMN,exist home sale jump annualize rate march national association realtor report well february upwardly revise pace sale also stomp expectation sale
374,ILMN,stock mcdonald mcd lead dow surge announce generally weak result pledge announce turnaround plan detail say share
375,ILMN,visa also help bolster dow gain
376,ILMN,tesla motor tsla broadcom brcm lead nasdaq more
377,ILMN,tesla jump note deutsche bank say energy storage system company plan launch april represent significant opportunity bank maintain stock buy rating price target tesla share have be rise late march month dive
378,ILMN,lead stock stage positive open ibd stock advance early trade gain loss be generally mild drugmaker grab early upside lead horizon pharma hznp akorn akrx more stock be trading just tuesday high akorn be also just cup base buy point
379,ILMN,list low end genetic test equipment maker illumina ilmn slump report generally positive result late tuesday full year guidance be mixed stock be form double bottom base buy point stock take mild loss quiet trading early wednesday earning report center action dow jone industrial average dip nasdaq fall loss boee ba chipotle grill cmg illumina ilmn intuitive surgical isrg weigh early trading volume be mixed stock market today shade higher nyse nasdaq compare same time tuesday morning economic news be good housing price rise february accord federal housing finance agency housing price index gain be better double january advance best view exist home sale jump annualize rate march national association realtor report well february upwardly revise pace sale also stomp expectation sale stock mcdonald mcd lead dow surge announce generally weak result pledge announce turnaround plan detail say share visa also help bolster dow gain tesla motor tsla broadcom brcm lead nasdaq more tesla jump note deutsche bank say energy storage system company plan launch april represent significant opportunity bank maintain stock buy rating price target tesla share have be rise late march month dive lead stock stage positive open ibd stock advance early trade gain loss be generally mild drugmaker grab early upside lead horizon pharma hznp akorn akrx more stock be trading just tuesday high akorn be also just cup base buy point list low end genetic test equipment maker illumina ilmn slump report generally positive result late tuesday full year guidance be mixed stock be form double bottom base buy point
380,ILMN,stock have trouble find direction morning be mildly higher go noon hour mixed bag earning report dominate action
381,ILMN,nasdaq rise less dow jone industrial average gain volume be tracking higher nyse lower nasdaq
382,ILMN,visa rise mastercard heavy volume china say let foreign company set bank card clear operation field dominate state run unionpay rule take effect june stock have be build flat basis
383,ILMN,amgen amgn break cup handle base gain quickly fade close tuesday company report better expect earning raise earning outlook
384,ILMN,illumina ilmn be report better expect earning cent share increase year cent estimate stock have trade higher hour action earning announcement tuesday
385,ILMN,chipotle grill cmg gap be trading lower top estimate earning miss sale
386,ILMN,restaurant stock yum brand yum break cup handle base rise profit beat analyst forecast same store sale china source half company revenue fall stock have trouble find direction morning be mildly higher go noon hour mixed bag earning report dominate action nasdaq rise less dow jone industrial average gain volume be tracking higher nyse lower nasdaq visa rise mastercard heavy volume china say let foreign company set bank card clear operation field dominate state run unionpay rule take effect june stock have be build flat basis amgen amgn break cup handle base gain quickly fade close tuesday company report better expect earning raise earning outlook illumina ilmn be report better expect earning cent share increase year cent estimate stock have trade higher hour action earning announcement tuesday chipotle grill cmg gap be trading lower top estimate earning miss sale restaurant stock yum brand yum break cup handle base rise profit beat analyst forecast same store sale china source half company revenue fall
387,ILMN,stock strengthen mixed volume go final hour trading wednesday nasdaq dow jone industrial average rise gain volume be tracking higher nyse lighter nasdaq stock market today
388,ILMN,tesla motor tsla rise more company say email analyst investor unveil home battery very large utility scale battery april company have report straight quarters decline earning growth
389,ILMN,wabtec wab rise more have be much higher earlier maker railroad equipment report earning revenue beat estimate company raise guidance stock break flat base
390,ILMN,facebook fb be less trader await earning close analyst be expect cent share increase year
391,ILMN,visa mastercard rise heavy volume china say let foreign company set bank card clear operation field dominate state run unionpay rule take effect june stock have be build flat basis
392,ILMN,amgen amgn break cup handle base gain quickly fade leave less higher late tuesday company report better expect earning raise earning outlook
393,ILMN,illumina ilmn be report better expect earning cent share increase year cent estimate stock initially surge result tuesday hour session
394,ILMN,chipotle grill cmg gap be trading lower top estimate earning miss sale stock strengthen mixed volume go final hour trading wednesday nasdaq dow jone industrial average rise gain volume be tracking higher nyse lighter nasdaq stock market today tesla motor tsla rise more company say email analyst investor unveil home battery very large utility scale battery april company have report straight quarters decline earning growth wabtec wab rise more have be much higher earlier maker railroad equipment report earning revenue beat estimate company raise guidance stock break flat base facebook fb be less trader await earning close analyst be expect cent share increase year visa mastercard rise heavy volume china say let foreign company set bank card clear operation field dominate state run unionpay rule take effect june stock have be build flat basis amgen amgn break cup handle base gain quickly fade leave less higher late tuesday company report better expect earning raise earning outlook illumina ilmn be report better expect earning cent share increase year cent estimate stock initially surge result tuesday hour session chipotle grill cmg gap be trading lower top estimate earning miss sale
395,ILMN,health care stock be move many make new high federal reserve last week signale interest rate increase be least few month combination have be good news health care reit be right sector help reit so do prospect continue low interest rate
396,ILMN,reit medical property trust mpw sabra healthcare sbra have form double bottom formation sabra already have break buy point be new high ground medical property be trading just buy point
397,ILMN,medical property buy hospital rehab center other specialty hospital lease back establish operator also finance construction new expansion exist medical facility be expand europe
398,ILMN,reit pay regular quarterly dividend cent share work annual dividend
399,ILMN,wall street expect increase fund operation reit equivalent earning increase
400,ILMN,sabra have portfolio real estate medical property be lease operator include senior housing facility
401,ILMN,sabra pay cent quarterly dividend work annualize yield analyst expect growth year next year ffo rise most recent quarter revenue year
402,ILMN,biom realty trust bmr own office laboratory lease business life science earlier year sign year lease illumina ilmn new square foot campus foster city calif biom expect turn facility illumina
403,ILMN,stock correct recent week re-cover much decline be now trading high health care stock be move many make new high federal reserve last week signale interest rate increase be least few month combination have be good news health care reit be right sector help reit so do prospect continue low interest rate reit medical property trust mpw sabra healthcare sbra have form double bottom formation sabra already have break buy point be new high ground medical property be trading just buy point medical property buy hospital rehab center other specialty hospital lease back establish operator also finance construction new expansion exist medical facility be expand europe reit pay regular quarterly dividend cent share work annual dividend wall street expect increase fund operation reit equivalent earning increase sabra have portfolio real estate medical property be lease operator include senior housing facility sabra pay cent quarterly dividend work annualize yield analyst expect growth year next year ffo rise most recent quarter revenue year biom realty trust bmr own office laboratory lease business life science earlier year sign year lease illumina ilmn new square foot campus foster city calif biom expect turn facility illumina stock correct recent week re-cover much decline be now trading high
404,ILMN,google fuel strength nasdaq composite index stock be mixed trading mostly lower go noon hour friday
405,ILMN,nasdaq rise be trading time high fall dow jone industrial average be volume stock market today be higher exchange
406,ILMN,nyse decline stock lead advance stock nearly margin nasdaq margin be nearly
407,ILMN,google gap be trading higher report earning thursday close
408,ILMN,ibd stock only be higher be lower
409,ILMN,best performer elite list be facebook fb reach time high heavy volume break flat base june be now extend buy point
410,ILMN,illumina ilmn rise canaccord initiate coverage buy rating price target stock be trading high be also extend buy point consolidation
411,ILMN,tractor supply tsco rise seventh straight day telsey advisory group up price target reiterate outperform rating
412,ILMN,domino pizza dpz fall nearly drop buy point flat base struggle hold day move average investor be disappoint wednesday earning report
413,ILMN,software maker solarwind swi be crushed drop report disappointing license growth google fuel strength nasdaq composite index stock be mixed trading mostly lower go noon hour friday nasdaq rise be trading time high fall dow jone industrial average be volume stock market today be higher exchange nyse decline stock lead advance stock nearly margin nasdaq margin be nearly google gap be trading higher report earning thursday close ibd stock only be higher be lower best performer elite list be facebook fb reach time high heavy volume break flat base june be now extend buy point illumina ilmn rise canaccord initiate coverage buy rating price target stock be trading high be also extend buy point consolidation tractor supply tsco rise seventh straight day telsey advisory group up price target reiterate outperform rating domino pizza dpz fall nearly drop buy point flat base struggle hold day move average investor be disappoint wednesday earning report software maker solarwind swi be crushed drop report disappointing license growth
414,ILMN,etf investor be incline let big hit miss earning season pass buy exchange trade fund instant diversification sidestep single stock risk
415,ILMN,not so fast
416,ILMN,earning season be particularly important investor industry sector focuse etfs say todd rosenbluth director etf research capital iq product tend be more concentrated stock level be definitely more concentrated industry level
417,ILMN,not unusual company story revenue growth be replicate multiple time same industry
418,ILMN,earning beat not be relevant look landscape rosenbluth say
419,ILMN,company rein cost beat earning have less control person buy product service
420,ILMN,take illumina ilmn wednesday leaderboard stock report sale miss earning beat be send ibd cut list maker genetic testing equipment be top stock ishare nasdaq biotechnology ibb
421,ILMN,give illumina glum revenue picture etf investor want watch spillover effect other life science company
422,ILMN,ibb allocate asset subindustry
423,ILMN,ibb hold stock roughly asset top holding celgene celg biogen biib together company report week
424,ILMN,heavyweight be also find broadly diversify ishare core ivv far smaller amount combine portfolio weighting be
425,ILMN,etf concentration
426,ILMN,care more result ve choose ibb biotech exposure concentrated bet rosenbluth say
427,ILMN,many successful investor have biotechnology company deliver steady growth ibb have soar build past year double digit gain
428,ILMN,broader etf such ivv rosenbluth add question ask be be most company beating expectation
429,ILMN,equally important biotech investor keep mind company have earning like synergy pharmaceutical sgyp radius health rdus prothena prta ibb have small stake have early stage drug yet come market
430,ILMN,price move be tie success lack thereof clinical trial have nothing do earning
431,ILMN,more mature company stock move base well company earning revenue come relative expectation rosenbluth say
432,ILMN,ibb fall wednesday disappointing stock market news new alzheimer drug development biogen illumina nose dive post earning etf investor be incline let big hit miss earning season pass buy exchange trade fund instant diversification sidestep single stock risk not so fast earning season be particularly important investor industry sector focuse etfs say todd rosenbluth director etf research capital iq product tend be more concentrated stock level be definitely more concentrated industry level not unusual company story revenue growth be replicate multiple time same industry earning beat not be relevant look landscape rosenbluth say company rein cost beat earning have less control person buy product service take illumina ilmn wednesday leaderboard stock report sale miss earning beat be send ibd cut list maker genetic testing equipment be top stock ishare nasdaq biotechnology ibb give illumina glum revenue picture etf investor want watch spillover effect other life science company ibb allocate asset subindustry ibb hold stock roughly asset top holding celgene celg biogen biib together company report week heavyweight be also find broadly diversify ishare core ivv far smaller amount combine portfolio weighting be etf concentration care more result ve choose ibb biotech exposure concentrated bet rosenbluth say many successful investor have biotechnology company deliver steady growth ibb have soar build past year double digit gain broader etf such ivv rosenbluth add question ask be be most company beating expectation equally important biotech investor keep mind company have earning like synergy pharmaceutical sgyp radius health rdus prothena prta ibb have small stake have early stage drug yet come market price move be tie success lack thereof clinical trial have nothing do earning more mature company stock move base well company earning revenue come relative expectation rosenbluth say ibb fall wednesday disappointing stock market news new alzheimer drug development biogen illumina nose dive post earning
433,ILMN,good stock idea isn much use don understand re look be institutional quality stock be cyclical play probably only profit industry cycle be turnaround story involve fix company problem be fad stock run hot person tire novelty
434,ILMN,strategy target differ situation vary kind uptrend market be peg stock wrong market wrong probably lose money least make less investor be go make big money institutional quality stock operate strong uptrend most often be investor best choice however be time cyclical stock turnaround fad stock deliver good gain investor find identify great stock idea weekly review ywr also know list be good place look friday ibd screen stock score ep rating relative price strength rating mean stock be top percentile stock ibd database stock also be month high chart be list industry group chart aren print stock additional stock be list fine print list last page ywr today big net make good place look stock idea low hurdle screen pick more cyclical turnaround fad stock high hurdle screen person sneer fad stock argue such stock be dangerous win last aren serious investor well stock be dangerous fad stock have shorter life sometimes re talk be solid company indirectly benefit fad example egg producer distributor cal maine food calm ride atkin diet big stock gain other case fad develop longer last trend instance decker outdoor deck buy ugg holding august eventually turn ugg boot once popular mostly surfer broader fashion trend october october decker outdoors share rise ugg deserving much credit be used let look screen be publish ibd oct not long market low oct follow day follow day soon market low be often best time breakout retake buy point bounce week move average see minichart investor ve find institutional quality stock soon set valid entry apple aapl celgene celg ulta beauty ulta illumina ilmn skywork swks gain varied cyclical eventually offer entry landstar system lstr old dominion freight line odfl fedex fdx lennar len gain run turnaround fad be scarce market be have be choppy be take profit apple be prudent
435,ILMN,stock ease tuesday day find direction prove be elusive task nasdaq fall hold small price range volume rise board give distribution day nasdaq loss be too small be consider heavy institutional selling day result widen gap
436,ILMN,most stock sector leader have already break illumina ilmn be gear make move stock appear thursday sector leader begin look start new flat base striking jan high past few day action shallow double bottom be take shape illumina be
437,ILMN,best mutual fund first quarter performance report michael kotlarz take rein oppenheimer capital appreciation fund july fund relative performance have jump year kotlarz take rein fund average annual gain be hold humble return bear market performance lag
438,ILMN,tech stock lead mixed show wall street tuesday earning report activity dominate headline early gain turn loss close dow also reversed lower fall weigh sluggish result dupont dd nasdaq trade tight range day end
439,ILMN,only prospective investor answer ultimate question be buy resource such ibd help guide decision take top medical stock tuesday sector leader biogen idec biib illumina ilmn lannett lci ibd stock have meet strict fundamental technical gauge make screen yet
440,ILMN,unsettled market make sense err side caution sometimes mean focuse less aggressive growth small cap name more liquid large cap name find week big cap big cap component be generally less volatile small cap name partly due heavy mutual fund sponsorship name
441,ILMN,pop top hold celgene celg drive ishare nasdaq biotechnology ibb second largest health care etf new high stock market today celgene announce late tuesday acquire san diego base receptos rcpt celgene robust earning revenue result also beat analyst consensus estimate new jersey base
442,ILMN,almost third stock sector leader list come highly rate medical industry only illumina ilmn be buy range several recent addition be worth watch gilead science gild have retreat buy point long cup base market week slide stock still boast
443,ILMN,heavy load distribution day nasdaq market uptrend be pressure here look ibd stock be hold wake monday plunge trading high ulta beauty ulta fleetmatic fltx manhattan associate manh ellie mae elli illumina ilmn ulta beauty be
444,ILMN,add internet thing obamacare get big change health care industry so say goldman sachs report call digital revolution come healthcare iot refer wireless technology connect industrial medical automotive consumer device web apple aapl recently introduce monitoring feature healthkit app apple
445,ILMN,wedbush security maxim group raise illumina ilmn price target day maker gene sequence system report fourth quarter earning beat analyst view huge rise ep wedbush note jan post earning report illumina turn result show gene sequence business be do even better pre announcement quarterly sale have suggest company pre announce sale earlier month investment house also note company entire system portfolio be also outperform expectation wedbush raise price target illumina stock wednesday keep outperform rating maxim group equity research raise price target illumina stock wednesday report note company strong report guidance sign growth let maxim keep buy rating stock growth be strongest unite state europe strong growth china be offset weakness japan maxim report say illumina say late tuesday have earn cent share rise last year top view cent revenue grow estimate illumina stock fall morning trading stock market today illumina seesaw close tuesday follow better expect earning report stock fluctuated loss gain post session trading announcement climb regular session end buy point buy range illumina have ibd composite rating putt top company number key factor include profit sale growth company be top developer genetic analysis tool used biotech drug diagnostic research analyze genetic underpinning different organism disease related drug firm report good outlook cloudy
446,ILMN,share illumina sank back base company report earning even result top expectation maker gene sequence equipment initially jump wednesday day illumina ilmn announce stock reversed lower market sell temporarily dip back buy point flat base reversal have be disappointing
447,ILMN,trail straight quarters jpmorgan mid cap growth be outperform year mutual fund be year go tuesday vs midcap peer track morningstar inc proxy stock market carry rating ibd month performance
448,ILMN,stock fund have not change stripe manager tim parton say interested investing strongest company biggest market share strongest competitive barrier give earning durability
449,ILMN,parton stock investment idea fall category consist call disrupter acuity brand ayi be build product firm be fund biggest position jan
450,ILMN,niche be commercial light driver be grow popularity lead light market share make dominant player space
451,ILMN,cost chip be heart led be fall make lead system more attractive customer be construct retrofitting building parton say
452,ILMN,led give property owner more control light lower key fix cost parton say
453,ILMN,acuity lead business have double year year parton add now total business mean average growth rate whole company be go
454,ILMN,jazz
455,ILMN,consolidator be parton category jazz pharmaceutical jazz be example
456,ILMN,replace valeant pharmaceutical vrx fund holding become too large midcap fund valeant jazz be base offshore low tax ireland jazz case quite advantage make acquisition parton say hasn be super active date probably be
457,ILMN,parton like jazz xyrem narcolepsy drug have little competition potential abuse concern attract strict regulatory oversight say
458,ILMN,overall company have strong cash flow low tax rate take platform layer more thing top parton say
459,ILMN,third category consist pioneer illumina ilmn be pretty much granddaddy genome sequence machine say sell machine well consumable
460,ILMN,cost sequence someone genome have plunge million dollar technology fall cost put illumina heart way medicine be do future parton say
461,ILMN,illumina dominance
462,ILMN,illumina be already pound gorilla field dominance be still grow parton say
463,ILMN,parton boost stake acadium health care achc consolidator june dec firm run chain psychiatric facility
464,ILMN,field be highly fragmented parton say business be improve lot tight professional management be acadium offer
465,ILMN,acadium continue make good acquisition good price so deal be highly accretive earning parton say trail straight quarters jpmorgan mid cap growth be outperform year mutual fund be year go tuesday vs midcap peer track morningstar inc proxy stock market carry rating ibd month performance stock fund have not change stripe manager tim parton say interested investing strongest company biggest market share strongest competitive barrier give earning durability parton stock investment idea fall category consist call disrupter acuity brand ayi be build product firm be fund biggest position jan niche be commercial light driver be grow popularity lead light market share make dominant player space cost chip be heart led be fall make lead system more attractive customer be construct retrofitting building parton say led give property owner more control light lower key fix cost parton say acuity lead business have double year year parton add now total business mean average growth rate whole company be go be parton category jazz pharmaceutical jazz be example replace valeant pharmaceutical vrx fund holding become too large midcap fund valeant jazz be base offshore low tax ireland jazz case quite advantage make acquisition parton say hasn be super active date probably be parton like jazz xyrem narcolepsy drug have little competition potential abuse concern attract strict regulatory oversight say overall company have strong cash flow low tax rate take platform layer more thing top parton say third category consist pioneer illumina ilmn be pretty much granddaddy genome sequence machine say sell machine well consumable cost sequence someone genome have plunge million dollar technology fall cost put illumina heart way medicine be do future parton say illumina be already pound gorilla field dominance be still grow parton say parton boost stake acadium health care achc consolidator june dec firm run chain psychiatric facility field be highly fragmented parton say business be improve lot tight professional management be acadium offer acadium continue make good acquisition good price so deal be highly accretive earning parton say
466,ILMN,just week ahead quarterly earning illumina ilmn stock be make big move share jump stock market today retake day line average volume anticipation president obama announce state union address new government initiative sequence genome be largely beneficial
467,ILMN,add internet thing obamacare get big change health care industry so say goldman sachs report call digital revolution come healthcare iot refer wireless technology connect industrial medical automotive consumer device web apple aapl recently introduce monitoring feature healthkit app apple watch
468,ILMN,article include correct information
469,ILMN,electric car maker tesla motor tsla moved massachusett technology review smartest company ranking gene sequence firm illumina ilmn slip first place
470,ILMN,apple aapl facebook fb neither make smartest company list be back ranking no respectively ranking smartest company include technology tech company
471,ILMN,tesla have be
472,ILMN,other tech company top be chinese smartphone maker xiaomi alibaba group baba tencent holding tcehy solarcity scty netflix nflx
473,ILMN,tech company make list fall top include google googl amazon com amzn techs fall list year include privately hold dropbox salesforce com crm payment startup square
474,ILMN,editor note version story post june incorrectly report datum mit smartest company list not list article include correct information electric car maker tesla motor tsla moved massachusett technology review smartest company ranking gene sequence firm illumina ilmn slip first place apple aapl facebook fb neither make smartest company list be back ranking no respectively ranking smartest company include technology tech company tesla have be other tech company top be chinese smartphone maker xiaomi alibaba group baba tencent holding tcehy solarcity scty netflix nflx tech company make list fall top include google googl amazon com amzn techs fall list year include privately hold dropbox salesforce com crm payment startup square editor note version story post june incorrectly report datum mit smartest company list not list
475,ILMN,stock market often do least expect certainly have be case lately consider recent occurrence heavy distribution day count nasdaq recent week didn do much damage market fact market uptrend resume thursday nasdaq marked time close high rise higher volume show sign climax top last month ambarella amba find support week move average again rise nearly week regeneron regn be hold high series breakout late stage basis right look centene cnc be go roll massive price run back day move averageso go today market good news be action several other ibd name have be far confuse ibd rise week ahead gain gain nasdaq celgene celg gap week cup shape base wednesday rise strong volume announce plan acquire receptos rcpt just receptos key drug be multiple sclerosis ulcerative colitis treatment ozanimod not approve yet early trial have be promising celgene weekly chart look solid still buy range just buy point small cap fleetmatic fltx member wednesday list be high end buy range cup handle buy point monster beverage mnst be similar boat trade buy point meanwhile several ibd name be report earning week illumina ilmn blackhawk network hawk report tuesday close celgene valeant vrx report thursday close valeant be work late stage flat base buy point base be strengthen several tight weekly close valeant have pursue aggressive growth acquisition strategy recent year earlier year buy salix pharmaceutical scoop bausch lomb nearly profit valeant be see rise year share
476,ILMN,stock future veer unevenly lower heavy slate earning report ahead wednesday open
477,ILMN,dow future be point fair market value have pare early loss nasdaq future be point slide future be also tick lower point
478,ILMN,week economic calendar finally kick gear et federal housing finance agency housing price index june exist home sale number national association realtor be due weekly crude oil inventory energy information administration follow
479,ILMN,big name be move ahead open stock market today boee ba microsoft msft coca cola ko whirlpool whr respond quarterly report
480,ILMN,apple aapl grab early headline stock slide more premarket trade late tuesday report better forecast earning gain surge sale expand profit margin fiscal third quarter
481,ILMN,fourth quarter revenue guidance didn quite measure however company separately didn break sale new apple watch apple share end tuesday just day move average shallow month consolidation
482,ILMN,apple supplier be also take early beating cirrus logic crus skywork solution swks more
483,ILMN,vasco datum security vdsi collapse company admit regulatory filing release tuesday product have be sell iran european subsidiary third party distributor
484,ILMN,sale potentially violate federal rule prohibit transaction proliferator weapon mass destruction supporter vasco share have pull back sharply late june high test support week move average
485,ILMN,illumina ilmn dim fall hard report late tuesday earning top revenue miss analyst consensus expectation first time year
486,ILMN,maker large scale genetic screening equipment also raise earning guidance line projection stock finished tuesday just monday high buy point week tight pattern
487,ILMN,blackhawk network hawk climb distributor prepay gift card report late tuesday sale earning clear analyst estimate ibd leaderboard stock end tuesday top buy range buy point cup base
488,ILMN,overseas europe market be pressure midday vote greece be expect pass further fiscal measure require recent bailout agreement eurozone creditor show decline support prime minister alexis tsipra london ftse show deepest loss benchmark index
489,ILMN,china hong kong hang seng index fall shanghai composite add tokyo nikkei japan fall yen rise dollar
490,ILMN,dollar rise vs euro oil gold be stock future veer unevenly lower heavy slate earning report ahead wednesday open dow future be point fair market value have pare early loss nasdaq future be point slide future be also tick lower point week economic calendar finally kick gear et federal housing finance agency housing price index june exist home sale number national association realtor be due weekly crude oil inventory energy information administration follow big name be move ahead open stock market today boee ba microsoft msft coca cola ko whirlpool whr respond quarterly report apple aapl grab early headline stock slide more premarket trade late tuesday report better forecast earning gain surge sale expand profit margin fiscal third quarter fourth quarter revenue guidance didn quite measure however company separately didn break sale new apple watch apple share end tuesday just day move average shallow month consolidation apple supplier be also take early beating cirrus logic crus skywork solution swks more vasco datum security vdsi collapse company admit regulatory filing release tuesday product have be sell iran european subsidiary third party distributor sale potentially violate federal rule prohibit transaction proliferator weapon mass destruction supporter vasco share have pull back sharply late june high test support week move average illumina ilmn dim fall hard report late tuesday earning top revenue miss analyst consensus expectation first time year maker large scale genetic screening equipment also raise earning guidance line projection stock finished tuesday just monday high buy point week tight pattern blackhawk network hawk climb distributor prepay gift card report late tuesday sale earning clear analyst estimate ibd leaderboard stock end tuesday top buy range buy point cup base overseas europe market be pressure midday vote greece be expect pass further fiscal measure require recent bailout agreement eurozone creditor show decline support prime minister alexis tsipra london ftse show deepest loss benchmark index china hong kong hang seng index fall shanghai composite add tokyo nikkei japan fall yen rise dollar dollar rise vs euro oil gold be
491,ILMN,ibd stock be buy range stock market today illumina ilmn technology avgo illumina have highest possible ibd composite rating monday mit put maker gene sequence system very top smartest company list university say highlight important innovation be happen right now other
492,ILMN,major index rally sharply wednesday help send couple spotlight stock fresh breakout helen troy hele clear flat base buy point hit new record high consumer product firm earn respectable composite rating trade thinner side average daily volume share helen troy be part
493,ILMN,stock seesaw mixed finish tuesday blue chip rise broader index take step back nasdaq end session low still lose snap day streak fall end day run help surge dupont dd dow jone industrial average squeeze gain dupont jump nearly reaction late monday news ceo ellen kullman step accord preliminary datum volume rise board stock market today illumina ilmn gap slump almost warning sale late monday intraday stock be much greatbatch gb gap day slump weak sale guidance regulatory filing date monday medical product maker cut sale guidance fiscal range prior outlook greatbatch also breach day move average autobytel abtl end session high follow monday add busy session close past buy point double bottom base lgi home lgih climb rise new high be well extend buy point flat base clear early august also extend rebound week move average follow vincent mao twitter ibd_vmao
494,ILMN,thursday supreme court ruling uphold obamacare subsidy boost hospital health insurer stock gain weren limit medical stock paycom software payc rise nearly day modest loss broader market oklahoma city base company provide cloud base human capital management software help business automate manage worker employment life cycle recruitment retirement
495,ILMN,stock future veer unevenly lower heavy slate earning report ahead wednesday open
496,ILMN,dow future be point fair market value have pare early loss nasdaq future be point slide future be also tick lower point
497,ILMN,week economic calendar finally kick gear et federal housing finance agency housing price index june exist home sale number national association realtor be due weekly crude oil inventory energy information administration follow
498,ILMN,big name be move ahead open stock market today boee ba microsoft msft coca cola ko whirlpool whr respond quarterly report
499,ILMN,apple aapl grab early headline stock slide more premarket trade late tuesday report better forecast earning gain surge sale expand profit margin fiscal third quarter
500,ILMN,fourth quarter revenue guidance didn quite measure however company separately didn break sale new apple watch apple share end tuesday just day move average shallow month consolidation
501,ILMN,apple supplier be also take early beating cirrus logic crus skywork solution swks more
502,ILMN,vasco datum security vdsi collapse company admit regulatory filing release tuesday product have be sell iran european subsidiary third party distributor
503,ILMN,sale potentially violate federal rule prohibit transaction proliferator weapon mass destruction supporter vasco share have pull back sharply late june high test support week move average
504,ILMN,illumina ilmn dim fall hard report late tuesday earning top revenue miss analyst consensus expectation first time year
505,ILMN,maker large scale genetic screening equipment also raise earning guidance line projection stock finished tuesday just monday high buy point week tight pattern
506,ILMN,blackhawk network hawk climb distributor prepay gift card report late tuesday sale earning clear analyst estimate ibd leaderboard stock end tuesday top buy range buy point cup base
507,ILMN,overseas europe market be pressure midday vote greece be expect pass further fiscal measure require recent bailout agreement eurozone creditor show decline support prime minister alexis tsipra london ftse show deepest loss benchmark index
508,ILMN,china hong kong hang seng index fall shanghai composite add tokyo nikkei japan fall yen rise dollar
509,ILMN,dollar rise vs euro oil gold be stock future veer unevenly lower heavy slate earning report ahead wednesday open dow future be point fair market value have pare early loss nasdaq future be point slide future be also tick lower point week economic calendar finally kick gear et federal housing finance agency housing price index june exist home sale number national association realtor be due weekly crude oil inventory energy information administration follow big name be move ahead open stock market today boee ba microsoft msft coca cola ko whirlpool whr respond quarterly report apple aapl grab early headline stock slide more premarket trade late tuesday report better forecast earning gain surge sale expand profit margin fiscal third quarter fourth quarter revenue guidance didn quite measure however company separately didn break sale new apple watch apple share end tuesday just day move average shallow month consolidation apple supplier be also take early beating cirrus logic crus skywork solution swks more vasco datum security vdsi collapse company admit regulatory filing release tuesday product have be sell iran european subsidiary third party distributor sale potentially violate federal rule prohibit transaction proliferator weapon mass destruction supporter vasco share have pull back sharply late june high test support week move average illumina ilmn dim fall hard report late tuesday earning top revenue miss analyst consensus expectation first time year maker large scale genetic screening equipment also raise earning guidance line projection stock finished tuesday just monday high buy point week tight pattern blackhawk network hawk climb distributor prepay gift card report late tuesday sale earning clear analyst estimate ibd leaderboard stock end tuesday top buy range buy point cup base overseas europe market be pressure midday vote greece be expect pass further fiscal measure require recent bailout agreement eurozone creditor show decline support prime minister alexis tsipra london ftse show deepest loss benchmark index china hong kong hang seng index fall shanghai composite add tokyo nikkei japan fall yen rise dollar dollar rise vs euro oil gold be
510,ILMN,world look bit flat market standpoint early tuesday global market commodity largely unmoved stock future steering market mixed open dow future be point ibm ibm pull hard downside future be fraction nasdaq future be point focal point stock market today microsoft msft yahoo yhoo chipotle grill cmg also report close do number lead stock include blackhawk network hawk illumina ilmn gopro gpro economic calendar be blank tuesday big name motion early earning report include verizon vz traveler trv lockheed martin lmt unchanged unite technology utx ibm drag lower report earning beat revenue fall slightly more analyst have expect be tech giant straight quarter decline revenue profit margin software division source half company profit narrow quarter ibm share have be gradual uptrend january fight climb month consolidation tesla motor tsla slump nearly ahead open stock have be nick ub downgrade sell note reportedly question company battery storage auto delivery target share rise almost strong trade monday stock be extend rebound week support cup handle buy point india base software engineer infosys infy surge country second largest software developer report better expect earning raise full year revenue guidance consensus expectation management say company sign contract quarter total value infosys have be consolidate february battle retake week line support past week dollar be mixed commodity be generally flat mining stock have drag hard monday be rebound agnico eagle aem barrick gold abx yamana gold auy newmont mining nem post solid premarket gain
511,ILMN,number spotlight stock hit new high tuesday market uptrend marched stock be top end buy range gilead science gild maker blockbuster hepatitis drug harvoni sovaldi be just barely buy limit entry long consolidation stock clear buy point june volume be light stock have manage make progress
512,ILMN,gilead have rise nearly past year however latest base be less risky first stage pattern form stock undercut prior base
513,ILMN,gilead have post triple digit profit sale growth past quarters earning be expect rise just share increase revenue analyst fret big cap company maintain strong growth
514,ILMN,illumina ilmn be top end buy range past entry handle stock boast best possible composite earning share rating putt top highly rate medical research equipment service industry ibd leaderboard stock be featured wednesday new america column
515,ILMN,ellie mae elli demand software handle entire mortgage application process be hover top buy range flat base entry
516,ILMN,post straight quarters triple digit profit growth sale growth have accelerate straight quarters jump latest period
517,ILMN,outerwall outr operate self service kiosk let shopper buy rent movie video game be just buy range entry odd shape base
518,ILMN,outerwall be leader top rank leisure movie related industry group
519,ILMN,fact so many spotlight stock be continue move higher be good sign breakout market be sixth week latest uptrend number spotlight stock hit new high tuesday market uptrend marched stock be top end buy range gilead science gild maker blockbuster hepatitis drug harvoni sovaldi be just barely buy limit entry long consolidation stock clear buy point june volume be light stock have manage make progress gilead have rise nearly past year however latest base be less risky first stage pattern form stock undercut prior base gilead have post triple digit profit sale growth past quarters earning be expect rise just share increase revenue analyst fret big cap company maintain strong growth illumina ilmn be top end buy range past entry handle stock boast best possible composite earning share rating putt top highly rate medical research equipment service industry ibd leaderboard stock be featured wednesday new america column ellie mae elli demand software handle entire mortgage application process be hover top buy range flat base entry post straight quarters triple digit profit growth sale growth have accelerate straight quarters jump latest period outerwall outr operate self service kiosk let shopper buy rent movie video game be just buy range entry odd shape base outerwall be leader top rank leisure movie related industry group fact so many spotlight stock be continue move higher be good sign breakout market be sixth week latest uptrend
520,ILMN,medical science seek uncover link genetic disease come precise treatment gene sequence make blueprint body molecular structure play critical role illumina ilmn play similarly crucial role provide researcher diagnostic company advanced tool need facilitate process tool include
521,ILMN,now market be back upswing sector leader include palo alto network panw skywork solution swks be extend stock remain buy range recent breakout apple chip supplier technology avgo initially rise much day past buy point come close
522,ILMN,take year big pharma biotech medical device firm bring product market contract research organization cro make life lot easier provide outsourced research service speed industry cro help customer bring product market faster ibd medical research equipment service industry group have be rise steadily
523,ILMN,even market chop back forth spotlight leader be work long weekly winning streak stock close higher multiple week row especially more noteworthy sign steady accumulation big fund be useful trait spot stock be base even have break be move higher stock break early stage base be able climb many week row signal share be big demand have good chance continue even higher future such stock be pra health science prah close higher eighth straight week friday stock be extend buy point have nearly double ipo price pra debut november be world largest contract research organization cro pra offer traditional project base trial service well call embed functional outsource service pra integrate client internal develop operation manage drug development pra operate more office worldwide approximately employee part highly rank medical research equipment industry group inc research holding incr icon iclr be other highly rate contract research organization group stock be work new base pattern other spotlight stock show weekly streak include medical gilead science gild illumina ilmn stock be buy range breaking week lengthy consolidation chip play inphi iphi have also climb straight week inphi share be hold just week tight buy point stock be also profit target buy late april
524,ILMN,stock index claw way modest gain early afternoon trading bounce session lows nasdaq lag trading flat biotechs solar energy technology stock perform poorly composite trim enough loss retake day move average be dow jone industrial average also be loss apple aapl walt disney stock fall day move average volume be tracking higher couple more stock break stock market today hd supply hds break flat base rally heavy trading stock clear buy point earning come expectation atlanta base outfit report adjust earning cent share sale climb roughly line view hd supply commercial part service distributor spun home depot hd december agree sell hardware business home depot illumina ilmn make more definitive move past buy point saucer type formation active trading be latest series pattern genomic company have form past month none have be able produce much price rally
525,ILMN,appeal big capitalization stock be resilience market sell off account big cap stock have do better job loss list range much monday broad market tumble most decline be
526,ILMN,volume stock be not excessive most have trading total be well normal other have increase
527,ILMN,consider massive selling market be significant not massive
528,ILMN,medical leader such unitedhealth group unh edward lifescience ew continue form basis hold new high
529,ILMN,facebook fb have modest decline close buy point most recent pattern volume be norm
530,ILMN,loss wasn alarm
531,ILMN,illumina ilmn also dip back buy point close just buy point clear couple week
532,ILMN,big cap stock be health care speak strength sector be pattern present not just big cap leader other area market ibd sector leader also have fair share medical stock
533,ILMN,gilead science gild fall buy point sell signal biotech so far
534,ILMN,volume be average not exactly avalanche seller more share nonetheless
535,ILMN,few big cap leader slide day move average institutional investor step buy dip watch rebound line evidence
536,ILMN,skywork solution swks be watch regard
537,ILMN,chipmaker come day line nearly double average volume not exactly gentle pullback chart reader look skywork find back favor rebound quickly strong volume
538,ILMN,walt disney share have be make new high streak come stop monday
539,ILMN,stock erased have be small gain buy point be back entry
540,ILMN,compare stumble other leader take entertainment colossus come day proceedings relatively minor damage
541,ILMN,starbucks sbux give shareholder best hope
542,ILMN,share fall volume average more important stock hold solid uptrend remain well extend january couple normal pullback week move average
543,ILMN,starbucks have notch week streak look firm lead stock appeal big capitalization stock be resilience market sell off account big cap stock have do better job loss list range much monday broad market tumble most decline be volume stock be not excessive most have trading total be well normal other have increase consider massive selling market be significant not massive medical leader such unitedhealth group unh edward lifescience ew continue form basis hold new high facebook fb have modest decline close buy point most recent pattern volume be norm loss wasn alarm illumina ilmn also dip back buy point close just buy point clear couple week big cap stock be health care speak strength sector be pattern present not just big cap leader other area market ibd sector leader also have fair share medical stock gilead science gild fall buy point sell signal biotech so far volume be average not exactly avalanche seller more share nonetheless few big cap leader slide day move average institutional investor step buy dip watch rebound line evidence skywork solution swks be watch regard chipmaker come day line nearly double average volume not exactly gentle pullback chart reader look skywork find back favor rebound quickly strong volume walt disney share have be make new high streak come stop monday stock erased have be small gain buy point be back entry compare stumble other leader take entertainment colossus come day proceedings relatively minor damage starbucks sbux give shareholder best hope share fall volume average more important stock hold solid uptrend remain well extend january couple normal pullback week move average starbucks have notch week streak look firm lead stock
544,ILMN,ibd index wrapped strong first quarter last week index pop versus just fractional gain let look back list first weekend quarter insight outperformance ibd column week focuse selling pressure market
545,ILMN,sony be comeback kid fight video game feb company report better expect december quarter result upgrade financial outlook fiscal year end march sony sne stock bounce news be more past month november cyberattack film
546,ILMN,key unify factor stock make ibd spotlight screen be be close week high simple fact be crucial make money buy properly superb growth stock break good base make new high nasdaq nyse chart be also meant
547,ILMN,biotechs continue rebound medical related stock remain center stage week big cap accounting half list edward lifescience ew gap past cup handle buy point initially clear tuesday rbc capital market upgrade heart valve maker outperform sector outperform lift price target friday
548,ILMN,market pause week have allow few sector leader pull back buy point give investor miss second chance winning stock pull back initial buy point resume advance study stock possible buy pullback best see gentle fall
549,ILMN,best mutual fund second quarter performance updatemanager lead mutual fund past month have be take profit ease buy top rate stock top mutual fund adjust portfolio summer month kick lot market volatility thank greece persistent debt wo nasdaq drop june fall dow be ibd market pulse turn pressure june medical giant include abiom abmd illumina ilmn hca holding hca also have be favore top perform fund latest report period ibd find top notch mutual fund add abiom investing estimate latest report period danver mass base firm make medical device design assist replace pump function heart abiom flagship product be heart pump impella receive fda approval elective urgent high risk percutaneous coronary intervention procedure abiom be plan expand operation danver headquarters add employee manufacturing capacity hit week high early stock have be etching second stage base sit just high earning growth have ramp past quarters several tech issue have continue draw interest top fund recent month include palo alto network panw technology avgo cyberark software cybr fleetmatic fltx tyler technology tyl nxp semiconductor nxpi monster beverage mnst continue pique investor interest best perform fund invest estimate latest report period energy drink maker coca cola ko complete previously announce strategic partnership coca cola now own stake monster sell sidetop fund have be selling big telecom cable stock such comcast cmcsa time warner twc latest report period investor also be unload retailer include drug store cvs health cvs wallgreen boot alliance wba restaurant yum brand yum starbucks sbux be axed top fund
550,ILMN,illumina have break cup handle base buy point have hit new high volume well average handle be short best see daily chart volume dry nicely handle grow base correct just so also be consider flat base
551,ILMN,illumina ilmn make equipment doctor medical researcher use genetic past quarters earning have rise analyst expect increase next report
552,ILMN,illumina year annualize ep growth rate be analyst forecast growth year next
553,ILMN,share gain day close
554,ILMN,knoll knl break flat base also hit new high gain close company sell household office furniture year annualize ep growth rate be just past quarters earning have increase analyst expect increase next report
555,ILMN,earning tend be cyclical decline gain nicely
556,ILMN,base be week flat base correct latest string basis break gradually work way higher trade thin side just share day
557,ILMN,cantel medical cmn explode flat base huge volume rise close
558,ILMN,company specialize product prevent infection such reprocess system endoscopy renal dialysis water purification disinfectant cleaner
559,ILMN,catalyst be earning report open ep be cent share increase year earlier be well estimate analyst be look increase next report
560,ILMN,regional bank be putt strong show bond yield rise anticipation federal reserve raise interest rate
561,ILMN,bofi hold bofi parent bofi federal bank operate internet single san diego office stock have break flat base rise tuesday
562,ILMN,click here view full list week new high lows illumina have break cup handle base buy point have hit new high volume well average handle be short best see daily chart volume dry nicely handle grow base correct just so also be consider flat base illumina ilmn make equipment doctor medical researcher use genetic past quarters earning have rise analyst expect increase next report illumina year annualize ep growth rate be analyst forecast growth year next share gain day close knoll knl break flat base also hit new high gain close company sell household office furniture year annualize ep growth rate be just past quarters earning have increase analyst expect increase next report earning tend be cyclical decline gain nicely base be week flat base correct latest string basis break gradually work way higher trade thin side just share day cantel medical cmn explode flat base huge volume rise close company specialize product prevent infection such reprocess system endoscopy renal dialysis water purification disinfectant cleaner catalyst be earning report open ep be cent share increase year earlier be well estimate analyst be look increase next report regional bank be putt strong show bond yield rise anticipation federal reserve raise interest rate bofi hold bofi parent bofi federal bank operate internet single san diego office stock have break flat base rise tuesday click here view full list week new high lows
563,ILMN,stock be still lower have slightly pare loss friday afternoon nasdaq cut deficit be dow jone industrial average fall turnover be again tracking sharply lower stock market today compare same time thursday acadium pharmaceutical acad gap plunge post wider expect loss late thursday intraday stock wipe gain past buy point cup handle base fall entry marked sell signal other biotechs such immunogen imgn kite pharma kite fall piece former also trigger sell signal buy point latter past entry be falter upside caesarstone cste rally bounce back day big loss share crater wednesday israeli maker quartz surface post disappointing quarterly sale give weak guidance fall additional thursday
564,ILMN,stock market inched higher tuesday rally last week lows start moderate nasdaq close higher small cap do little better russell add be unremarkable day not just index meager movement volume ease nasdaq rise slightly
565,ILMN,do razzle dazzle health care etfs disguise weakness many investor exchange trade fund real concern sector be handily beating peer have several year ibd leaderboard stock illumina ilmn mallinckrodt mnk show biotech pharma stock still have oomph institutional buyer be pile name well know actavis radar
566,ILMN,best mutual fund performance report
567,ILMN,corporate takeover be theme boost mutual fund hold stock testify resilience economy even mixed economic datum trickle
568,ILMN,parade pairing includedcharter chtr time warner twc avgo broadcom brcm asna ann ann cvs cvs omnicare ocr verizon vz aol aol dhr pall pll
569,ILMN,activity continue support stock market russ blackrock global chief investment strategist write deal allow company expand new market well gain efficiency earning leverage
570,ILMN,come perhaps sluggish manufacturing activity economy shrank first quarter fact weak datum paradoxically boost stock alleviate concern aggressive federal reserve rate hike regime add
571,ILMN,diversify equity fund rise average accord lipper inc general domestic taxable bond fund fall
572,ILMN,growth fund market cap spectrum continue notch biggest gain small cap growth fund beat last month advance average take year date gain midcap growth fund rally same period
573,ILMN,value fund be catch post tidy gain lag year date
574,ILMN,sector focuse mutual fund hold health biotech stock prove stellar again trump other domestic fund category soar month end
575,ILMN,strong health care earning
576,ILMN,health care company show strong first quarter earning growth overall top sector stock such ibd sector leader actavis act illumina ilmn be profit robust demand innovative drug testing equipment well acquisition smaller company streamline diversify operation
577,ILMN,interest rate stay lower longer mutual fund investor be seek income produce equity utility telecom fund eke gain last month year date re laggard
578,ILMN,advise income investor focus dividend growth fund many sector offer high yield such utility be expensive most vulnerable rise rate say instead yield hungry investor look technology financial health care select energy company offer rise dividend
579,ILMN,price gold end roughly higher stronger dollar weigh bullion month wear mutual fund investing precious metal commodity manage turn gain average course last month virtually other commodity fund ag base energy focuse see loss
580,ILMN,precious metal equity fund such hold mining stock give re more influenced operational condition not just underlie metal price
581,ILMN,modest gain abroad
582,ILMN,reversal previous month investor turn foreign market successful investing peg slight decline
583,ILMN,still several international region manage beat sell naysayer include rally india japan europe china stock mutual fund fall vs outsize gain april
584,ILMN,year date china region fund still lead international peer surge be hurt stock market news shrink factory activity weak export growth
585,ILMN,overall world equity fund drop vs gain previous month
586,ILMN,international market have do pretty well year date say matthew dobbs head global small company schroder investment management so not entirely surprising see bit reversion back
587,ILMN,dobbs manage part vanguard international explorer fund rise be invest asset japan biggest single country allocation
588,ILMN,japanese mutual fund rise re year
589,ILMN,large cap japan power performance say dobbs fall yen give company tend have sizable exposure foreign earning boost
590,ILMN,vinex also assign asset continental europe european fund rally last month year date re massive stimulus measure have kick start market
591,ILMN,thing be get little bit better person expect start year dobbs say bank be more willing lend stock look less pricey best mutual fund performance reportcorporate takeover be theme boost mutual fund hold stock testify resilience economy even mixed economic datum trickle parade pairing includedcharter chtr time warner twc avgo broadcom brcm asna ann ann cvs cvs omnicare ocr verizon vz aol aol dhr pall pll activity continue support stock market russ blackrock global chief investment strategist write deal allow company expand new market well gain efficiency earning leverage come perhaps sluggish manufacturing activity economy shrank first quarter fact weak datum paradoxically boost stock alleviate concern aggressive federal reserve rate hike regime add diversify equity fund rise average accord lipper inc general domestic taxable bond fund fall growth fund market cap spectrum continue notch biggest gain small cap growth fund beat last month advance average take year date gain midcap growth fund rally same period value fund be catch post tidy gain lag year date sector focuse mutual fund hold health biotech stock prove stellar again trump other domestic fund category soar month end strong health care earningshealth care company show strong first quarter earning growth overall top sector stock such ibd sector leader actavis act illumina ilmn be profit robust demand innovative drug testing equipment well acquisition smaller company streamline diversify operation interest rate stay lower longer mutual fund investor be seek income produce equity utility telecom fund eke gain last month year date re laggard advise income investor focus dividend growth fund many sector offer high yield such utility be expensive most vulnerable rise rate say instead yield hungry investor look technology financial health care select energy company offer rise dividend price gold end roughly higher stronger dollar weigh bullion month wear mutual fund investing precious metal commodity manage turn gain average course last month virtually other commodity fund ag base energy focuse see loss precious metal equity fund such hold mining stock give re more influenced operational condition not just underlie metal price modest gain abroadin reversal previous month investor turn foreign market successful investing peg slight decline still several international region manage beat sell naysayer include rally india japan europe china stock mutual fund fall vs outsize gain april year date china region fund still lead international peer surge be hurt stock market news shrink factory activity weak export growth overall world equity fund drop vs gain previous month international market have do pretty well year date say matthew dobbs head global small company schroder investment management so not entirely surprising see bit reversion back dobbs manage part vanguard international explorer fund rise be invest asset japan biggest single country allocation japanese mutual fund rise re year large cap japan power performance say dobbs fall yen give company tend have sizable exposure foreign earning boost vinex also assign asset continental europe european fund rally last month year date re massive stimulus measure have kick start market thing be get little bit better person expect start year dobbs say bank be more willing lend stock look less pricey
592,ILMN,best mutual fund performance report franklin growth opportunity fund be gain head steam fund gain year top large cap growth rival track morningstar inc be better peer beat gain prior month
593,ILMN,stock market hold mild thursday do best continue week rise path nasdaq reduce advance just close also fade come away only advance small cap russell keep pace broad market rise dow transportation
594,ILMN,main stock index make positive price reversal tuesday latest market run mixed signal nasdaq much early close only lower weakness biotech solar technology stock hurt composite nasdaq do close back day move average make reversal more interesting
595,ILMN,promising early rebound fizzle wednesday leave major index flat finish indeed such movement continue stock market expect more player get worn rather shake divergence lie leadership however market pulse table show more top quality growth stock rise heavy volume fall average trade
596,ILMN,ibd big cap leader screen filter highly liquid large cap stock strong record earning growth top notch medical stock make screen cut be valeant pharmaceutical vrx gilead science gild celgene celg actavis act biogen biib regeneron regn shire shpg illumina ilmn
597,ILMN,valeant pharmaceutical have highest possible ibd composite rating meaning share outperform stock market measure fundamental technical factor factor be earning sale growth profit margin return equity relative price performance
598,ILMN,valeant complete acquisition salix pharmaceutical april salix partner pharm group come monday good interim datum phase clinical trial conestat alfa drug ruconest develop treatment angioedema attack allergy related swell
599,ILMN,valeant share ease tuesday be extend past cup handle base buy point initially clear last december
600,ILMN,actavis partner perrigo prgo announce tuesday new drug application guaifenesin pseudoephedrine tablet mucinex alternative be give fda approval
601,ILMN,last week eluxadoline drug viberzi treatment irritable bowel syndrome also receive fda approval
602,ILMN,actavis be try stay cup handle base buy point initially clear last wednesday close tuesday actavis have composite rating best
603,ILMN,gilead have ibd composite rating biotech announce sunday phase trial result idelalisib drug zydelig combination ofatumumab show improvement progression free survival previously treat patient chronic lymphocytic leukemia cll
604,ILMN,last week european medicine agency validate gilead marketing application emtricitabine tenofovir alafenamide combination hiv treatment investigational combination be now evaluation european medicine agency
605,ILMN,share barely close tuesday be buy point month long price consolidation
606,ILMN,celgene be biotech composite rating bmo capital last week reiterate outperform rating celgene part future prospect pleiotropic modulator cc
607,ILMN,stock be form price consolidation buy point
608,ILMN,biogen biotech earn composite rating be now trading march peak price be reach nearly month long run price consolidation
609,ILMN,regeneron break cup handle base buy point mid gain much level tuesday session biotech share dip back buy range regeneron boast composite rating
610,ILMN,shire clear buy point flat base ethical drug maker stock be now trading back level shire have composite rating
611,ILMN,illumina make gene sequence system be work price consolidation buy point last week share get pivot be now trading level
612,ILMN,follow alissa william twitter ibd_awilliam ibd big cap leader screen filter highly liquid large cap stock strong record earning growth top notch medical stock make screen cut be valeant pharmaceutical vrx gilead science gild celgene celg actavis act biogen biib regeneron regn shire shpg illumina ilmn valeant pharmaceutical have highest possible ibd composite rating meaning share outperform stock market measure fundamental technical factor factor be earning sale growth profit margin return equity relative price performance valeant complete acquisition salix pharmaceutical april salix partner pharm group come monday good interim datum phase clinical trial conestat alfa drug ruconest develop treatment angioedema attack allergy related swell valeant share ease tuesday be extend past cup handle base buy point initially clear last december actavis partner perrigo prgo announce tuesday new drug application guaifenesin pseudoephedrine tablet mucinex alternative be give fda approval last week eluxadoline drug viberzi treatment irritable bowel syndrome also receive fda approval actavis be try stay cup handle base buy point initially clear last wednesday close tuesday actavis have composite rating best gilead have ibd composite rating biotech announce sunday phase trial result idelalisib drug zydelig combination ofatumumab show improvement progression free survival previously treat patient chronic lymphocytic leukemia cll last week european medicine agency validate gilead marketing application emtricitabine tenofovir alafenamide combination hiv treatment investigational combination be now evaluation european medicine agency share barely close tuesday be buy point month long price consolidation celgene be biotech composite rating bmo capital last week reiterate outperform rating celgene part future prospect pleiotropic modulator cc stock be form price consolidation buy point biogen biotech earn composite rating be now trading march peak price be reach nearly month long run price consolidation regeneron break cup handle base buy point mid gain much level tuesday session biotech share dip back buy range regeneron boast composite rating shire clear buy point flat base ethical drug maker stock be now trading back level shire have composite rating illumina make gene sequence system be work price consolidation buy point last week share get pivot be now trading level follow alissa william twitter ibd_awilliam
613,ILMN,evaluate stock fundamental good ask question have do lately consistent track record strong earning share growth be place also good ask question be go do go forward
614,ILMN,case good know kind ep growth be expect current quarter full year
615,ILMN,fundamental drive stock price performance big quarterly ep sale growth high return equity peak profit margin be important positive growth prospect also matter
616,ILMN,minimum annual ep estimate look be many aggressive growth name show year year gain stronger
617,ILMN,good see strong growth current year well follow year
618,ILMN,year re fishing right pond
619,ILMN,be careful not look quarterly annual estimate vacuum just stock be expect boost quarterly earning annual earning doesn mean buy growth doesn mean much institutional investor be heavily selling stock
620,ILMN,estimate datum be find page ibd well stock checkup investor com quarterly earning estimate show sector leader mini chart day tuesday thursday re also ipo leader
621,ILMN,quarterly annual estimate be available ibd stock screen be publish monday wednesday ibd
622,ILMN,recent ibd nearly half name list be expect increase annual earning least current fiscal year
623,ILMN,be careful big estimate don always go hand hand strong stock
624,ILMN,accord thomson reuter second quarter profit southwest airline luv be see rise year full year earning be expect jump strong growth indeed southwest share distribution now day move average market be concern sharp deceleration annual earning growth southwest annual profit be see rise only
625,ILMN,ibd big cap be publish tuesday ibd recent list name be expect boost annual earning least pretty respectable large cap stock keep mind company get bigger tough maintain strong growth rate
626,ILMN,exception be valeant pharmaceutical vrx market capitalization north second quarter earning be see rise year even more impressive full year profit ethical drug giant be expect jump year
627,ILMN,salesforce com crm illumina ilmn be other large cap name top fundamental be expect show healthy growth year next
628,ILMN,wall street analyst see salesforce earning jump cent share fiscal end january illumina ep year evaluate stock fundamental good ask question have do lately consistent track record strong earning share growth be place also good ask question be go do go forward case good know kind ep growth be expect current quarter full year fundamental drive stock price performance big quarterly ep sale growth high return equity peak profit margin be important positive growth prospect also matter minimum annual ep estimate look be many aggressive growth name show year year gain stronger good see strong growth current year well follow year year re fishing right pond be careful not look quarterly annual estimate vacuum just stock be expect boost quarterly earning annual earning doesn mean buy growth doesn mean much institutional investor be heavily selling stock estimate datum be find page ibd well stock checkup investor com quarterly earning estimate show sector leader mini chart day tuesday thursday re also ipo leader quarterly annual estimate be available ibd stock screen be publish monday wednesday ibdin recent ibd nearly half name list be expect increase annual earning least current fiscal year be careful big estimate don always go hand hand strong stock accord thomson reuter second quarter profit southwest airline luv be see rise year full year earning be expect jump strong growth indeed southwest share distribution now day move average market be concern sharp deceleration annual earning growth southwest annual profit be see rise only ibd big cap be publish tuesday ibd recent list name be expect boost annual earning least pretty respectable large cap stock keep mind company get bigger tough maintain strong growth rate exception be valeant pharmaceutical vrx market capitalization north second quarter earning be see rise year even more impressive full year profit ethical drug giant be expect jump year salesforce com crm illumina ilmn be other large cap name top fundamental be expect show healthy growth year next wall street analyst see salesforce earning jump cent share fiscal end january illumina ep year
629,ILMN,be thin rally follow day only handful stock breaking have go virtually nowhere few sector leader have see multiple consecutive week gain bullish sign be ambarella amba go fifth straight week advance find support day move average
630,ILMN,medical sector continue show strength biotech stock illumina ilmn be get ready break san diego base firm be global leader genomic provide researcher tool conduct large scale analysis genetic variation big pharma leader valeant pharmaceutical vrx abbvie abbv be also recently featured ibd stock
631,ILMN,major average have barely inched higher follow leader have make bullish move many more be set week ibd climb outperform major average nasdaq rise outperformance come highly rate chip stock have bounce back
632,ILMN,stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today
633,ILMN,volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange
634,ILMN,ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high
635,ILMN,integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday
636,ILMN,worst performer ibd be regeneron pharmaceutical regn more
637,ILMN,energy name be day best perform industry group push oil price be higher
638,ILMN,chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base
639,ILMN,sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday worst performer ibd be regeneron pharmaceutical regn more energy name be day best perform industry group push oil price be higher chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs
640,ILMN,stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace
641,ILMN,blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high
642,ILMN,integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner
643,ILMN,ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average
644,ILMN,housing related stock get bad news november pending home sale drop unexpectedly
645,ILMN,however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average housing related stock get bad news november pending home sale drop unexpectedly however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume
646,ILMN,big drug company give mixed fourth quarter report guidance tuesday patent loss foreign exchange rate cloud term future gene sequencer illumina post better expect earning close amgen amgn say earning rise share beating consensus cent revenue big biotech rise more view company affirm guidance single digit sale profit growth issue october stock be nearly hour also close illumina ilmn report profit cent share year earlier quarter cent ahead estimate also affirm previous guidance company preannounce sale earlier month other company report open bristol myer squibb bmy say profit exclude time item be cent share cent analyst consensus accord thomson reuter sale fall beating view year earning rise share sale slip company guide ep range miss street estimate sale guidance also miss conference call analyst executive say impact strong dollar shave guidance cent ep guidance strong dollar make export more expensive less competitive shrink profit sale american company make euro other denomination firm bring money back home morningstar analyst damien conover write research note patent loss continue depress operate result year bullish bristol immuno oncology pipeline start recently approve opdivo call analyst seek more clarity get more datum many clinical trial work management be reluctant make prediction bristol stock fall fraction tuesday pfizer pfe report earning exclude time item shrank cent share penny consensus sale drop street number year earning rise share sale dip pfizer guide ep sale analyst have expect statement cfo frank amelio say revenue guidance reflect anticipate negative impact due recent expect product loss exclusivity well result recent adverse change essentially foreign exchange rate relative dollar capital iq analyst jeffrey loo lower rating pfizer hold buy bmo capital market analyst alex arfaei say guidance underscore company need deal failure buy astrazeneca azn last year pfizer call ceo ian read decline comment rumor pfizer have be rebuff other large target say don feel need do large deal pfizer stock fall fraction novartis nvs have softer other stock rise give more encourage forecast operate growth novartis sale decline miss street estimate earning rise share line full year sale rise ep rise company say fx shave income constant currency basis sale year rise midsingle digit earning increase high single digit follow corporate restructure expect novartis post stronger margin have scale be stronger competitive position remain business line drug eye care product generic conover write note tuesday
647,ILMN,stock weaken final minute trading largely erase intraday rebound effort nasdaq fall dow jone industrial average accord preliminary number volume be higher nasdaq lower nyse stock market today nasdaq fall back day move average retake line thursday russell give just small cap outperformed again market have lot digest tuesday full plate high profile earning report economic datum stock open lower disappointing quarterly report microsoft msft caterpillar cat durable good report miss forecast aos jump huge volume release fourth quarter result top analyst expectation share maker commercial residential water heater hit time high tuesday close gene sequencer illumina ilmn report earning grow jump revenue share be slightly hour follow gain new high regular session biotech giant amgen amgn climb nearly hour trading follow earning report top expectation apple aapl jump more hour trading shedding regular session close apple report earning sale easily top analyst forecast
648,ILMN,afternoon rally fizzle final hour tuesday send stock back morning lows nasdaq fall dow jone industrial average volume be heavier nyse nasdaq accord preliminary datum silicon motion simo rise result top estimate stock open lower then show increase strength session progressed volume be well average stock market today medical research equipment maker illumina ilmn add gain buy point stock be volatile extend trading company report quarterly result stock open sharply lower mixed economic datum disappointing quarterly report caterpillar cat microsoft msft stock gap ibd stock rise fall worst performer be packaging corp america pkg report monday evening miss forecast
649,ILMN,stock turn mixed midday monday round similarly mixed earning report well economic report foreign domestic
650,ILMN,nasdaq turn loss gain biotechs software issue outperformed pare deficit dow jone industrial average fall volume be tracking sharply lower board stock market today compare same time friday
651,ILMN,highly rate stock globant glob rally nearly time high clear buy point heavy trading hour session thin stock already match day average volume
652,ILMN,nike nke climb more new high be upgrade buy hold bb now past buy point athletic apparel footwear giant be recently mentioned new high column
653,ILMN,downside microsemi mscc drop news offer buy pmc sierra pmcs bid top buyout offer apple aapl supplier skywork solution swks microsemi fall buy point consolidation clear friday pmc share jump
654,ILMN,valeant vrx slump beating view raise guidance open canadian drugmaker post adjust earning share year sale grow third straight period acceleration almost lift full year sale forecast
655,ILMN,profit be now expect share prior outlook last week valeant say receive subpoena federal prosecutor massachusett new york request information patient assistance program drug pricing decision
656,ILMN,follow vincent mao twitter ibd_vmao stock turn mixed midday monday round similarly mixed earning report well economic report foreign domestic nasdaq turn loss gain biotechs software issue outperformed pare deficit dow jone industrial average fall volume be tracking sharply lower board stock market today compare same time friday highly rate stock globant glob rally nearly time high clear buy point heavy trading hour session thin stock already match day average volume nike nke climb more new high be upgrade buy hold bb now past buy point athletic apparel footwear giant be recently mentioned new high column downside microsemi mscc drop news offer buy pmc sierra pmcs bid top buyout offer apple aapl supplier skywork solution swks microsemi fall buy point consolidation clear friday pmc share jump valeant vrx slump beating view raise guidance open canadian drugmaker post adjust earning share year sale grow third straight period acceleration almost lift full year sale forecast profit be now expect share prior outlook last week valeant say receive subpoena federal prosecutor massachusett new york request information patient assistance program drug pricing decision follow vincent mao twitter ibd_vmao
657,ILMN,real estate investment trust start year bang number lead reit reach fresh week high isbiom realty trust bmr build lease redevelop acquire finance property life science company
658,ILMN,rise fifth straight day thursday close monday announce have sign year lease agreement illumina ilmn new square foot campus be used office laboratory foster city calif san francisco stanford university
659,ILMN,illumina make tool used researcher doctor study gene sequence have be stock market leader past few year impressive earning growth company also have option square foot build foster city site facility be be turn illumina
660,ILMN,biom realty call largest life science lease transaction past year
661,ILMN,san diego base reit have square foot space worldwide tenant include big public biotech company also research institutes university include harvard university university pennsylvania university california san diego say have more relationship
662,ILMN,biom realty have grow fund operation reit equivalent earning year analyst forecast increase ffo decline year
663,ILMN,most recent quarter ffo rise rise revenue follow straight quarters ffo decline
664,ILMN,biom pay regular quarterly dividend cent share work annualize yield
665,ILMN,december reit paid cent special dividend result sale property rockville md real estate investment trust start year bang number lead reit reach fresh week high isbiom realty trust bmr build lease redevelop acquire finance property life science company rise fifth straight day thursday close monday announce have sign year lease agreement illumina ilmn new square foot campus be used office laboratory foster city calif san francisco stanford university illumina make tool used researcher doctor study gene sequence have be stock market leader past few year impressive earning growth company also have option square foot build foster city site facility be be turn illumina biom realty call largest life science lease transaction past year san diego base reit have square foot space worldwide tenant include big public biotech company also research institutes university include harvard university university pennsylvania university california san diego say have more relationship biom realty have grow fund operation reit equivalent earning year analyst forecast increase ffo decline year most recent quarter ffo rise rise revenue follow straight quarters ffo decline biom pay regular quarterly dividend cent share work annualize yield december reit paid cent special dividend result sale property rockville md
666,ILMN,columbia select large cap growth fund happy day be here again least moment mutual fund gain investor top just large cap growth peer track morningstar inc so far year go tuesday fund gain top direct rival stock fund
667,ILMN,ibd stock have outperformed new rally be confirm then ibd have gain nasdaq be just outperformance just handful breakout follow day have produce decent gain skywork solution swks technology avgo synaptic syna regeneron pharmaceutical regn papa john pzza
668,ILMN,stock rebound confidently wednesday index erase part previous session loss nasdaq jump dow jone industrial average skip higher tune respectively small cap russell gain volume stock market today run higher nasdaq lower nyse accord preliminary datum
669,ILMN,blue chip rally dozen stock stock dow gain more microsoft msft intel intc lead gain respectively microsoft intel have so so fundamental
670,ILMN,top rate stock also show strength breakout include chip designer technology avgo drug developer abbvie abbv
671,ILMN,new high top rate stock include bank ozark ozrk chip designer ambarella amba nxp semiconductor nxpi silicon motion technology simo hospital chain universal health service uhs drugmaker zoetis zts aerospace play spirit aerosystem spr tv station chain gray television gtn pizza restaurant papa john international pzza
672,ILMN,other leader show positive action retailer ulta beauty ulta retook day line strong volume illumina ilmn climb close buy point consolidation
673,ILMN,overall abundance top stock show good action be encourage development stock market uptrend
674,ILMN,company report quarterly result include apparel marketer michael kor kor gap earning miss weak outlook homebuilder toll bro tol skid revenue miss combine earning beat
675,ILMN,follow paul whitfield twitter ibd_pwhitfield stock rebound confidently wednesday index erase part previous session loss nasdaq jump dow jone industrial average skip higher tune respectively small cap russell gain volume stock market today run higher nasdaq lower nyse accord preliminary datum blue chip rally dozen stock stock dow gain more microsoft msft intel intc lead gain respectively microsoft intel have so so fundamental top rate stock also show strength breakout include chip designer technology avgo drug developer abbvie abbv new high top rate stock include bank ozark ozrk chip designer ambarella amba nxp semiconductor nxpi silicon motion technology simo hospital chain universal health service uhs drugmaker zoetis zts aerospace play spirit aerosystem spr tv station chain gray television gtn pizza restaurant papa john international pzza other leader show positive action retailer ulta beauty ulta retook day line strong volume illumina ilmn climb close buy point consolidation overall abundance top stock show good action be encourage development stock market uptrend company report quarterly result include apparel marketer michael kor kor gap earning miss weak outlook homebuilder toll bro tol skid revenue miss combine earning beat follow paul whitfield twitter ibd_pwhitfield
676,ILMN,stock wake foul mood tuesday partly due better expect economic datum put interest rate hike worry back front burner strengthen dollar didn help matter nasdaq lose give back volume nyse nasdaq be average come friday level result
677,ILMN,stock take thump monday energy stock lead way lower oil price briefly drop barrel investor stock market today also worry event greece slowdown europe economy dollar rise sharply hurt exporter international firm large holding outside nasdaq fall drop dow jone industrial average be volume be heavier exchange energy related industry group fared worst mostly solar energy stock be group only gold miner manage nearly gain gold rise flight safety electric car maker tesla tsla drop nearly national bank greece nbg american depositary share trade nyse gap close lower stock have collapse november high investor think possible election austerity government greece lead default national debt german chancellor angela merkel be quote say be prepared let greece exit eurozone petrobra pbr national oil company brazil gap close lower produce barrel day much high cost offshore platform russian economy be be savage fall oil price european sanction time leader qiwi qiwi operate cash dispense kiosk russia drop nearly ibd stock be be best performer be medical stock akorn akrx illumina ilmn worst performer be fleetcor technology flt make payment product commercial fleet oil company fall more slice day move average
678,ILMN,recent ipo pra health science have get tepid reception investor gate global contract research organization cro have be make lose time ever pra prah go public november set range prospectus pra stock finished first day trading
679,ILMN,stock power start gate wednesday mixed economic news take back seat optimism potential development eurozone dow jone industrial average nasdaq be climb volume rise nasdaq nyse exchange stock market today continue carefully watch ongoing greece eurozone crisis letter greek leader tuesday night concede more creditor austerity demand request extension now expire bailout support additional fund reuter report german official be skeptical proposal say door be still open negotiation early economic news be mixed new job layoff increase june june manufacturing softened purchasing manager index ease tad shy view ism index institute supply management be more positive rise be tally narrowly consensus estimate construction spending slow sharply commerce department say rise vs april downwardly revise increase still number be better increase forecast economist automaker report june sale nissan motor nsany lead increase fiat chrysler fcau report gain month ford sale gain general motor gm sale fall stock insurer traveler trv pop lead dow stock be possibly boost morning news switzerland base ace ace buy new jersey base insurer chubb cb deal value chubb share spiked open ace climb nasdaq wynn resort wynn spiked stretch leg second day regulator china ease travel restriction visitor mainland china macau wynn competitor operate hive casino wynn have be correction month ibd stock france criteo crto spark start gate move lift stock buy range buy point epam system epam leap nearly move top buy range almost past buy point group few early decline taser international tasr slip bit less stock remain just day move average retake support light trade tuesday
680,ILMN,nasdaq suffer distribution tuesday investor give thumb earning report dow component microsoft msft caterpillar cat weaker expect durable good report also weigh sentiment major average rally nicely lows early afternoon trading seller come back market late nasdaq take hardest hit fall gap
681,ILMN,stock overcome early weakness finish higher monday add last week positive action nasdaq rise bounce back loss monday marked tech heavy index sixth straight gain longest winning streak late november break streak nasdaq go pullback also rebound
682,ILMN,nasdaq reversed better gain early wednesday re-cover bit early afternoon trading techs get boost early apple aapl report strong earning late tuesday nasdaq add dow jone industrial average gain rise nyse volume be tracking higher tuesday level nasdaq volume fall slightly day fed meeting conclude today policy statement due et oil gas related group take hit crude oil take dive fall stock market today ss technology ssnc jump nearly bloomberg report company be talk acquire advent software advs share advent soar elsewhere illumina ilmn open nicely higher strong earning early gain fade loss provider gene sequence technology be volatile jpmorgan health care conference san francisco recently reclaim buy point paycom software payc surge clear base buy point paycom be featured today stock spotlight facebook fb reclaim day move average rise ahead earning report close
683,ILMN,stock open lower battle tightly mixed terrain early wednesday
684,ILMN,edge nasdaq be close only fraction higher dow jone industrial average sag
685,ILMN,volume be unevenly mixed just nasdaq nyse vs trading level record early tuesday
686,ILMN,stock market today face early headwind mixed housing datum show december housing start slower expect rate build permit issue month europe market turn slim gain mixed action afternoon trade market earning report be morning center attention
687,ILMN,netflix nflx spike bolster nasdaq company report record growth new subscriber fourth quarter
688,ILMN,ibm ibm fall drag dow report late tuesday adjust earning decline less expect analyst revenue slip more expect however management project earning analyst consensus stock long slow correction deepen sharply company report october
689,ILMN,ibd list open red biggest slip be decline illumina ilmn maker large scale gene sequence equipment surge heavy trade tuesday wednesday early slip left share week move average buy point
690,ILMN,baidu bidu hammer gain run head list china lead search engine be hover week move average shallow month consolidation
691,ILMN,busy docket earning report be due today close american express axp unite rental uri sandisk sndk ebay ebay company schedule report stock open lower battle tightly mixed terrain early wednesday edge nasdaq be close only fraction higher dow jone industrial average sag volume be unevenly mixed just nasdaq nyse vs trading level record early tuesday stock market today face early headwind mixed housing datum show december housing start slower expect rate build permit issue month europe market turn slim gain mixed action afternoon trade market earning report be morning center attention netflix nflx spike bolster nasdaq company report record growth new subscriber fourth quarter ibm ibm fall drag dow report late tuesday adjust earning decline less expect analyst revenue slip more expect however management project earning analyst consensus stock long slow correction deepen sharply company report october ibd list open red biggest slip be decline illumina ilmn maker large scale gene sequence equipment surge heavy trade tuesday wednesday early slip left share week move average buy point baidu bidu hammer gain run head list china lead search engine be hover week move average shallow month consolidation busy docket earning report be due today close american express axp unite rental uri sandisk sndk ebay ebay company schedule report
692,ILMN,stock be still higher tuesday midday gain have fade
693,ILMN,trim gain nasdaq pare advance just dow jone industrial average stay session high gain caterpillar cat chevron cvx exxon mobil xom be biggest winner blue chip index volume be run higher board stock market today
694,ILMN,lead stock linkedin lnkd rise goldman sachs put share conviction buy list raise price target professional networking operator report earning thursday analyst poll thomson reuter see profit rise cent share linkedin be base buy point
695,ILMN,lithia motor lad tack fast trade stock stage upside reversal find support day line monday car dealer report earning feb lithia be expect earn share year
696,ILMN,rival asbury automotive group abg be also flat base entry
697,ILMN,downside stratasys ssys be still whopping reaction late monday disappointing preliminary fiscal result outlook piper jaffray brean capital downgrade share tuesday stock be still higher tuesday midday gain have fade trim gain nasdaq pare advance just dow jone industrial average stay session high gain caterpillar cat chevron cvx exxon mobil xom be biggest winner blue chip index volume be run higher board stock market today lead stock linkedin lnkd rise goldman sachs put share conviction buy list raise price target professional networking operator report earning thursday analyst poll thomson reuter see profit rise cent share linkedin be base buy point lithia motor lad tack fast trade stock stage upside reversal find support day line monday car dealer report earning feb lithia be expect earn share year rival asbury automotive group abg be also flat base entry downside stratasys ssys be still whopping reaction late monday disappointing preliminary fiscal result outlook piper jaffray brean capital downgrade share tuesday
698,ILMN,stock big cap screen be work basis have form secondary pattern earning report loom mylan myl maker generic drug be work flat base base pattern buy point stock rebound day move average monday heavy volume profit fourth quarter
699,ILMN,many lead growth stock stumble market uptrend come pressure last week few defy turmoil investor react negatively federal reserve statement wednesday policymaker say inflation be run central bank target even economy be pick fall oil price slow growth overseas have raise specter
700,ILMN,stock market close lower monday retailer have bumpy session nasdaq dow jone industrial average fall slip volume rise be surprise friday half session decline stock lead advancer nyse nasdaq stock market today transportation medical retail industry group be weakest monday energy mining stock be strongest lululemon athletica lulu gap loss sink right back day move average analyst fbr capital market downgrade lululemon underperform market perform cut price target investor grow pessimistic early holiday shopping indication other retailer sell heavy trading include ulta beauty ulta urban outfitter urbn regeneron pharmaceutical regn have worst loss ibd bid past buy point have unraveled close unitedhealth group unh say be back forecast earning share revenue be project be health insurer warn nov earning hit obamacare exchange related business cite higher medical cost individual market customer soft enrollment outlook unitedhealth share rise slightly extend trading several economic report be due tuesday manufacturing report purchasing manager institute supply management be due morning automaker report november sale earning report tuesday include fifth street finance fsc guidewire software gwre follow juan carlos arancibia twitter ibd_jarancibia
701,ILMN,latest big cap be lead large cap growth stock build basis still buy range recent breakout expect market back confirm uptrend healthy chart weren common few week distribution day nasdaq be make presence feel
702,ILMN,many sector leader remain buy range be set potential end tumultuous week stock market now market be confirm uptrend thursday follow let highlight top name be friday issue page hff inc hf be
703,ILMN,be frustrate environment growth stock investor recent breakout have be mixed bag best most big cap leader be hover just just recent buy point best way handle lackluster market be keep exposure modest more breakout prove show decent gain
704,ILMN,cut loss sell signal start appear keep good portion powder dry stock have be able hold recent entry include abbvie abbv cigna ci analog device adi
705,ILMN,abbvie break cup handle base heavy volume share have trade tight remain buy range past buy point
706,ILMN,giant drugmaker report accelerate earning sale most recent quarter
707,ILMN,manage health care provider cigna be still buy range past flat base buy point clear heavy trade
708,ILMN,analog device be pull back heavy volume share be still buy range many chip stock early gain be danger disappear other hand stock nike nke skywork solution swks cognizant technology solution ctsh carmax kmx have slip recent buy point
709,ILMN,be sell signal so far
710,ILMN,nike be testing support week line buy point latest pattern be part base base stretch back november
711,ILMN,nike be expect report profit growth release fiscal fourth quarter result end sale be expect climb
712,ILMN,carmax break cup handle base friday light trade turn lower monday share remain just buy point
713,ILMN,carmax report fiscal result june market open analyst be look earning climb cent share revenue growth
714,ILMN,be used car dealer fifth straight quarter double digit earning sale growth
715,ILMN,decent initial progress skywork solution have return flat base buy point volume have be mostly light stock pull back be positive sign watch see long time leader find support price week move average
716,ILMN,side regeneron regn be act well low volume base be late stage share have gain much buy point remain extend buy range
717,ILMN,stock still base include salesforce com crm facebook fb gilead gild illumina ilmn be frustrate environment growth stock investor recent breakout have be mixed bag best most big cap leader be hover just just recent buy point best way handle lackluster market be keep exposure modest more breakout prove show decent gain cut loss sell signal start appear keep good portion powder dry stock have be able hold recent entry include abbvie abbv cigna ci analog device adi abbvie break cup handle base heavy volume share have trade tight remain buy range past buy point giant drugmaker report accelerate earning sale most recent quarter manage health care provider cigna be still buy range past flat base buy point clear heavy trade analog device be pull back heavy volume share be still buy range many chip stock early gain be danger disappear other hand stock nike nke skywork solution swks cognizant technology solution ctsh carmax kmx have slip recent buy point be sell signal so far nike be testing support week line buy point latest pattern be part base base stretch back november nike be expect report profit growth release fiscal fourth quarter result end sale be expect climb carmax break cup handle base friday light trade turn lower monday share remain just buy point carmax report fiscal result june market open analyst be look earning climb cent share revenue growth be used car dealer fifth straight quarter double digit earning sale growth decent initial progress skywork solution have return flat base buy point volume have be mostly light stock pull back be positive sign watch see long time leader find support price week move average side regeneron regn be act well low volume base be late stage share have gain much buy point remain extend buy range stock still base include salesforce com crm facebook fb gilead gild illumina ilmn
718,ILMN,new high total stay subdue friday week range bound volatile trading bullish move market have largely be isolate tie favorable earning release recent session few highly rate stock try break friday reversed lower close apple aapl share briefly touch new high clear flat base
719,ILMN,judge recent price action health care name today ipo leader screen market be optimistic future growth prospect
720,ILMN,ipo price propose range usually soft demand wasn case pra health science prah provider clinical development outsource service biotech pharmaceutical industry go public november propose range stock close first day trading be then be consolidate gain late december watch base take shape here
721,ILMN,company lose money be expect earn share
722,ILMN,leadership isn hard find ibd medical research equipment service group illumina ilmn parexel prxl icon iclr be other top performer
723,ILMN,meanwhile high fly biotech agio pharmaceutical agio have be tear july ipo agio early stage drug ag show promise treatment various blood cancer celgene be investor june large cap biotech leader exercise option give global right agio leukemia compound
724,ILMN,highly regard fidelity contrafund have be build position agio recent quarters
725,ILMN,monster september agio have ride week move average higher point best new base form buy
726,ILMN,elsewhere early december aldr be also extend sharp drop wednesday be hold comfortably week line
727,ILMN,stock relative strength be noteworthy especially news september bristol myer squibb bmy walk away collaboration deal regard rheumatoid arthritis drug clazakizumab be seek new partner due positive phase study result report date
728,ILMN,october start phase clinical trial migraine drug ald primary endpoint datum trial be expect second half judge recent price action health care name today ipo leader screen market be optimistic future growth prospect ipo price propose range usually soft demand wasn case pra health science prah provider clinical development outsource service biotech pharmaceutical industry go public november propose range stock close first day trading be then be consolidate gain late december watch base take shape here company lose money be expect earn share leadership isn hard find ibd medical research equipment service group illumina ilmn parexel prxl icon iclr be other top performer meanwhile high fly biotech agio pharmaceutical agio have be tear july ipo agio early stage drug ag show promise treatment various blood cancer celgene be investor june large cap biotech leader exercise option give global right agio leukemia compound highly regard fidelity contrafund have be build position agio recent quarters monster september agio have ride week move average higher point best new base form buy elsewhere early december aldr be also extend sharp drop wednesday be hold comfortably week line stock relative strength be noteworthy especially news september bristol myer squibb bmy walk away collaboration deal regard rheumatoid arthritis drug clazakizumab be seek new partner due positive phase study result report date october start phase clinical trial migraine drug ald primary endpoint datum trial be expect second half
729,ILMN,institutional selling be leave mark market average lead stock gain rally confirm october have diminish many leader defensive investing posture be warrant number ibd name close week move average decisively first time friday volume be generally average be deceptive
730,ILMN,stock struggle direction end narrowly mixed wednesday better expect new home sale second day testimony fed chief janet yellen stock make wave hour
731,ILMN,salesforce com crm bolt extend trading post result meet view earning come cent share double year sale rise more
732,ILMN,technology avgo rally deliver fiscal result view chip designer also announce be buy emulex elx be soar hour
733,ILMN,mercadolibre meli be also extend trading post mixed quarterly result
734,ILMN,regular session nasdaq ease fraction end day run slip dow jone industrial average rise accord preliminary datum volume end higher major exchange stock market today
735,ILMN,aruba network arun soar report talk be buy hewlett packard hpq report quarterly result late tuesday late surge send aruba buy point consolidation intraday
736,ILMN,leaderboard name grubhub grub rally nearly strong volume clear cup handle buy point earlier month provider online food order service beat view earning surge sale jump
737,ILMN,system ddd air lease al iconix brand group icon kohl kss ross store rost splunk splk be lead stock report earning thursday
738,ILMN,weekly jobless claim consumer price durable good be thursday morning atlanta fed president dennis lockhart also be speaking thursday stock struggle direction end narrowly mixed wednesday better expect new home sale second day testimony fed chief janet yellen stock make wave hour salesforce com crm bolt extend trading post result meet view earning come cent share double year sale rise more technology avgo rally deliver fiscal result view chip designer also announce be buy emulex elx be soar hour mercadolibre meli be also extend trading post mixed quarterly result regular session nasdaq ease fraction end day run slip dow jone industrial average rise accord preliminary datum volume end higher major exchange stock market today aruba network arun soar report talk be buy hewlett packard hpq report quarterly result late tuesday late surge send aruba buy point consolidation intraday leaderboard name grubhub grub rally nearly strong volume clear cup handle buy point earlier month provider online food order service beat view earning surge sale jump system ddd air lease al iconix brand group icon kohl kss ross store rost splunk splk be lead stock report earning thursday weekly jobless claim consumer price durable good be thursday morning atlanta fed president dennis lockhart also be speaking thursday
739,ILMN,earning season wind investor analyst have have chance look new crop market lead stock today screen day be leader rise estimate feature top rate stock such technology avgo have have greatest increase upward earning estimate revision analyst today list include hot stock
740,ILMN,technology illumina ilmn leader genetic test equipment have help bring cost genomic testing recent year just launch initiative develop standardized fda approve kit improve cancer diagnostic treatment decision key fundamental sale growth have be solid steady range past quarters
741,ILMN,gene sequence giant illumina ilmn hit new high stock market today outlined strategic vision annual investor day get price target increase late thursday illumina issue press release unveil strategic road map follow meeting outline strategy investor analyst company have already announce new sequence
742,ILMN,columbia select large cap growth fund take chin monday add setback friday biotech stock plunge several house democrat ask gilead science gild justify price hepatitis drug sovaldi portfolio fall friday be most severely hit large cap growth fund track morningstar
743,ILMN,several big cap stock have just break basis be buy zone close few other seem be set basis
744,ILMN,medical name remain leader recent correction valeant pharmaceutical vrx be stock have form long late stage base buy stock come late stage base have outstanding fundamental be aware higher failure rate
745,ILMN,valeant attempt dec pass buy point then fall back light volume correct few day then gap buy point jan volume average company raise guidance range share revenue guidance
746,ILMN,quebec headquarter company sell brand drug counter product specialize dermatology eye health
747,ILMN,have year annualize earning growth rate analyst expect growth year
748,ILMN,most recent report earning grow revenue year analyst forecast ep increase next report
749,ILMN,medical research equipment maker illumina ilmn break flat base jan stock fall much monday find support day move average be fuel barclay start coverage equal weight rating price target
750,ILMN,several quarters sluggish earning growth illumina be once again acceleration mode ep growth rise analyst be forecasting increase next report
751,ILMN,year annualize ep growth rate be return equity be pretax margin be number have remain constant several year
752,ILMN,nonmedical stock have vault base be chipotle grill cmg moved past cup handle buy point late december then pull back day move average gapping new high jan past trading session pull back quietly
753,ILMN,too have couple quarters slow growth earning growth reaccelerate rise past quarters analyst be forecasting increase next report be due feb close
754,ILMN,year annualize ep growth rate be earning stability rating scale low number correspond steady earning growth
755,ILMN,restaurant be strong industry group rank group analyst forecast earning growth year several big cap stock have just break basis be buy zone close few other seem be set basis medical name remain leader recent correction valeant pharmaceutical vrx be stock have form long late stage base buy stock come late stage base have outstanding fundamental be aware higher failure rate valeant attempt dec pass buy point then fall back light volume correct few day then gap buy point jan volume average company raise guidance range share revenue guidance quebec headquarter company sell brand drug counter product specialize dermatology eye health have year annualize earning growth rate analyst expect growth year most recent report earning grow revenue year analyst forecast ep increase next report medical research equipment maker illumina ilmn break flat base jan stock fall much monday find support day move average be fuel barclay start coverage equal weight rating price target several quarters sluggish earning growth illumina be once again acceleration mode ep growth rise analyst be forecasting increase next report year annualize ep growth rate be return equity be pretax margin be number have remain constant several year nonmedical stock have vault base be chipotle grill cmg moved past cup handle buy point late december then pull back day move average gapping new high jan past trading session pull back quietly too have couple quarters slow growth earning growth reaccelerate rise past quarters analyst be forecasting increase next report be due feb close year annualize ep growth rate be earning stability rating scale low number correspond steady earning growth restaurant be strong industry group rank group analyst forecast earning growth year
756,ILMN,stock remain depress monday hour left trading session modest rally attempt day fail gain momentum nasdaq fall dow jone industrial average drop stock market today volume be tracking higher friday level ibd stock be higher be lower easily worst performer be volatile bitauto bita run automobile related website china chinese automaker say sale rise compare best performer ibd be celgene celg offer upbeat forecast beat analyst estimate say currency effect have negative effect revenue share be heavy trading share rise support day move average medical research equipment maker illumina ilmn drop sharply et be mount recovery be make presentation jpmorgan healthcare conference stock fall much buy point rebound energy stock be worst perform industry group oil drop barrel gold miner be best performer precious metal rise tif drop reduce outlook cite disappointing holiday sale fall sharply day move average well past buy point
757,ILMN,hasn be easy year growth investor didn stop market deliver solid winner common bond strong fundamental
758,ILMN,share illumina ilmn be close year earning sale growth have ramp recent quarters fuel stock price performance
759,ILMN,point look past stock market winner be know look fundamental technical perspective big price move goal be apply knowledge current research decade ibd research show thing history repeat stock market
760,ILMN,illumina make life science tool integrate system analysis genetic variation function cater variety customer academic institution government laboratory big pharmaceutical biotech firm
761,ILMN,january swiss drug giant roche rhhby announce hostile bid illumina roche sweeten bid few month later deal never come fruition
762,ILMN,hasn always be bed rose illumina stock lose third market value profit sale growth ground halt illumina show turnaround story be highly profitable stock find foot improve fundamental
763,ILMN,illumina clear cup shape base april then surge nearly week later company report strong result earning rise year sale rise result marked third straight quarter earning sale growth exceed
764,ILMN,time illumina boast composite rating earning share rating relative price strength rating smr rating accumulation distribution rating end month be member ibd
765,ILMN,cup base early april work well be first stage base lot seller have be shake stock prior month make easier buyer regain control
766,ILMN,flat basis tight trading follow
767,ILMN,institutional selling hit stock february march give investor profitable position chance take solid profit
768,ILMN,illumina last base be cup handle base june time buy point be trade have be bit choppy then illumina have manage hold buy point be trading high partly due straight quarters accelerate earning sale growth high quality mutual fund sponsorship hasn hurt
769,ILMN,quick reminder buy breakout remember have best chance succeed early stage market uptrend not big move market breakout have be challenge lately high quality growth name have have hard time make headway not only big market rally many case stock have moved lot too hasn be easy year growth investor didn stop market deliver solid winner common bond strong fundamental share illumina ilmn be close year earning sale growth have ramp recent quarters fuel stock price performance point look past stock market winner be know look fundamental technical perspective big price move goal be apply knowledge current research decade ibd research show thing history repeat stock market illumina make life science tool integrate system analysis genetic variation function cater variety customer academic institution government laboratory big pharmaceutical biotech firm january swiss drug giant roche rhhby announce hostile bid illumina roche sweeten bid few month later deal never come fruition hasn always be bed rose illumina stock lose third market value profit sale growth ground halt illumina show turnaround story be highly profitable stock find foot improve fundamental illumina clear cup shape base april then surge nearly week later company report strong result earning rise year sale rise result marked third straight quarter earning sale growth exceed time illumina boast composite rating earning share rating relative price strength rating smr rating accumulation distribution rating end month be member ibd cup base early april work well be first stage base lot seller have be shake stock prior month make easier buyer regain control flat basis tight trading follow institutional selling hit stock february march give investor profitable position chance take solid profit illumina last base be cup handle base june time buy point be trade have be bit choppy then illumina have manage hold buy point be trading high partly due straight quarters accelerate earning sale growth high quality mutual fund sponsorship hasn hurt quick reminder buy breakout remember have best chance succeed early stage market uptrend not big move market breakout have be challenge lately high quality growth name have have hard time make headway not only big market rally many case stock have moved lot too
770,ILMN,bull trample bear second straight session thursday market make bullish signal nasdaq dow jone industrial average rolled higher ibd add volume rise major exchange thursday action nasdaq constitute follow mean market be confirm uptrend technically
771,ILMN,top rate medical stock such illumina ilmn be bullish jpmorgan healthcare conference san francisco week several talk earning sale prospect announce new takeover deal
772,ILMN,ibd screen day be big cap leader top rate stock generally price market capitalization least today screen include large drug other medical stock proven track record
773,ILMN,illumina outlook cautious
774,ILMN,gene sequence equipment maker illumina monday say collaborate lockheed martin lmt develop next generation gene sequence gear envision advantage early national adoption country globe lower health care cost lockheed health life science vice president horace blackman say
775,ILMN,monday jpmorgan conference illumina report preliminary revenue beating estimate full year guidance be conservative ibd leaderboard stock just clear flat base last week hit intraday peak friday stock fall monday tuesday fall close day move average
776,ILMN,biogen buy convergence
777,ILMN,cambridge mass base biogen idec biib develop treatment variety ailment include multiple sclerosis cancer autoimmune disease
778,ILMN,sunday biogen agree buy privately hold base drugmaker convergence pharmaceutical milestone be meet expand biogen presence pain management drug convergence be develop drug treat chronic nerve pain
779,ILMN,biogen rise high tuesday whisker time high set dec close
780,ILMN,shire buy nps pharma
781,ILMN,january ireland base shire shpg buy biotech viropharma specialize rare disease drug shire begin buyout bid nps pharmaceutical npsp biopharma focuse rare disease
782,ILMN,shire share plunge more oct abbvie abbv withdraw buyout offer treasury department tighten rule limit tax inversion tax inversion be maneuver company buy company base country shift own headquarters country get lower tax rate
783,ILMN,shire have partly re-cover stock fall monday stock close tuesday day line
784,ILMN,actavis see exceptional sale
785,ILMN,actavis act irish drugmaker recently agree buy botox maker allergan agn top hostile bid valeant pharmaceutical vrx pairing create global top drugmaker combine annual revenue more deal be expect close second quarter
786,ILMN,actavis say monday jpmorgan conference expect ep top wall street estimate strong sale actavis consolidated late november monday rise time high touch intraday high tuesday pull back close
787,ILMN,celgene bullish revlimid
788,ILMN,monday conference summit base drugmaker celgene celg give generally bullish forecast flagship cancer fight drug revlimid account estimate sale
789,ILMN,celgene expect overall sale climb
790,ILMN,term celgene guide sale view partly negative currency effect preliminary ep top wall street target sale revlimid climb drug gain approval treat more type cancer
791,ILMN,celgene stock form cup handle base january mid june buy point gap have rise tuesday stock rise hit new high rise monday celgene stock clear month consolidation too short be proper base be extend day day average
792,ILMN,follow james detar twitter ibd_jdetar top rate medical stock such illumina ilmn be bullish jpmorgan healthcare conference san francisco week several talk earning sale prospect announce new takeover deal ibd screen day be big cap leader top rate stock generally price market capitalization least today screen include large drug other medical stock proven track record illumina outlook cautiousgene sequence equipment maker illumina monday say collaborate lockheed martin lmt develop next generation gene sequence gear envision advantage early national adoption country globe lower health care cost lockheed health life science vice president horace blackman say monday jpmorgan conference illumina report preliminary revenue beating estimate full year guidance be conservative ibd leaderboard stock just clear flat base last week hit intraday peak friday stock fall monday tuesday fall close day move average biogen buy mass base biogen idec biib develop treatment variety ailment include multiple sclerosis cancer autoimmune disease sunday biogen agree buy privately hold base drugmaker convergence pharmaceutical milestone be meet expand biogen presence pain management drug convergence be develop drug treat chronic nerve pain biogen rise high tuesday whisker time high set dec close shire buy nps pharmain january ireland base shire shpg buy biotech viropharma specialize rare disease drug shire begin buyout bid nps pharmaceutical npsp biopharma focuse rare disease shire share plunge more oct abbvie abbv withdraw buyout offer treasury department tighten rule limit tax inversion tax inversion be maneuver company buy company base country shift own headquarters country get lower tax rate shire have partly re-cover stock fall monday stock close tuesday day line actavis see exceptional salesactavis act irish drugmaker recently agree buy botox maker allergan agn top hostile bid valeant pharmaceutical vrx pairing create global top drugmaker combine annual revenue more deal be expect close second quarter actavis say monday jpmorgan conference expect ep top wall street estimate strong sale actavis consolidated late november monday rise time high touch intraday high tuesday pull back close celgene bullish revlimidon monday conference summit base drugmaker celgene celg give generally bullish forecast flagship cancer fight drug revlimid account estimate sale celgene expect overall sale climb term celgene guide sale view partly negative currency effect preliminary ep top wall street target sale revlimid climb drug gain approval treat more type cancer celgene stock form cup handle base january mid june buy point gap have rise tuesday stock rise hit new high rise monday celgene stock clear month consolidation too short be proper base be extend day day average follow james detar twitter ibd_jdetar
793,ILMN,stock shave bulk loss monday afternoon even oil largely remain pressure
794,ILMN,nasdaq pare loss trim loss meanwhile dow jone industrial average fall volume be tracking higher board stock market today
795,ILMN,west texas intermediate brent crude drop respectively earlier opec say not revise output
796,ILMN,stock ibd be lower epam system epam be hardest hit drop fast trade stock be now past buy point cup handle base have be much
797,ILMN,universal insurance holding uve noah holding noah fall former cool week streak latter be extend last week dive
798,ILMN,elsewhere illumina ilmn fall breach day line fall buy point double bottom base wipe gain
799,ILMN,improvement market leader continue be few
800,ILMN,restoration hardware rh rise rebound friday downside reversal upscale home furnishing retailer deliver better expect result last week stock shave bulk loss monday afternoon even oil largely remain pressure nasdaq pare loss trim loss meanwhile dow jone industrial average fall volume be tracking higher board stock market today west texas intermediate brent crude drop respectively earlier opec say not revise output stock ibd be lower epam system epam be hardest hit drop fast trade stock be now past buy point cup handle base have be much universal insurance holding uve noah holding noah fall former cool week streak latter be extend last week dive elsewhere illumina ilmn fall breach day line fall buy point double bottom base wipe gain improvement market leader continue be few restoration hardware rh rise rebound friday downside reversal upscale home furnishing retailer deliver better expect result last week
801,ILMN,come develop cut edge real estate big pharma tech firm alexandrium real estate equity ceo joel marcus have refine try true formula start marcus back alexandrium be be real estate investment trust focuse develop science technology campuse top urban cluster adjacent lead academic medical institution order create collaborative environment company activity be center science hub such cambridge mass san francisco bay area san diego new york city platform focus irreplaceable urban innovation center marcus tell ibd re great place recruit talent transportation be good have work play environment add try own operate dominate market irreplaceable market facility be high tech advanced say include kind infrastructure company need do research development take campus location state art facility marry intersection science technology marcus say really be secret success build big namesusing approach alexandrium have develop campuse drugmaker such eli lilly lly novartis nvs pfizer pfe ibd leaderboard stock illumina ilmn genetic testing equipment maker year mark alexandrium anniversary company have have plenty cause celebrate earning have start grow again double digit increase past quarters gain end third quarter earning rise share analyst poll thomson reuter expect earning rise share follow decline prior year see rise increase alexandrium stock price have lift year be fuel growth marcus say alexandrium have several factor work favor re very good economic environment fed have keep interest rate low ve see substantially rise rent urban innovation market say also constrain supply demand re see life science tech sector be highest level ve see year history company marcus add company be see strong internal growth drive high occupancy increase rental rate core market cambridge san francisco new york alexandrium have pipeline project construction be lease negotiation say marcus highest pre lease level alexandrium have have company have pipeline project put play say add pipeline help drive strong demand continue earning next few year marcus used work capital market lawyer founder alexandrium address real estate infrastructure need biotech industry say be unfilled time have first mover advantage almost market real estate development say focus urban innovation campuse else really do healthy outlook rbc capital market analyst michael carroll say competitor be biom realty trust bmr reit focuse provide real estate life science industry other reit also dabble space add location alexandrium campuse urban cluster market differentiate factor carroll say macro environment life science industry look good re start see pharma tenant used own own real estate other location be find re get better result term ability do research collaborate more person industry move core cluster market own other landlord alexandrium have be able create cluster market campuse major market carroll add now tech tenant be find atmosphere re get demand tech tenant too say recent tech project announce september be strategic partnership app developer uber technology low fare ride sharing service have catch taxi alternative project include acquisition key parcel mission bay area san francisco deal uber parcel support rentable square foot new ground facility joint venture be own alexandrium uber let uber expand corporate headquarters san francisco conjunction year lease entire project alexandrium be expect break ground project january finish end mission bay be home campus university california san francisco well alexandrium science technology cluster be recently select house future arena golden state warrior nba marcus say uber venture be very significant have very strong yield shareholder reap benefit great cash flow represent milestone bring more tech company mission bay historically be more life science destination marcus add carroll also call venture uber significant lot demand area mission bay south market soma san francisco market cap alexandrium be smaller company ibd finance property reit industry group largest be simon property group spg market cap group rank performance ibd track medical ethical drug industry group several alexandrium customer reside rank medical biom biotech rank
802,ILMN,big cap list be little change week several name be hang buy point appear final stage base build medical issue illumina ilmn be just buy zone buy point double bottom base oct have moved mostly sideway
803,ILMN,few medical lead stock have slide otherwise ibd remain good shape last week illumina ilmn akorn akrx have fall buy point alexion pharmaceutical alxn celgene celg exhibit weakness own even fall short trigger clear sell signal few other ibd stock outside health
804,ILMN,market again uptrend investor put money work lead stock number issue stock spotlight be buy range
805,ILMN,illumina ilmn be buy range rise past entry double bottom base score new high wednesday volume surge more time average wednesday cast little doubt occur
806,ILMN,trade ideally be least average stock take buy point base also investor avoid buy once stock rise more past buy point chasing stock leave prone shakeout
807,ILMN,tuesday illumina have already rally reaction better expect result earning jump sale grow top bottom line growth accelerate third straight quarter
808,ILMN,facebook fb be buy zone retake early buy point flat base monday stock initially clear trigger fall more oct fine buy again initial have fail note volume be merely average facebook reclaim buy point monday
809,ILMN,social network giant release earning close tuesday analyst poll thomson reuter see profit rise cent share prior quarters triple digit growth
810,ILMN,actavis act be also bounce back fail regain buy point flat base tuesday turnover be well average also barely regain day line tuesday
811,ILMN,lannett lci be cup handle base buy point stock handle correct just be well outside normal range decline generic drug maker have deliver long streak triple digit profit gain be expect fiscal end september market again uptrend investor put money work lead stock number issue stock spotlight be buy range illumina ilmn be buy range rise past entry double bottom base score new high wednesday volume surge more time average wednesday cast little doubt occur trade ideally be least average stock take buy point base also investor avoid buy once stock rise more past buy point chasing stock leave prone shakeout tuesday illumina have already rally reaction better expect result earning jump sale grow top bottom line growth accelerate third straight quarter facebook fb be buy zone retake early buy point flat base monday stock initially clear trigger fall more oct fine buy again initial have fail note volume be merely average facebook reclaim buy point monday social network giant release earning close tuesday analyst poll thomson reuter see profit rise cent share prior quarters triple digit growth actavis act be also bounce back fail regain buy point flat base tuesday turnover be well average also barely regain day line tuesday lannett lci be cup handle base buy point stock handle correct just be well outside normal range decline generic drug maker have deliver long streak triple digit profit gain be expect fiscal end september
812,ILMN,gene sequence company illumina late monday report blowout third quarter earning sale growth raise full year guidance send stock hour trading earning exclude time item rise vs year earlier cent share top analyst consensus cent accord thomson reuter sale rise best year year
813,ILMN,stock slip mixed trade go noon hour tuesday trader continue handicap upcoming earning report nasdaq be dow jone industrial average rise smidgen stock market today volume run higher same time monday nyse nasdaq exchange
814,ILMN,hawaiian holding parent hawaiian airline be only claw way back loss morning stock report earning beat estimate close monday sidoti co downgrade stock neutral cowen raise price maintain market perform rating
815,ILMN,amazon amzn fall tuesday morning report consumer intelligence research partner say amazon prime have customer spend average year site triple size year research organization say
816,ILMN,amazon report earning close thursday analyst forecast loss cent share
817,ILMN,facebook fb have carved similar pattern amazon be slightly touch new intraday high stock be find resistance century mark open jeffery lift price target facebook
818,ILMN,ibd company be higher be lower best performer be bank ozark ozrk nearly break cup handle base late monday announce have buy atlanta base community southern holding stock
819,ILMN,worst performer be egg producer cal maine food calm fall pull back hit new high monday
820,ILMN,follow ken hoover twitter ibd_khoover stock slip mixed trade go noon hour tuesday trader continue handicap upcoming earning report nasdaq be dow jone industrial average rise smidgen stock market today volume run higher same time monday nyse nasdaq exchange hawaiian holding parent hawaiian airline be only claw way back loss morning stock report earning beat estimate close monday sidoti co downgrade stock neutral cowen raise price maintain market perform rating amazon amzn fall tuesday morning report consumer intelligence research partner say amazon prime have customer spend average year site triple size year research organization say amazon report earning close thursday analyst forecast loss cent share facebook fb have carved similar pattern amazon be slightly touch new intraday high stock be find resistance century mark open jeffery lift price target facebook ibd company be higher be lower best performer be bank ozark ozrk nearly break cup handle base late monday announce have buy atlanta base community southern holding stock worst performer be egg producer cal maine food calm fall pull back hit new high monday follow ken hoover twitter ibd_khoover
821,ILMN,stock market again correct investor be look create stock watch list next uptrend fast grow large capitalization company be good place look today screen day be big cap leader large company top notch fundamental generally market cap higher second sort find top
822,ILMN,big cap name week be medical related field reveal leadership name past few year have continue october correction whittle more nasdaq alexion pharmaceutical alxn develop drug treat blood disorder be extend buy point cup handle base
823,ILMN,stock pound bear thursday index pile solid gain fourth time past session nasdaq leap add ibd pop volume rise nyse fall nasdaq advance issue lead loser ratio nyse
824,ILMN,hot company lead respective industry group report quarterly earning close apple aapl chipotle cmg illumina ilmn here look analyst expect quarter well result affect growth stability ibd tv alissa william report
825,ILMN,stock pound early gain firm trade tuesday
826,ILMN,nasdaq jump pop dow jone industrial average add
827,ILMN,volume notch stock market today rise nasdaq nyse compare trade same time monday
828,ILMN,build real estate sector receive bump exist home sale improve september annualize rate accord national association realtor estimate be august tally shade consensus forecast
829,ILMN,stock apple aapl hoist nasdaq rise heavy trade report solid fiscal fourth quarter performance monday close
830,ILMN,lockheed martin lmt crumble third quarter result come short revenue line
831,ILMN,chipmaker hammer healthy gain open glaring exception arm holding armh tumble base supplier smartphone tablet microprocessor report earning line consensus forecast revenue growth stop short view management raise revenue guidance consensus projection arm have be deepen consolidation january earning top expectation company give full year revenue earning guidance line forecast lockheed share be trading high
832,ILMN,illumina ilmn lead ibd list easily outpace consensus view third quarter earning revenue gain snap share back day move average just buy point first stage double bottom base
833,ILMN,akorn pharmaceutical akrx pop crack open new high market be correction gain be technically clear buy point second stage cup base
834,ILMN,low end list tal education xrs scratch report third quarter result slip left stock oct high stifle attempt regain day move average stock pound early gain firm trade tuesday nasdaq jump pop dow jone industrial average add volume notch stock market today rise nasdaq nyse compare trade same time monday build real estate sector receive bump exist home sale improve september annualize rate accord national association realtor estimate be august tally shade consensus forecast stock apple aapl hoist nasdaq rise heavy trade report solid fiscal fourth quarter performance monday close lockheed martin lmt crumble third quarter result come short revenue line chipmaker hammer healthy gain open glaring exception arm holding armh tumble base supplier smartphone tablet microprocessor report earning line consensus forecast revenue growth stop short view management raise revenue guidance consensus projection arm have be deepen consolidation january earning top expectation company give full year revenue earning guidance line forecast lockheed share be trading high illumina ilmn lead ibd list easily outpace consensus view third quarter earning revenue gain snap share back day move average just buy point first stage double bottom base akorn pharmaceutical akrx pop crack open new high market be correction gain be technically clear buy point second stage cup base low end list tal education xrs scratch report third quarter result slip left stock oct high stifle attempt regain day move average
835,ILMN,major average further extend gain little more hour left tuesday regular session
836,ILMN,nasdaq rally advanced dow industrial add volume be tracking sharply higher board stock market today compare same time monday
837,ILMN,stock get early start help flurry earning report economic news exist home sale improve september annualize rate forecast august
838,ILMN,medical research gear solar transportation stock be big gainer industry group track ibd mortgage service wood product restaurant lag chipotle grill cmg weigh eatery group drop concern same store sale growth outlook
839,ILMN,illumina ilmn lead medical research equipment service group gain gap surge retake day move average nearly quadruple usual trade gene sequence company report earning revenue top view
840,ILMN,other ibd stock celgene celg gap rise heavy volume stock be flat base buy point clear aug pull back much entry last week vienna conference biotech present full datum phase trial ged drug crohn disease
841,ILMN,airline stock be fly high report industrywide domestic fare hike american airline group aal soar spirit airline save southwest airline luv rise unite continental holding ual fast turnover
842,ILMN,follow nancy gondo twitter ibd_ngondo major average further extend gain little more hour left tuesday regular session nasdaq rally advanced dow industrial add volume be tracking sharply higher board stock market today compare same time monday stock get early start help flurry earning report economic news exist home sale improve september annualize rate forecast august medical research gear solar transportation stock be big gainer industry group track ibd mortgage service wood product restaurant lag chipotle grill cmg weigh eatery group drop concern same store sale growth outlook illumina ilmn lead medical research equipment service group gain gap surge retake day move average nearly quadruple usual trade gene sequence company report earning revenue top view other ibd stock celgene celg gap rise heavy volume stock be flat base buy point clear aug pull back much entry last week vienna conference biotech present full datum phase trial ged drug crohn disease airline stock be fly high report industrywide domestic fare hike american airline group aal soar spirit airline save southwest airline luv rise unite continental holding ual fast turnover follow nancy gondo twitter ibd_ngondo
843,ILMN,stock market back confirm uptrend investor want look big cap company high accumulation distribution grade point large institution buy stock alexion pharmaceutical alxn illumina ilmn micron mu fleetcor technology flt be company ibd big cap screen day have accumulation distribution grade
844,ILMN,successful investing require longevity lifelong pursuit so objective number be keep game ibd golden rule be sell stock fall price paid simple rule keep game many mistake follow always give chance take advantage future opportunity positively understand first rule highly successful individual investor be always cut short limit single loss ibd founder william neil write book make money stock be not always necessary loss selling stock isn act right general market be severe distribution make sense cut loss even faster rule be not arbitrary ibd research have show lead stock breaking proper base rarely fall proper buy point so stock proper buy point be give valuable feedback take loss row then be likely problem stock selection general market be roll case pay pause examine recent trade critical reason cut loss short be basic math large loss work portfolio loss require gain break even size loss grow require break even gain grow even faster loss require gain loss require whopping gain just recover loss investor have hard time imagine stock selection fall big loss stock market start small loss consider average stock ibd model book huge market winner correct once finally top investing stock be simply too uncertain play defensive safety net let take look loss cut rule action illumina ilmn back early july stock be set base base pattern follow powerful prior run base be second stage well construct show several week tight trading july illumina break past buy point volume average relative strength line be new high slim investor have confidently step buy share yet session later stock be proper buy point trigger automatic sell signal disappointing not devastate happened next stock rally back day line high perhaps make feel foolish selling low however stock then implode dramatic fashion drop buy point less month fall illumina report quarters sale decline take year stock recover go wrong key point get stock be think hesitation time reason surface portfolio have suffer serious unnecessary damage
845,ILMN,stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace
846,ILMN,blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high
847,ILMN,integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner
848,ILMN,ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average
849,ILMN,housing related stock get bad news november pending home sale drop unexpectedly
850,ILMN,however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average housing related stock get bad news november pending home sale drop unexpectedly however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume
851,ILMN,cancer therapy bullish earning forecast take spotlight monday open jpmorgan healthcare conference week san francisco largest annual biotech conference worldwide
852,ILMN,celgene celg provide bullish forecast cancer drug revlimid generally positive preliminary result long term financial outlook bristol myer squibb bmy announce positive trial result lung cancer drug opdivo
853,ILMN,celgene expect ep vs year earlier wall street see cent net product sale be include negative foreign currency shift dollar hit multiyear high vs euro yen
854,ILMN,analyst have expect sale
855,ILMN,be exceptional year celgene momentum core business position year outstanding execution say ceo bob hugin statement
856,ILMN,celgene estimate ep product sale wall street have see ep sale
857,ILMN,celgene long term outlook
858,ILMN,forecast net product sale wall street estimate be strong dollar other currency shift hurt net product sale celgene forecast adjust ep consensus
859,ILMN,sale core drug revlimid climb celgene gain wider approval treat more type cancer ongoing global expansion revlimid be used treat multiple myeloma type lymphoma
860,ILMN,celgene expect total revenue ep hematology franchise top
861,ILMN,celgene outlook be impressive write michael yee analyst rbc capital market report reason cite celgene beat narrowing guidance upper end most importantly long term guidance well previously publish estimate
862,ILMN,opdivo superior survival
863,ILMN,ahead jpmorgan event bristol myer squibb say sunday phase trial drug opdivo result superior overall survival lung cancer patient take pharma giant rise monday hit year high early
864,ILMN,several sunday pharma announcement swiss drug giant roche rhhby say buy foundation medicine fmi foundation make genomic test cancer shot roche share rise
865,ILMN,other jpmorgan news monday gene sequence equipment maker illumina ilmn report preliminary revenue estimate
866,ILMN,illumina expect revenue rise ep slightly cautious vs wall street forecast ep sale growth
867,ILMN,illumina share close trading low stock hit record friday
868,ILMN,actavis act say expect gaap earning top wall street estimate cite exceptional sale drugmaker share rise hit record intraday
869,ILMN,actavis recently win bidding war botox maker allergan agn offer trumping valeant pharmaceutical vrx valeant share shot new high last week give upbeat preliminary result cancer therapy bullish earning forecast take spotlight monday open jpmorgan healthcare conference week san francisco largest annual biotech conference worldwide celgene celg provide bullish forecast cancer drug revlimid generally positive preliminary result long term financial outlook bristol myer squibb bmy announce positive trial result lung cancer drug opdivo celgene expect ep vs year earlier wall street see cent net product sale be include negative foreign currency shift dollar hit multiyear high vs euro yen analyst have expect sale be exceptional year celgene momentum core business position year outstanding execution say ceo bob hugin statement celgene estimate ep product sale wall street have see ep sale celgene long term forecast net product sale wall street estimate be strong dollar other currency shift hurt net product sale celgene forecast adjust ep consensus sale core drug revlimid climb celgene gain wider approval treat more type cancer ongoing global expansion revlimid be used treat multiple myeloma type lymphoma celgene expect total revenue ep hematology franchise top celgene outlook be impressive write michael yee analyst rbc capital market report reason cite celgene beat narrowing guidance upper end most importantly long term guidance well previously publish estimate opdivo superior survival ahead jpmorgan event bristol myer squibb say sunday phase trial drug opdivo result superior overall survival lung cancer patient take pharma giant rise monday hit year high early several sunday pharma announcement swiss drug giant roche rhhby say buy foundation medicine fmi foundation make genomic test cancer shot roche share rise other jpmorgan news monday gene sequence equipment maker illumina ilmn report preliminary revenue estimate illumina expect revenue rise ep slightly cautious vs wall street forecast ep sale growth illumina share close trading low stock hit record friday actavis act say expect gaap earning top wall street estimate cite exceptional sale drugmaker share rise hit record intraday actavis recently win bidding war botox maker allergan agn offer trumping valeant pharmaceutical vrx valeant share shot new high last week give upbeat preliminary result
870,ILMN,medical sector stock deliver strong gain
871,ILMN,stock week big cap medical related issue gain last year be stock poise deliver further price gain be stock spend
872,ILMN,let look basis aren late stage
873,ILMN,stock san diego base gene sequence company illumina ilmn rise
874,ILMN,full year earning be tally street expect growth ep be best earning growth
875,ILMN,analyst expect earning growth slow be roughly line company year growth rate respectively
876,ILMN,growth be slim minimum earning beat year bring gain most recent quarter earning top view tax margin be almost best least quarters
877,ILMN,illumina be sketch flat base be early stage base count reset october usual entry be left side high cent
878,ILMN,however daily chart show pattern arguably earlier entry
879,ILMN,individual investor interested establish position watch see stock clear area strong volume
880,ILMN,abc post gain stock price pharmaceutical sourcing distribution company be industry group carry thin profit margin tax margin be be typical
881,ILMN,earning be expect grow fiscal end september slowdown vs fiscal pop
882,ILMN,amerisource be extend october however stock have retreat week line first time first second trip line present buy opportunity stock bounce line strong volume
883,ILMN,stock price medical software provider cerner cern rise last year roughly line nasdaq gain
884,ILMN,earning grow street expect nearly same then pickup growth firm year growth rate respectively
885,ILMN,pretax margin step year least swing almost full year result be expect early february
886,ILMN,cerner be just buy zone clear buy point october base be first stage
887,ILMN,growth investor illumina cerner look more appeal amerisource earning growth rate be higher margin be much stronger medical sector stock deliver strong gain stock week big cap medical related issue gain last year be stock poise deliver further price gain be stock spend let look basis aren late stage stock san diego base gene sequence company illumina ilmn rise full year earning be tally street expect growth ep be best earning growth analyst expect earning growth slow be roughly line company year growth rate respectively growth be slim minimum earning beat year bring gain most recent quarter earning top view tax margin be almost best least quarters illumina be sketch flat base be early stage base count reset october usual entry be left side high cent however daily chart show pattern arguably earlier entry individual investor interested establish position watch see stock clear area strong volume abc post gain stock price pharmaceutical sourcing distribution company be industry group carry thin profit margin tax margin be be typical earning be expect grow fiscal end september slowdown vs fiscal pop amerisource be extend october however stock have retreat week line first time first second trip line present buy opportunity stock bounce line strong volume stock price medical software provider cerner cern rise last year roughly line nasdaq gain earning grow street expect nearly same then pickup growth firm year growth rate respectively pretax margin step year least swing almost full year result be expect early february cerner be just buy zone clear buy point october base be first stage growth investor illumina cerner look more appeal amerisource earning growth rate be higher margin be much stronger
888,ILMN,stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace
889,ILMN,blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high
890,ILMN,integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner
891,ILMN,ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average
892,ILMN,housing related stock get bad news november pending home sale drop unexpectedly
893,ILMN,however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average housing related stock get bad news november pending home sale drop unexpectedly however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume
894,ILMN,difference year make earning expectation uncertainty global economy facebook fb many semiconductor company be head earning season much higher expectation accord upward ep revision thomson reuter say wall street analyst now expect facebook earn cent share item compare
895,ILMN,stock lose grip most day gain thursday index head final hour trade nasdaq be be midday dow jone industrial average hold pop respectively volume stock market today be run much slower previous session widely hold issue thrust higher volume average nasdaq be respectively so far year have hold steady gain dividend be part reason ugly market dividend stock start look good investor have increase dividend consecutive year current annualize yield be stock price have be rangebound more year stock have find repeat resistance area support level stock be trading just ibd list stock best rating fundamental technical carter cri gain volume third faster normal marketer clothe baby child be work stage base however stock need do more work right side carter be high stage base mean stock be form second consolidation start advance breakout first consolidation be more likely work later stage ibd industry group coal oil stock grab biggest gain funeral service book stock take hardest hit follow paul whitfield twitter ibd_pwhitfield
896,ILMN,market have show thing recent week condition turn dime nasdaq notch follow jan distribution day jan call viability rally question thursday nasdaq score big percentage gain higher volume european central
897,ILMN,re wonder next life change technology appear american landscape look further genomic re look genomic company invest look further illumina genomic be branch genetic study genome dna sequence make person genetic map acid better know dna be
898,ILMN,medical stock be flex muscle latest big cap list ve more double number prior week even few medical sector make cut biotechs be well represent group earn top ranking monday issue industry group track ibd big improvement week alexion pharmaceutical alxn reversed upward edge higher follow last week gain stock be extend past entry second stage base trigger sell rule oct quickly re-cover buy point biotech thursday beat view earning year increase sale also lift full year profit sale guidance cheshire conn base company sole commercial drug soliris treat rare blood disease now submission process fda approval second drug alfa treat genetic bone disease call amgen amgn new high be extend cup handle buy point clear late july stock correct oct didn undercut entry share be hour oak calif base biotech be announce earning rise share sale increase consensus estimate amgen recently say work bill melinda gate foundation other group try find alternative method produce zmapp experimental ebola drug make mapp san diego celgene celg close slightly lower striking new high intraday monday be still extend past buy point surpass mid august alexion trigger sell rule oct quickly bounce back summit base biotech thursday report earning top view revenue line forecast celgene focus drug treat chancer immune inflammatory related disease revlimid vidaza abraxane be biggest seller regeneron pharmaceutical regn extend gain fifth straight session be now extend past flat base buy point tarrytown base biotech develop drug treat eye disease inflammatory disease cancer oct report clinical trial result eylea eye drug outperformed compete treatment patient diabetic macular edema other health care stock big cap include genetic analysis system maker illumina ilmn valeant pharmaceutical vrx maker dermatology neurology eye health drug
899,ILMN,stock be mixed moderately higher go last hour trading thursday market put see see day
900,ILMN,nasdaq rise gain dow jone industrial average be flat volume be run lighter previous day exchange
901,ILMN,oil related stock have decline price oil recent day be top performer pipeline operator refiner fared best
902,ILMN,crude oil rise less thursday meanwhile yield year treasury note rise basis point
903,ILMN,market open government report stunning drop weekly jobless claim lowest april
904,ILMN,unite rental uri climb nearly report estimate beating share quarterly ep increase year stock have be selling recent week gain meant only stock climb day move average stock market today
905,ILMN,ibd stock be be best performer be illumina ilmn get upgrade piper jaffray open raise price target
906,ILMN,worst performer be discounter give back gain previous day remain day line be work right side long deep base stock be mixed moderately higher go last hour trading thursday market put see see day nasdaq rise gain dow jone industrial average be flat volume be run lighter previous day exchange oil related stock have decline price oil recent day be top performer pipeline operator refiner fared best crude oil rise less thursday meanwhile yield year treasury note rise basis point market open government report stunning drop weekly jobless claim lowest april unite rental uri climb nearly report estimate beating share quarterly ep increase year stock have be selling recent week gain meant only stock climb day move average stock market today ibd stock be be best performer be illumina ilmn get upgrade piper jaffray open raise price target worst performer be discounter give back gain previous day remain day line be work right side long deep base
907,ILMN,stock reversed lower wednesday end day run nasdaq
908,ILMN,nasdaq fall lose be much wednesday high dow jone industrial average lose johnson johnson jnj be rare winner blue chip index ceo alex gorsky tell fox business network company hope have dose ebola vaccine
909,ILMN,accord preliminary datum volume end mixed stock market today nasdaq trade be smidge higher nyse volume slip
910,ILMN,super micro computer smci gap surge reaction late tuesday solid quarterly result thank strong server sale earning more double revenue grow stock touch new high wednesday then fade bit super micro have fail past buy point flat base
911,ILMN,illumina ilmn rise heavy trade breaking past buy point double bottom base move follow surge tuesday illumina report strong quarterly earning sale monday
912,ILMN,strong quarterly result also help yahoo yhoo gap rally nearly month high tuesday close internet search portal report rise earning biggest gain year company deliver gain sale first increase quarters
913,ILMN,biogen idec biib end well session low still lose heavy trading share be much follow mixed quarterly result biotech share also come pressure news patient die take tecfidera multiple sclerosis treatment stock reversed lower wednesday end day run nasdaq nasdaq fall lose be much wednesday high dow jone industrial average lose johnson johnson jnj be rare winner blue chip index ceo alex gorsky tell fox business network company hope have dose ebola vaccine accord preliminary datum volume end mixed stock market today nasdaq trade be smidge higher nyse volume slip super micro computer smci gap surge reaction late tuesday solid quarterly result thank strong server sale earning more double revenue grow stock touch new high wednesday then fade bit super micro have fail past buy point flat base illumina ilmn rise heavy trade breaking past buy point double bottom base move follow surge tuesday illumina report strong quarterly earning sale monday strong quarterly result also help yahoo yhoo gap rally nearly month high tuesday close internet search portal report rise earning biggest gain year company deliver gain sale first increase quarters biogen idec biib end well session low still lose heavy trading share be much follow mixed quarterly result biotech share also come pressure news patient die take tecfidera multiple sclerosis treatment
914,ILMN,stock turn negative midday wednesday give small early gain
915,ILMN,dow jone industrial average fall nasdaq volume be tracking lower yesterday level nasdaq nyse
916,ILMN,market weakness few highly rate stock stage breakout stock market today
917,ILMN,illumina ilmn rise heavy trade breaking past buy point double bottom base move follow surge tuesday illumina report strong quarterly earning sale
918,ILMN,manhattan associate manh also break double bottom pattern heavy volume maker supply chain development software be hover just buy point give back gain
919,ILMN,apple aapl hit new high intraday be trading just buy point flat base
920,ILMN,downside vmware vmw top analyst forecast third quarter earning sale slump weak fourth quarter revenue guidance virtualization software maker be downtrend high
921,ILMN,material handle industry group be worst perform group midday group member system ddd plunge report preliminary earning sale figure fall short analyst expectation printer company be expect report full third quarter result nov stock turn negative midday wednesday give small early gain dow jone industrial average fall nasdaq volume be tracking lower yesterday level nasdaq nyse market weakness few highly rate stock stage breakout stock market today illumina ilmn rise heavy trade breaking past buy point double bottom base move follow surge tuesday illumina report strong quarterly earning sale manhattan associate manh also break double bottom pattern heavy volume maker supply chain development software be hover just buy point give back gain apple aapl hit new high intraday be trading just buy point flat base downside vmware vmw top analyst forecast third quarter earning sale slump weak fourth quarter revenue guidance virtualization software maker be downtrend high material handle industry group be worst perform group midday group member system ddd plunge report preliminary earning sale figure fall short analyst expectation printer company be expect report full third quarter result nov
922,ILMN,wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum
923,ILMN,stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya
924,ILMN,noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters
925,ILMN,medical product stock cambrex cbm rise more better expect earning report also climb right side new base
926,ILMN,post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high
927,ILMN,share real estate zillow be hour follow result
928,ILMN,also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman
929,ILMN,lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday
930,ILMN,economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters medical product stock cambrex cbm rise more better expect earning report also climb right side new base post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high share real estate zillow be hour follow result also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct
931,ILMN,stock future tuesday advanced open second straight day show bit more strength monday premarket session
932,ILMN,dow future be ahead point well monday premarket level rise nasdaq future climb point fair market value future show healthy point gain small cap also look good shape russell future point
933,ILMN,stock market today roll december automaker release november sale number session fiat chrysler fcau report gain sale best level november year jeep sale drive result rise vs decline chrysler product slip dodge fall fiat auto
934,ILMN,auto researcher edmund forecast total light vehicle sell month year accurate make best november automaker
935,ILMN,institute supply management release november ism index commerce department report october construction spending
936,ILMN,retailer strong online presence get bump datum release adobe system adbe show shopper spend total cyber monday monday follow black friday launch holiday shopping season be designate day technology online shopping special amount be record last year cyber monday sale adobe say adobe also estimate thanksgiving cyber monday receipt top year year also record
937,ILMN,third dow issue be positive premarket action rest be flat best gain come home depot hd add
938,ILMN,adobe system rise lead nasdaq baidu bidu post nasdaq largest decline nearly
939,ILMN,automate network control specialist infoblox blox rocket higher open santa clara calif base company report late monday fiscal first quarter earning revenue guidance expectation management announce share buyback initiative
940,ILMN,mattress firm hold mfrm bounce higher announce late monday buy hmk mattress hold owner sleepy retail chain deal company say expect year cost saving mattress firm also announce fiscal sale rise say expect ep gain line consensus view
941,ILMN,china base qihoo technology qihu add wall street journal report investor group be prepared offer take internet security content provider market american depositary receipt deal be complete come week report say plan then call relisting company china domestic exchange
942,ILMN,qihoo be most recent wave privatization china base company trading china base issue ikang healthcare kang announce monday be be take private group investor adr
943,ILMN,leader stock ibd list be quiet ahead open most group remain flat few gain loss hold less same be true stock ibd weekly review list
944,ILMN,overseas market asia gain pmi gauge tracking china manufacturing service sector show further divergence month european market be narrowly mixed midday
945,ILMN,follow alan elliott twitter ibd_aelliott stock future tuesday advanced open second straight day show bit more strength monday premarket session dow future be ahead point well monday premarket level rise nasdaq future climb point fair market value future show healthy point gain small cap also look good shape russell future point stock market today roll december automaker release november sale number session fiat chrysler fcau report gain sale best level november year jeep sale drive result rise vs decline chrysler product slip dodge fall fiat auto auto researcher edmund forecast total light vehicle sell month year accurate make best november automaker institute supply management release november ism index commerce department report october construction spending retailer strong online presence get bump datum release adobe system adbe show shopper spend total cyber monday monday follow black friday launch holiday shopping season be designate day technology online shopping special amount be record last year cyber monday sale adobe say adobe also estimate thanksgiving cyber monday receipt top year year also record third dow issue be positive premarket action rest be flat best gain come home depot hd add adobe system rise lead nasdaq baidu bidu post nasdaq largest decline nearly automate network control specialist infoblox blox rocket higher open santa clara calif base company report late monday fiscal first quarter earning revenue guidance expectation management announce share buyback initiative mattress firm hold mfrm bounce higher announce late monday buy hmk mattress hold owner sleepy retail chain deal company say expect year cost saving mattress firm also announce fiscal sale rise say expect ep gain line consensus view china base qihoo technology qihu add wall street journal report investor group be prepared offer take internet security content provider market american depositary receipt deal be complete come week report say plan then call relisting company china domestic exchange qihoo be most recent wave privatization china base company trading china base issue ikang healthcare kang announce monday be be take private group investor adr leader stock ibd list be quiet ahead open most group remain flat few gain loss hold less same be true stock ibd weekly review list overseas market asia gain pmi gauge tracking china manufacturing service sector show further divergence month european market be narrowly mixed midday follow alan elliott twitter ibd_aelliott
946,ILMN,jason weiner be green bay packer quarterback aaron rodger
947,ILMN,season season keep perform high level
948,ILMN,feb weiner become signal caller now fidelity growth discovery fund adviser sell twin advisor equity growth fund growth discovery have notch average annual gain vs performance rank top large cap growth peer track morningstar inc
949,ILMN,weiner have used same approach most not tenure say seek undervalue growth story stock potential price earning expansion avoid overly costly name
950,ILMN,weiner year old talk ibd office boston invest
951,ILMN,ibd jason ever have mentor be
952,ILMN,weiner ve have ton mentor rare occasion fidelity roll meet mbas visit fidelity tell find mentor outside workplace preferably
953,ILMN,super important go back be have first job get family friend lou be great influence be lou nargiso own gas station auto repair shop be world war ii vet learn auto repair army
954,ILMN,be very well educate person philosophical like debate thing everyone work lou be very loyal be shop be also kind clubhouse world war ii vet buddy hung good time
955,ILMN,ibd fidelity
956,ILMN,weiner fidelity manager fidelity contrafund advisor new insight series opportunistic insight advisor series opportunistic insight have be great mentor
957,ILMN,don remember exactly kick have be be train be go southern connecticut visit parent sit next other work later gain lot wisdom be super focuse study decade understand monster stock decade be elephant hunting business hunting stock go make monster gain
958,ILMN,own dell next year nothing else matter beauty incredible growth story be focuse have adopt strategy
959,ILMN,ibd overall look undervalue growth story stock potential price earning expansion right
960,ILMN,weiner only get paid thing growth stock first expansion second underlie earning growth company invest
961,ILMN,typically focus growth rate company fundamental research bring value try leverage fidelity research engine lot
962,ILMN,little harder predict
963,ILMN,ibd try avoid valuation be too high correct
964,ILMN,weiner enter name controversy doubt cast lower great opportunity
965,ILMN,ibd give example please
966,ILMN,weiner best recent year be facebook fb facebook botch ipo
967,ILMN,stock have go public trade immediately bottom even company be do great be cloud controversy pummeled stock
968,ILMN,buy ipo didn buy day average price share be
969,ILMN,stock be go company be roll newsfeed ad seem ancient history newsfeed ad be relatively new time ipo stop rely ad pc base service shift newsfeed ad appear mobile device be fundamental transformation business model facebook story today
970,ILMN,ibd person think growth discovery garp growth reasonable price strategy
971,ILMN,weiner lot fund be recognizable garp basket addition try buy best growth name market one be go turn big sustainable valuable franchise little different garp
972,ILMN,top name be asset not name become brand new unbelievable franchise already have great franchise become great look decade know publication william neil send so look monster stock be never many try buy sort name
973,ILMN,ibd be allow invest market cap size fund have be large cap oriented long time heaviest weighting be megacaps one
974,ILMN,weiner let take piece first economy be do better average develop nation so fortuitous be investor day
975,ILMN,so many megacaps look internet model successful one be global scalable enjoy incredible network effect be viral want
976,ILMN,point facebook biggest company enjoy increase return get bigger
977,ILMN,be manufacturer year have experience decrease return single additional widget make have be sell lower margin incent market buy product internet age opposite increase return
978,ILMN,other thing internet be winner take most dynamic google googl be leader search be winner take battle win
979,ILMN,be determine ota online travel agency space ve get facebook expedia expe tripadvisor trip bunch other one also turn winner take space haven invest priceline pcln have skin game
980,ILMN,ibd do boost apple aapl weighting oct less march june
981,ILMN,weiner full disclosure have not do great job trading apple last year give low mark make long list apple positive negative ve focuse negative last year not go do more
982,ILMN,live block apple store iphone come be line block be crazy ignore
983,ILMN,lecture smartphone be fully penetrate rate innovation be slow android have outshipped apple io usually volume leader win tech actually always do negative haven matter apple stock performance
984,ILMN,ibd so ve decide least moment be not lose apple
985,ILMN,weiner key bucket stock ve avoid be large cap tech legacy player oracle orcl emc emc hewlett packard hpq microsoft msft generally underweight mindful have secular challenge happen never know catch ibm ibm year face somehow always punch good earning be change last quarter be terrible
986,ILMN,secular challenge catch company be tech analyst cover compaq tandem digital stratus datum general face secular challenge wave hit fall don exist now independent company
987,ILMN,apple be huge good legacy story relative other legacy player justification own apple
988,ILMN,ibd hold illumina ilmn oct re fan outlook gene sequence right
989,ILMN,weiner yes illumina be incredible company help unlock secret sequence genome just way practice medicine be change company illumina
990,ILMN,look backward person be do human genome now re sequence thousand future have genome go doctor illumina come
991,ILMN,ibd alexion alxn remain play single drug soliris
992,ILMN,weiner alexion thesis latest disclosure be be super orphan drug company only go indication small patient population get lot money life save drug
993,ILMN,ve increase number indication soliris be sell be drug re hope fda approval new set indication
994,ILMN,hard society say not pay drug child live only couple year society pay drug child have normal outcome big ethic debate bottom line country be pay drug
995,ILMN,ibd similar be gilead gild story
996,ILMN,weiner have great risk reward beat competition be other cure hepatitis get market share gilead get majority market share have hep want drug immediately
997,ILMN,knock drug be person don invest company cure disease then treatment be shot deal person say isn better develop treatment hiv require patient take pill day still plenty room hep drug be million patient don have drug yet
998,ILMN,ibd chipotle cmg earning growth have accelerate quarters
999,ILMN,weiner great franchise ton room growth secret be person pay more food think be higher quality
1000,ILMN,ibd sherwin william shw
1001,ILMN,weiner be greatest company nobody recognize
1002,ILMN,paint store franchise be so valuable re vertically integrate professional painter make first daily stop sherwin william not home depot hd lowe low know treat pro have lot pricing power material cost be not big deal most end user be person restore remodel home do not depend home sale
1003,ILMN,ibd drife ulta beauty ulta
1004,ILMN,weiner ulta be beauty have high emotional content woman ulta give ability walk mall base completely dedicate beauty retailer not have walk halfway department store get beauty counter ulta have grow number prestige brand year prestige brand wouldn sell now do
1005,ILMN,beauty product have high margin profit same store sale sale square foot be grow
1006,ILMN,last year profit have actually be muted ceo mary dillon be investing heavily commerce tell credible story street investment do so person be board
1007,ILMN,ibd be fan alibaba baba latest disclosure right
1008,ILMN,weiner alibaba be legend name year person talk ceo jack term be commerce leader china full stop china be big market be grow
1009,ILMN,jack have do very good job build huge business massive gross merchandise value attract merchant low take rate mean small medium business alibaba be great tool grow business
1010,ILMN,also have mall place global brand sell safe place be counterfeit
1011,ILMN,get payment financial service back pocket
1012,ILMN,alibaba gross merchandise value be larger amazon amzn ebay ebay combine jason weiner be green bay packer quarterback aaron rodger season season keep perform high level feb weiner become signal caller now fidelity growth discovery fund adviser sell twin advisor equity growth fund growth discovery have notch average annual gain vs performance rank top large cap growth peer track morningstar inc weiner have used same approach most not tenure say seek undervalue growth story stock potential price earning expansion avoid overly costly name weiner year old talk ibd office boston invest ibd jason ever have mentor be weiner ve have ton mentor rare occasion fidelity roll meet mbas visit fidelity tell find mentor outside workplace preferably super important go back be have first job get family friend lou be great influence be lou nargiso own gas station auto repair shop be world war ii vet learn auto repair army be very well educate person philosophical like debate thing everyone work lou be very loyal be shop be also kind clubhouse world war ii vet buddy hung good time ibd fidelity weiner fidelity manager fidelity contrafund advisor new insight series opportunistic insight advisor series opportunistic insight have be great mentor don remember exactly kick have be be train be go southern connecticut visit parent sit next other work later gain lot wisdom be super focuse study decade understand monster stock decade be elephant hunting business hunting stock go make monster gain own dell next year nothing else matter beauty incredible growth story be focuse have adopt strategy ibd overall look undervalue growth story stock potential price earning expansion right weiner only get paid thing growth stock first expansion second underlie earning growth company invest typically focus growth rate company fundamental research bring value try leverage fidelity research engine lot little harder predict ibd try avoid valuation be too high correct weiner enter name controversy doubt cast lower great opportunity ibd give example please weiner best recent year be facebook fb facebook botch ipo stock have go public trade immediately bottom even company be do great be cloud controversy pummeled stock buy ipo didn buy day average price share be stock be go company be roll newsfeed ad seem ancient history newsfeed ad be relatively new time ipo stop rely ad pc base service shift newsfeed ad appear mobile device be fundamental transformation business model facebook story today ibd person think growth discovery garp growth reasonable price strategy weiner lot fund be recognizable garp basket addition try buy best growth name market one be go turn big sustainable valuable franchise little different garp top name be asset not name become brand new unbelievable franchise already have great franchise become great look decade know publication william neil send so look monster stock be never many try buy sort name ibd be allow invest market cap size fund have be large cap oriented long time heaviest weighting be megacaps one weiner let take piece first economy be do better average develop nation so fortuitous be investor day so many megacaps look internet model successful one be global scalable enjoy incredible network effect be viral want point facebook biggest company enjoy increase return get bigger be manufacturer year have experience decrease return single additional widget make have be sell lower margin incent market buy product internet age opposite increase return other thing internet be winner take most dynamic google googl be leader search be winner take battle win be determine ota online travel agency space ve get facebook expedia expe tripadvisor trip bunch other one also turn winner take space haven invest priceline pcln have skin game ibd do boost apple aapl weighting oct less march june weiner full disclosure have not do great job trading apple last year give low mark make long list apple positive negative ve focuse negative last year not go do more live block apple store iphone come be line block be crazy ignore lecture smartphone be fully penetrate rate innovation be slow android have outshipped apple io usually volume leader win tech actually always do negative haven matter apple stock performance ibd so ve decide least moment be not lose apple weiner key bucket stock ve avoid be large cap tech legacy player oracle orcl emc emc hewlett packard hpq microsoft msft generally underweight mindful have secular challenge happen never know catch ibm ibm year face somehow always punch good earning be change last quarter be terrible secular challenge catch company be tech analyst cover compaq tandem digital stratus datum general face secular challenge wave hit fall don exist now independent company apple be huge good legacy story relative other legacy player justification own apple ibd hold illumina ilmn oct re fan outlook gene sequence right weiner yes illumina be incredible company help unlock secret sequence genome just way practice medicine be change company illumina look backward person be do human genome now re sequence thousand future have genome go doctor illumina come ibd alexion alxn remain play single drug soliris weiner alexion thesis latest disclosure be be super orphan drug company only go indication small patient population get lot money life save drug ve increase number indication soliris be sell be drug re hope fda approval new set indication hard society say not pay drug child live only couple year society pay drug child have normal outcome big ethic debate bottom line country be pay drug ibd similar be gilead gild story weiner have great risk reward beat competition be other cure hepatitis get market share gilead get majority market share have hep want drug immediately knock drug be person don invest company cure disease then treatment be shot deal person say isn better develop treatment hiv require patient take pill day still plenty room hep drug be million patient don have drug yet ibd chipotle cmg earning growth have accelerate quarters weiner great franchise ton room growth secret be person pay more food think be higher quality ibd sherwin william shw weiner be greatest company nobody recognize paint store franchise be so valuable re vertically integrate professional painter make first daily stop sherwin william not home depot hd lowe low know treat pro have lot pricing power material cost be not big deal most end user be person restore remodel home do not depend home sale ibd drife ulta beauty ulta weiner ulta be beauty have high emotional content woman ulta give ability walk mall base completely dedicate beauty retailer not have walk halfway department store get beauty counter ulta have grow number prestige brand year prestige brand wouldn sell now do beauty product have high margin profit same store sale sale square foot be grow last year profit have actually be muted ceo mary dillon be investing heavily commerce tell credible story street investment do so person be board ibd be fan alibaba baba latest disclosure right weiner alibaba be legend name year person talk ceo jack term be commerce leader china full stop china be big market be grow jack have do very good job build huge business massive gross merchandise value attract merchant low take rate mean small medium business alibaba be great tool grow business also have mall place global brand sell safe place be counterfeit get payment financial service back pocket alibaba gross merchandise value be larger amazon amzn ebay ebay combine
1013,ILMN,market still look bearish top rate medical stock include biogen idec alexion have remain strong demand new treatment breakthrough overcome investor skittishness elsewhere
1014,ILMN,latest ibd list include thrive medical stock report quarterly result week outlook be healthy revenue earning growth vs same quarter year
1015,ILMN,biotech drugmaker biogen idec biib announce result early wednesday consensus be earning share shot share jump revenue
1016,ILMN,biogen blockbuster oral multiple sclerosis drug tecfidera be approve last year europe february management expect european launch be slow last earning call company say uptake be proceed similar pace uptake
1017,ILMN,stock boast highest possible composite rating ep rating earning growth last quarters
1018,ILMN,alexion alxn specialty drugmaker be expect record spike ep thursday morning increase revenue
1019,ILMN,company blockbuster drug soliris treat rare blood disease march alexion say expect soliris sale year
1020,ILMN,earning call alexion likely talk pipeline drug alfa soliris be target rare orphan disease alfa be design treat genetic disorder affect bone formation child quickly
1021,ILMN,last wednesday alexion submit application medical official japan approval drug
1022,ILMN,company stock have hold recent market turmoil almost retook day move average friday give alexion solid relative strength rating
1023,ILMN,celgene celg develop treatment cancer immune inflammatory disease be also slate announce earning early thursday big cap biotech be branch last week present datum new treatment crohn disease debilitating bowel ailment medical conference vienna
1024,ILMN,wall street be look hike ep cent rise sale
1025,ILMN,july celgene say drug otezla fail trial inflammatory spinal disease failure wasn surprise analyst earlier year celgene drug abraxane win approval europe use combination rival eli lilly lly gemzar fight metastatic pancreatic cancer
1026,ILMN,illumina ilmn be pound gorilla market high speed gene sequence machine be partner pharma giant amgen amgn astrazeneca azn well diagnostic testing company quest diagnostic dgx
1027,ILMN,analyst project illumina have have beaten earning estimate quarters row report rise ep cent surge revenue
1028,ILMN,stock have also weather market sell be near day line well
1029,ILMN,several ibd stock not medical field be also report week include atv maker polaris industry pii railroad giant union pacific unp staffing service provider robert half rhi supply chain management software developer manhattan associate manh
1030,ILMN,follow james detar twitter ibd_jdetar market still look bearish top rate medical stock include biogen idec alexion have remain strong demand new treatment breakthrough overcome investor skittishness elsewhere latest ibd list include thrive medical stock report quarterly result week outlook be healthy revenue earning growth vs same quarter year biotech drugmaker biogen idec biib announce result early wednesday consensus be earning share shot share jump revenue biogen blockbuster oral multiple sclerosis drug tecfidera be approve last year europe february management expect european launch be slow last earning call company say uptake be proceed similar pace uptake stock boast highest possible composite rating ep rating earning growth last quarters alexion alxn specialty drugmaker be expect record spike ep thursday morning increase revenue company blockbuster drug soliris treat rare blood disease march alexion say expect soliris sale year earning call alexion likely talk pipeline drug alfa soliris be target rare orphan disease alfa be design treat genetic disorder affect bone formation child quickly last wednesday alexion submit application medical official japan approval drug company stock have hold recent market turmoil almost retook day move average friday give alexion solid relative strength rating celgene celg develop treatment cancer immune inflammatory disease be also slate announce earning early thursday big cap biotech be branch last week present datum new treatment crohn disease debilitating bowel ailment medical conference vienna wall street be look hike ep cent rise sale july celgene say drug otezla fail trial inflammatory spinal disease failure wasn surprise analyst earlier year celgene drug abraxane win approval europe use combination rival eli lilly lly gemzar fight metastatic pancreatic cancer illumina ilmn be pound gorilla market high speed gene sequence machine be partner pharma giant amgen amgn astrazeneca azn well diagnostic testing company quest diagnostic dgx analyst project illumina have have beaten earning estimate quarters row report rise ep cent surge revenue stock have also weather market sell be near day line well several ibd stock not medical field be also report week include atv maker polaris industry pii railroad giant union pacific unp staffing service provider robert half rhi supply chain management software developer manhattan associate manh follow james detar twitter ibd_jdetar
1031,ILMN,shortage damage chart ibd few other show interesting potential market be attempt rally confirmation new uptrend happen time week signal be come average chart take greater importance potential leader be health care drugmaker akorn ticker
1032,ILMN,major average reversed early gain wednesday didn crimp wednesday new high list several top rate name turn solid performance illumina ilmn surge heavy volume clear double bottom buy point day wall street cheer strong earning report late monday gene sequence company report earning share cent
1033,ILMN,dow jone industrial average end higher monday nasdaq re-cover early loss resilient performance close nasdaq fall less lower be much still hold day move average find support april dow jone industrial average add rise preliminary datum show nyse nasdaq volume come well friday level stock market today apple aapl be bright spot thursday gap price strong earning share rise week high elsewhere pfizer pfe be best gainer dow share rise news drugmaker be interested re start talk astrazeneca azn regard merger early january pfizer offer share cash stock astrazeneca reject bid too low share astrazeneca soar downside nasdaq list name baidu bidu illumina ilmn wynn resort wynn take hit fall anywhere baidu report quarter strong growth last week stock be now day move average wynn hasn report earning yet be result next few day meanwhile seller continue hammer facebook fb share lose heavy volume deliver outstanding earning last week price action lately show institutional investor have be unwinding position watch earning report tuesday like spirit airline save therapeutic anik trinity industry trn
1034,ILMN,san francisco biotechnology continue take spotlight jpmorgan healthcare conference illumina regeneron offer strong preliminary result former rolled new gene sequence product meanwhile beleaguered robotic surgery firm intuitive surgical stock rebound update beat expectation illumina ilmn ceo jay flatley say revenue rise year earlier
1035,ILMN,sell market lead stock be able grab week high natus medical baby bolt nearly time average trade score time high wednesday be now extend rebound day line break flat base earlier month be
1036,ILMN,stock rally fourth straight session tuesday extend recent rebound effort heavy batch earning report apple aapl report better expect quarterly result late monday help boost nasdaq gain jump regain day move average hurt loss ibm ibm coca cola ko dow jone industrial average lag advance trade jump major exchange stock market today illumina ilmn bolt huge volume reaction result late monday genetic sequence firm also lift full year earning outlook gap day move average near buy point double bottom base akorn akrx rally time high blow past buy point second stage cup base specialty drugmaker report earning nov analyst poll thomson reuter see profit rise cent share akorn growth have picked recently due buyout tech pharmacal vpi holding amtrust financial service afsi surge heavy trading too stage stock recently joined sector leader clear aggressive buy point base base pattern downside tal education group xrs gap tumble report disappointing fiscal sale chinese provider tutor service also guide fiscal revenue view
1037,ILMN,buyer be short supply early afternoon trading thursday wave institutional selling hit nasdaq
1038,ILMN,tech laden index slump weigh weakness apple aapl dow jone industrial average lose nyse volume be tracking close wednesday level nasdaq volume rise sharply
1039,ILMN,coal mining steel stock be particularly hard hit
1040,ILMN,economic datum weren bad weekly jobless claim rise economist expect slightly bigger increase
1041,ILMN,meanwhile durable good order plunge august bit consensus estimate drop weakness be attribute plunge aircraft order ex transportation order rise just consensus estimate
1042,ILMN,stock market today apple crash day move average fall report surface wednesday io smartphone software update cause iphone user lose cellular service apple be also get complaint warp phone
1043,ILMN,apple be biggest decliner nasdaq illumina ilmn avgo biogen biib
1044,ILMN,gopro gpro continue rapid ascent rise company newest wearable camera gopro hero be release early mid october gopro go public late june have nearly quadruple price
1045,ILMN,israel cyberark cybr extend gain wednesday ipo share rise additional heel wednesday gain company provide security solution protect organization cyberattack
1046,ILMN,polaris industry pii be sole gainer ibd share rise meanwhile selling pressure be muted ibd name tal education xrs salix pharmaceutical slxp spirit airline save buyer be short supply early afternoon trading thursday wave institutional selling hit nasdaq tech laden index slump weigh weakness apple aapl dow jone industrial average lose nyse volume be tracking close wednesday level nasdaq volume rise sharply coal mining steel stock be particularly hard hit economic datum weren bad weekly jobless claim rise economist expect slightly bigger increase meanwhile durable good order plunge august bit consensus estimate drop weakness be attribute plunge aircraft order ex transportation order rise just consensus estimate stock market today apple crash day move average fall report surface wednesday io smartphone software update cause iphone user lose cellular service apple be also get complaint warp phone apple be biggest decliner nasdaq illumina ilmn avgo biogen biib gopro gpro continue rapid ascent rise company newest wearable camera gopro hero be release early mid october gopro go public late june have nearly quadruple price israel cyberark cybr extend gain wednesday ipo share rise additional heel wednesday gain company provide security solution protect organization cyberattack polaris industry pii be sole gainer ibd share rise meanwhile selling pressure be muted ibd name tal education xrs salix pharmaceutical slxp spirit airline save
1047,ILMN,plenty ibd name be show resilience hold high damage chart be exception not rule good news bad news be new buy aren easy find growth investor look put new money work mild follow day nasdaq aug have work so far
1048,ILMN,daunting headline technology sector didn stop nasdaq turn solid performance monday nasdaq jump nearly fourth day rally attempt normally be strong enough gain qualify follow day nyse nasdaq volume be well friday level volume be unusually
1049,ILMN,stock finished big gain friday post best day session
1050,ILMN,blue chip lead dow jone industrial average rise climb nasdaq finished higher preliminary datum show volume come lower yesterday board
1051,ILMN,nasdaq finished week fractionally trimming majority loss low week
1052,ILMN,walt disney rise more heavy trade friday climb back day move average stock close day line wednesday first time december
1053,ILMN,gilead science gild akorn akrx be top performer ibd stock remain base build mode
1054,ILMN,worst perform industry group stock market today be gold miner medical software maker
1055,ILMN,medical software firm athenahealth athn be heavy trading report line earning issue disappointing guidance
1056,ILMN,come week be busy earning report monday illumina ilmn chipotle grill cmg apple aapl valeant pharmaceutical vrx be company report stock finished big gain friday post best day session blue chip lead dow jone industrial average rise climb nasdaq finished higher preliminary datum show volume come lower yesterday board nasdaq finished week fractionally trimming majority loss low week walt disney rise more heavy trade friday climb back day move average stock close day line wednesday first time december gilead science gild akorn akrx be top performer ibd stock remain base build mode worst perform industry group stock market today be gold miner medical software maker medical software firm athenahealth athn be heavy trading report line earning issue disappointing guidance come week be busy earning report monday illumina ilmn chipotle grill cmg apple aapl valeant pharmaceutical vrx be company report
1057,ILMN,stock slump second straight session monday putt blemish new market uptrend nasdaq shed close back day move average chip solar stock be area weakness tech heavy index biotechs buck weakness also end selling energy stock day
1058,ILMN,best perform stock mutual fund past month have continue stock health transportation chip stock latest report period airliner southwest luv republic airway rjet unite continental ual jetblue jblu have be perform well oil bear market have take brent crude oil price fresh multiyear lows
1059,ILMN,stock open weak extend loss midday monday
1060,ILMN,nasdaq fall drop dow jone industrial average lose volume stock market today be tracking higher board compare friday session
1061,ILMN,fall day move average be pace biggest loss dec
1062,ILMN,small cap stock hold relatively better russell
1063,ILMN,oil giant exxon mobil xom chevron cvx weigh dow crude fall more multiyear low
1064,ILMN,leader volume be few network ffiv rise more heavy trading stock have hover buy range november past
1065,ILMN,vipshop vip rise heavy volume stock try climb right side late stage base
1066,ILMN,illumina ilmn be top performer ibd climb nearly heavy volume be approach early buy point flat base stock open weak extend loss midday monday nasdaq fall drop dow jone industrial average lose volume stock market today be tracking higher board compare friday session fall day move average be pace biggest loss dec small cap stock hold relatively better russell oil giant exxon mobil xom chevron cvx weigh dow crude fall more multiyear low leader volume be few network ffiv rise more heavy trading stock have hover buy range november past vipshop vip rise heavy volume stock try climb right side late stage base illumina ilmn be top performer ibd climb nearly heavy volume be approach early buy point flat base
1067,ILMN,prescription stir investor enthusiasm ipo market inc research holding nasdaq incr have find answer inc be contract research organization cro provide phase phase clinical development outsource service biopharma medical device industry have narrow therapeutic focus oncology central nervous system disorder
1068,ILMN,special report best mutual fund january performance report
1069,ILMN,fall oil price greece possible exit eurozone stock market start first month year volatility
1070,ILMN,best perform mutual fund past month slow buy january outlook ibd market pulse toggle correction market pressure stock market
1071,ILMN,top mutual fund have be add heavy hit medical issue such celgene celg biogen idec biib latest report period other include actavis act illumina ilmn shire shpg
1072,ILMN,ibd industry medical subgroup rank top tuesday biotech biom group rank
1073,ILMN,top perform fund continue give much love airline stock include southwest airline luv unite continental holding ual jetblue airway jblu
1074,ILMN,real estate stock make way new buy list property reit such pebblebrook hotel peb extra space storage exr regency center reg be stellar performer lipper real estate mutual fund category be second best perform group january notch gain
1075,ILMN,ibd spot lead mutual fund add nautilus nls investing estimate
1076,ILMN,jpmorgan small cap value fund add share latest report period
1077,ILMN,vancouver wash base firm make market fitness product include home gym free weight equipment treadmill indoor cycling equipment elliptical fitness accessory portfolio fitness brand include bowflex nautilus schwinn universal sell retail direct sale consumer
1078,ILMN,nautilus have be pump sale growth past quarters analyst see growth opportunity nautilus continue deliver innovative product
1079,ILMN,stock be currently form handle third stage cup handle base trading buy point
1080,ILMN,sell side
1081,ILMN,lead fund have be take profit several big reit stock such simon property group spg federal realty investment trust frt aviv aviv public storage psa
1082,ILMN,top perform fund be also selling biotech stock include gilead science gild isis pharmaceutical isis special report best mutual fund january performance reportamid fall oil price greece possible exit eurozone stock market start first month year volatility best perform mutual fund past month slow buy january outlook ibd market pulse toggle correction market pressure stock market top mutual fund have be add heavy hit medical issue such celgene celg biogen idec biib latest report period other include actavis act illumina ilmn shire shpg ibd industry medical subgroup rank top tuesday biotech biom group rank top perform fund continue give much love airline stock include southwest airline luv unite continental holding ual jetblue airway jblu real estate stock make way new buy list property reit such pebblebrook hotel peb extra space storage exr regency center reg be stellar performer lipper real estate mutual fund category be second best perform group january notch gain ibd spot lead mutual fund add nautilus nls investing estimate jpmorgan small cap value fund add share latest report period vancouver wash base firm make market fitness product include home gym free weight equipment treadmill indoor cycling equipment elliptical fitness accessory portfolio fitness brand include bowflex nautilus schwinn universal sell retail direct sale consumer nautilus have be pump sale growth past quarters analyst see growth opportunity nautilus continue deliver innovative product stock be currently form handle third stage cup handle base trading buy point sell sidelead fund have be take profit several big reit stock such simon property group spg federal realty investment trust frt aviv aviv public storage psa top perform fund be also selling biotech stock include gilead science gild isis pharmaceutical isis
1083,ILMN,stock be best level hold firmly higher midday thursday
1084,ILMN,nasdaq lead stock market today dow jone industrial average add number lead stock rise volume picked sharply thursday
1085,ILMN,restoration hardware rh climb heavy trade new high stock break cup handle pattern dec be now extend past gap entry
1086,ILMN,consult firm accenture acn shot new time high report fiscal first quarter result end november earning rise jump sale top analyst estimate company also raise revenue forecast fiscal
1087,ILMN,illumina ilmn jump heavy trade retake day move average double bottom buy point stock be also shape flat base early entry
1088,ILMN,professional networking linkedin lnkd bolt higher heavy volume stock have shape new buy point be view high handle flat base
1089,ILMN,economic news philadelphia fed survey show manufacturing growth mid atlantic region stay positive fall just short economist estimate
1090,ILMN,meanwhile conference board lead indicator index rise third straight month match consensus estimate stock be best level hold firmly higher midday thursday nasdaq lead stock market today dow jone industrial average add number lead stock rise volume picked sharply thursday restoration hardware rh climb heavy trade new high stock break cup handle pattern dec be now extend past gap entry consult firm accenture acn shot new time high report fiscal first quarter result end november earning rise jump sale top analyst estimate company also raise revenue forecast fiscal illumina ilmn jump heavy trade retake day move average double bottom buy point stock be also shape flat base early entry professional networking linkedin lnkd bolt higher heavy volume stock have shape new buy point be view high handle flat base economic news philadelphia fed survey show manufacturing growth mid atlantic region stay positive fall just short economist estimate meanwhile conference board lead indicator index rise third straight month match consensus estimate
1091,ILMN,major average be sharply lower hour thursday session nasdaq slump apple cast pall tech sector
1092,ILMN,dow jone industrial average lose small cap take hit russell crater nyse volume be tracking close wednesday level nasdaq volume rise sharply
1093,ILMN,stock market today apple aapl slump heavy volume fall day move average report surface wednesday io smartphone software update cause iphone user lose cellular service company also receive complaint warp phone
1094,ILMN,apple be biggest decliner nasdaq illumina ilmn celgene celg biogen biib
1095,ILMN,elsewhere valeant pharmaceutical vrx jump nearly issue upbeat guidance late wednesday
1096,ILMN,smart final sfs extend gain rise wednesday debut price tuesday night close first day trading company operate grocery food service store western state northern mexico cash carry store
1097,ILMN,ibd selling pressure be scant name ulta beauty ulta tal education xrs polaris pii
1098,ILMN,economic news weekly jobless claim rise economist expect slightly bigger increase week move average claim fall second straight week meanwhile durable good order plunge august bit consensus estimate drop weakness be attribute plunge aircraft order ex transportation order rise just consensus estimate
1099,ILMN,tomorrow final revision gdp be release et economist expect growth last estimate major average be sharply lower hour thursday session nasdaq slump apple cast pall tech sector dow jone industrial average lose small cap take hit russell crater nyse volume be tracking close wednesday level nasdaq volume rise sharply stock market today apple aapl slump heavy volume fall day move average report surface wednesday io smartphone software update cause iphone user lose cellular service company also receive complaint warp phone apple be biggest decliner nasdaq illumina ilmn celgene celg biogen biib elsewhere valeant pharmaceutical vrx jump nearly issue upbeat guidance late wednesday smart final sfs extend gain rise wednesday debut price tuesday night close first day trading company operate grocery food service store western state northern mexico cash carry store ibd selling pressure be scant name ulta beauty ulta tal education xrs polaris pii economic news weekly jobless claim rise economist expect slightly bigger increase week move average claim fall second straight week meanwhile durable good order plunge august bit consensus estimate drop weakness be attribute plunge aircraft order ex transportation order rise just consensus estimate tomorrow final revision gdp be release et economist expect growth last estimate
1100,ILMN,stock advanced quiet volume friday nasdaq close day line first time late september nasdaq rise ibd lead gain volume fall board nasdaq retook day move average further testing be likely remain just
1101,ILMN,illumina ilmn system target array genetic analysis have huge implication medical research private government lab university drug biotech agri genomic industry be illumina client system enable analysis genetic variation gene expression gleaning info gene make synthetic gene product report see april illumina say ep rise year quarter cent share beating consensus cent sale climb also beating view illumina quarterly record be bit choppy profit rise follow report show gain earning grow consensus say medical research group stand place ibd industry june research note health care focuse investment bank leerink swann outline potential risk say be overall attractive picture cut research budget lower stimulus spending growth initiative outside company research sweet spot diagnostic consumer genetic
1102,ILMN,stock gap be flash bullish sign gap mean stock open higher price previous day range further stock stay previous day high session result be air chart big cap feature quite few stock have gap recent week month online social platform operator facebook fb stage gap late july then advanced strongly late december stock deliver stingy look gap low gap be barely high previous day facebook slide sideway week poor man gap discipline investor probably ve cut loss choppy period more convince facebook gap occur jan stock thrust higher heavy volume then make new high stock close gap session biogen biib gap november find support day line biom stock consolidated gap be gap day close gene sequence company illumina ilmn have deliver series gap up april stock gap april july october jan stock be past close april gap past most recent gap sometimes stock move sideway gap advance again other time advance immediately gap cyber memory company micron technology mu do stock gap march then shape break week flat base later stock gap immediately begin advance last month micron gap stock make new high monday consolidate shallow pattern month google goog gap oct stock advanced additional gap close google advance come report quarterly result top street view earning revenue be fairly common facebook jan gap also be strong quarterly result same be true micron technology sometimes investor wonder buy stock earning report be wait earning report then buy fundamentally strong stock gap earning be probably better bet problem buy quarterly release be stock gap result disappoint boee ba former big cap stock gap jan strong earning cautious guidance be second gap session selling first gap jan ve offer protection
1103,ILMN,stock future stumble mixed terrain ahead friday open
1104,ILMN,dow future be relatively steady point fair market value future keep narrow point gain nasdaq future backed early gain be fraction possibly hurt micron technology mu premarket slide follow weak fiscal third quarter report deliver late thursday
1105,ILMN,clear stock market today have lot chew
1106,ILMN,accord eurozone greece appear be table friday analyst project last ditch deal be reach weekend party start week resign greek default payment owe tuesday international monetary fund global market reflect investor position eventuality
1107,ILMN,push europe lead index modest loss midday friday benchmark index paris frankfurt be still tracking gain range week euro edge dollar
1108,ILMN,china mainland market dig serious correction shanghai composite diving tech heavy shenzhen composite friday market be hit liquidity concern trigger wave ipos last week lead fear frothy market be set unwind second week steep decline left index respectively june peak
1109,ILMN,hong kong larger more internationally expose hang seng index fall friday end week effectively flat
1110,ILMN,market have remain hold pattern week end thursday even day line nasdaq be drift day move average
1111,ILMN,only real datum point friday economic front be university michigan final june consumer sentiment estimate due et
1112,ILMN,stock nike nke muscle nearly ahead open report solid fiscal fourth quarter result late thursday earning jump fourth straight double digit gain revenue gain better expect analyst attribute surprise tight cost control stock have be lilting uptrend gain only buy point mid
1113,ILMN,athletic shoe retailer finish line finl soar healthy result earning gain foiled consensus expectation decline revenue gain also top expectation stock have be steady uptrend december low rout month consolidation
1114,ILMN,chipmaker micron slump ahead open report late thursday fiscal third quarter sale earning decline more expect stock have be decline correction december peak
1115,ILMN,agricultural commodity be motion friday continue rain midwest raise concern lose production wheat future jump bushel be week corn rise more friday nearly last friday settle
1116,ILMN,other commodity be mixed west texas intermediate crude oil brent crude fraction gold add few penny rise ounce week wti oil natural gas be essentially unchanged gold be stock future stumble mixed terrain ahead friday open dow future be relatively steady point fair market value future keep narrow point gain nasdaq future backed early gain be fraction possibly hurt micron technology mu premarket slide follow weak fiscal third quarter report deliver late thursday clear stock market today have lot chew accord eurozone greece appear be table friday analyst project last ditch deal be reach weekend party start week resign greek default payment owe tuesday international monetary fund global market reflect investor position eventuality push europe lead index modest loss midday friday benchmark index paris frankfurt be still tracking gain range week euro edge dollar china mainland market dig serious correction shanghai composite diving tech heavy shenzhen composite friday market be hit liquidity concern trigger wave ipos last week lead fear frothy market be set unwind second week steep decline left index respectively june peak hong kong larger more internationally expose hang seng index fall friday end week effectively flat market have remain hold pattern week end thursday even day line nasdaq be drift day move average only real datum point friday economic front be university michigan final june consumer sentiment estimate due et stock nike nke muscle nearly ahead open report solid fiscal fourth quarter result late thursday earning jump fourth straight double digit gain revenue gain better expect analyst attribute surprise tight cost control stock have be lilting uptrend gain only buy point mid athletic shoe retailer finish line finl soar healthy result earning gain foiled consensus expectation decline revenue gain also top expectation stock have be steady uptrend december low rout month consolidation chipmaker micron slump ahead open report late thursday fiscal third quarter sale earning decline more expect stock have be decline correction december peak agricultural commodity be motion friday continue rain midwest raise concern lose production wheat future jump bushel be week corn rise more friday nearly last friday settle other commodity be mixed west texas intermediate crude oil brent crude fraction gold add few penny rise ounce week wti oil natural gas be essentially unchanged gold be
1117,ILMN,young gun company illumina ilmn jazz pharmaceutical jazz old west counterpart be know ability successfully go older more experience company day today screen day be young gun top rate company less year old be establish new sheriff town
1118,ILMN,illumina ilmn maker dna sequence product say thursday have strike strategic partnership several big drugmaker develop call universal next generation sequence base oncology test system cancer diagnosis initial strategic partner include astrazeneca azn janssen biotech sanofi sny illumina say system be used conduct clinical trial specific cancer therapy help identify cancer respond target therapy assess specific mutation gene know be associate response resistance specific cancer therapy goal be develop commercialize multus gene panel therapeutic selection provide more precise comprehensive tool fight cancer illumina stock be fraction morning trading stock market today illumina stock be year company rank wednesday midweek update ibd illumina sport ibd relative strength rating putt top stock performance past month astrazeneca meanwhile have see london stock rise week renew speculation takeover attempt pfizer pfe follow company unsuccessful takeover bid astrazeneca stock be nearly morning trading nasdaq related drugmaker astrazeneca return growth
1119,ILMN,top perform medical stock be panacea depress portfolio today tech leader medical screen feature heavy hitter pharmaceutical field maker disorder drug such pepcid salix pharmaceutical slxp be recent week topic now dormant takeover talk allergan agn fought valeant pharmaceutical vrx allergan maker botox
1120,ILMN,stock seesaw narrowly thursday eventually close virtually flat nasdaq lose less dow jone industrial average end nearly flat add almost volume stock market today be major exchange accord preliminary datum ibd industry group rise least apparel paper internet stock worst performer be airline homebuilder individual stock least include online social platform operator facebook fb rail equipment maker wabtec wab kapstone paper ks side medical sector stock illumina ilmn drop economic news be mixed purchasing manager manufacturing index july new home sale june miss street estimate however jobless claim be fewest kansa city federal reserve manufacturing survey july be stronger expect foreign stock market rise italy ftse mib gain spain ibex brazil bovespa downside japan nikkei fall
1121,ILMN,share gene sequence company illumina ilmn rise more afternoon trading stock market today time high analyst hike estimate follow firm earning report release late monday illumina earning handily beat estimate lead guidance increase turn lead analyst hike number
1122,ILMN,stock stretched higher thursday afternoon busy economic calendar fresh earning report give investor plenty digest
1123,ILMN,nasdaq lead gain add dow jone industrial average volume be tracking lighter nyse nasdaq exchange stock market today
1124,ILMN,most economic datum disappoint conference board lead economic indicator index edge april better march read ahead analyst forecast gain
1125,ILMN,downside april exist home sale come weaker expect national association realtor report sale annualize rate upwardly revise march forecast increase
1126,ILMN,philadelphia fed business outlook survey preliminary purchasing manager index markit also disappoint
1127,ILMN,major retailer dollar tree dltr best buy bby moved higher big volume report quarterly result dollar tree initially fall report earning sale figure narrowly miss estimate then reversed gain share be base build mode week high
1128,ILMN,best buy report earning cent share sale top analyst forecast comparable store sale rise ceo hubert joly note strong product cycle large screen television mobile phone help result share jump more news
1129,ILMN,drugstore chain cvs health cvs climb big volume news be acquire nursing home pharmacy operator omnicare ocr cvs health share be just record high flat base buy point stock stretched higher thursday afternoon busy economic calendar fresh earning report give investor plenty digest nasdaq lead gain add dow jone industrial average volume be tracking lighter nyse nasdaq exchange stock market today most economic datum disappoint conference board lead economic indicator index edge april better march read ahead analyst forecast gain downside april exist home sale come weaker expect national association realtor report sale annualize rate upwardly revise march forecast increase philadelphia fed business outlook survey preliminary purchasing manager index markit also disappoint major retailer dollar tree dltr best buy bby moved higher big volume report quarterly result dollar tree initially fall report earning sale figure narrowly miss estimate then reversed gain share be base build mode week high best buy report earning cent share sale top analyst forecast comparable store sale rise ceo hubert joly note strong product cycle large screen television mobile phone help result share jump more news drugstore chain cvs health cvs climb big volume news be acquire nursing home pharmacy operator omnicare ocr cvs health share be just record high flat base buy point
1130,ILMN,stock open short week trading quick reversal sudden drop oil price help turn open gain mild loss dow jone industrial average drop fall nasdaq keep fractional loss buffer apple aapl advance volume be soft nasdaq lower nyse oil related issue be take beating early action stock market today price crude benchmark west texas intermediate fall back barrel drag be strong enough reverse premarket gain make halliburton hal schlumberger slb fourth quarter earning report halliburton fall schlumberger be start trade weak oil price be also key positive report delta air line dal launch airline group head early trade delta earning narrowly top expectation company report fuel cost saving increase refinery profit delta spirit airline save surge unite continental holding ual american airline aal alaska air group alk jetblue jblu gain apiece dow johnson johnson jnj slip medical health care good provider report better expect earning revenue stop short projection hurt change currency exchange rate management also raise full year profit guidance analyst expectation illumina ilmn rise retake day line support healthy trade maker large scale genetic screening test equipment drop last week follow brief buy point number china base stock be take hard hit early trade asset manager noah holding noah drop stock have stumble last week be now trading december high bitauto bita also add last week loss diving online car information provider be january high economic news show builder confidence january national association homebuilder housing market index dip be december forecast change
1131,ILMN,re prep small patch land shovel hoe home depot hd suffice have acre dig then ll need industrial size earth move equipment
1132,ILMN,stock market take big money professional investor such mutual fund hedge fund pension fund send stock significantly higher order gauge pro level activity stock investor need pay attention ibd accumulation distribution rating
1133,ILMN,quick gauge professional buy
1134,ILMN,investor track pro be buy stock heavily selling hard rating proprietary indicator analyze daily price volume change past week rating go heavy accumulation heavy distribution
1135,ILMN,buy order round lot uncle joe aunt mary win push stock sharply higher ll take lot more demand send stock past proper point rise more demand come professional account most activity major stock exchange
1136,ILMN,rating be quick way see stock professional be heavily buy
1137,ILMN,professional buy buy big amount have million dollar put work investor buy share want disrupt price so take week longer bank mutual fund insurer build full position
1138,ILMN,rating pick fund manager buy sell activity time
1139,ILMN,scout stock watch list ideally pick rating don buy stock just high rating
1140,ILMN,use rating stock chart
1141,ILMN,buy lead stock break base secondary setup big volume stay away stock pro be selling stock rating sell stock once rating drop know be late sell signal
1142,ILMN,find rating many place ibd ibd weekly review research table rating main market index be find market trend page investor also find rating stock checkup investor com
1143,ILMN,nov edition ibd wood product build material giant boise cascade bcc have rating highest possible stock have run clear buy point week pattern oct day market follow
1144,ILMN,akorn akrx illumina ilmn sport rating former also break oct follow big volume
1145,ILMN,have fall apart reach double digit gain even stock hasa strong rating investor still need pay close attention chart action
1146,ILMN,illumina clear double bottom base day follow illumina rally time high past buy point then stock have pull back slightly re prep small patch land shovel hoe home depot hd suffice have acre dig then ll need industrial size earth move equipment stock market take big money professional investor such mutual fund hedge fund pension fund send stock significantly higher order gauge pro level activity stock investor need pay attention ibd accumulation distribution rating quick gauge professional buyinginvestor track pro be buy stock heavily selling hard rating proprietary indicator analyze daily price volume change past week rating go heavy accumulation heavy distribution buy order round lot uncle joe aunt mary win push stock sharply higher ll take lot more demand send stock past proper point rise more demand come professional account most activity major stock exchange rating be quick way see stock professional be heavily buy professional buy buy big amount have million dollar put work investor buy share want disrupt price so take week longer bank mutual fund insurer build full position rating pick fund manager buy sell activity time scout stock watch list ideally pick rating don buy stock just high rating use rating stock chartsbuy lead stock break base secondary setup big volume stay away stock pro be selling stock rating sell stock once rating drop know be late sell signal find rating many place ibd ibd weekly review research table rating main market index be find market trend page investor also find rating stock checkup investor com nov edition ibd wood product build material giant boise cascade bcc have rating highest possible stock have run clear buy point week pattern oct day market follow akorn akrx illumina ilmn sport rating former also break oct follow big volume have fall apart reach double digit gain even stock hasa strong rating investor still need pay close attention chart action illumina clear double bottom base day follow illumina rally time high past buy point then stock have pull back slightly
1147,ILMN,own fast grow company sound winning formula superior stock market gain company stock price tend follow earning growth stock usually exhibit biggest gain
1148,ILMN,average large cap growth mutual fund have have trouble beating market chunk past year
1149,ILMN,investment average large cap growth fund have grow nov year accord morningstar inc datum far produce large cap core fund invest growth value stock lag large cap value fund
1150,ILMN,not bad news large cap growth fund have do much better job april market low several top perform large cap fund stand far peer vanguard capital opportunity have generate average annual return past year vs be proxy broad stock market
1151,ILMN,fund recent holding include biogen idec biib amgen amgn southwest airline luv illumina ilmn own fast grow company sound winning formula superior stock market gain company stock price tend follow earning growth stock usually exhibit biggest gain average large cap growth mutual fund have have trouble beating market chunk past year investment average large cap growth fund have grow nov year accord morningstar inc datum far produce large cap core fund invest growth value stock lag large cap value fund not bad news large cap growth fund have do much better job april market low several top perform large cap fund stand far peer vanguard capital opportunity have generate average annual return past year vs be proxy broad stock market fund recent holding include biogen idec biib amgen amgn southwest airline luv illumina ilmn
1152,ILMN,youth have advantage young company often come gate strong strong growth keep look young
1153,ILMN,today young gun screen day feature hot pick have go public last year particular stock list have show accelerate earning share sale growth latest result
1154,ILMN,chipotle grill cmg earning surge share easily top view report third quarter result last week sale popular burrito taco eatery chain grow vs view mark fourth straight quarter accelerate sale growth second straight quarter earning growth
1155,ILMN,company earn ibd ep rating mean have outperformed other publicly trade company earning growth restaurant chain report earning advance prior quarter
1156,ILMN,maker gene sequence system illumina ilmn also boast ep rating last week raise full year earning guidance handily top earning sale view
1157,ILMN,earning exclude time item sky-rocket cent share beating cent revenue grow company best year year advance more year also top
1158,ILMN,share company have rise more jan
1159,ILMN,singapore base technology avgo apple aapl iphone chip supplier last report earning late august establish fifth straight quarter rise earning revenue growth
1160,ILMN,equip ep rating company share earning soar top view cent net revenue double surpass forecast
1161,ILMN,fellow apple supplier nxp semiconductor nxpi also top share earning rise revenue rise netherlands base chipmaker develop field communication nfc technology reportedly be used iphone have ep rating
1162,ILMN,share synchronoss technology sncr have ep rating get mighty boost time high cloud service earning exclude item jump cent top cent revenue perked vs view
1163,ILMN,company share have grow more start year synchronoss cloud service revenue sky-rocket cloud growth previous year
1164,ILMN,fellow young gun facebook fb report tuesday revenue growth top slightly decelerate previous quarters social network experience year year earning rise item cent beating view cent healthy gain hefty double digit growth nevertheless marked decline triple digit earning advance last quarters
1165,ILMN,related
1166,ILMN,chipotle back rally mode earning scare
1167,ILMN,illumina pound earning estimate lift guidance
1168,ILMN,nxp semiconductor guidance beat stock fall
1169,ILMN,synchronoss technology soar cloudyouth have advantage young company often come gate strong strong growth keep look young today young gun screen day feature hot pick have go public last year particular stock list have show accelerate earning share sale growth latest result chipotle grill cmg earning surge share easily top view report third quarter result last week sale popular burrito taco eatery chain grow vs view mark fourth straight quarter accelerate sale growth second straight quarter earning growth company earn ibd ep rating mean have outperformed other publicly trade company earning growth restaurant chain report earning advance prior quarter maker gene sequence system illumina ilmn also boast ep rating last week raise full year earning guidance handily top earning sale view earning exclude time item sky-rocket cent share beating cent revenue grow company best year year advance more year also top share company have rise more jan singapore base technology avgo apple aapl iphone chip supplier last report earning late august establish fifth straight quarter rise earning revenue growth equip ep rating company share earning soar top view cent net revenue double surpass forecast fellow apple supplier nxp semiconductor nxpi also top share earning rise revenue rise netherlands base chipmaker develop field communication nfc technology reportedly be used iphone have ep rating share synchronoss technology sncr have ep rating get mighty boost time high cloud service earning exclude item jump cent top cent revenue perked vs view company share have grow more start year synchronoss cloud service revenue sky-rocket cloud growth previous year fellow young gun facebook fb report tuesday revenue growth top slightly decelerate previous quarters social network experience year year earning rise item cent beating view cent healthy gain hefty double digit growth nevertheless marked decline triple digit earning advance last quarters related chipotle back rally mode earning scareillumina pound earning estimate lift guidancenxp semiconductor guidance beat stock technology soar cloud
1170,ILMN,ibd find few sign distress fair share success story even market uptrend moderate be month market start climb august lows main index have slow ascent little complain ibd nearly half
1171,ILMN,single stock screen be best uptrend different uptrend reward different kind stock screen reflect reality example last bear market aggressive growthy complexion ibd then ibd fade stock make list oct include el paso electric ee campbell soup cpb procter gamble pg johnson johnson jnj mention equity alone say bear market early november screen have be top perform screen past month be gain ibd be make be way use screen micro approach macro approach micro approach study list find stock be buy point have few miss slim standard macro approach look pattern list kind stock be make list small cap big cap sector industry group be plentiful be stock make screen aggressive defensive let contemplate screen ibd also know weekly review friday newspaper generally ibd be collection stock have higher rating screen ibd have higher rating stock do better long strong uptrend quality growth stock likely correct more sharply defensive stock market run trouble be advantage screen pick more turnaround stock ibd turnaround stock be less likely have strong annual rating past year looser standard mean also more likely pick stock benefit sector rotation also pick more small thinly trade stock ibd sector rotation angle have be apparent recently small bank industry group account stock end october yet only bank stock make ibd bank ozark ozrk signature bank sbny many bank stock be thinly trade still attract quality mutual fund holder table show
1172,ILMN,stock weaken be narrowly mixed late tuesday dow jone industrial average be nasdaq lose turnover be run lower major exchange stock market today compare same time monday
1173,ILMN,major average have seesaw mixed economic datum
1174,ILMN,medical stock be comeback mode be slam monday biogen biib celgene celg regeneron pharmaceutical regn have gain range fraction amn healthcare service universal health service uhs impax laboratory ipxl lose
1175,ILMN,elsewhere chuy chuy ease be still share restaurant operator be nearly be start outperform give price target research firm telsey advisory group
1176,ILMN,post holding post drop lowest level aug monday stock have already tumble trigger sell rule entry week tight pattern
1177,ILMN,follow vincent mao twitter ibd_vmao stock weaken be narrowly mixed late tuesday dow jone industrial average be nasdaq lose turnover be run lower major exchange stock market today compare same time monday major average have seesaw mixed economic datum medical stock be comeback mode be slam monday biogen biib celgene celg regeneron pharmaceutical regn have gain range fraction amn healthcare service universal health service uhs impax laboratory ipxl lose elsewhere chuy chuy ease be still share restaurant operator be nearly be start outperform give price target research firm telsey advisory group post holding post drop lowest level aug monday stock have already tumble trigger sell rule entry week tight pattern follow vincent mao twitter ibd_vmao
1178,ILMN,earning season full force investor focus very best company elite ibd rank top rate growth stock factor strong relative price strength top fundamental ibd have several company report earning come week here be top due report earning wednesday social networking giant facebook fb
1179,ILMN,first half year wasn so good ibd big cap top growth stock market cap least gain just jan july compare
1180,ILMN,ibd also underperform benchmark gain first half year
1181,ILMN,several stock big cap index be close buy point be illumina ilmn develop system used medical other researcher large scale analysis genetic variation
1182,ILMN,illumina set cup handle base buy point break june volume be only average less consider minimum stock didn make much progress pull back buy point monday be close
1183,ILMN,company grow ep most recent quarter estimate sale analyst be expect earning growth next report year annualize growth rate be have return equity just minimum investor demand pretax profit margin
1184,ILMN,medical research equipment service industry group be rank group track ibd
1185,ILMN,big cap name have just break base be keurig green mountain gmcr maker keurig single cup coffee tea pack
1186,ILMN,stock break cup handle base buy point stock close monday just day
1187,ILMN,earning growth have be slow recent quarters ep have go last quarters analyst be forecasting growth next report sale growth most recent quarter be
1188,ILMN,year annualize growth rate be
1189,ILMN,return equity be impressive pretax margin be run wholesale food industry group be rank
1190,ILMN,borg warner bwa make engine drive train component auto industry be still buy zone drop monday close
1191,ILMN,break june volume be deficient day picked next day stock pull back later resume advance
1192,ILMN,stock have form cup handle base have yet break be chipotle grill cmg buy point be
1193,ILMN,national chain burrito joint have year annualize ep growth rate recent quarterly figure show slow earning be most recent quarter stock fall close first half year wasn so good ibd big cap top growth stock market cap least gain just jan july compare ibd also underperform benchmark gain first half year several stock big cap index be close buy point be illumina ilmn develop system used medical other researcher large scale analysis genetic variation illumina set cup handle base buy point break june volume be only average less consider minimum stock didn make much progress pull back buy point monday be close company grow ep most recent quarter estimate sale analyst be expect earning growth next report year annualize growth rate be have return equity just minimum investor demand pretax profit margin medical research equipment service industry group be rank group track ibd big cap name have just break base be keurig green mountain gmcr maker keurig single cup coffee tea pack stock break cup handle base buy point stock close monday just day earning growth have be slow recent quarters ep have go last quarters analyst be forecasting growth next report sale growth most recent quarter be year annualize growth rate be return equity be impressive pretax margin be run wholesale food industry group be rank borg warner bwa make engine drive train component auto industry be still buy zone drop monday close break june volume be deficient day picked next day stock pull back later resume advance stock have form cup handle base have yet break be chipotle grill cmg buy point be national chain burrito joint have year annualize ep growth rate recent quarterly figure show slow earning be most recent quarter stock fall close
1194,ILMN,large cap stock often get labele bore overall sluggish price action latest ibd big cap list lead large cap growth be far bore
1195,ILMN,recent health care related name alexion pharmaceutical alxn illumina ilmn celgene celg regeneron pharmaceutical continue trade well post technology name haven disappoint
1196,ILMN,linkedin lnkd look solid report strong earning last week close just buy point monday
1197,ILMN,quarterly profit rise year cent share sale rise total revenue come talent solution segment get fee company headhunter seek hire sale rise year
1198,ILMN,company end quarter member year period new member come outside china be burgeon market linkedin
1199,ILMN,elsewhere big cap salesforce com crm be trading well recent enterprise software maker recently enter boom datum analytic market wave software
1200,ILMN,earning growth have be bit choppy recent quarters full year earning be expect ramp fiscal fiscal sale growth have be remarkably consistent recent quarters range past quarters
1201,ILMN,meanwhile headline have be positive lately regeneron regn ahead earning report tuesday open thomson reuter consensus estimate call profit share year sale be see rise
1202,ILMN,regeneron blockbuster drug be eylea popular treatment age related wet macular degeneration lead cause blindness elderly fda recently approve eylea additional indication treatment diabetic macular edema
1203,ILMN,regeneron pipeline be strong company partner sanofi recently announce start phase study dupilumab patient atopic dermatitis drug also perform well phase study patient chronic sinusitis
1204,ILMN,alriocumab meanwhile be show promise ldl cholesterol lower treatment
1205,ILMN,caveat regeneron be lengthy uptrend regeneron never reset base count latest be stage base argue however recent consolidation start october start earlier year march be enough shake seller stock go line thought then regeneron latest be consider early stage large cap stock often get labele bore overall sluggish price action latest ibd big cap list lead large cap growth be far bore recent health care related name alexion pharmaceutical alxn illumina ilmn celgene celg regeneron pharmaceutical continue trade well post technology name haven disappoint linkedin lnkd look solid report strong earning last week close just buy point monday quarterly profit rise year cent share sale rise total revenue come talent solution segment get fee company headhunter seek hire sale rise year company end quarter member year period new member come outside china be burgeon market linkedin elsewhere big cap salesforce com crm be trading well recent enterprise software maker recently enter boom datum analytic market wave software earning growth have be bit choppy recent quarters full year earning be expect ramp fiscal fiscal sale growth have be remarkably consistent recent quarters range past quarters meanwhile headline have be positive lately regeneron regn ahead earning report tuesday open thomson reuter consensus estimate call profit share year sale be see rise regeneron blockbuster drug be eylea popular treatment age related wet macular degeneration lead cause blindness elderly fda recently approve eylea additional indication treatment diabetic macular edema regeneron pipeline be strong company partner sanofi recently announce start phase study dupilumab patient atopic dermatitis drug also perform well phase study patient chronic sinusitis alriocumab meanwhile be show promise ldl cholesterol lower treatment caveat regeneron be lengthy uptrend regeneron never reset base count latest be stage base argue however recent consolidation start october start earlier year march be enough shake seller stock go line thought then regeneron latest be consider early stage
1206,ILMN,facebook fb have be huge roll even more user worldwide social networking giant want more ceo founder mark zuckerberg stunned chinese university student wednesday half hour discussion mandarin zuckerberg have be learn language several year part charm offensive get facebook china
1207,ILMN,market confirm uptrend large highly rate company be steam full power ahead today screen day be big cap leader company top notch fundamental market capitalization least list include company be project show fastest earning growth quarter technology avgo singapore base
1208,ILMN,become pound gorilla industry don suddenly decide pound be enough instead start look way reach pound weight break scale altogether market high speed gene sequence machine product illumina ilmn be pound gorilla firm already dominate rival
1209,ILMN,special report race retirement
1210,ILMN,talk scary last year year old burt hiester portfolio slump almost loss come reit hold aim dividend yield retire cumberland md insurance salesman focuse mortgage reit category lose average last year accord nareit com
1211,ILMN,be great year most investor soar
1212,ILMN,so hiester trade tdameritrade be high alert ahead know year market be suppose be tougher choppier married so portfolio impact wife well
1213,ILMN,add concern federal reserve ongoing taper bond buy loom guillotine bond proxy such reit ditto prospect rate hike point
1214,ILMN,widely expect slow growth economy be head wind other big portion portfolio royalty trust invest oil gas production
1215,ILMN,so hiester million investor be retire plan retirement have grapple tweak portfolio year respond question mark hang market
1216,ILMN,investor used proven individual stock strategy base buy sell rule investment blueprint
1217,ILMN,other investor investor rely mutual fund do not zig zag much adviser urge
1218,ILMN,ve already get target asset allocation stick say senior financial planner rowe price
1219,ILMN,don have get crack add
1220,ILMN,portfolio be diversify weighting stock bond domestic foreign reflect goal time horizon risk tolerance say
1221,ILMN,rebalance once year don try outfox market re diversify market do volatility thing ve always get something do well re not depend entirely thing be not do well say
1222,ILMN,hand shareholder want fine tune asset allocation sort advice lisa emsbo mattingly give fund manager fidelity investment be director research asset allocation
1223,ILMN,fed taper prospect higher rate be more hurdle stock fund domestic one say be wary emerge market have not take step cut trade deficit fed taper rate move make harder get financing currency risk be devalue
1224,ILMN,japan have similar problem proceed caution japan stock trading partner emsbo mattingly say
1225,ILMN,contrast europe have take bitter medicine most exciting place cyclical basis say
1226,ILMN,have largely adjust rise rate fed taper so far rate sensitive part economy housing benefit anything used debt so financial system commercial real estate residential real estate consumer durable benefit environment
1227,ILMN,steer away company export emerge market company commodity complex energy continue see lackluster pricing volume growth say
1228,ILMN,tech emsbo mattingly be comfortable bet strong player mobility cloud information technology
1229,ILMN,wary hardware semiconductor name semiconductor be global cyclical hurt weakness emerge market
1230,ILMN,health care like biotech leader historically love low rate environment say
1231,ILMN,eddie yoon leader fidelity health care sector team like segment benefit cost cut pressure such information technology firm help hospital control cost also say advent low cost gene sequence generate many new business opportunity next year just birth internet do
1232,ILMN,run select health care hold illumina ilmn leader sequence last disclosure
1233,ILMN,bond emsbo mattingly like investment grade debt treasury hedge shock jolt equity
1234,ILMN,brian burmeister schwab private client portfolio consultant also advise retirement oriented investor adjust portfolio
1235,ILMN,already hold emerge market stock fund have decline consider harvesting capital loss offset taxable gain then turn re establish position take advantage low valuation do way avoid wash sale rule say
1236,ILMN,likewise be time buy emerge market bargain bin price add demographically growth come next few decade
1237,ILMN,beware company fragile market brazil india indonesia south africa turkey rate hike monetary reform be too young not yet begin say
1238,ILMN,china burmeister urge caution recent reform prove value
1239,ILMN,investor especially high income tax state consider municipal bond fund home state federally tax exempt income price be beaten lot last year note
1240,ILMN,concern be volatility then rebalance harvest gain last year rotate proceed asset class underperform include bond burmeister say
1241,ILMN,harvesting gain restore target allocation stock bond big small foreign taxable tax exempt put back risk tolerance category say add give freedom not worry market movement special report race retirementtalk scary last year year old burt hiester portfolio slump almost loss come reit hold aim dividend yield retire cumberland md insurance salesman focuse mortgage reit category lose average last year accord nareit com be great year most investor soar so hiester trade tdameritrade be high alert ahead know year market be suppose be tougher choppier married so portfolio impact wife well add concern federal reserve ongoing taper bond buy loom guillotine bond proxy such reit ditto prospect rate hike point widely expect slow growth economy be head wind other big portion portfolio royalty trust invest oil gas production so hiester million investor be retire plan retirement have grapple tweak portfolio year respond question mark hang market investor used proven individual stock strategy base buy sell rule investment blueprint other investor investor rely mutual fund do not zig zag much adviser urge ve already get target asset allocation stick say senior financial planner rowe price don have get crack add portfolio be diversify weighting stock bond domestic foreign reflect goal time horizon risk tolerance say rebalance once year don try outfox market re diversify market do volatility thing ve always get something do well re not depend entirely thing be not do well say hand shareholder want fine tune asset allocation sort advice lisa emsbo mattingly give fund manager fidelity investment be director research asset allocation fed taper prospect higher rate be more hurdle stock fund domestic one say be wary emerge market have not take step cut trade deficit fed taper rate move make harder get financing currency risk be devalue japan have similar problem proceed caution japan stock trading partner emsbo mattingly say contrast europe have take bitter medicine most exciting place cyclical basis say have largely adjust rise rate fed taper so far rate sensitive part economy housing benefit anything used debt so financial system commercial real estate residential real estate consumer durable benefit environment steer away company export emerge market company commodity complex energy continue see lackluster pricing volume growth say tech emsbo mattingly be comfortable bet strong player mobility cloud information technology wary hardware semiconductor name semiconductor be global cyclical hurt weakness emerge market health care like biotech leader historically love low rate environment say eddie yoon leader fidelity health care sector team like segment benefit cost cut pressure such information technology firm help hospital control cost also say advent low cost gene sequence generate many new business opportunity next year just birth internet do run select health care hold illumina ilmn leader sequence last disclosure bond emsbo mattingly like investment grade debt treasury hedge shock jolt equity brian burmeister schwab private client portfolio consultant also advise retirement oriented investor adjust portfolio already hold emerge market stock fund have decline consider harvesting capital loss offset taxable gain then turn re establish position take advantage low valuation do way avoid wash sale rule say likewise be time buy emerge market bargain bin price add demographically growth come next few decade beware company fragile market brazil india indonesia south africa turkey rate hike monetary reform be too young not yet begin say china burmeister urge caution recent reform prove value investor especially high income tax state consider municipal bond fund home state federally tax exempt income price be beaten lot last year note concern be volatility then rebalance harvest gain last year rotate proceed asset class underperform include bond burmeister say harvesting gain restore target allocation stock bond big small foreign taxable tax exempt put back risk tolerance category say add give freedom not worry market movement
1242,ILMN,be healthy week leader more ibd list top rate growth stock press new high stage breakout nearly list continue intently work base pattern drugmaker grab brass ring energy stock be list star player week salix pharmaceutical slxp lead crew performance left share new high buy point late stage base pattern investor jump stock north carolina base drugmaker report positive result phase trial irritable bowel syndrome treatment rifaximin cantor fitzgerald william blair raise price target stock respectively jazz pharmaceutical jazz surge week ireland base pharma jump wednesday news have purchase american right drug defibrotide drug buy jazz acquisition gentium treat rare disease affect blood circulation liver stock end buy range buy point second stage cup handle base mutual fund rating base year performance hold share jazz lake forest ill base akorn akrx end week higher ease back spike result left share buy point cup handle base undercut prior pattern reset akorn base count stock clear buy point april light trade gilead science gild climb new high end week not quite buy point cup base have be tepid volume average day last week deep base undercut flat base december january reset stock base count illumina ilmn add be overall light trade week finished buy point cup handle base outside pharmaceutical space vipshop holding vip pop breaking buy point week tight pattern china base online discount retailer clear late stage cup handle buy point june
1243,ILMN,stock be narrowly mixed firm slightly go final hour trading monday volume run ahead friday pace
1244,ILMN,stock market today nasdaq rise be dow jone industrial average be smidgen
1245,ILMN,ibd stock be be indicate strength top perform growth stock best performer be chinese automotive bitauto bita rise nearly average trade new time high stock recently emerge late stage cup handle base
1246,ILMN,top performer be ilumina ilmn health care name clear cup handle base better volume be run only slightly average company make system used medical researcher open illumina say sign agreement several company use system
1247,ILMN,drugmaker akorn akrx be extend bolt new high better
1248,ILMN,last week hot new issue wearable camera maker gopro gpro be still blast higher third day trading be offer thursday be now close
1249,ILMN,security software firm palo alto network panw gap be trading higher clear cup handle base morgan stanley raise price target say palo alto be favorite pick stock be narrowly mixed firm slightly go final hour trading monday volume run ahead friday pace stock market today nasdaq rise be dow jone industrial average be smidgen ibd stock be be indicate strength top perform growth stock best performer be chinese automotive bitauto bita rise nearly average trade new time high stock recently emerge late stage cup handle base top performer be ilumina ilmn health care name clear cup handle base better volume be run only slightly average company make system used medical researcher open illumina say sign agreement several company use system drugmaker akorn akrx be extend bolt new high better last week hot new issue wearable camera maker gopro gpro be still blast higher third day trading be offer thursday be now close security software firm palo alto network panw gap be trading higher clear cup handle base morgan stanley raise price target say palo alto be favorite pick
1250,ILMN,sterne agee raise earning estimate price target molecular research amri cite contract research manufacturing company buyout oso close last week
1251,ILMN,report issue monday morning sterne agee analyst greg bolan say be officially incorporating estimate accretion earning year next year
1252,ILMN,july close acquisition osobio contract manufacturer complex injectable drug product include sterile liquid suspension lyophilize formulation
1253,ILMN,statement follow announcement deal ceo william marth say osobio add significantly sterile manufacturing capability extend industry lead position early stage contract manufacturing now include osobio preeminent large scale commercial production
1254,ILMN,monday note analyst bolan raise full year earning estimate cent share prior estimate cent also raise ep estimate cent
1255,ILMN,analyst poll thomson reuter expect post ep cent
1256,ILMN,bolan also raise price target stock still well company current stock price share set year high july
1257,ILMN,believe investor have become enamored amri roll strategy fail recognize take more leverage dilute ep equity offer company be limit now term purchasing power note bolan have underperform rating
1258,ILMN,have ibd composite rating be part ibd medical research equipment service group rank industry track ibd
1259,ILMN,leader include illumina ilmn composite rating myriad genetic mygn composite rating sterne agee raise earning estimate price target molecular research amri cite contract research manufacturing company buyout oso close last week report issue monday morning sterne agee analyst greg bolan say be officially incorporating estimate accretion earning year next year july close acquisition osobio contract manufacturer complex injectable drug product include sterile liquid suspension lyophilize formulation statement follow announcement deal ceo william marth say osobio add significantly sterile manufacturing capability extend industry lead position early stage contract manufacturing now include osobio preeminent large scale commercial production monday note analyst bolan raise full year earning estimate cent share prior estimate cent also raise ep estimate cent analyst poll thomson reuter expect post ep cent bolan also raise price target stock still well company current stock price share set year high july believe investor have become enamored amri roll strategy fail recognize take more leverage dilute ep equity offer company be limit now term purchasing power note bolan have underperform rating have ibd composite rating be part ibd medical research equipment service group rank industry track ibd leader include illumina ilmn composite rating myriad genetic mygn composite rating
1260,ILMN,big cap biotechs celgene alexion pharmaceutical modestly beat estimate raise guidance early thursday share tumble wall street seem turn sector celgene celg earning rise year earlier quarter cent share beating consensus penny sale increase
1261,ILMN,main index close new high tuesday sign market be get danger climb touch new high midday cede gain last time market tumble april take more week make new high time be
1262,ILMN,new buy list top perform fund past month show heavy buy top rate stock nation lead fund have be stocking medical issue fared well market resume uptrend august large heavy hit medical stock be buy top fund latest report period include gilead science gild jazz pharmaceutical ticker
1263,ILMN,stock be narrowly mixed tuesday halftime morning rally bring mostly better expect economic datum lose steam
1264,ILMN,be dow jone industrial average be fractionally lower meanwhile nasdaq be fractionally higher pare gain nasdaq volume be tracking higher stock market today nyse trade be run lower
1265,ILMN,lead stock netflix nflx gap slump be cut hold buy stifel nicolaus stock breach support level hit month low netflix be add leaderboard cut list september
1266,ILMN,workday wday be session lows still nearly follow late monday result lose cent share report quarter strong sale growth sale rise
1267,ILMN,upside palo alto network panw gap rally new high response late monday fiscal result credit suisse citigroup stifel nicolaus deutsche bank raise price target stock palo alto be well extend buy point week tight pattern
1268,ILMN,vasco datum security international vdsi industry peer palo alto jump record high follow clear buy point week tight pattern monday stock be narrowly mixed tuesday halftime morning rally bring mostly better expect economic datum lose steam be dow jone industrial average be fractionally lower meanwhile nasdaq be fractionally higher pare gain nasdaq volume be tracking higher stock market today nyse trade be run lower lead stock netflix nflx gap slump be cut hold buy stifel nicolaus stock breach support level hit month low netflix be add leaderboard cut list september workday wday be session lows still nearly follow late monday result lose cent share report quarter strong sale growth sale rise upside palo alto network panw gap rally new high response late monday fiscal result credit suisse citigroup stifel nicolaus deutsche bank raise price target stock palo alto be well extend buy point week tight pattern vasco datum security international vdsi industry peer palo alto jump record high follow clear buy point week tight pattern monday
1269,ILMN,several day indecisive trading market break funk tuesday buyer reassert have close straight day nothing more change price suddenly jump close session high nasdaq composite have go straight session nary move change
1270,ILMN,share sigma aldrich sial major provider chemical other product life science industry jump more time high stock market today german drugmaker merck kgaa announce buy company cash merck do business emd millipore avoid confusion
1271,ILMN,manager lead mutual fund recent month have continue stock large medical stock such illumina ilmn alexion pharmaceutical alxn celgene celg jazz pharmaceutical jazz allergan agn centene cnc
1272,ILMN,biotech biom group be rank industry tuesday big cap biotech medical stock hold better volatile market
1273,ILMN,sector theme be play be semiconductor
1274,ILMN,fabless chipmaker such technology avgo nxp semiconductor nxpi ambarella amba have be top performer also act well be chipmaker skywork solution swks
1275,ILMN,food beverage stock such keurig green mountain coffee gmcr monster beverage mnst cal maine food calm hain celestial group hain be also favore best perform fund
1276,ILMN,ibd spot top perform fund have recently buy ulta beauty ulta investing estimate
1277,ILMN,mainstay large cap growth fund add ulta holding latest report period
1278,ILMN,bolingbrook ill base ulta be beauty retailer provide stop shopping beauty product salon service america
1279,ILMN,stock be month second stage base small handle fail attempt break last week put buy point
1280,ILMN,ulta increase earning healthy double digit pace past quarters revenue growth also be robust range same period
1281,ILMN,more depth coverage drive ulta growth see monday edition manage success page
1282,ILMN,first half october spook investor sharp drop major stock index
1283,ILMN,most correction earlier year market rebound quickly resume uptrend late october
1284,ILMN,sell side
1285,ILMN,america top notch fund lighten credit card payment firm visa mastercard latest report period
1286,ILMN,have rally past week set get new high
1287,ILMN,few retailer have be sell such lowe low petsmart petm william sonoma wsm manager lead mutual fund recent month have continue stock large medical stock such illumina ilmn alexion pharmaceutical alxn celgene celg jazz pharmaceutical jazz allergan agn centene cnc biotech biom group be rank industry tuesday big cap biotech medical stock hold better volatile market sector theme be play be semiconductor fabless chipmaker such technology avgo nxp semiconductor nxpi ambarella amba have be top performer also act well be chipmaker skywork solution swks food beverage stock such keurig green mountain coffee gmcr monster beverage mnst cal maine food calm hain celestial group hain be also favore best perform fund ibd spot top perform fund have recently buy ulta beauty ulta investing estimate mainstay large cap growth fund add ulta holding latest report period bolingbrook ill base ulta be beauty retailer provide stop shopping beauty product salon service america stock be month second stage base small handle fail attempt break last week put buy point ulta increase earning healthy double digit pace past quarters revenue growth also be robust range same period more depth coverage drive ulta growth see monday edition manage success page first half october spook investor sharp drop major stock index most correction earlier year market rebound quickly resume uptrend late october sell sideamerica top notch fund lighten credit card payment firm visa mastercard latest report period have rally past week set get new high few retailer have be sell such lowe low petsmart petm william sonoma wsm
1288,ILMN,ibd just capped best week performance more year run produce batch breakout index rally past week best week period july ibd roar last week ibd add be comparable nasdaq
1289,ILMN,quiet volume have be chief characteristic stock market recent week last time nasdaq show average volume week be week end aug many leader big cap be also keep low profile facebook fb be king quiet right now
1290,ILMN,stock follow european stock lower wednesday sentiment weaken europe increase sign economic weakness eurozone manufacturing datum show contraction germany france austria greece accord markit economic meanwhile italy lower gdp forecast ahead thursday ecb meeting dow jone industrial average lose weigh boee ba johnson johnson jnj nasdaq fall give russell fall be now recent high distribution day be take shape nyse nasdaq volume be tracking higher tuesday level nasdaq titan facebook fb illumina ilmn baidu bidu lose more home front private employer add job september accord latest datum adp separately ism manufacturing index drop september august drop be little expect stock market today acuity brand ayi be few bright spot share surge company report strong earning fuel strength light emit diode lead product mining utility stock also do well growth stock come heavy selling pressure half stock ibd lose more polaris pii fleetcor flt akorn akrx crash day move average leader ibd transportation equipment manufacturing group also give day line greenbrier gbx tank trinity industry trn lose
1291,ILMN,stock open lower battle tightly mixed terrain early wednesday
1292,ILMN,edge nasdaq be close only fraction higher dow jone industrial average sag
1293,ILMN,volume be unevenly mixed just nasdaq nyse vs trading level record early tuesday
1294,ILMN,stock market today face early headwind mixed housing datum show december housing start slower expect rate build permit issue month europe market turn slim gain mixed action afternoon trade market earning report be morning center attention
1295,ILMN,netflix nflx spike bolster nasdaq company report record growth new subscriber fourth quarter
1296,ILMN,ibm ibm fall drag dow report late tuesday adjust earning decline less expect analyst revenue slip more expect however management project earning analyst consensus stock long slow correction deepen sharply company report october
1297,ILMN,ibd list open red biggest slip be decline illumina ilmn maker large scale gene sequence equipment surge heavy trade tuesday wednesday early slip left share week move average buy point
1298,ILMN,baidu bidu hammer gain run head list china lead search engine be hover week move average shallow month consolidation
1299,ILMN,busy docket earning report be due today close american express axp unite rental uri sandisk sndk ebay ebay company schedule report stock open lower battle tightly mixed terrain early wednesday edge nasdaq be close only fraction higher dow jone industrial average sag volume be unevenly mixed just nasdaq nyse vs trading level record early tuesday stock market today face early headwind mixed housing datum show december housing start slower expect rate build permit issue month europe market turn slim gain mixed action afternoon trade market earning report be morning center attention netflix nflx spike bolster nasdaq company report record growth new subscriber fourth quarter ibm ibm fall drag dow report late tuesday adjust earning decline less expect analyst revenue slip more expect however management project earning analyst consensus stock long slow correction deepen sharply company report october ibd list open red biggest slip be decline illumina ilmn maker large scale gene sequence equipment surge heavy trade tuesday wednesday early slip left share week move average buy point baidu bidu hammer gain run head list china lead search engine be hover week move average shallow month consolidation busy docket earning report be due today close american express axp unite rental uri sandisk sndk ebay ebay company schedule report
1300,ILMN,major average deliver solid gain higher volume less hour remain thursday session
1301,ILMN,index be session high nasdaq jump add dow jone industrial average picked volume nasdaq be tracking higher wednesday nyse volume rise
1302,ILMN,wall street be good mood open european central bank take step stave deflation eurozone addition reduce main lend rate ecb also start charge commercial bank keep money ecb interest rate euro hit month low news recoup early loss
1303,ILMN,stock market today amazon com amzn pop day move average recently correct high share rise anticipation june special event company be widely expect unveil long await smartphone capability retina scan technology
1304,ILMN,elsewhere verint system vrnt gap first stage base rise strong earning provider datum analytic software report fourth straight quarter accelerate sale growth
1305,ILMN,ibd illumina ilmn extend gain wednesday hesitant attempt cup handle pattern share rise buy point be now buy point
1306,ILMN,downside vera bradley vra plunge day move average fall much handbag accessory designer suggest product aren connect consumer quarterly profit fall year sale fall same store sale drop company lower earning outlook current quarter full year
1307,ILMN,employment report loom large friday economist expect nonfarm payroll increase april economy create job unemployment rate be expect tick higher major average deliver solid gain higher volume less hour remain thursday session index be session high nasdaq jump add dow jone industrial average picked volume nasdaq be tracking higher wednesday nyse volume rise wall street be good mood open european central bank take step stave deflation eurozone addition reduce main lend rate ecb also start charge commercial bank keep money ecb interest rate euro hit month low news recoup early loss stock market today amazon com amzn pop day move average recently correct high share rise anticipation june special event company be widely expect unveil long await smartphone capability retina scan technology elsewhere verint system vrnt gap first stage base rise strong earning provider datum analytic software report fourth straight quarter accelerate sale growth ibd illumina ilmn extend gain wednesday hesitant attempt cup handle pattern share rise buy point be now buy point downside vera bradley vra plunge day move average fall much handbag accessory designer suggest product aren connect consumer quarterly profit fall year sale fall same store sale drop company lower earning outlook current quarter full year employment report loom large friday economist expect nonfarm payroll increase april economy create job unemployment rate be expect tick higher
1308,ILMN,stock rise start gate healthy trade thursday quickly reversed narrow loss
1309,ILMN,be first give early gain slip nasdaq follow suit be equal amount dow jone industrial average show fractional decline
1310,ILMN,volume climb sharply nasdaq be higher nyse compare trade same time wednesday
1311,ILMN,stock market today receive early boost europe central bank amp effort fight deflation lower interest rate adopt measure ease lend eurozone economy job datum come weak side however layoff rise month high weekly jobless claim rise slightly more expect
1312,ILMN,stock mining equipment maker joy global joy jump massive trade milwaukee base company report fiscal second quarter earning less forecast analyst revenue slip slightly more expect third quarter full year earning guidance be line expectation iron ore global coal market remain pressure management say coal situation improve copper outlook be positive
1313,ILMN,stock be work climb right side shallow month consolidation
1314,ILMN,chip stock come early pressure post generally strong gain wednesday marvell technology group mrvl dive start gate worst slip philadelphia semiconductor index stock bermuda base chipmaker remain flat base buy point
1315,ILMN,lead stock hammer positive start ibd issue show gain early trade
1316,ILMN,illumina ilmn jump moved head ibd list maker genetic analysis system announce wednesday issue convertible debt goldman sachs bank america initial buyer thursday move hoist share buy point cup handle base stock rise start gate healthy trade thursday quickly reversed narrow loss be first give early gain slip nasdaq follow suit be equal amount dow jone industrial average show fractional decline volume climb sharply nasdaq be higher nyse compare trade same time wednesday stock market today receive early boost europe central bank amp effort fight deflation lower interest rate adopt measure ease lend eurozone economy job datum come weak side however layoff rise month high weekly jobless claim rise slightly more expect stock mining equipment maker joy global joy jump massive trade milwaukee base company report fiscal second quarter earning less forecast analyst revenue slip slightly more expect third quarter full year earning guidance be line expectation iron ore global coal market remain pressure management say coal situation improve copper outlook be positive stock be work climb right side shallow month consolidation chip stock come early pressure post generally strong gain wednesday marvell technology group mrvl dive start gate worst slip philadelphia semiconductor index stock bermuda base chipmaker remain flat base buy point lead stock hammer positive start ibd issue show gain early trade illumina ilmn jump moved head ibd list maker genetic analysis system announce wednesday issue convertible debt goldman sachs bank america initial buyer thursday move hoist share buy point cup handle base
1317,ILMN,today screen day feature institutional quality drug medical big cap stock solid fundamental
1318,ILMN,jazz pharmaceutical jazz have market cap earn ibd composite rating mean have outperformed stock key metric such earning sale
1319,ILMN,best selling narcolepsy medication xyrem make third jazz second quarter sale company acquire italian biotech gentium earlier year
1320,ILMN,jazz share rise stock market tuesday best close month
1321,ILMN,salix pharmaceutical slxp be spotlight lately potential takeover candidate allergan agn maker botox allergan be aim put stopper valeant pharmaceutical vrx hostile takeover attempt
1322,ILMN,salix share soar aug report talk reportedly be dormant salix be largely hold gain move sideway
1323,ILMN,salix have market cap also have highest possible composite rating salix most recent result miss view earning share more double revenue shot
1324,ILMN,gilead science gild behemoth market cap be mutual fund favorite big stock mover deutsche bank expect company upcoming combo hepatitis treatment have higher expect price point
1325,ILMN,gilead make blockbuster hepatitis drug sovaldi also boast composite rating
1326,ILMN,gilead share fall tuesday be week
1327,ILMN,illumina ilmn have market cap composite rating develop system medical researcher study gene variation function
1328,ILMN,company recently say have form strategic partnership number drugmaker include astrazeneca azn sanofi sny create universal next generation sequence base oncology test system
1329,ILMN,follow elaine low twitter ibd_elow today screen day feature institutional quality drug medical big cap stock solid fundamental jazz pharmaceutical jazz have market cap earn ibd composite rating mean have outperformed stock key metric such earning sale best selling narcolepsy medication xyrem make third jazz second quarter sale company acquire italian biotech gentium earlier year jazz share rise stock market tuesday best close month salix pharmaceutical slxp be spotlight lately potential takeover candidate allergan agn maker botox allergan be aim put stopper valeant pharmaceutical vrx hostile takeover attempt salix share soar aug report talk reportedly be dormant salix be largely hold gain move sideway salix have market cap also have highest possible composite rating salix most recent result miss view earning share more double revenue shot gilead science gild behemoth market cap be mutual fund favorite big stock mover deutsche bank expect company upcoming combo hepatitis treatment have higher expect price point gilead make blockbuster hepatitis drug sovaldi also boast composite rating gilead share fall tuesday be week illumina ilmn have market cap composite rating develop system medical researcher study gene variation function company recently say have form strategic partnership number drugmaker include astrazeneca azn sanofi sny create universal next generation sequence base oncology test system follow elaine low twitter ibd_elow
1330,ILMN,analyst be singing praise life science giant gilead science gild illumina ilmn wednesday morning surge estimate late tuesday share company be stock market today
1331,ILMN,gilead sale new hepatitis drug sovaldi be call most impressive beat biopharma history piper jaffray joshua schimmer increase price target only dollar gilead be morning trading wednesday
1332,ILMN,rbc capital market analyst michael yee lift sale estimate previous add full year ep estimate now expect sovaldi sale hit next year ep reach
1333,ILMN,nomura ian somaiya lift price target write gilead position hcv market be sustainable say sovaldi new sovaldi base combo pill expect launch later year be superior compete product abbvie abbv merck mrk
1334,ILMN,cowen phil nadeau be also impressed note lengthy discussion payor pushback tuesday earning call provide probably not nearly enough resolution satisfy investor pharmacy benefit manager express script esrx insurer unite health unh have criticize sovaldi price
1335,ILMN,gilead do discuss argument support price sovaldi such value cure health care system cost treat patient end stage liver disease yr nadeau write find gilead discussion datapoint encourage suspect investor concern payor ability limit access sovaldi shuttle patient compete regimen linger abbv pricing strategy be know presumably approval payor strategy be defined early
1336,ILMN,meanwhile gene testing company illumina be wednesday morning beat estimate raise guidance sale rise year earlier quarter nearly consensus earning climb cent share top estimate cent
1337,ILMN,company now expect full year sale growth ep range be consensus
1338,ILMN,leerink analyst dan leonard write note tuesday report exceed even have consider best case scenario face multiple new instrument launch lift price target write launch new hiseq miseq gene sequence system do not appear be cannibalize older version add order hiseq system illumina announce january fanfare due claim sequence genome apiece be double initial target
1339,ILMN,isi group ross muken note demand be illumina entire sequence portfolio raise price target reflect increase ep forecast however maintain neutral rating stock say current price already reflect annual revenue growth
1340,ILMN,follow amy reeve twitter be singing praise life science giant gilead science gild illumina ilmn wednesday morning surge estimate late tuesday share company be stock market today gilead sale new hepatitis drug sovaldi be call most impressive beat biopharma history piper jaffray joshua schimmer increase price target only dollar gilead be morning trading wednesday rbc capital market analyst michael yee lift sale estimate previous add full year ep estimate now expect sovaldi sale hit next year ep reach nomura ian somaiya lift price target write gilead position hcv market be sustainable say sovaldi new sovaldi base combo pill expect launch later year be superior compete product abbvie abbv merck mrk cowen phil nadeau be also impressed note lengthy discussion payor pushback tuesday earning call provide probably not nearly enough resolution satisfy investor pharmacy benefit manager express script esrx insurer unite health unh have criticize sovaldi price gilead do discuss argument support price sovaldi such value cure health care system cost treat patient end stage liver disease yr nadeau write find gilead discussion datapoint encourage suspect investor concern payor ability limit access sovaldi shuttle patient compete regimen linger abbv pricing strategy be know presumably approval payor strategy be defined early meanwhile gene testing company illumina be wednesday morning beat estimate raise guidance sale rise year earlier quarter nearly consensus earning climb cent share top estimate cent company now expect full year sale growth ep range be consensus leerink analyst dan leonard write note tuesday report exceed even have consider best case scenario face multiple new instrument launch lift price target write launch new hiseq miseq gene sequence system do not appear be cannibalize older version add order hiseq system illumina announce january fanfare due claim sequence genome apiece be double initial target isi group ross muken note demand be illumina entire sequence portfolio raise price target reflect increase ep forecast however maintain neutral rating stock say current price already reflect annual revenue growth follow amy reeve twitter ibd_areeve
1341,ILMN,leader buy range get tougher find market uptrend continue stock break new high
1342,ILMN,raft medical play today weekly review be show fairly healthy action work basis move buy point few institutional quality drugmaker have even successfully break third stage later basis tend be riskier
1343,ILMN,nordisk nvo be form right side second stage cup base doesn carve handle potential buy point be danish drugmaker key diabetes therapy include novolog victoza be await fda approval next generation insulin treatment tresiba be already market country have maintain double digit quarterly share profit growth mid analyst expect gain
1344,ILMN,generic drugmakermylan myl round trip gain last form third stage base possible buy point weekly chart show few wide price swing have tighten recently be better see more upside volume right side build
1345,ILMN,myriad genetic mygn kick current second stage base early reset base count late last year regain week line last week be still potential entry genetic product maker profit growth be solid have slow
1346,ILMN,thinly trade taro pharmaceutical industry taro be near buy point flat base be work week generic drugmaker rally flat base september so current base be second stage pattern
1347,ILMN,other lead medical related stock have clear third stage later basis include actavis act illumina ilmn salix pharmaceutical slxp leader buy range get tougher find market uptrend continue stock break new high raft medical play today weekly review be show fairly healthy action work basis move buy point few institutional quality drugmaker have even successfully break third stage later basis tend be riskier nordisk nvo be form right side second stage cup base doesn carve handle potential buy point be danish drugmaker key diabetes therapy include novolog victoza be await fda approval next generation insulin treatment tresiba be already market country have maintain double digit quarterly share profit growth mid analyst expect gain generic drugmakermylan myl round trip gain last form third stage base possible buy point weekly chart show few wide price swing have tighten recently be better see more upside volume right side build myriad genetic mygn kick current second stage base early reset base count late last year regain week line last week be still potential entry genetic product maker profit growth be solid have slow thinly trade taro pharmaceutical industry taro be near buy point flat base be work week generic drugmaker rally flat base september so current base be second stage pattern other lead medical related stock have clear third stage later basis include actavis act illumina ilmn salix pharmaceutical slxp
1348,ILMN,stock future be volatile pare loss rapidly ahead monday open
1349,ILMN,dow future scrap overnight rally dig deep early loss have trim trade point fair market value nasdaq future pare fractional loss future be mild point
1350,ILMN,major economic news schedule stock market today be likely revolve largely earning report ibm ibm open action weak show apple aapl report close chipotle grill cmg illumina ilmn texas instrument txn other apple trade nearly premarket action
1351,ILMN,ibm other hand groan lower earning revenue come well short expectation third quarter company statement cite marked slowdown september client buy behavior ibm share have be wending shallow consolidation month
1352,ILMN,oilfield service heavyweight halliburton hal climb ahead open clear lower expectation revenue earning growth third quarter drive production activity europe africa
1353,ILMN,halliburton share have skid key level support week sell end friday july high
1354,ILMN,ebola related stock appear set continue last week pullback tuesday high most person expose texas ebola victim thomas eric duncan clear day wait period protective clothing maker industry lake alpha pro technology apt dive
1355,ILMN,datum service atm maker ncr ncr stumble lower duluth ga company warn earning miss consensus forecast lower revenue guidance company also say full year revenue undercut prior guidance
1356,ILMN,management cite challenge retail market well difficult global macroeconomic condition stock have be deepen correction year
1357,ILMN,overseas hotspot world market be tokyo nikkei charge higher buyer step last week decline report circulate japan government pension investment fund expand stock holding portfolio prior upper limit
1358,ILMN,china market open week mild gain european market slump lower european central bank announce have begin new stimulus effort purchasing cover bond frankfurt dax slip furthest major index stock future be volatile pare loss rapidly ahead monday open dow future scrap overnight rally dig deep early loss have trim trade point fair market value nasdaq future pare fractional loss future be mild point major economic news schedule stock market today be likely revolve largely earning report ibm ibm open action weak show apple aapl report close chipotle grill cmg illumina ilmn texas instrument txn other apple trade nearly premarket action ibm other hand groan lower earning revenue come well short expectation third quarter company statement cite marked slowdown september client buy behavior ibm share have be wending shallow consolidation month oilfield service heavyweight halliburton hal climb ahead open clear lower expectation revenue earning growth third quarter drive production activity europe africa halliburton share have skid key level support week sell end friday july high ebola related stock appear set continue last week pullback tuesday high most person expose texas ebola victim thomas eric duncan clear day wait period protective clothing maker industry lake alpha pro technology apt dive datum service atm maker ncr ncr stumble lower duluth ga company warn earning miss consensus forecast lower revenue guidance company also say full year revenue undercut prior guidance management cite challenge retail market well difficult global macroeconomic condition stock have be deepen correction year overseas hotspot world market be tokyo nikkei charge higher buyer step last week decline report circulate japan government pension investment fund expand stock holding portfolio prior upper limit china market open week mild gain european market slump lower european central bank announce have begin new stimulus effort purchasing cover bond frankfurt dax slip furthest major index
1359,ILMN,stock drop start gate tuesday investor processed news down jet global travel alert sharp drop consumer confidence
1360,ILMN,nasdaq drop loss hung line dow jone industrial average slip
1361,ILMN,volume rise sharply nasdaq higher nyse compare very weak level early monday
1362,ILMN,stock market today reflect other thing uncertainty tie down russian jet turkish syrian border release alert american traveler state department
1363,ILMN,detail be not yet clear down russian fighter turkish source say turkish shot russian aircraft warning be violate turkey airspace russian official reportedly deny account say warplane have not violate protocol be fly meter be shot ground
1364,ILMN,state department travel alert advise american be wary travele likelihood terror attack continue alert say member isil da esh return syrium iraq alert caution traveler be aware immediate surrounding avoid large crowds crowd place
1365,ILMN,result send airline travel book stock morning worst loss oil price surge lift oil related group best gain industry group early trade
1366,ILMN,conflict warning overpower expect revision gdp growth commerce department lift economy performance gain vs initial estimate growth
1367,ILMN,case shiller city home price index september be also mildly positive show year year gain consensus view increase price advanced vs august better projection improvement
1368,ILMN,consumer outlook fall hard november conference board report consumer confidence index pull back far october tally optimistic consensus view upshift
1369,ILMN,top campbell soup cpb ladle advance start trade camden base soup sauce broth maker report strong fiscal first quarter earning beat revenue line consensus expectation management project lower sale ep consensus expectation
1370,ILMN,chipmaker analog device adi pop boost surge fiscal ep vs consensus view gain revenue also top forecast first quarter sale earning guidance be line expectation
1371,ILMN,low end weaker forecast quarterly report send ray veterinary supply firm patterson pdco retail chain signet jeweler sig loss left signet ibd stock just day move average oct high gamestop gme drop oppenheimer add name list brokerage downgrading video game retailer report sale earning miss monday
1372,ILMN,ibd list trade lower early action dycom dy skywork solution swks chalk high end nearly gain put dycom buy range nearly past flat base buy point
1373,ILMN,skywork continue feel way underside day move average bound month consolidation
1374,ILMN,leader ibd weekly review list maxlinear mxl surge take new high carlsbad cal base chipmaker be past buy point early october stock drop start gate tuesday investor processed news down jet global travel alert sharp drop consumer confidence nasdaq drop loss hung line dow jone industrial average slip volume rise sharply nasdaq higher nyse compare very weak level early monday stock market today reflect other thing uncertainty tie down russian jet turkish syrian border release alert american traveler state department detail be not yet clear down russian fighter turkish source say turkish shot russian aircraft warning be violate turkey airspace russian official reportedly deny account say warplane have not violate protocol be fly meter be shot ground state department travel alert advise american be wary travele likelihood terror attack continue alert say member isil da esh return syrium iraq alert caution traveler be aware immediate surrounding avoid large crowds crowd place result send airline travel book stock morning worst loss oil price surge lift oil related group best gain industry group early trade conflict warning overpower expect revision gdp growth commerce department lift economy performance gain vs initial estimate growth case shiller city home price index september be also mildly positive show year year gain consensus view increase price advanced vs august better projection improvement consumer outlook fall hard november conference board report consumer confidence index pull back far october tally optimistic consensus view upshift top campbell soup cpb ladle advance start trade camden base soup sauce broth maker report strong fiscal first quarter earning beat revenue line consensus expectation management project lower sale ep consensus expectation chipmaker analog device adi pop boost surge fiscal ep vs consensus view gain revenue also top forecast first quarter sale earning guidance be line expectation low end weaker forecast quarterly report send ray veterinary supply firm patterson pdco retail chain signet jeweler sig loss left signet ibd stock just day move average oct high gamestop gme drop oppenheimer add name list brokerage downgrading video game retailer report sale earning miss monday ibd list trade lower early action dycom dy skywork solution swks chalk high end nearly gain put dycom buy range nearly past flat base buy point skywork continue feel way underside day move average bound month consolidation leader ibd weekly review list maxlinear mxl surge take new high carlsbad cal base chipmaker be past buy point early october
1375,ILMN,major average rise session high early afternoon trading friday undeterred news airstrike iraq
1376,ILMN,dow industrial lead way rise nasdaq add volume be tracking lower board stock market today
1377,ILMN,economic news labor department say worker productivity rise well forecast gain datum follow sharp drop productivity
1378,ILMN,drugstore chain be session outperformer largely due wag climb work recoup loss slump wednesday biggest chain say day buy rest european pharmacy chain alliance boot doesn already own also say not move headquarters overseas lower taxe
1379,ILMN,couple restaurant stock gain higher volume sonic sonc jump retake day move average first time week continue shape flat base potential buy point drive burger chain say thursday pay first quarterly cash dividend cent share nov also authorize share buyback program fiscal
1380,ILMN,fiesta restaurant group frgi gain nearly twice usual volume stock be now cup handle buy point clear wednesday taco cabana pollo tropical operator report better expect earning
1381,ILMN,ibd stock illumina ilmn advanced average trade stock recently trigger sell signal fall cup handle buy point gene sequence system maker have step sale profit growth past quarters
1382,ILMN,follow nancy gondo twitter ibd_ngondo major average rise session high early afternoon trading friday undeterred news airstrike iraq dow industrial lead way rise nasdaq add volume be tracking lower board stock market today economic news labor department say worker productivity rise well forecast gain datum follow sharp drop productivity drugstore chain be session outperformer largely due wag climb work recoup loss slump wednesday biggest chain say day buy rest european pharmacy chain alliance boot doesn already own also say not move headquarters overseas lower taxe couple restaurant stock gain higher volume sonic sonc jump retake day move average first time week continue shape flat base potential buy point drive burger chain say thursday pay first quarterly cash dividend cent share nov also authorize share buyback program fiscal fiesta restaurant group frgi gain nearly twice usual volume stock be now cup handle buy point clear wednesday taco cabana pollo tropical operator report better expect earning ibd stock illumina ilmn advanced average trade stock recently trigger sell signal fall cup handle buy point gene sequence system maker have step sale profit growth past quarters follow nancy gondo twitter ibd_ngondo
1383,ILMN,stock open uptick thursday then quickly turn mixed strong dose support economic datum report
1384,ILMN,dow jone industrial average climb nasdaq reversed early gain slip add volume be also mixed nyse lower nasdaq
1385,ILMN,stock market today set current uptrend good standing plenty headline rolled overnight intensified fight ukraine weak manufacturing datum china have shake timid market rise dollar also add pressure many case work early stock gain
1386,ILMN,stock open better expect read weekly unemployment claim addition manufacturing rebound month low july lift markit preliminary august manufacturing purchasing manager index sharply july be highest read year
1387,ILMN,exist home sale climb highest annualize rate year unit national association realtor report sale have increase straight month remain year level
1388,ILMN,philadelphia federal reserve business outlook survey jump august third consecutive gain highest read march analyst have project slowdown july read broad indicator future activity increase new order shipment employment fall july level
1389,ILMN,growth also accelerate conference board lead economic index july vs gain prior month signal suggest economy be gain traction group say statement growth continue strong pace remainder year
1390,ILMN,be relatively quiet morning company news front bank america bac rise word record set settlement department justice dollar general dg family dollar store fdo slip fraction announce family dollar have reject peer takeover bid family dollar reaffirm prior agreement dollar tree dltr dollar tree share slip earning miss analyst consensus view
1391,ILMN,leader athm fall
1392,ILMN,china base provider online automotive information have be diligently build right side month ipo base base be deep increase risk weigh produce
1393,ILMN,illumina ilmn gain open san diego calif base maker genetic screening technology announce strategic partnership astrazeneca azn janssen sanofi sny develop universal next generation sequence base oncology test system stock have just climb back week move average seventh week possible base stock open uptick thursday then quickly turn mixed strong dose support economic datum report dow jone industrial average climb nasdaq reversed early gain slip add volume be also mixed nyse lower nasdaq stock market today set current uptrend good standing plenty headline rolled overnight intensified fight ukraine weak manufacturing datum china have shake timid market rise dollar also add pressure many case work early stock gain stock open better expect read weekly unemployment claim addition manufacturing rebound month low july lift markit preliminary august manufacturing purchasing manager index sharply july be highest read year exist home sale climb highest annualize rate year unit national association realtor report sale have increase straight month remain year level philadelphia federal reserve business outlook survey jump august third consecutive gain highest read march analyst have project slowdown july read broad indicator future activity increase new order shipment employment fall july level growth also accelerate conference board lead economic index july vs gain prior month signal suggest economy be gain traction group say statement growth continue strong pace remainder year be relatively quiet morning company news front bank america bac rise word record set settlement department justice dollar general dg family dollar store fdo slip fraction announce family dollar have reject peer takeover bid family dollar reaffirm prior agreement dollar tree dltr dollar tree share slip earning miss analyst consensus view leader athm fall china base provider online automotive information have be diligently build right side month ipo base base be deep increase risk weigh produce illumina ilmn gain open san diego calif base maker genetic screening technology announce strategic partnership astrazeneca azn janssen sanofi sny develop universal next generation sequence base oncology test system stock have just climb back week move average seventh week possible base
1394,ILMN,lead manager matthew kamm work market garden variety treat young sprout differently mature produce differently crop ready reap
1395,ILMN,approach be work have make artisan mid cap fund top performer largest diversify stock portfolio
1396,ILMN,month end jan return top midcap growth peer track morningstar inc average annual gain past year top rival
1397,ILMN,kamm year old discuss investment course ibd office milwaukee
1398,ILMN,ibd addition mid cap run artisan global opportunity small cap do manage different cap size style fund help
1399,ILMN,kamm team include group analyst portfolio manager work collaboratively identify best idea ve be year level tenure trust be important
1400,ILMN,look market cap scale globally give broad perspective think re better midcap investor know small cap competitor international emerge market competitor midcap company increasingly face
1401,ILMN,ibd divide portfolio type stock advantage
1402,ILMN,kamm nomenclature use be garden crop harvest
1403,ILMN,garden stock be one believe be just emerge try be early guard risk keep garden position small
1404,ILMN,garden position turn right profit growth play allocate more push crop bucket portfolio be largest position fewest position feel profit cycle have be largely risk
1405,ILMN,third area be harvest reduce position
1406,ILMN,ibd be tweak new buy cope expect slow growth economy
1407,ILMN,kamm ve be focuse uniquely position franchise be expose strong growth trend see sign especially economy be get better housing job be example emerge market be struggle grow same rate experience few year
1408,ILMN,re focuse durable high quality franchise re less interested high commodity business material business model be very cyclical economy sensitive tend not meet franchise characteristic criterium
1409,ILMN,ibd be real world example please latest disclosure
1410,ILMN,kamm re focuse innovation health care re year past first sequence human genome now re see benefit novel drug target
1411,ILMN,regeneron regn be example have drug call eylea be retinal drug age related macular degeneration lead cause blindness elderly be launch second full year sell strong driver company sale profit
1412,ILMN,regeneron also have diverse pipeline additional opportunity extend profit cycle future
1413,ILMN,be discover regeneron own lab primarily funded sanofi large french drug company return ability market drug share profit
1414,ILMN,ibd chipotle grill cmg recently gap report strong result guidance earning share growth be second straight quarterly acceleration thesis
1415,ILMN,kamm think re position growth have very strong brand associate high quality ingredient have significant opportunity grow footprint restaurant ultimately internationally
1416,ILMN,re execute well re get customer serve line quicker ve enhance menu re offer office cater re able drive solid same store comp year year make restaurant more profitable higher volume
1417,ILMN,ve resist increase price same extent lot restaurant have instead re drive growth higher volume traffic
1418,ILMN,ibd alexion pharmaceutical alxn have have great run just gap other day make think still have room run
1419,ILMN,kamm fit innovation theme sale profit be drive solaris biologic drug approve ultrarare very serious disease not just globally
1420,ILMN,still have room run used solaris still have lot growth ahead still lot opportunity reach more patient
1421,ILMN,solaris be also be test additional ultrarare disease early clinical datum be encourage year be additional treatment approval solaris
1422,ILMN,also have alpha target certain bone disease tooth loss be expect be approve later year
1423,ILMN,ibd be broker dealer lpl financial lpla play grow economy
1424,ILMN,kamm re largest independent broker dealer country ve grow attract financial adviser away big bank wire house give independence grow practice way see fit let keep larger percent profit
1425,ILMN,continue gain market share market share gainer company outgrow market sustainable way
1426,ILMN,also lpl capture float cash balance customer keep float refer earning cash time customer authorize disbursement cash actually leave account rate be low be not so much float capture rate rise economy improve then lpl earning accelerate
1427,ILMN,ibd innovation stock athletic wear seller armour ua
1428,ILMN,kamm innovation be new material deliver better performance sweat wicking shielding athlete heat cold company armour nike nke adida have be able grow innovate product line drive increase value customer
1429,ILMN,armour have great brand athlete especially young athlete be incline spend more re expand other category such footwear cleat translate more traditional ware run shoe
1430,ILMN,ve be mostly brand re extend brand internationally drive additional growth outside so think still have long runway re bucket category
1431,ILMN,ibd be right think illumina ilmn genomic sequence advance
1432,ILMN,kamm gene sequence be technology launch next generation sequence platform cost sequence begin fall lead big growth market launch jan new product hiseq deliver first genome target researcher have be fix year
1433,ILMN,so re center action human genetic research have significant growth opportunity make tool even more affordable
1434,ILMN,ibd tripadvisor trip have pull back nov high earning share fall most recent quarter aren concern
1435,ILMN,kamm re lead review site hotel other travel destination globally ve moved bidding model company bid placement tripadvisor site almost bidding google goog search term earning have decline process be transition re foregoing older advertising measure move customer new bidding system new system start mature profit be lower
1436,ILMN,be expect garden investment move get transitional period
1437,ILMN,ibd cepheid cphd have uptrended june have show so much volatility quarterly earning
1438,ILMN,kamm be crop position make diagnostic system let hospital easily identify molecular marker disease patient used be complex time consume process require highly trained staff cepheid make genexpert automate put blood sample plastic cartridge go instrument get answer so more hospital do molecular testing
1439,ILMN,company run manufacturing challenge hurt earning past year ve address issue exit better place term inventory ability provide test cartridge customer have broad pipeline new test ve bring market now have leverage new system do broader range test
1440,ILMN,ibd be fortune brand fbhs play housing rebound
1441,ILMN,kamm re lead housing product company be crop position
1442,ILMN,have lead position fixture kitchen bathroom cabinet faucet lock tend be attractive segment become clear last year housing market be come depth downturn fortune have be gain share key market deliver strong margin expansion margin be still peak last housing cycle so reasonable assume margin continue rise
1443,ILMN,ibd rate growth linkedin lnkd earning share have decline quarters ve add stake several recent disclosure game plan
1444,ILMN,kamm linkedin have transform recruit hire market main advantage be person update resume profile even re not actively look job person be hire access rich database not just job seeker also person be open right opportunity valuable corporate hr department
1445,ILMN,recent year linkedin have be investing improve mobile smartphone tablet tool provide more content more article expert topic be relevant bring person site more frequently higher level engagement translate more advertising dollar linkedin not only grow number recruiter subscribe platform also grow advertising business have long way run
1446,ILMN,ibd begin current stake melco crown entertainment mpel september do particular casino stock
1447,ILMN,kamm re lead casino operator macau cotai strip macau be well know high growth market noticeably larger la vegas subtle shift market recent year be market be longer drive primarily high roller ultrahigh net worth individual gaming macau be drive mass market today
1448,ILMN,melco property be well position serve mass market part market be more profitable high net worth part melco be work open new property expand earning potential
1449,ILMN,also transportation macau be improve re see change make more attractive destination travel not just gamble demand
1450,ILMN,ibd stake tractor supply tsco have edge
1451,ILMN,kamm re lead supply store recreational farm rural lifestyle have store today think have potential least store grow ve do good job increase productivity exist store ve do good job understand business datum
1452,ILMN,ve do good job commerce leverage brand outside physical store ve do good job layer private label good store provide different price point help expand own margin driver have potential come year lead manager matthew kamm work market garden variety treat young sprout differently mature produce differently crop ready reap approach be work have make artisan mid cap fund top performer largest diversify stock portfolio month end jan return top midcap growth peer track morningstar inc average annual gain past year top rival kamm year old discuss investment course ibd office milwaukee ibd addition mid cap run artisan global opportunity small cap do manage different cap size style fund help kamm team include group analyst portfolio manager work collaboratively identify best idea ve be year level tenure trust be important look market cap scale globally give broad perspective think re better midcap investor know small cap competitor international emerge market competitor midcap company increasingly face ibd divide portfolio type stock advantage kamm nomenclature use be garden crop harvest garden stock be one believe be just emerge try be early guard risk keep garden position small garden position turn right profit growth play allocate more push crop bucket portfolio be largest position fewest position feel profit cycle have be largely risk third area be harvest reduce position ibd be tweak new buy cope expect slow growth economy kamm ve be focuse uniquely position franchise be expose strong growth trend see sign especially economy be get better housing job be example emerge market be struggle grow same rate experience few year re focuse durable high quality franchise re less interested high commodity business material business model be very cyclical economy sensitive tend not meet franchise characteristic criterium ibd be real world example please latest disclosure kamm re focuse innovation health care re year past first sequence human genome now re see benefit novel drug target regeneron regn be example have drug call eylea be retinal drug age related macular degeneration lead cause blindness elderly be launch second full year sell strong driver company sale profit regeneron also have diverse pipeline additional opportunity extend profit cycle future be discover regeneron own lab primarily funded sanofi large french drug company return ability market drug share profit ibd chipotle grill cmg recently gap report strong result guidance earning share growth be second straight quarterly acceleration thesis kamm think re position growth have very strong brand associate high quality ingredient have significant opportunity grow footprint restaurant ultimately internationally re execute well re get customer serve line quicker ve enhance menu re offer office cater re able drive solid same store comp year year make restaurant more profitable higher volume ve resist increase price same extent lot restaurant have instead re drive growth higher volume traffic ibd alexion pharmaceutical alxn have have great run just gap other day make think still have room run kamm fit innovation theme sale profit be drive solaris biologic drug approve ultrarare very serious disease not just globally still have room run used solaris still have lot growth ahead still lot opportunity reach more patient solaris be also be test additional ultrarare disease early clinical datum be encourage year be additional treatment approval solaris also have alpha target certain bone disease tooth loss be expect be approve later year ibd be broker dealer lpl financial lpla play grow economy kamm re largest independent broker dealer country ve grow attract financial adviser away big bank wire house give independence grow practice way see fit let keep larger percent profit continue gain market share market share gainer company outgrow market sustainable way also lpl capture float cash balance customer keep float refer earning cash time customer authorize disbursement cash actually leave account rate be low be not so much float capture rate rise economy improve then lpl earning accelerate ibd innovation stock athletic wear seller armour ua kamm innovation be new material deliver better performance sweat wicking shielding athlete heat cold company armour nike nke adida have be able grow innovate product line drive increase value customer armour have great brand athlete especially young athlete be incline spend more re expand other category such footwear cleat translate more traditional ware run shoe ve be mostly brand re extend brand internationally drive additional growth outside so think still have long runway re bucket category ibd be right think illumina ilmn genomic sequence advance kamm gene sequence be technology launch next generation sequence platform cost sequence begin fall lead big growth market launch jan new product hiseq deliver first genome target researcher have be fix year so re center action human genetic research have significant growth opportunity make tool even more affordable ibd tripadvisor trip have pull back nov high earning share fall most recent quarter aren concern kamm re lead review site hotel other travel destination globally ve moved bidding model company bid placement tripadvisor site almost bidding google goog search term earning have decline process be transition re foregoing older advertising measure move customer new bidding system new system start mature profit be lower be expect garden investment move get transitional period ibd cepheid cphd have uptrended june have show so much volatility quarterly earning kamm be crop position make diagnostic system let hospital easily identify molecular marker disease patient used be complex time consume process require highly trained staff cepheid make genexpert automate put blood sample plastic cartridge go instrument get answer so more hospital do molecular testing company run manufacturing challenge hurt earning past year ve address issue exit better place term inventory ability provide test cartridge customer have broad pipeline new test ve bring market now have leverage new system do broader range test ibd be fortune brand fbhs play housing rebound kamm re lead housing product company be crop position have lead position fixture kitchen bathroom cabinet faucet lock tend be attractive segment become clear last year housing market be come depth downturn fortune have be gain share key market deliver strong margin expansion margin be still peak last housing cycle so reasonable assume margin continue rise ibd rate growth linkedin lnkd earning share have decline quarters ve add stake several recent disclosure game plan kamm linkedin have transform recruit hire market main advantage be person update resume profile even re not actively look job person be hire access rich database not just job seeker also person be open right opportunity valuable corporate hr department recent year linkedin have be investing improve mobile smartphone tablet tool provide more content more article expert topic be relevant bring person site more frequently higher level engagement translate more advertising dollar linkedin not only grow number recruiter subscribe platform also grow advertising business have long way run ibd begin current stake melco crown entertainment mpel september do particular casino stock kamm re lead casino operator macau cotai strip macau be well know high growth market noticeably larger la vegas subtle shift market recent year be market be longer drive primarily high roller ultrahigh net worth individual gaming macau be drive mass market today melco property be well position serve mass market part market be more profitable high net worth part melco be work open new property expand earning potential also transportation macau be improve re see change make more attractive destination travel not just gamble demand ibd stake tractor supply tsco have edge kamm re lead supply store recreational farm rural lifestyle have store today think have potential least store grow ve do good job increase productivity exist store ve do good job understand business datum ve do good job commerce leverage brand outside physical store ve do good job layer private label good store provide different price point help expand own margin driver have potential come year
1453,ILMN,market shift higher gear thursday index post sizable gain rise volume nasdaq advanced rise small cap leap ibd add volume be higher major exchange advance higher volume be impressive light friday loom job report
1454,ILMN,stock make solid gain thursday putt nasdaq point time high hail distance high water mark
1455,ILMN,nasdaq rise gain dow jone industrial average lag gain stock market today volume be higher wednesday nasdaq only smidgen more nyse accord preliminary datum
1456,ILMN,nasdaq close compare intraday high june beat close high june
1457,ILMN,garmin grmn gap lose report disappointing earning have be much be hurt wearable market fitbit fit activity tracker apple aapl recently launch apple watch
1458,ILMN,fitbit rise less be high apple rise more recently find support day move average poke day line thursday
1459,ILMN,netflix be star day gapping close gain stock split report earning well estimate even be year earlier figure company be foregoing short term profit dramatically grow subscriber base
1460,ILMN,domino pizza dpz drop reaction disappointing earning report lose nearly stay buy point flat base stock make solid gain thursday putt nasdaq point time high hail distance high water mark nasdaq rise gain dow jone industrial average lag gain stock market today volume be higher wednesday nasdaq only smidgen more nyse accord preliminary datum nasdaq close compare intraday high june beat close high june garmin grmn gap lose report disappointing earning have be much be hurt wearable market fitbit fit activity tracker apple aapl recently launch apple watch fitbit rise less be high apple rise more recently find support day move average poke day line thursday netflix be star day gapping close gain stock split report earning well estimate even be year earlier figure company be foregoing short term profit dramatically grow subscriber base domino pizza dpz drop reaction disappointing earning report lose nearly stay buy point flat base
1461,ILMN,index many leader be rebound correction have not end have top fund cope jpmorgan mid cap growth fund be top midcap growth peer group track morningstar inc year go tuesday be vs peer
1462,ILMN,major average end mixed close intraday high tuesday trading fairly narrow range
1463,ILMN,nasdaq dow finished fractionally higher be barely lower facebook fb jump be most active nasdaq volume be slightly heavier monday exchange stock market today accord preliminary datum
1464,ILMN,illumina ilmn extend gain seventh straight session advance twice normal turnover stock be buy point cup handle clear last week heavy trade
1465,ILMN,ypf ypf gain busy action be now past cup handle entry stock initially break early pull back day move average argentine oil gas driller have post better profit growth past quarters analyst expect gain
1466,ILMN,downside tyson food tsn fall near day move average more triple usual trade credit suisse cut stock underperform neutral cite share meat processor pay hillshire brand hsh tyson monday slump winning bidding war vs pilgrim pride ppc hillshire
1467,ILMN,verint system vrnt gap drop heavy volume topple monday close high security software maker monday announce propose public offer common share convertible senior note due
1468,ILMN,follow nancy gondo twitter https twitter com email protected major average end mixed close intraday high tuesday trading fairly narrow range nasdaq dow finished fractionally higher be barely lower facebook fb jump be most active nasdaq volume be slightly heavier monday exchange stock market today accord preliminary datum illumina ilmn extend gain seventh straight session advance twice normal turnover stock be buy point cup handle clear last week heavy trade ypf ypf gain busy action be now past cup handle entry stock initially break early pull back day move average argentine oil gas driller have post better profit growth past quarters analyst expect gain downside tyson food tsn fall near day move average more triple usual trade credit suisse cut stock underperform neutral cite share meat processor pay hillshire brand hsh tyson monday slump winning bidding war vs pilgrim pride ppc hillshire verint system vrnt gap drop heavy volume topple monday close high security software maker monday announce propose public offer common share convertible senior note due follow nancy gondo twitter https twitter com email protected
1469,ILMN,market week signale confirm uptrend make crucial time find stock buy proper buy point
1470,ILMN,many lead stock have already break past buy point especially true transportation energy food see strength ahead week bullish signal
1471,ILMN,several high rate stock haven yet reach buy point so here rundown weekly review stock worth closer look
1472,ILMN,technology sector chipmaker be emerge leader
1473,ILMN,diod fail bid april be now set flat base buy point
1474,ILMN,nxp semiconductor nxpi try break couple week get knock base look new entry
1475,ILMN,web com wwww service provider be form right side cup type base bullish reversal high volume week give base solid bottom
1476,ILMN,medical sector still flourish strong stock
1477,ILMN,actavis act need rise reach new high base be well round be late stage
1478,ILMN,globus medical gmed be try get week line be slow development latest base maker spinal product post ep gain past quarters still earn composite rating
1479,ILMN,therapeutic anik be just inch away buy point cup handle
1480,ILMN,illumina ilmn be shape right side base recent quarterly earning gain have be modest stock still garner lofty composite rating sale growth have be solid range past quarters help composite score
1481,ILMN,advance auto part aap be form flat base see volatility watch share clear resistance
1482,ILMN,wynn resort wynn have reclaim week line putt base build better foot market week signale confirm uptrend make crucial time find stock buy proper buy point many lead stock have already break past buy point especially true transportation energy food see strength ahead week bullish signal several high rate stock haven yet reach buy point so here rundown weekly review stock worth closer look technology sector chipmaker be emerge leader diod fail bid april be now set flat base buy point nxp semiconductor nxpi try break couple week get knock base look new entry web com wwww service provider be form right side cup type base bullish reversal high volume week give base solid bottom medical sector still flourish strong stock actavis act need rise reach new high base be well round be late stage globus medical gmed be try get week line be slow development latest base maker spinal product post ep gain past quarters still earn composite rating therapeutic anik be just inch away buy point cup handle illumina ilmn be shape right side base recent quarterly earning gain have be modest stock still garner lofty composite rating sale growth have be solid range past quarters help composite score advance auto part aap be form flat base see volatility watch share clear resistance wynn resort wynn have reclaim week line putt base build better foot
1483,ILMN,stock build earlier gain afternoon trading thursday dow jone industrial average step new territory
1484,ILMN,nasdaq rise dow tack volume be tracking higher board compare wednesday level
1485,ILMN,hesitate morning institutional investor decide approve european central bank announcement be lower overnight interest rate take other action fight deflation
1486,ILMN,ibd stock market today be higher be lower
1487,ILMN,bitauto bita vipshop holding vip illumina ilmn unite rental uri gain more
1488,ILMN,china base bitauto be recover sell work erratic base vipshop chinese internet stock be work late stage cup handle base
1489,ILMN,illumina meanwhile extend gain wednesday lackluster cup handle attempt buy point
1490,ILMN,unite rental be extend time high
1491,ILMN,twitter twtr rise more report talk buy soundcloud music sharing platform pacific crest security also start coverage buy rating
1492,ILMN,ciena cien maker network infrastructure used telecom cable provider gap rise furious volume report better expect earning forecasting strong second half stock build earlier gain afternoon trading thursday dow jone industrial average step new territory nasdaq rise dow tack volume be tracking higher board compare wednesday level hesitate morning institutional investor decide approve european central bank announcement be lower overnight interest rate take other action fight deflation ibd stock market today be higher be lower bitauto bita vipshop holding vip illumina ilmn unite rental uri gain more china base bitauto be recover sell work erratic base vipshop chinese internet stock be work late stage cup handle base illumina meanwhile extend gain wednesday lackluster cup handle attempt buy point unite rental be extend time high twitter twtr rise more report talk buy soundcloud music sharing platform pacific crest security also start coverage buy rating ciena cien maker network infrastructure used telecom cable provider gap rise furious volume report better expect earning forecasting strong second half
1493,ILMN,stock slump start gate monday home sale black friday return chicago manufacturing datum put pressure open trade
1494,ILMN,nasdaq slip furthest dow jone industrial average dip apiece small cap run slightly grain russell rise small cap index nearly early trade
1495,ILMN,volume be well friday morning level surprise lame duck trading session thanksgiving day break
1496,ILMN,stock market today receive break early economic news
1497,ILMN,chicago purchasing manager index drop november kingsbury international report be sharply october read well economist consensus expectation gauge be generally take precursor more closely watch institute supply management pmi index be due tuesday morning
1498,ILMN,pending home sale tick feeble october national association realtor say gain be improvement month decline well forecast increase pending home sale have flattened fall nar say release consumer face rise price dwindle inventory home
1499,ILMN,stock computer science csc jump company divide separate publicly trade operation csra csra combine csc government contractor business operation sra international csc announce august acquire begin trading monday csra ticker csc commercial operation continue trade csc nyse csra share trade early action
1500,ILMN,retailer be take notable hit early tally begin roll black friday launch holiday shopping season armour ua urban outfitter urbn drop ugg maker decker outdoor deck dive fashion designer steve madden shoo dump
1501,ILMN,ibd stock tal education xrs jump nearly bump new high china base chain school tutor clinic have gain recent session process clear buy point cup handle base share be now extend almost
1502,ILMN,china base issue noah noah climb nearly group second best gain asset management firm have fail decisively clear buy point flaw cup handle base
1503,ILMN,nike nke slip more take ibd worst early decline also largest decline dow stock dip left share just buy point flat base stock slump start gate monday home sale black friday return chicago manufacturing datum put pressure open trade nasdaq slip furthest dow jone industrial average dip apiece small cap run slightly grain russell rise small cap index nearly early trade volume be well friday morning level surprise lame duck trading session thanksgiving day break stock market today receive break early economic news chicago purchasing manager index drop november kingsbury international report be sharply october read well economist consensus expectation gauge be generally take precursor more closely watch institute supply management pmi index be due tuesday morning pending home sale tick feeble october national association realtor say gain be improvement month decline well forecast increase pending home sale have flattened fall nar say release consumer face rise price dwindle inventory home stock computer science csc jump company divide separate publicly trade operation csra csra combine csc government contractor business operation sra international csc announce august acquire begin trading monday csra ticker csc commercial operation continue trade csc nyse csra share trade early action retailer be take notable hit early tally begin roll black friday launch holiday shopping season armour ua urban outfitter urbn drop ugg maker decker outdoor deck dive fashion designer steve madden shoo dump ibd stock tal education xrs jump nearly bump new high china base chain school tutor clinic have gain recent session process clear buy point cup handle base share be now extend almost china base issue noah noah climb nearly group second best gain asset management firm have fail decisively clear buy point flaw cup handle base nike nke slip more take ibd worst early decline also largest decline dow stock dip left share just buy point flat base
1504,ILMN,market be back confirm uptrend several big cap stock be flex little muscle shape turn be valid basis
1505,ILMN,candidate worthy investor watch list be keurig green mountain gmcr shape cup handle base buy point negative be earning growth have be decelerate last quarters analyst be forecasting increase current quarter stock gap feb favorable earning report announcement partnership coca cola ko be base then
1506,ILMN,year annualize ep growth rate be
1507,ILMN,illumina ilmn be big cap stock form base be do early work handle
1508,ILMN,company make system large scale study genetic variation biological function
1509,ILMN,illumina have straight quarters revenue growth ep growth past quarters have be only
1510,ILMN,year growth rate be return equity be pretax profit margin be
1511,ILMN,apple aapl be news monday announce new operate system mac iphone ipad line worldwide developer conference san francisco
1512,ILMN,usual speculation be abundant past few week company announce
1513,ILMN,software be release fall be free
1514,ILMN,apple break consolidation earning report april have be rally ever close monday close
1515,ILMN,manage health care provider aetna aet shape base break soft volume be hold own be still buy range buy point
1516,ILMN,aetna have year annualize growth rate analyst be forecasting growth
1517,ILMN,earning past quarters have grow analyst be forecasting ep increase current quarter
1518,ILMN,company have pretax margin return equity boost somewhat debt equity ratio
1519,ILMN,american airline group aal merger american airline airway hit time high monday close
1520,ILMN,stock have moved base move lack punch solid
1521,ILMN,company earn share lose money straight year analyst be forecasting increase earning increase
1522,ILMN,company have quarters accelerate sale market be back confirm uptrend several big cap stock be flex little muscle shape turn be valid basis candidate worthy investor watch list be keurig green mountain gmcr shape cup handle base buy point negative be earning growth have be decelerate last quarters analyst be forecasting increase current quarter stock gap feb favorable earning report announcement partnership coca cola ko be base then year annualize ep growth rate be illumina ilmn be big cap stock form base be do early work handle company make system large scale study genetic variation biological function illumina have straight quarters revenue growth ep growth past quarters have be only year growth rate be return equity be pretax profit margin be apple aapl be news monday announce new operate system mac iphone ipad line worldwide developer conference san francisco usual speculation be abundant past few week company announce software be release fall be free apple break consolidation earning report april have be rally ever close monday close manage health care provider aetna aet shape base break soft volume be hold own be still buy range buy point aetna have year annualize growth rate analyst be forecasting growth earning past quarters have grow analyst be forecasting ep increase current quarter company have pretax margin return equity boost somewhat debt equity ratio american airline group aal merger american airline airway hit time high monday close stock have moved base move lack punch solid company earn share lose money straight year analyst be forecasting increase earning increase company have quarters accelerate sale
1523,ILMN,tech stock outperformed monday be mostly quiet session nyse index software stock do most heavy lift many gain sector look dead cat bounce sharp sell off close nasdaq rise dow jone industrial average preliminary datum show nyse nasdaq volume come lower friday stock market today salesforce com crm bounce nearly ahead tuesday earning report still day move average correct high nasdaq apple aapl add stock have be make new high heel report last week company be interested acquire headphone music stream company beat electronic apple stock split take place next month record date be june share start trading split adjust price june other big percentage gainer nasdaq include illumina ilmn tripadvisor trip network ffiv stock seem be bottom correction meanwhile straight heavy volume decline thursday friday grifol grfs rally heavy volume close just buy point trucking space hunt transport service jbht flirted cup handle pattern share rise come cent buy point tuesday watch earning report dick sporting good dks home depot hd tjx company tjx
1524,ILMN,oil gas play continue dominate week big cap list half name hail sector not surprisingly most have outperformed market be extend result few other lead nonenergy stock currently work basis provide watch list fodder market come correction
1525,ILMN,new analyst report cowen co offer upbeat assessment medical research equipment stock ahead first quarter earning thank improve end market
1526,ILMN,report life science diagnostic tool sector tuesday analyst doug schenkel write most company be poise meet beat expectation
1527,ILMN,expectation combine confidence build forward look commentary positive update end market help share price sector recover recent slump schenkel add
1528,ILMN,company reckon be best position beat estimate be fluidigm fldm illumina ilmn myriad genetic mygn orasure technology osur perkinelmer pki thermo fisher scientific tmo
1529,ILMN,fluidigm belong ibd medical system equipment group rank industry track illumina myriad perkinelmer thermo fisher be ibd medical research equipment service group rank orasure be medical product group rank
1530,ILMN,stock myriad have highest ibd composite rating be follow illumina perkinelmer thermo fisher orasure fluidigm
1531,ILMN,myriad have have best stock action late reach year high friday share be more begin year
1532,ILMN,company life science diagnostic tool benefit growth most end market schenkel say
1533,ILMN,coverage universe include major customer end market academic government industrial apply biopharma healthcare hospital
1534,ILMN,have be show improvement say
1535,ILMN,base check management commentary past few month continue believe academic government end market be stable improve schenkel note
1536,ILMN,industrial cyclical end market not be improve quickly hope say be encourage sign
1537,ILMN,remain enthused outlook improve end market favorable comparison drive continue relative outperformance schenkel write
1538,ILMN,related myriad tata motor rs leader correction new analyst report cowen co offer upbeat assessment medical research equipment stock ahead first quarter earning thank improve end market report life science diagnostic tool sector tuesday analyst doug schenkel write most company be poise meet beat expectation expectation combine confidence build forward look commentary positive update end market help share price sector recover recent slump schenkel add company reckon be best position beat estimate be fluidigm fldm illumina ilmn myriad genetic mygn orasure technology osur perkinelmer pki thermo fisher scientific tmo fluidigm belong ibd medical system equipment group rank industry track illumina myriad perkinelmer thermo fisher be ibd medical research equipment service group rank orasure be medical product group rank stock myriad have highest ibd composite rating be follow illumina perkinelmer thermo fisher orasure fluidigm myriad have have best stock action late reach year high friday share be more begin year company life science diagnostic tool benefit growth most end market schenkel say coverage universe include major customer end market academic government industrial apply biopharma healthcare hospital have be show improvement say base check management commentary past few month continue believe academic government end market be stable improve schenkel note industrial cyclical end market not be improve quickly hope say be encourage sign remain enthused outlook improve end market favorable comparison drive continue relative outperformance schenkel write related myriad tata motor rs leader correction
1539,ILMN,major average be little change friday weak post holiday trading nasdaq be edge dow jone industrial be flat volume friday half day session be run sharply lower same time wednesday last trading session thanksgiving universal display oled maker light emit flat panel display jump heavy volume new report product be used apple aapl iphone model due stock be approach buy point deep cup base fall oil price hurt energy stock help airline stock market today coal producer consol energy cnx oil stock southwestern energy swn longtime laggard drop weigh other hand american airline aal unite continental ual rise line decline oil price ibd stock hawaiian rise meanwhile walt disney drop heavy volume drag medium stock announce late wednesday espn sport network have lose subscriber past year stock drop cup handle buy point clear nov viacom viab fall time warner twx be
1540,ILMN,gene sequence company illumina late monday beat analyst estimate eighth quarter row send share hour trading
1541,ILMN,illumina ilmn report third quarter profit cent share year earlier quarter cent analyst consensus accord thomson reuter sale jump more expect
1542,ILMN,company also raise full year guidance speculation wall street government shutdown have hit customer now expect revenue growth last year ep last year
1543,ILMN,earlier monday illumina announce new deal university cambridge genomic england sequence whole genome child adult rare genetic disease pilot program british national health service plan sequence genome
1544,ILMN,news go way soothing street anxiety have be putt volatility stock hit time high oct illumina stock have drop rebound quickly however help partly price target increase reassure note cowen analyst doug schenkel
1545,ILMN,schenkel write oct stock drop seem be due variety factor worry federal government shutdown reduce business customer depend fund national institutes health estimate however affect only sale
1546,ILMN,company have also warn seasonal slowdown product line schenkel write momentum seem be grow hiseq gene sequencer well verinata prenatal testing business
1547,ILMN,be bear monday report product revenue account much sale beat analyst consensus call illumina beat service account other revenue
1548,ILMN,conference call analyst illumina ceo jay flatley say sale be strong geography most product line
1549,ILMN,flatley say shipment be commercial nonprofit hospital customer step firm longer term goal get sale such apply market order reduce dependence government funding
1550,ILMN,government shutdown be very unfortunate few customer ve not see material impact spending pattern flatley say importantly most customer external funding be flow expect shutdown government now open operate continue resolution re see customary purchasing pattern
1551,ILMN,letter shareholder last week flatley outlined company plan rearrange business unit
1552,ILMN,currently company divide report sale product service product divide type
1553,ILMN,new structure align key market company appoint new president now flatley job create business division life science reproductive genetic health incorporate verinata health acquire earlier year oncology enterprise informatic new emerge market
1554,ILMN,call flatley say change help continue growth exist market take next step new market further catalyze use technology clinic ve better align business unit customer centralize core cross company function consolidated commercial channel
1555,ILMN,say company update investor progress plan next year gene sequence company illumina late monday beat analyst estimate eighth quarter row send share hour trading illumina ilmn report third quarter profit cent share year earlier quarter cent analyst consensus accord thomson reuter sale jump more expect company also raise full year guidance speculation wall street government shutdown have hit customer now expect revenue growth last year ep last year earlier monday illumina announce new deal university cambridge genomic england sequence whole genome child adult rare genetic disease pilot program british national health service plan sequence genome news go way soothing street anxiety have be putt volatility stock hit time high oct illumina stock have drop rebound quickly however help partly price target increase reassure note cowen analyst doug schenkel schenkel write oct stock drop seem be due variety factor worry federal government shutdown reduce business customer depend fund national institutes health estimate however affect only sale company have also warn seasonal slowdown product line schenkel write momentum seem be grow hiseq gene sequencer well verinata prenatal testing business be bear monday report product revenue account much sale beat analyst consensus call illumina beat service account other revenue conference call analyst illumina ceo jay flatley say sale be strong geography most product line flatley say shipment be commercial nonprofit hospital customer step firm longer term goal get sale such apply market order reduce dependence government funding government shutdown be very unfortunate few customer ve not see material impact spending pattern flatley say importantly most customer external funding be flow expect shutdown government now open operate continue resolution re see customary purchasing pattern letter shareholder last week flatley outlined company plan rearrange business unit currently company divide report sale product service product divide type new structure align key market company appoint new president now flatley job create business division life science reproductive genetic health incorporate verinata health acquire earlier year oncology enterprise informatic new emerge market call flatley say change help continue growth exist market take next step new market further catalyze use technology clinic ve better align business unit customer centralize core cross company function consolidated commercial channel say company update investor progress plan next year
1556,ILMN,wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum
1557,ILMN,stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya
1558,ILMN,noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters
1559,ILMN,medical product stock cambrex cbm rise more better expect earning report also climb right side new base
1560,ILMN,post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high
1561,ILMN,share real estate zillow be hour follow result
1562,ILMN,also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman
1563,ILMN,lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday
1564,ILMN,economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters medical product stock cambrex cbm rise more better expect earning report also climb right side new base post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high share real estate zillow be hour follow result also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct
1565,ILMN,daniel kelley manager fidelity trend fund say path successful investing entail buy growth stock reasonable price so trim well price decline explain rotation away stock technology sector other sector especially health care consumer cyclical tech name make robust stock
1566,ILMN,illumina ilmn stock vault nearly time high stock market tuesday morning wake strong quarterly report guidance increase late monday company beat estimate straight quarter analyst attribute largely strength hiseq gene sequence system leerink swann analyst dan leonard note
1567,ILMN,vipshop holding vip system ddd be top stock outperform overall market have be trend higher recent week today screen day be bolt relative strength line stock rs line hit new high prior session ibd rs rating measure stock price change last month
1568,ILMN,choppy condition again dictate friday session top rate stock be able muster new high especially medical stock perrigo prgo add more twice average volume stock follow thursday past buy point cup handle base drugmaker give gain hour trading
1569,ILMN,bad investing usually come word impatience
1570,ILMN,cash position market correction make so anxious just have jump back stock here time lose trend have odd side
1571,ILMN,wait ipo form base seem time waste learn cost short cut
1572,ILMN,rush stock company have yet earn dime have great story then skip stock read novel fiction unhappy ending be less painful
1573,ILMN,patience win let market do tough work separate dog hunt dog hunt
1574,ILMN,patience wait market uptrend base
1575,ILMN,illumina ilmn launch initial public offer july wasn best time debut bear market be way
1576,ILMN,san diego base maker genetic analysis tool beat odd late september stock hit ipo close
1577,ILMN,bear market however eventually prove too much march stock have fall
1578,ILMN,smart money wouldn have get catch buzz see reason first sell rule ve identify exit long stock lose value
1579,ILMN,second illumina have never turn annual profit year incorporation smart money know puppy have yet prove hunt
1580,ILMN,story change illumina deliver annual profit cent share first many
1581,ILMN,flash forward market correction illumina clear back back sloppy consolidation then nasdaq deliver follow day confirm uptrend be way
1582,ILMN,illumina have stay profitable struggle recession ep grow vs year period fall
1583,ILMN,september however earning be turnaround path annual gain
1584,ILMN,illumina clear buy point almost triple daily volume base be previous consolidation rise less month bad investing usually come word impatience cash position market correction make so anxious just have jump back stock here time lose trend have odd side wait ipo form base seem time waste learn cost short cut rush stock company have yet earn dime have great story then skip stock read novel fiction unhappy ending be less painful patience win let market do tough work separate dog hunt dog hunt patience wait market uptrend base illumina ilmn launch initial public offer july wasn best time debut bear market be way san diego base maker genetic analysis tool beat odd late september stock hit ipo close bear market however eventually prove too much march stock have fall smart money wouldn have get catch buzz see reason first sell rule ve identify exit long stock lose value second illumina have never turn annual profit year incorporation smart money know puppy have yet prove hunt story change illumina deliver annual profit cent share first many flash forward market correction illumina clear back back sloppy consolidation then nasdaq deliver follow day confirm uptrend be way illumina have stay profitable struggle recession ep grow vs year period fall september however earning be turnaround path annual gain illumina clear buy point almost triple daily volume base be previous consolidation rise less month
1585,ILMN,day hundred new high just few stock break basis several reversed lower illumina ilmn gap week consolidation rise volume be more time average week correction be technically bit too deep flat base often subjective field
1586,ILMN,market shift confirm uptrend want fundamentally strong stock watch list satisfy several requirement stock sector be strong industry group be strong base not be late stage least now san diego base illumina ilmn fit bill midcap company make tool genetic analysis
1587,ILMN,gene sequence giant illumina beat second quarter estimate raise guidance announce new acquisition send share higher hour trading illumina ilmn say sale climb year quarter beating analyst consensus nearly accord thomson reuter wall street have expect profit be flat instead climb cent
1588,ILMN,similar wise buy decision exit certain underperformer right time help maximize portfolio return selling loser be difficult share price estimate be fall be time get rid security more loss hit portfolio such stock want consider drop be bioscience inc apto free report have witness significant price decline past week have see negative earning estimate revision current quarter current year zack rank strong sell further confirm weakness apto key reason move have be negative trend earning estimate revision full year have see estimate move past day compare upward revision trend have cause consensus estimate trend lower go loss cent share month current level loss cent also current quarter bioscience have see downward estimate revision versus revision opposite direction drag consensus estimate loss cent share loss cent past day stock also have see pretty dismal trading lately share price have drop past month bioscience inc price consensus bioscience inc price consensus bioscience inc quote so not be good decision keep stock portfolio anymore least don have long time horizon be still interested medical biomedical genetic industry instead consider better rank stock illumina inc ilmn free report stock currently hold zack rank strong buy be better selection time see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1589,ILMN,revival ever volatile biotech sector have not live expectation so far performance biotech bigwig have be affected slowdown progress key drug competitive pressure have also adversely impact top line issue drug pricing competition remain headwind ace investor know biotech sector be lucrative market investment moreover be widely expect sector rebound second half year new drug approval have boost investor sentiment certain extent first half moreover approval drug boost respective company top line few be struggle decline sale legacy drug believe new drug approval label expansion exist high profile drug pipeline progress grow demand drug especially rare treat disease age population increase health care spending be factor positively impact performance owing competitive pressure quite few company have re-sort cost cut initiative turn propel bottom line somewhat meanwhile merger acquisition have picked pace sector slowdown mature product have force company eye lucrative acquisition bolster pipeline additionally increase activity be also be propel implementation new tax law have slash corporate tax rate new tax reform be also lure corporate bring back huge cash hold overseas time tax rate expect many more such deal latter half well industry lag shareholder returnseven macroeconomic condition look better price performance so far have not be impressive mentioned decline sale legacy drug pipeline setback have adversely impact price performance key biotech player turn have pull average industry zack biomedical genetic industry be stock group broader zack medical sector have underperform sector belong year date basis stock industry have collectively decline zack composite zack medical sector have rise decline year date respectively magnitude decline bigger company have more offset gain record small biotechnology company year date price performance biotech stock trading cheapgiven industry so far year valuation look cheap now valuation be tricky business biotech company take several year drug get regulatory approval so regular price multiple ratio do not provide fair picture biotech company more importantly company spend lot hence be more complex account such high expense uncertain future revenue stream be always uncertainty regard trial result fda decision get good sense industry relative valuation look price book ratio industry currently have price book ttm ratio be highest level past year well past year compare highest level median level past year believe investor dip enter market space also look inexpensive compare medical market large current well median price book ttm ratio medical sector be respectively price book trail month ttm compare zack composite too space look inexpensive current ratio median level same period be zack biomedical genetic industry respective ratio price book trail month ttm addition used price book ratio be standard multiple value company price free cash flow be good metric evaluate smaller biotech company do not have approve drug portfolio be more less dependent collaboration funding give high level be good metric judge biotech company even used price free cash flow adjust metric space look inexpensive compare medical market large current price free cash flow adjust ratio medical market be medical biomedical genetic industry be price free cash flow earning outlook look negativewhile ratio analysis show be solid value oriented path ahead not really consider current price level good entry point be convince reason predict rebound term reliable measure help investor understand industry prospect be earning outlook member company empirical research show company earning outlook significantly influence performance stock get good sense company earning outlook compare consensus earning expectation current financial year last year report number effective measure be magnitude direction recent change earning estimate trend earning estimate revision have not be favorable pipeline setback have lead many company slash outlook price consensus zack biomedical genetic industrylooking aggregate earning estimate revision appear analyst have start lose confidence group earning potential consensus ep estimate current fiscal year have be revise downward current fiscal year ep estimate revision zack industry rank indicate prospect group zack industry rank be basically average zack rank member stock zack biomedical genetic industry currently carry zack industry rank place bottom more zack industry research show top zack rank industry outperform bottom factor more proprietary heat map show industry rank have deteriorate considerably past week small biotechs promise long term growthwhile term outlook be not encourage long term year ep growth estimate zack biotech industry appear promising group mean estimate long term ep growth rate reach trough start quarter have revive thereafter reach current level also compare favorably zack composite highest level past year mean estimate long term ep growth rate important indication solid long term prospect smaller biotech company be improvement free cash flow yield image show consistence performance group free cash flow yield free cash flow yield zack biomedical genetic industry grow demand drug particularly target personalize therapy increase incidence chronic disease technological advancement evolve treatment regimen age population increase health care spending be factor keep sector track long term faster drug approval process propose removal outdated regulation push cost slowdown innovation also provide benefit bottom linethe biomedical genetic industry be continuously evolve largely volatile such scenario biotech company be expect adopt innovative business model invest new technology increase investment personalize medicine seek external partner collabora tor complementary strength sector be stumble challenge pose drug pricing issue pricing re imbursement pressure increase competition slowdown legacy product sale loss patent exclusivity key drug pipeline related setback however pipeline success innovative important therapeutic area cost cut share buyback new product launch increase activity appropriate utilization cash bring sector back track year industry currently have quite few stock sport zack rank strong buy buy here list few such stock have also be witness positive earning estimate revision amgen inc amgn free report be lead biotech company world consensus ep estimate base company have moved higher current year last day zack rank stock have rally so far year see complete list today zack rank stock here price consensus amgnani pharmaceutical inc anip free report have be see positive revision earning estimate last day analyst have revise estimate upward current year further zack rank stock have gain so far year price consensus anipillumina inc ilmn free report have be see positive revision earning estimate last day analyst have revise estimate upward current year further zack rank stock have surge year price consensus ilmn today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1590,ILMN,plc alk free report announce fda have approve aristada initio aripiprazole lauroxil extend release product treatment schizophrenia adult approval aristada initio make aristada first only long act atypical antipsychotic be initiate day play significant role treat complex disease schizophrenia aristada initio leverage proprietary nanocrystal technology drug utilize smaller particle size aristada injectable atypical antipsychotic medication also contain aripiprazole lauroxil previously standard regimen include be dose aristada consecutive day once first dose start however aristada initio regimen provide patient relevant level aripiprazole day initiation be alternative initiation regimen allow physician caregiver fully dose patient month coverage proven medication system aristada aristada initio contain aripiprazole lauroxil medication be not interchangeable differ pharmacokinetic profile aristada initio provide faster dissolution lead more rapid achievement relevant level aripiprazole aristada initio be expect be available mid july aristada initio be used initiation dose aristada mg mg mg monthly mg once week mg once month offer wide range flexible dose option patient healthcare provider approval aristada initio further strengthen portfolio boost revenue year date share have decline compare industry decline company have candidate alk phase iii be evaluate treatment schizophrenia top line datum study be expect fourth quarter study be positive company expect submit new drug application nda first half plc price plc price plc quote zack rank stock consideralkerme have zack rank hold better rank stock same space be illumina inc ilmn free report aeglea biotherapeutic inc agle free report ani pharmaceutical inc anip free report carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ani pharmaceutical earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1591,ILMN,look broad exposure healthcare broad segment equity market consider ark genomic revolution multus sector etf arkg free report passively manage exchange trade fund launch increasingly popular option retail institutional investor passively manage etfs offer low cost transparency flexibility tax efficiency be also excellent vehicle long term investor additionally sector etfs offer convenient way gain low risk diversify exposure broad group company particular sector healthcare broad be broad zack sector zack industry classification be currently rank place bottom index fund be sponsored ark investment management have amassed asset make average size etfs attempt match performance healthcare broad segment equity market etf be active do not track benchmark costsinvestor also pay attention etf expense ratio lower cost product produce better result higher cost assume other metric remain same annual operate expense etf be make more expensive product space have month trail dividend yield sector exposure top holdingsetfs offer diversify exposure thus minimize single stock risk be still important delve fund holding investing most etfs be very transparent product many disclose holding daily basis look individual holding intellium therapeutic inc ntla free report account total asset follow illumina inc ilmn free report edita medicine inc edit free report top holding account total asset management performance riskyear date ark genomic revolution multus sector etf have add roughly so far be last month arkg have trade past week period etf have beta standard deviation trail year period make high risk choice space holding have more concentrated exposure peer bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
1592,ILMN,investor interested stock medical biomedical genetic sector have probably already hear amgen amgn free report illumina ilmn free report stock offer value investor better bang buck right now ll need take closer look have find best way great value opportunity be pair strong zack rank great grade value category style score system zack rank be proven strategy target company positive earning estimate revision trend style score work grade company base specific trait amgen illumina be sporting zack rank buy right now system place emphasis company have see positive earning estimate revision so investor feel comfortable know stock have improve earning outlook be just piece puzzle value investor value investor also try analyze wide range traditional figure metric help determine company be undervalue current share price level style score value grade factor variety key fundamental metric include popular ratio ratio earning yield cash flow share number other key stat be commonly used value investor amgn currently have forward ratio ilmn have forward also note amgn have peg ratio popular figure be similar widely used ratio peg ratio also consider company expect ep growth rate ilmn currently have peg ratio notable valuation metric amgn be ratio be method compare stock market value book value be defined total asset total liability comparison ilmn have metric several other help amgn earn value grade ilmn have be give value grade amgn ilmn be impressive stock solid earning outlook base valuation figure feel amgn be superior value option right now
1593,ILMN,biotime inc btx free report be big mover last session company see share rise more day move come solid volume too far more share change hand normal session stock remain volatile trade range past month time frame witness sharp increase yesterday company have see flat track record come estimate revision past few week zack consensus estimate current quarter have also remain unchanged recent price action be encourage so make sure keep close watch firm future biotime currently have zack rank buy earning esp be biotime inc price biotime inc price biotime inc quote stock worth consider medical sector be illumina inc ilmn free report carry zack rank strong buy see complete list today zack rank stock here be btx go predict see other think hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1594,ILMN,decode mystery human dna genomic sequence be far fetch idea just decade not forget take year investment more first human genomic sequence now genome be sequence just couple day cost lesser latest iphone healthcare news analyst believe grow demand personalize medicine solid investment rise research activity have propel growth buoy trend genomic have receive warm response medtech investment space healthcare market market global genomic market be worth be expect reach cagr fact zack medical biomedical genetic industry rise month time compare index return so here discuss genomic have be create opportunity medtech investor be keen putt money healthcare space solid gain favorable trend drive genomic marketsthe global genomic market have be favore streak solid development sequence microarray pcr polymerase chain reaction nucleic acid extraction purification technique further implication artificial intelligence ai cloud base technology increase focus have provide company significant exposure genomic lend competitive edge medtech space late gene editing synthetic dna production already vogue be not very far era gene be customize requirement research report techcrunch suggest highly advanced crispr technology be capable splice editing gene lung cancer leukemia regard pacific bioscience california pacb free report single molecule real time smrt sequence technology deserve mention technology help scientist observe dna synthesis real time harness natural process replication start enzyme dna polymerase lead medical instrument company have strong exposure genomic carry zack rank hold pacific bioscience flagship platform sequel system have be fortify company international footprint system be nucleic acid sequence platform base smrt technology other company be also poise gain rise influence genomic medtech stock have vgm style score carry zack rank higher illumina inc ilmn free report illumina portfolio sequence platform comprise system be design meet output accuracy demand full range sequence application company miseq sequence system be low cost desktop sequence platform provide individual researcher rapid turnaround time high accuracy streamline illumina new product launch genomic portfolio consistently contribute top line management be optimistic recently launch novaseq flow cell reagent kit company also receive product approval certificate nextseq dx instrument ministry food drug safety mfds south korea past year illumina have outperformed industry stock have gain stock have zack rank buy thermo fisher scientific inc tmo free report thermo fisher offer comprehensive portfolio genotyp solution snp indel cnv analysis buyout affymetrix be worth mention discuss genomic portfolio affymetrix work multiplex simultaneous analysis biological system cell protein gene level facilitate transition research tool clinical apply market have start boost thermo fisher offer fast grow flow cytometry market advanced antibody portfolio moreover genetic analysis affymetrix technology complement thermo fisher product target clinical apply market total synergy value be peg third year post completion deal comprise cost synergy adjust operate income benefit past year thermo fisher have successfully outperformed industry stock have gain company have zack rank qiagen qgen free report various analyst opine qiagen currently offer broadest portfolio molecular technology human healthcare company announce lab develop test woman man health feature gene panel get know individual risk hereditary cancer type company also provide service pharmacogenomic first quarter company announce receipt japan ministry health labor welfare approval quantiferon tb gold qft diagnostic detect tuberculosis tb infection past year qiagen have be outperform industry stock have gain company have zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1595,ILMN,investor focuse medical space have likely hear illumina ilmn free report be stock perform well comparison rest sector peer take look stock year date performance comparison medical peer be able answer question illumina be member medical group include different company currently sit zack sector rank zack sector rank consider different sector group average zack rank individual stock group be measure sector be list best worst zack rank be proven model highlight variety stock right characteristic outperform market next month system emphasize earning estimate revision favor company improve earning outlook ilmn be currently sporting zack rank buy past day zack consensus estimate ilmn full year earning have moved higher be sign improve analyst sentiment positive earning outlook trend base most recent datum ilmn have return so far year same time medical stock have gain average see illumina be perform better sector calendar year breaking thing more ilmn be member medical biomedical genetic industry include individual company currently sit zack industry rank average stock group have lose year meaning ilmn be perform better term year date return investor medical sector want keep close eye ilmn attempt continue solid performance
1596,ILMN,nordisk nvo free report have announce number result various study treat diabetes nordisk announce positive new result phase iiia study pioneer compare mg oral formulation ozempic compare placebo monotherapy week adult type ii diabetes study meet primary objective demonstrate person treat dose oral ozempic achieve significant reductionsin blood glucose level hba compare placebo furthermore person treat mg oral ozempic achieve significant reduction weight versus placebo weight reduction mg mg dose do not reach statistical significance company also announce result sustain study show ozempic mg mg provide greater weight reduction compare dulaglutide mg mg respectively adult type ii diabetes regardless baseline body mass index bmi greatest reduction occur adult baseline bmi greater kg primary endpoint sustain be change hba post exploratory analysis examine secondary endpoint change body weight baseline bmi company also announce datum confirm study compare effectiveness tresiba insulin degludec injection versus insulin glargine more adult type ii diabetes be start basal insulin first time study show month treat tresiba have significantly lower hba compare treat insulin glargine secondary endpoint be lower rate hypoglycaemic episode tresiba compare insulin glargine study also show secondary endpoint person treat tresiba be more likely stay treatment treat insulin glargine have higher rate discontinue treatment year release company also post result dual ix study show xultophy insulin degludec liraglutide injection provide superior hba insulin glargine vs respectively used add sglt oral diabetes medication share company have moved year date compare industry decline datum look encourage bode well company candidate help generate revenue once get approve nordisk price nordisk price nordisk quote zack rank stock considernovo nordisk have zack rank sell better rank stock same space be illumina inc ilmn free report aeglea biotherapeutic inc agle free report ani pharmaceutical inc anip free report illumina sport zack rank strong buy aeglea ani pharmaceutical carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ani pharmaceutical earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1597,ILMN,share therapeutic inc anik free report slump company report disappointing datum phase iii cingal study trial compare cingal combination cross link triamcinolone hexacetonide alone cross link treat patient osteoarthritis oa knee primary endpoint be comparison pain reduction cingal compare alone week cingal achieve greater pain reduction numerically time point study difference week do not reach statistical significance year date share price company decrease compare industry decline study show strong safety profile match previous clinical study phase iii study duration pain reduction be also similar previous study patient improvement cingal injection be maintain peak level week duration study company expect cingal perform do other study difference pain reduction see study do not reach statistically significant level month be currently follow patient prospectively design extension phase trial collect datum week cingal be first only commercially available combination viscosupplement be currently be used successfully physician provide rapid long last relief pain discomfort cause oa patient grow number country company continue monitor result ongoing month extension study be actively review datum plan work closely regulator come understand next step require gain regulatory approval cingal therapeutic inc price therapeutic inc price therapeutic inc quotezack rank stock consideranika have zack rank hold better rank stock same space be illumina inc ilmn free report aeglea biotherapeutic inc agle free report ani pharmaceutical inc anip free report illumina sport zack rank strong buy aeglea ani pharmaceutical carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ani pharmaceutical earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1598,ILMN,alexion pharmaceutical inc alxn free report submit biologic license application bla fda approval alxn company investigational long act complement inhibitor treatment patient paroxysmal nocturnal hemoglobinurium pnh company used rare disease priority review voucher enable fda expedite review month instead standard month priority review designation fda be generally grant drug have potential provide significant improvement safety effectiveness treatment prevention diagnosis serious disease application be support datum rigorous phase iii study largest population patient pnh ever study study include patient have never receive complement inhibitor patient be stable alexion lead drugsoliris eculizumab switch alxn objective study be demonstrate patient pnh be effectively safely switch treatment soliris week treatment alxn week weight optimized treatment alxn week demonstrated inferiority treatment week soliris primary endpoint key secondary endpoint study moreover none patient treat alxn experience breakthrough hemolysis key secondary endpoint compare patient treat soliris addition bla unite state alexion be prepare submission approval alxn treatment patient pnh european union eu mid year japan second half year year date share alexion have increase industry decline further alexion be enrolling pediatric pnh patient phase iii study alxn study include patient have never receive treatment complement inhibitor enter study stabilize soliris patient be also be enrolled dose phase iii trial alxn administer intravenously week complement inhibitor treatment naive adolescent adult patient atypical hemolytic uremic syndrome ahus company be expect complete enrollment second quarter announce result fourth quarter enrollment dose be also ongoing phase iii trial alxn pediatric patient ahus alexion pharmaceutical inc price alexion pharmaceutical inc price alexion pharmaceutical inc quote zack rank stock consideralexion have zack rank hold better rank stock same space be illumina inc ilmn free report aeglea biotherapeutic inc agle free report ani pharmaceutical inc anip free report illumina sport zack rank strong buy aeglea ani pharmaceutical carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ani pharmaceutical earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1599,ILMN,roche rhhby free report announce phase iii study impassion evaluate combination tecentriq atezolizumab chemotherapy abraxane nab paclitaxel compare placebo combination nab paclitaxel patient locally advanced metastatic triple negative breast cancer tnbc have not receive prior systemic therapy metastatic breast cancer mbc meet co primary endpoint progression free survival pfs result demonstrated combination tecentriq chemotherapy significantly reduce risk disease worsening death pfs pd positive population metastatic unresectable locally advanced tnbc overall survival os be encourage pd positive population interim analysis safety tecentriq nab paclitaxel arm appear consistent know safety profile individual medicine new safety signal be identify combination impassion be first positive phase iii immunotherapy study tnbc currently roche be conduct phase iii study investigate tecentriq tnbc company plan present result upcoming medical meeting also submit result fda european medicine agency ema year date share roche have decline compare industry decline note tecentriq be important contributor roche revenue be immune oncology drug fda grant accelerate approval tecentriq treatment patient suffering locally advanced metastatic urothelial carcinoma initial uptake drug have be encourage oct tecentriq become first only pdl cancer immunotherapy be approve fda treatment metastatic small cell lung cancer nsclc drug have also be approve europe roche hold ag price roche hold ag price roche hold ag quote zack rank stock considerroche have zack rank hold better rank stock same space be illumina inc ilmn free report aeglea biotherapeutic inc agle free report ani pharmaceutical inc anip free report carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ani pharmaceutical earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1600,ILMN,share valeant pharmaceutical international inc vrx free report plunge company announce division ortho dermatologic have receive complete response letter crl fda new drug application nda duobrii crl be issue due question related pharmacokinetic datum however crl do not mention deficiency related clinical efficacy safety duobrii duobrii lotion halobetasol propionate tazarotene idp be be evaluate treatment plaque psoriasis valeant now work fda resolve matter news come big disappointment valeant be now banking new drug approval propel top line duobrii be key product pipeline delay approval dampen management projection ortho dermatologic continue be impact transition issue valeant have project duobrii key growth driver go forward potential approval have boost company struggle dermatology portfolio well fda have earlier approve psoriasis treatment siliq follow drug be launch siliq be approve treatment moderate severe plaque psoriasis adult patient be candidate systemic therapy phototherapy have fail respond have lose response other systemic therapy valeant enter collaboration agreement astrazeneca plc azn free report grant former exclusive license develop commercialize siliq globally japan certain other asian country right be hold kyowa hakko kirin co ltd agreement be amend july entitle valeant right develop commercialize siliq europe hence potential approval duobrii have further boost dermatology portfolio market plaque psoriasis hold great potential once acquisition giant valeant have be catch various controversy october late thing be look valeant company start rebuild process ceo joseph papa even be still early comment rebuild process company effort sell core asset pay huge level debt be commendable valeant stock have gain year so far compare gain industry meanwhile new drug approval have boost investor sentiment company valeant receive clearance thermage flx system invasively skin face eye body earlier company receive fda filing acceptance nda plenvu ner novel low volume polyethylene glycol base bowel preparation colonoscopy company also obtain fda approval vyzulta treatment option glaucoma fda also approve lumify counter eye drop low dose brimonidine treatment eye redness fda have also accept new drug application altreno idp acne treatment lotion form pdufa action date aug bryhali idp topical treatment plaque psoriasis pdufa action date oct zack rank key picksvaleant currently carry zack rank hold couple better rank stock pharma sector include illumina inc ilmn free report aeglea biotherapeutic inc agle free report illumina sport zack rank strong buy aeglea carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1601,ILMN,jun issue update research report qiagen qgen free report company business be expect get boost flourishing molecular diagnostic market international expansion extend test menu growth drive strategic collaboration stock carry zack rank hold netherlands base molecular diagnostic provider offer innovative technology product pre analytical sample preparation molecular diagnostic solution share company have outperformed broader industry past month stock have rally versus decline industry qiagen end first quarter solid note be impressed year year growth most segment company also deliver strong performance respect operate margin meanwhile commitment return more shareholder increase repurchase reflect sturdy cash position expectation favorable currency movement ongoing year also buoy optimism investor be also upbeat qiagen progress test menu expansion strategy april company announce receipt fda pre market approval partosure same month launch qiastat dx europe follow closure recently announce stat dx acquisition completion defined development activity stat dx company be plan launch test unite state well other geography qiagen also launch novel liquid biopsy panel namely adnatest ar kit adnatest lungcancer kit first quarter qiagen announce receive approval japan ministry health labor welfare quantiferon tb gold qft diagnostic detect tuberculosis tb infection further recently change guideline issue world health organization center disease control international panel physician association add new impetus rise popularity proactive latent tb screening treatment also look forward implementation recently draw strategy boost top line contribution ngs next generation sequence portfolio meanwhile qiagen be expose stiff competition company be face severe rivalry firm provide competitive pre analytical solution other product used qiagen customer fact market company product be highly aggressive price sensitive further aggravate company wo also heavy reliance collaboration decline hpv human papillomavirus sale unite state be other negative industry player zack rank key picksqiagen currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report sporting zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1602,ILMN,hologic inc holx free report recently announce receipt health canada approval new panther fusion system panther fusion assay respiratory virus infection panther fusion respiratory assay include panther fusion flu rsv panther fusion paraflu panther fusion adv hmpv rv test further pcr polymerase chain reaction base assay offer highly advanced approach syndromic testing ability run assay single patient specimen base patient requirement accord company new assay combine aptima transcription mediate amplification tma assay enable panther fusion system only instrument combine tma real time tma real time pcr full sample result automation notably panther fusion module be lab upgrade original panther instrument apart panther platform exist benefit new system add flexibility pcr proven performance tma used panther system further result new system certain additional benefit increase flexibility enhance time cost efficiency also be obtain laboratory company regulatory approval be also obtain new assay flu respiratory infection extend variety diagnostic test capable be run hologic system market prospectsper cision molecular diagnostic market be project reach cagr consider huge market potential believe company latest development be quite strategic hologic be consistently try expand diagnostic segment generate total revenue last report quarter face year year decline segment molecular diagnostic revenue increase constant exchange rate stock performance solidover past month hologic have outperformed industry stock have gain decline industry recent regulatory approval glancerecently hologic announce receipt medical device license issue health canada distribute cynosure invasive body contour product sculpsure treat back inner outer thigh submental area moreover company announce fda have grant premarket approval pma thinprep integrate imager make automate imaging pap test broadly available laboratory cytologist unite state april company clarity hd high resolution imaging intelligent imaging technology have also receive pma approval fda be now available dimension breast tomosynthesis system again january hologic announce fda have grant pma approval aptima hbv quant assay quantitation hepatitis viral load fully automate panther system cynosure division also announce launch tempsure envi same month be fda clear advanced radiofrequency device minimize facial fine line wrinkle tighten skin soft tissue coagulation improve appearance cellulite believe recent spree regulatory approval company array product be go boost share price further zack rank key pickshologic currently carry zack rank hold few better rank stock broader medical sector be illumina inc ilmn free report amedisys inc am free report walgreen boot alliance inc wba free report illumina amedisys sport zack rank strong buy walgreen boot carry zack rank buy see complete list today zack rank stock here illumina expect long term earning growth amedisys have expect long term earning growth rate walgreen boot have expect long term earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1603,ILMN,company favorable efficiency level be likely be investor radar irrespective market condition efficiency be potential indicator company financial health moreover company favorable efficiency level be expect provide impressive return be believe be positively correlated price performance measure efficiency have consider popular ratio order find efficient company have potential provide impressive return inventory level be key indicator company business health high inventory level indicate company be go rough patch term sale dwindle level indicate run stock favorable sale condition be inventory turnover come play be ratio month cost good sell cog quarter average inventory thus high value ratio indicate low level inventory relative cog low ratio signal company have excess inventory receivables ratio be used measure company capability extend credit collect debt basis credit receivables turnover ratio account receivable turnover ratio debtor turnover ratio be calculate divide month sale quarter average receivables high ratio indicate company efficiently collect account receivables have quality customer low ratio signal company have inefficient collection procedure have low quality customer inefficient credit policy asset be widely used measure company efficiency asset utilization indicate company potential utilize asset be ratio total sale past month last quarter average total asset so higher ratio greater be chance company utilize asset efficiently contrary low value ratio signal be fail use asset effectively operate marginanother popular efficiency ratio be operate margin operate profit margin be simply operate income past month divide sale same period indicate well company be control operate expense company have high operate profit margin relation competitor be do better job control operate expense ratio be consider effective measure compare different company particular sector industry be reason have consider only company have higher ratio respective industry average screening parametersin addition abovemention ratio have add favorable zack rank strong buy buy screen objective make strategy more profitable see complete list today zack rank stock here inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer use few criterium have narrow universe stock only here be stock make screen illumina inc ilmn free report provide sequence array base solution genetic analysis company have average quarter positive earning surprise stock sport zack rank lululemon athletica inc lulu free report athletic apparel company together subsidiary design distribute retail athletic apparel accessory woman man female youth company have zack rank company have average quarter positive earning surprise surmodic inc srdx free report provide medical device diagnostic technology healthcare industry unite state ireland company have zack rank company have average quarter positive earning surprise more conocophillip cop free report explore produce transport market crude oil bituman natural gas liquefy natural gas lng natural gas liquid worldwide company have zack rank company have average quarter positive earning surprise get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
1604,ILMN,nordisk nvo free report announce have enter research collaboration option kallyope inc privately hold new york biotechnology platform developer aim develop novel therapy diabetes obesity agreement kallyope receive upfront payment research support activity conduct collaboration addition milestone sale royalty other incentive nordisk have option license product exclusive basis company effort be focus potential application peptide gut brain axis gut brain axis be involved many important aspect physiology play significant role appetite regulation energy homoeostasis kallyope have develop innovative platform interrogate gut brain axis new medicine multiple therapeutic area deal allow nordisk use kallyope unique development platform target gut brain axis novel biologic kallyope contribute discovery process nordisk be solely responsible further drug development nordisk be know expertise discovery development peptide therapeutic well commitment leadership therapeutic obesity diabetes nordisk capability kallyope unique sophisticated platform provide strategic collaboration kallyope share nordisk have decline year date compare industry decline nordisk have be entee agreement various company order strengthen portfolio april nordisk also inked global licence deal biotech company epidestiny sickle cell disease scd program epi inclusion epi nordisk portfolio be boost company candidate form part company exist business thus company enter new therapeutic area also utilize core research development commercial capability make significant difference patient live serious chronic disease nordisk price nordisk price nordisk quote zack rank stock considernovo nordisk have zack rank strong sell better rank stock same space be illumina inc ilmn free report aeglea biotherapeutic inc agle free report ani pharmaceutical inc anip free report illumina sport zack rank strong buy aeglea ani pharmaceutical carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ani pharmaceutical earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1605,ILMN,dr reddy laboratory ltd rdy free report mylan myl free report announce fda have approve first generic version suboxone buprenorphine naloxone sublingual film tongue film treatment opioid addiction company sell generic version drug fda approval be aim make treatment available more person buprenorphine naloxone be used treat adult opioid dependence addiction buprenorphine help suppress withdrawal symptom cause discontinuation opioid drug naloxone reverse block effect opioid suboxone brand have sale approximately mat most recent month end april accord im health share dr reddy have decrease year date compare industry growth last month indivior plc enter settlement agreement par pharmaceutical inc par pharmaceutical company inc endo international plc collectively par intelgenx technology corp resolve patent litigation related suboxone sublingual film litigation be pending district court district delaware result par submission abbreviated new drug application anda fda seek approval market generic version suboxone film settlement permit par begin selling generic version suboxone film jan earlier certain circumstance note dr reddy enjoy strong position generic market mar dr reddy have generic filing abbreviated new drug application anda new drug application be pending fda approval dr reddy laboratory ltd price dr reddy laboratory ltd price dr reddy laboratory ltd quote zack rank stock considerdr reddy sha zack rank hold better rank stock same space be illumina inc ilmn free report aeglea biotherapeutic inc agle free report illumina sport zack rank strong buy aeglea carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1606,ILMN,jun issue update research report walgreen boot alliance inc wba free report be currently look forward company modify rite aid contract expect benefit company long run stock carry zack rank hold be encourage company consistent sale increase retail pharmacy international business moreover walgreen boot have be gain traction slew strategic tie up bring more patient pharmacy be also upbeat company alliance express script company aim expand respective exist group purchasing effort latest pact be expect improve express script supply chain make medicine include biosimilar affordable accessible patient walgreen boot alliance inc price walgreen boot alliance inc price walgreen boot alliance inc quote positive apart walgreen boot decision buy stake china sinopharm hold guoda drugstore look promising provide strong impetus company worldwide retail pharmacy business limit number rite aid store acquisition also impress company have recently secure regulatory approval however walgreen boot face headwind form fierce competition tough industry condition even company continue reap benefit growth initiative major business tycoon be already advance pharmacy business fair market share notably slowdown generic introduction last few year have be affect walgreen boot margin also escalate reimbursement pressure generic drug cost inflation have be hamper walgreen boot margin significantly past month share walgreen boot have underperform industry stock have lose industry increase key pickssome better rank stock broader medical sector be illumina inc ilmn free report intuitive surgical isrg free report cheme corporation che free report illumina intuitive surgical sport zack rank strong buy cheme carry zack rank buy see complete list today zack rank stock here illumina expect long term earning growth intuitive surgical have expect long term earning growth rate cheme have expect long term earning growth rate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1607,ILMN,medical device industry have be benefit favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model further consider favorable demographic change market dynamic artificial intelligence ai big datum application increase business investment sector have be go strong broadly speaking latest tax cut job act slash corporate tax rate earlier have also buoy optimism investor additionally senate decision defer implementation industry wide excise tax know medical device couple year have instilled confidence investor tax be effective jan bill also delay cadillac tax tax employer insurance emergo medical device industry be project reach market value boston scientific corporation bsx free report baxter international inc bax free report be close contender space notably stock carry zack rank buy raise investor optimism here make detailed analysis company fundamental determine stock be currently position better medical product space market cap boston scientific be lead manufacturer medical device product used various interventional medical specialty worldwide other hand base deerfield il baxter be lead global medical technology company company have market cap price performancein past year boston scientific share have gain compare industry increase stock have also surpass index increase share baxter have rise period earning zack consensus estimate boston scientific current year earning be peg share reflect year year project growth same baxter be peg indicate year year rise moreover last year datum boston scientific earning share have witness cagr baxter earning be project negative cagr totale hence boston scientific win round sale zack consensus estimate boston scientific current year revenue be peg show year year growth same baxter be pin reflect year year growth boston scientific revenue witness cagr reach baxter revenue depict negative cagr here too boston scientific win baxter factor drive stocksboston scientificover recently report quarters boston scientific demonstrated growth business line geography view also paint bright picture company achieve clinical milestone ranger drug coat balloon watchman left atrial appendage closure device also post suspension lotus valve europe acurate tavr valve platform continue build momentum boston scientific recently announce several acquisition include nxthera nvision urology pelvic health emcision endoscopy securus ep millipede structural heart inorganic expansion plan bode well stock operational growth demand baxter crrt injectable pharmaceutical iv solution peritoneal dialysis therapy be positive buyout recothorm preveleak be noteworthy well recently company get fda approval spectrum iq infusion system baxter surgical portfolio be highly diversify product available more country include exclusive product floseal hemostatic matrix tisseel fibrin sealant coseal surgical sealant vascu guard patch other conclusionour comparative analysis indicate boston scientific be position better baxter consider price performance well earning sale growth other key picksother top rank stock broader medical sector be illumina inc ilmn free report idexx laboratory inc idxx free report illumina sport zack rank strong buy idexx carry zack rank see complete list today zack rank stock here illumina expect long term earning growth idexx have expect long term earning growth rate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1608,ILMN,agio pharmaceutical inc agio free report announce initiation phase iii activate study evaluateit lead rare genetic disease candidate ag patient pyruvate kinase pk deficiency do not receive regular blood transfusion activate study enroll adult patient pk deficiency do not receive regular blood transfusion activate study aim demonstrate treatment ag lead sustain increase hemoglobin patient ag be also undergo phase iii study call activate single arm pivotal study adult pk deficiency patient receive regular blood transfusion pyruvate kinase deficiency be genetic blood disorder characterize low level enzyme call pyruvate kinase be used red blood cell pyruvate kinase red blood cell break too easily result low level cell hemolytic anemia activate study aim demonstrate treatment ag lead sustain increase hemoglobin patient activate study be divide part primary endpoint study be proportion patient achieve least dl increase hemoglobin sustain multiple visit part study december last year agio report impressive datum phase ii study adult transfusion independent patient pk deficiency datum study demonstrated candidate potential first disease modify therapy patient pk deficiency share company rise follow announcement news year date share ofagio have increase compare industry gain other ag agio also have several interesting candidate pipeline lead cancer pipeline include tibsovo be priority review unite state most advanced candidate target mutate isocitrate dehydrogenase idh december agio submit new drug application nda fda tibsovo have be develop treat patient relapse refractory acute myeloid leukemia aml idh mutation other candidate include ag target mutate idh mutate idh mutation be find wide range hematological malignancy solid tumor include aml chondrosarcoma treatment option prognosis patient be poor candidate ag first class methionine mat inhibitor be be evaluate phase dose escalation study patient phosphorylase mtap delete tumor agio pharmaceutical inc price agio pharmaceutical inc price agio pharmaceutical inc quotezack rank stock consider agio have zack rank hold better rank stock same space be illumina inc ilmn free report aeglea biotherapeutic inc agle free report ani pharmaceutical inc anip free report illumina sport zack rank strong buy aeglea ani pharmaceutical carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ani pharmaceutical earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1609,ILMN,company favorable efficiency level be likely be investor radar irrespective market condition be company favorable efficiency level be expect provide impressive return be believe be positively correlated price performance key ratio identify become difficult measure efficiency level company be reason consider popular efficiency ratio select stock efficiency ratio be inventory turnover ratio month cost good sell cog quarter average inventory be consider most popular efficiency ratio indicate company ability maintain suitable inventory position high value indicate company have relatively low level inventory compare cog low value show company be face decline sale have result excess inventory receivables turnover be ratio month sale quarter average receivables show company potential extend credit collect debt term credit high receivables turnover ratio account receivable turnover ratio debtor turnover ratio be desirable show company be capable collect account receivables have quality customer asset utilization ratio indicate company capability convert asset output be thus widely know measure efficiency level be calculate divide total sale past month last quarter average total asset ratio high asset utilization indicate company be efficient operate margin efficiency measure be ratio operate income past month sale same period measure company ability control operate expense hence high value ratio indicate company manage operate expense more efficiently peer screening parametersin addition mentioned ratio have add favorable zack rank strong buy buy screen objective make strategy more profitable see complete list today zack rank stock here inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer use few criterium have narrow universe stock only here be stock make screen lululemon athletica inc lulu free report athletic apparel company together subsidiary design distribute retail athletic apparel accessory woman man female youth company have average quarter positive earning surprise stock sport zack rank sirius xm holding inc siri free report provide satellite radio service unite state company have average quarter positive earning surprise stock carry zack rank nutrisystem inc ntri free report provide weight management product service woman man unite state company have average quarter positive earning surprise stock have zack rank illumina inc ilmn free report provide sequence array base solution genetic analysis company have average quarter positive earning surprise stock sport zack rank get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
1610,ILMN,flex pharma inc flk free report announce company be end phase ii study pipeline candidate flx indication company discontinue ongoing phase ii study flx amyotrophic lateral sclerosis al charcot marie tooth cmt due oral tolerability concern observed study concern be observed subset patient be treat oral disintegrate tablet formulation mg take time day share company fall follow news flx have show positive efficacy datum multiple sclerosis ms al recent observation oral intolerability current dose formulation patient study indicate more formulation dose range study be require however be challenge company consider availability current resource company board director management be assess strategic alternative include potential sale merger company company continue operate reduce internal team focus assess potential flx dysphagia difficulty swallow operate hotshot consumer business strategic review be ongoing flex pharma state plan reduce workforce approximately layoff be implement end month result company expect realize annualize cost saving begin third quarter company expect incur time cost approximately restructure plan share company have decrease year date compare industry decline flex pharma inc price flex pharma inc price flex pharma inc quote zack rank stock considerflex pharma have zack rank hold better rank stock same space be illumina inc ilmn free report aeglea biotherapeutic inc agle free report ani pharmaceutical inc anip free report illumina sport zack rank strong buy aeglea ani pharmaceutical carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ani pharmaceutical earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1611,ILMN,roche rhhby free report announce fda have approve label expansion oncology drug avastin bevacizumab fda approve avastin combination chemotherapy carboplatin paclitaxel follow avastin single agent treatment woman advanced stage iii iv ovarian cancer follow initial surgical resection approval be base datum phase iii gog study study show woman receive avastin combination chemotherapy continue use avastin alone have median progression free survival pfs month compare month woman receive chemotherapy alone year date share company have decrease compare industry decline approval avastin be now approve distinct used different type cancer unite state avastin be approve europe treatment advanced stage breast cancer colorectal cancer small cell lung cancer kidney cancer ovarian cancer cervical cancer be available unite state treatment colorectal cancer small cell lung cancer kidney cancer cervical cancer recurrent platinum resistant platinum sensitive ovarian cancer recurrent glioblastoma avastin be lead drug roche portfolio however sale avastin fall first quarter due increase use cancer immunotherapy medicine lung cancer stiff competition biosimilar loom large avastin amgen amgn free report obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer entry biosimilar key drug adversely impact sale roche hold ag price roche hold ag price roche hold ag quotezack rankroche have zack rank hold better rank stock same space be illumina inc ilmn free report aeglea biotherapeutic inc agle free report illumina sport zack rank strong buy aeglea carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1612,ILMN,iovance biotherapeutic inc iova free report be big mover last session company see share rise more day move come solid volume too far more share change hand normal session reverse recent trend company stock be now past month time frame company have see change come estimate revision past few week zack consensus estimate current quarter have also remain unchanged recent price action be encourage so make sure keep close watch firm future iovance biotherapeutic currently have zack rank hold earning esp be negative lion biotechnology inc price lion biotechnology inc price lion biotechnology inc quoteinvestor interested medical biomedical genetic industry consider illumina inc ilmn free report have zack rank strong buy see complete list today zack rank stock here be iova go predict see other think medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1613,ILMN,issue update research report bayer ag bayry free report bayer be face generic threat competition many product include yaz franchise oral contraceptive genericization key drug negatively impact revenue expect decline yaz sale trend persist continue weak performance key drug impact company top line pull stock bayer have number candidate pipeline adverse pipeline related news have potential impact stock adversely bayer announce termination phase ii study adempas patient pulmonary hypertension associate idiopathic interstitial pneumonia decision follow recommendation independent datum monitoring committee observed patient dose adempas be greater risk death other serious adverse event placebo arm june bayer announce phase ii study evaluate investigational oncology compound anetumab ravtansine bay monotherapy patient recurrent malignant pleural mesothelioma mpm be previously treat do not meet primary endpoint progression free survival bayer dependence pharmaceutical segment growth remain concern year date share company have decline compare industry decline nevertheless bayer be look acquire cash transaction worth approximately combine business be expect boost bayer crop science business provide accretion core earning first full year close transaction slate close second quarter follow double digit percentage growth october bayer conclude agreement sell select crop science business basf company intend divest asset part strategy complete plan acquisition further april bayer sign agreement sell further crop science business basf zack rank stock considerbayer have zack rank sell better rank stock same space be illumina inc ilmn free report ligand pharmaceutical lgnd free report enanta pharmaceutical inc enta free report illumina sport zack rank strong buy ligand enanta carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ligand earning share estimate have be revise upward past day company come positive earning surprise trail quarters average beat company share have rally year date enanta earning share estimate have moved north cent past day company pull positive surprise past quarters average beat stock have soar so far year bayer price bayer price bayer quote more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1614,ILMN,resm inc rmd free report have be gain investor confidence consistently positive result stock have soar year compare rise industry increase company have market cap year historical growth rate be also favorable compare industry average consider solid prospect zack rank buy stock be attractive bet investor moment factor act favorlet take look possible growth propeller solid performanceresm exit fiscal third quarter promising note better expect earning revenue encouragingly note company achieve solid double digit revenue growth quarter lead sale software service business well new mask product device expand international businessin third quarter fiscal revenue unite state canada latin american country grow year year same europe asia other market rise year year cer growth be particularly strong france japan europe asia back connect health solution adoption include airsense aircurve airview myair notably company late receive reimbursement approval mandibular repositioning device france further accelerate uptake resm dental device help treat sleep apnea resm inc price resm inc price resm inc quote solid horizon growth strategyresm have identify growth horizon term progress first focus resm core sleep apnea franchise company have be make advanced technology combine digital health connect care solution second horizon be dedicate growth adjacent product geographic market include homecare ventilation chronic obstructive pulmonary disease amyotrophic lateral sclerosis other respiratory disorder regard company also recently introduce first self brand portable oxygen concentrator name mobi fiscal first quarter company re launch portable oxygen concentrator call activox be also target growth emerge market china india brazil third growth horizon incorporate portfolio opportunity new market include clinical adjacency such atrial fibrillation heart failure preserve ejection fraction asthma chronic disease management well sleep health wellness focus product developmentin order maintain leadership position sdb sleep disorder breathe market drive sale resm be concentrate product development innovation earlier company introduce world smallest cpap continious positive airway pressure call airmini launch airmini be achieve impressive early adoption product category small second use travel friendly cash pay cpap apap automatic positive airway pressure device company be well place fiscal work pipeline new product connect care solution sleep apnea copd chronic obstructive pulmonary disease neuromuscular disease other clinical adjacency other key picksother top rank stock broader medical sector include intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank see complete list today zack rank stock here intuitive surgical have project long term earning growth rate illumina expect long term earning growth amedisys expect long term earning growth rate stand more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1615,ILMN,steris plc ste free report have be gain investor confidence consistently positive result past year company have gain industry decline also company have outperformed gain developer manufacturer marketer infection prevention decontamination microbial reduction surgical support product service have market cap company long term historical earning growth rate be higher solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction however earning estimate remain flat let find latest trend be sustainable solid quarterly exit fourth quarter fiscal better expect earning revenue be also encourage favorable underlie market trend new product service offering company strong organic growth specialty service life science apply sterilization segment also buoy optimism synergy health consolidation tracksteris acquisition base outsourced sterilization service provider synergy health plc have continue remain significant move company combine steris infection prevention service business synergy health hospital sterilization service earlier management say expect save least end fiscal balance divide evenly next fiscal company also anticipate cost synergy year synergy health transaction next fiscal strategic buyout recent past steris have be look expand adjacent market acquisition dilution follow synergy health buyout company sell synergy health healthcare consumable solution hcs business vernacare november apart company make acquisition fiscal company aim strengthen healthcare product healthcare specialty service apply sterilization technology business solid balance sheet positionsteris exit fiscal cash cash equivalent compare end fiscal company have long term debt end fourth quarter fiscal compare year other key picksa few other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1616,ILMN,amedisys inc am free report have be gain investor confidence consistent positive result past month company share price have outperformed industry stock have gain compare growth record industry also company have outperformed increase renown home health hospice service provider have market cap company year project growth rate be favorable compare industry solid prospect zack rank strong buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction resultantly earning estimate increase share style score amedisys sport growth score be reflective company strong prospect research show stock growth style score combine zack rank buy offer best upside potential let find recent positive trend be sustainable strategic buyoutsamedisys be develop acquire business line complement exist home care hospice business past year company make number strategic acquisition recent be east tennessee personal care service etpcs personal care provider headquarter knoxville tn accord amedisys buyout expand company personal care footprint outside massachusett florida currently management expect company have enough cash balance make number acquisition future favorable home health final ruleaccord report healthcarefirst decision home health final rule be take implementation home health grouping model hhgm schedule rollout amedisys be optimistic implementation rule expect positively impact business future personal care prospect amedisys integrate new operate segment business personal care management segment be stabilize perform company expectation integrate recent tuck acquisition company be look forward huge growth prospect segment intercity acquisition have close successfully integrate personal care acquisition complete buyout east tennessee personal care service february moreover company be work expand geographical presence personal care business favorable demographic home health industry be poise tremendous growth long term drive age population patient desire independence home health cheaper care modality company continue benefit age demographic population need higher acuity patient be take care home nursing environment other key picksother top rank stock broader medical sector be illumina inc ilmn free report cheme corporation che free report walgreen boot alliance inc wba free report illumina sport zack rank walgreen boot cheme carry zack rank see complete list today zack rank stock here illumina expect long term earning growth cheme have expect long term earning growth rate walgreen boot have expect long term earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1617,ILMN,medtronic plc mdt free report have make encourage move respect aortic peripheral vascular apv business company recently announce receipt fda approval mm mm length pact admiral drug coat balloon dcb treat long superficial femoral artery sfa lesion patient peripheral artery disease pad company april medtronic receive approval treat sfa lesion mm length back support clinical datum complex lesion imaging cohort pact global study also cover long lesion stent restenosis chronic total occlusion group lesion length mm note pact admiral dcb receive fda approval december treat superficial femoral popliteal artery moreover be commercially available europe receipt ce mark approval so far more pad patient europe have be treat device glimpse apv medtronic revenue apv division improve year year constant exchange rate fourth quarter fiscal moreover peripheral vascular business grow low single digit latest development boost company performance segment market strategy gain traction peripheral vascular sub segment seem be align datum provide report interventional cardiology peripheral vascular device market be expect see cagr reach value believe high incidence peripheral artery disease due unhealthy lifestyle age population penetration company untapped market rise need minimally invasive angioplasty procedure technological advancement increase awareness person continue drive global acceptance technology view encourage factor believe company development regard pact admiral dcb be strategic be expect broaden customer base share price past month medtronic have be underperform broader industry stock have gain comparison industry increase nevertheless believe latest fda approval boost investor confidence stock zack rank key picksmedtronic currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report sporting zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1618,ILMN,astrazeneca azn free report announce fda have approve lokelma sodium zirconium cyclosilicate formerly know zs treatment hyperkalemia adult hyperkalemia be serious condition characterize high level potassium blood lokelma be highly selective oral potassium remove agent fda approval be support datum double blind placebo controlled trial open label long term trial drug have demonstrated trial lower potassium level patient chronic kidney disease heart failure diabetes take renin angiotensin aldosterone system raas inhibitor drug be approve eu march year remind investor company hsd receive complete response letter crl lokelma fda thus delay drug entry marketa company receive first crl second be receive mar first crl have cite observation pre approval manufacturing inspection receipt new datum be yet be review astrazeneca re submit nda oct second crl however do not require new clinical datum generation inspection manufacturing facility fda be need lokelma become part astrazeneca pipeline follow dec acquisition zs pharma approval lokelma also boost revenue company year date share company have increase industry decline separate press release astrazeneca announce submission supplemental new drug application snda japan label expansion diabetes medicine forxiga treatment type diabetes be also review europe same indication forxiga first class selective inhibitor human sglt be indicated monotherapy part combination therapy improve glycaemic control zack rank stock have zack rank hold better rank stock same space be illumina inc ilmn free report ligand pharmaceutical lgnd free report enanta pharmaceutical inc enta free report illumina sport zack rank strong buy ligand enanta carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat stock have surge so far year stock have rally so far year ligand earning share estimate have be revise upward past day company come positive earning surprise trail quarters average beat company share have rally year date enanta searning share estimate have moved north cent past day company pull positive surprise last quarters average beat stock have soar so far year astrazeneca plc price astrazeneca plc price astrazeneca plc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1619,ILMN,zack rank have proven be valuable resource experience begin investor alike be model be simple identify stock be poise outperform market next month harness power earning estimate earning estimate revision follow estimate trend be easiest way track analyst sentiment profit improvement particular company term outlook believe strong buy pick be strongest option base zack rank model only several company track earn designation time story learn particular company help show strength zack rank investor have follow ranking system flag innovative biotech company have witness massive profit illumina inc ilmn free report illumina be pioneer biotechnology industry have help reduce cost human genome sequence significantly company operate developer manufacturer service assist analysis genetic variation biological function service be market research center government organization other medical company ilmn have be flag zack rank number time past year start first buy designation week july position be earn analyst become bullish company upcoming earning report be publish just few day later report ilmn post earning share crush zack consensus estimate earning momentum be only just get go ilmn never dip hold once again earn buy again oct designation come wake impressive earning report ilmn time see impressive growth quarter ilmn post earning share beating zack consensus estimate cent improve more year period revenue quarter be well ahead estimate nearly year year earning revenue success help usher incredibly impressive stretch ilmn see share price forward look ep estimate move higher then company shock investor late april quarterly earning beat consensus projection nearly improve staggering prior year quarter ilmn have be hold zack rank strong buy then chart demonstrate price performance ilmn month forward ep estimate red start stock earn first buy designation back july see ilmn be massive winner follow zack rank stock have gain month list chart include solid nearly month run strong buy recently ilmn be yet example predictive power zack rank want more market analysis author make sure follow ryan_mcqueeney twitter today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1620,ILMN,investor focuse medical space have likely hear illumina ilmn free report be stock perform well comparison rest sector peer simple way answer question be take look year date performance ilmn rest medical group stock illumina be member medical sector group include individual stock currently hold zack sector rank zack sector rank include different group be list order best worst term average zack rank individual company sector zack rank emphasize earning estimate estimate revision find stock improve earning outlook system have long record success stock tend be track beat market next month ilmn be currently sporting zack rank strong buy past day zack consensus estimate ilmn full year earning have moved higher show analyst sentiment have improve company earning outlook be stronger base most recent datum ilmn have return so far year same time medical stock have gain average mean illumina be perform better sector term year date return look more specifically ilmn belong medical biomedical genetic industry include individual stock currently sit zack industry rank average stock group have lose year meaning ilmn be perform better term year date return investor interest medical stock continue track ilmn stock be look continue solid performance
1621,ILMN,myriad genetic inc mygn free report recently announce definitive agreement buy counsyl leader expand carrier invasive prenatal screening notably buyout cost myriad genetic meeting certain customary close condition receive regulatory approval transaction be expect close first quarter fiscal financial detail dealmyriad genetic intend use combination cash hand exist revolve credit facility issuance common stock pay buyout buyout integration expect synergy benefitsmyriad genetic plan retain counsyl wholly own subsidiary post successful completion acquisition further integrate counsyl reproductive testing product hereditary cancer test myriad genetic plan solidify position lead woman health genetic testing company management acquisition deal help exist customer base counsyl reproductive test expand almost fold further encouragingly note counsyl reproductive genetic test be currently be cover commercial insurance unite state more room expand coverage foresight expand carrier screening prelude invasive prenatal screening test term market opportunity post buyoutper datum provide company believe myriad genetic decision foray high potential reproductive testing market be strategically align company roughly carrier screening test invasive prenatal screening test be estimate be carry unite state fiscal myriad genetic market be expect reach worth more fiscal reproductive genetic test perform unite state take dealmyriad genetic exit last report quarter promising note company observed strong revenue growth genesight vectra da prolaris test also hereditary cancer volume expansion be impressive be upbeat company witness growth new product volume success elevate program further raise fy guidance instill confidence stock consider myriad genetic strong fundamental business prospect buyout be expect help company cash bountiful opportunity high potential reproductive testing market share price performanceover past month share myriad genetic have outperformed industry latest price movement stock have gain industry decline zack rank stock considermyriad genetic currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1622,ILMN,jun issue update research report cvs health cvs free report increase demand pbm pharmacy benefit management specialty pharmacy be major growth driver stock dull retail performance last few quarters seem have disappoint investor company carry zack rank hold share company have outperformed industry past month stock have lose compare decrease broader industry cvs health end first quarter mixed note earning be ahead zack consensus estimate revenue lag same however top line year year growth be drive strong pharmacy service segment benefit upside specialty service strong pbm selling season be favorable factor notably company be already more halfway renewal retention rate be currently line rate have witness last few year tough pricing competition cvs health currently gain momentum high level service execution competitive pricing unique integrate model allow company provide differentiate product service generate saving better health outcome well convenience moreover solid year year retail ltc comparison be encourage company be presently move achieve completion aetna deal cvs health landmark acquisition health insurance giant introduce vast change healthcare landscape unite state investor be hopeful cvs health earn draw term synergy aetna transaction post closure meanwhile company commencement momentous healthcare consolidation be keep analyst upbeat successful culmination cvs health expect reap low mid single digit accretion second year post close buyout flip side company highly competitive retail pharmacy business be big concern face stiff rivalry pharmacy segment be availability low cost pharmacy option other retail business continue add pharmacy department portfolio particularly discount retailer have make substantial inroad gain major market share apart cvs health deliver sluggish number retail long term care business recent past company decision restrict participate tricare network many fully insure prime network be due negative impact pharmacy sale script comp key picksa few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1623,ILMN,resm inc rmd free report recently announce positive result company sponsored research support efficiency bilevel device result be present sleep annual joint meeting american academy sleep medicine sleep research society bilevel rescue study detailresm compare compliant patient medicare guideline switch bilevel therapy result demonstrated therapy compliance be achieve patient be shift positive airway pressure pap therapy first day treatment company bilevel device release distinct pressure inhalation other exhalation patient be pressure intolerant have persistent evidence apnea higher pressure be often prescribe advanced bilevel device believe positive result study be expect boost uptake company bilevel device glimpse companyresm achieve strong global revenue growth past few quarters lead sale sleep device respiratory care device mask system well software solution believe resm product launch strategy be anticipate gain traction sleep apnea market be expect drive growth company term recent development company inform first self brand portable oxygen concentrator mobi subject launch fiscal third quarter have also introduce airmini smallest pap positive airway pressure device world resm recently receive reimbursement approval mandibular repositioning device france further announce south korea start reimburse diagnosis therapeutic treatment sleep apnea term moreover company recently announce definitive agreement buy healthcarefirst privately hold provider software solution service home health hospice agency boost software service business market potentialper report sleep apnea device market be expect worth roughly cagr view datum conclude developmental step undertake company seem be progressive be strategically align share price performancein past month resm have outperformed industry stock have gain compare growth record industry zack rank other key picksresm currently carry zack rank buy few other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1624,ILMN,resm inc rmd free report recently demonstrated favorable outcome clinical analysis field chronic obstructive pulmonary disease copd study be conduct unite kingdom unite state highlight cost effectiveness combine home oxygen therapy home invasive ventilation niv therapy persistent hypercapnia patient suffer exacerbation copd combo regimen home oxygen therapy home mechanical ventilation home niv together know hot hmv have be present american thoracic society international conference be company sponsored health economic study go study hot hmv treatment reduce exacerbation frequency day hospital readmission datum analysis be used develop economic model national health service perspective study demonstrated reduction day readmission hot hmv patient compare home oxygen alone evidently indicated treatment be hugely cost effective resm analysis be base study study find be utilize build economic model payer perspective be optimistic entire development resm take consideration widely grow market copd treatment datum provide gbi research global copd market be currently worth be project reach value accord research report gape demand be meet numerous new efficient convenient product make inroad market undoubtedly resm hot hmv study related favorable outcome be step forward company intensify footprint niche market notably resm achieve strong global revenue growth past few quarters lead sale sleep device respiratory care device mask system well software solution believe resm product launch strategy gain traction sdb market be expect drive growth company term recent development company inform first self brand portable oxygen concentrator mobi subject fiscal third quarter launch have also introduce airmini world smallest pap positive airway pressure device past month resm have outperformed industry stock have gain compare rise industry zack rank key picksresm currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report cooper company inc coo free report intuitive surgical illumina sport zack rank strong buy cooper company carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate illumina have long term expect earning growth rate cooper company have long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1625,ILMN,jun issue update research report steris plc ste free report company have be actively try expand adjacent market strengthen core business acquisition dilution however company operate tough competitive landscape be concern stock carry zack rank buy share developer manufacturer marketer infection prevention decontamination microbial reduction surgical support product service have outperformed industry past month stock have rally industry decline be encourage steris witness favorable underlie market trend new product service offering company strong organic growth specialty service life science apply sterilization segment also buoy optimism further growth free cash flow reserve be indicative company strong cash balance company have also make certain divestment organizational change expect better align operation recent past steris have be pursue growth footprint adjacent market acquisition dilution follow synergy health buyout company sell synergy health healthcare consumable solution hcs business vernacare november hcs business used generate roughly annual revenue apart company make consolidation fiscal transaction company aim strengthen healthcare product healthcare specialty service apply sterilization technology business believe steris chase back back acquisition long run order widen business customer base courtesy solid financial position meanwhile steris compete pharmaceutical research industrial customer several large company extensive product portfolio global reach well small entity limit product offering operation few country company worry face fierce competition new infection prevention sterile process contamination control surgical support product service enter market hamper steris growth considerably moreover multiple steris client be undergo consolidation partly due healthcare cost reduction measure initiate competitive pressure well legislator regulator third party payor think company fail check customer consolidation rate now adversely impact business well financial condition other key picksa few other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report varian medical system inc var free report intuitive surgical illumina sport zack rank strong buy varian medical carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth varian medical expect earning growth rate be peg current year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1626,ILMN,amedisys inc am free report recently purchase back half kkr co holding common share more specifically company buy back more common stock global investment firm total transaction value deal also include aggregate outstanding share company common stock repurchase deal reflect price be yesterday close value transaction be immediately accretive company bottom line follow news share amedisys inched close trading monday jun amedisys be expect finance deal used available cash exist revolve credit facility company be left cash hand outstanding borrowing credit facility turn result net leverage ratio approximately home health hospice care provider amedisys be upbeat recent development remain line strategy deploy capital accretive manner maintain low leverage substantial borrow capacity future investment regard amedisys accretive acquisition continue be first priority capital deployment accordingly company consider transaction best utility capital give current buyout multiple company business prospect company also note kkr continue remain significant shareholder amedisys accordingly nathaniel zilkha member general partner kkr co still remain director amedisys board other recent acquisition amedisysover past year company make number strategic acquisition recent be east tennessee personal care service etpcs personal care provider headquarter knoxville tn amedisys buyout enlarge company personal care footprint outside massachusett florida apart company buy intercity home care personal care provider base malden notably intercity home care entire asset base have be take associate home care amedisys believe have wider presence massachusett other important acquisition late include home health center illinois massachusett texas hospice care center arizona massachusett tenet healthcare asset home staff earlier february last year share price performanceover past month share amedisys have outperformed industry belong stock have rally compare industry rise zack rank other key picksamedisys currently carry zack rank buy few other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report varian medical system inc var free report intuitive surgical illumina sport zack rank strong buy varian medical carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth varian medical have expect earning growth rate current year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1627,ILMN,jun issue update research report medtronic plc mdt free report be encourage global acceptance company advanced therapy escalate cost expense raise concern stock have zack rank hold past month share medtronic have outperformed industry stock have grow industry decline notably medtronic exit fiscal solid note better expect fourth quarter performance major business group contribute solid top line growth cer highlight sustainability group region addition display successful integration achievement synergy target also gradually stabilize cardiac rhythm heart failure crhf market buoy optimism medtronic plc price medtronic plc price medtronic plc quote receipt fda approval dbs deep brain stimulation therapy adjunctive treatment reduce partial onset seizure raise hope company target medical market medtronic be also focuse geographical diversification business company be highly positive foray standalone cgm continuous glucose monitoring market guardian connect be currently upbeat medtronic recently launch restructure initiative call enterprise excellence plan aim annual growth run rate saving end fiscal company new program have be design increase effectiveness growth related reinvestment ability provide consistent boost margin expansion drive ep leverage flip side company have be expose steep cost expense weigh heavily margin also guidance remain conservative apprehension lackluster cardiac vascular group cvg minimally invasive therapy group mitg performance turn dampen investor confidence stock key picksa few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1628,ILMN,illumina inc ilmn free report have be gain investor confidence consistently positive result past year company share price have outperformed industry stock have gain industry fall also company have outperformed gain renown sequence array base genetic analysis solution provider have market cap company have earning growth rate next year solid prospect zack rank strong buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction resultantly earning estimate rise let find recent positive trend be sustainable solid quarterly exit first quarter solid note better expect earning revenue be also encourage significant year year growth count substantial upside be attribute strong consumable growth illumina sequence portfolio new product bode wellwe be upbeat illumina product launch continue contribute top line management be hopeful recently launch novaseq flow cell reagent kit company also receive product approval certificate nextseq dx instrument ministry food drug safety mfds south korea last november illumina introduce nextseq dx instrument well be company second fda regulate ce ivd marked next generation sequence ngs system effort grow oncology spacellumina collaboration bristol myer squibb loxo oncology field clinical oncology application be expect garner positive result alliance bristol myer squibb utilize illumina ngs technology develop globally commercialize diagnostic ivd assay support bristol myer squibb oncology portfolio also look forward grail illumina recently develop company focuse cancer screening market believe grail be expect significantly expand illumina share multus dollar oncology market geographic expansionapart north america illumina market distribute product directly customer europe latin america asia pacific apac region direct selling force distributor specialize life science product first quarter illumina witness growth apac region propel shipment growth greater china obviously emerge market china be currently most favorable space illumina business recent time management have noticed considerable increase demand customer attempt set nipt operation china believe recent progress china open avenue illumina thereby enhance business growth other key picksother top rank stock broader medical sector be intuitive surgical isrg free report cheme corporation che free report amedisys inc am free report intuitive surgical cheme sport zack rank amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate cheme have long term expect earning growth rate amedisys have long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1629,ILMN,medtronic plc mdt free report restorative therapiesgroup rtg have be strong growth trajectory late encourage contribution majority sub segment expect strength reflect fourth quarter fiscal result be schedule release open bell click here know company overall performance be expect be rtg focusmedtronic rtg presently comprise spine brain therapy specialty therapy pain therapy division note management expect revenue growth rtg business fourth quarter fiscal management guidance balance ongoing strength pain brain therapy segment adverse impact weaken spine market consequently rtg zack consensus estimate revenue indicate rise year quarter medtronic plc price ep surprise medtronic plc price ep surprise medtronic plc quotein last report quarter segment record improvement sale drive low double digit growth brain therapy mid single digit growth specialty therapy high single digit growth pain therapy cer however revenue spine business remain flat cer year year basis let see thing be shape sub segment fourth quarter result brain therapy brain therapy now include neurovascular neurosurgery business company have be witness major development neurovascular business receive solid contribution stroke portfolio last report quarter medtronic announce receipt fda approval riptide aspiration system january add valuable tool company acute ischemic stroke ais product portfolio benefit get reflect yet be report quarter further april medtronic announce ce mark receipt launch visualase mri guide laser ablation system europe notably visualase system be used neurosurgery procedure provide advanced mri guide laser ablation technology development help company continue witness strength brain therapy business pain therapy pain therapy division now include pain spinal cord stimulation drug pump interventional spine business contribute encouragingly company top line third quarter fiscal pain therapy witness growth solid uptake intelli platform spinal cord stimulation well strength drug pump january company announce receipt fda approval new clinician programmer use synchrome ii intrathecal drug delivery system again april medtronic announce launch optisphere embolization sphere resorbable embolic platform develop embolization hypervascular tumor view company effort develop pain therapy division believe solid trend continue reflect be report quarter result well spine medtronic spine division include core spine bmp kanghui business last report quarter low single digit decline core spine be more offset mid single digit growth bmp cer management combination enable technology imaging navigation power instrument nerve monitoring mazor robotic spine implant have spur growth division expect encourage top line contribution business be report quarter zack rank stock currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate illumina have long term expect earning growth rate amedisys have long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1630,ILMN,issue update research report idexx laboratory inc idxx free report company robust worldwide commercial capability best class product include next generation chemistry analyzer catalyst be key growth driver term stock carry zack rank hold lead molecular diagnostic company have outperformed industry stock have increase industry decrease notably idexx exit first quarter strong note better expect earning revenue improvement solid year year growth organic revenue raise ep guidance be also encourage stellar performance be drive robust sale companion animal group cag business fuel firm global catalyst uptake international revenue first quarter be organically drive organic gain international cag diagnostic recur revenue reflect continue consumable revenue gain support catalyst instrument base increase average testing utilization sturdy growth european lab revenue companion animal market fundamental remain safe sound tremendous global runway growth additionally be upbeat company expand premium instrument base unite state well international market include growth competitive instrument placement increase utilization consistent customer retention idexx innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth report quarter moreover company healthy top line growth be drive considerable contribution rest business segment additionally company boast strong cash balance allow carry share repurchase meanwhile majority idexx consolidated revenue be be derive sale product international market thus strengthen dollar exchange rate relative other currency have negative impact revenue derive currency other money well profit draw product manufacture unite state sell internationally adverse currency translation affected adjust earning share tune cent also company heavy dependence third party distributor be drag key picksa few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina have expect long term earning growth rate amedisys have expect long term earning growth rate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1631,ILMN,abbott free report recently announce result amplatzer amulet left atrial appendage laa occlusion device bid fortify core structural heart business datum be present europcr annual meeting european association percutaneous cardiovascular intervention eapci paris further result be publish be amplatzer amulet occlusion device amplatzer amulet occluder be advanced minimally invasive laa occlusion device design seal laa person suffering valvular atrial fibrillation time efficient manner device block laa open reduce chance blood clot reach bloodstream cause stroke amplatzer amulet device come several size cater several type complex patient anatomy moreover be claim be used patient blood thinner medication be not very safe option be contraindicate notably amplatzer amulet device be currently investigational device unite state study amplatzer amulet observational post market study have valvular af patient enrolled worldwide amulet device be effectively implanted enrolled patient follow period month post device implant assessment notably result year follow demonstrate treatment amplatzer amulet have lower risk ischemic stroke also reduce chance ischemic stroke transient ischemic attack systemic embolism glimpse structural heart structural heart business have maintain impressive top line performance last report quarter sale segment rise report basis notably structural heart business account total revenue broader medical device segment upside be lead continue double digit growth mitraclip company market lead device repair mr company recently announce encourage result global study tendyne transcatheter mitral valve replacement tmvr system march company announce receipt national reimbursement japan same notably nearly country more person have be treat mitraclip ministry health labour welfare mhlw approve mitraclip system japan last november further company announce receipt fda approval world smallest rotatable bileaflet mechanical heart valve master hp mm approval company have expand master series portfolio structural heart market prospectsabbott strategy gain traction structural heart segment seem be align datum provide ally market research company report global atrial fibrillation market be estimate reach worth cagr company almost person suffer atrial fibrillation globally share price have be gain investor confidence consistently positive result past month stock have outperformed industry stock have gain comparison industry zack rank stock considerabbott currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1632,ILMN,zimmer biomet holding inc zbh free report recently announce receipt clearance fda zyston strut open titanium interbody spacer system be expect revitalize spine division notably product be company first titanium spinal implant be build used printing technology zyston strut open titanium system zyston strut open titanium system be family lumbar cage be available various size meet patient requirement further system have be develop increase strength capacity graft visualization interbody spacer spinal fusion case also encompass surgical instrument enable insertion manipulation elimination implant be printing technology also know additive manufacturing printing be process turn digital model solid dimensional physical object add material layer layer article hub further printing have also receive warm response medtech space healthcare notably research firm future market insight expect global print medical device market see cagr zimmer biomet latest offer zyston strut open titanium system be build used printing process allow physician develop unique cage architecture maximize graft volume implantation zimmer biomet have announce receipt clearance unite bridge fixation system foot ankle business notably innovative product be result combination company osseoti porous metal technology printing process glimpse spine divisionzimmer biomet spine thoracic spine cmf segment revenue be cer first quarter company have be face revenue dissynergy related spine sale force integration meanwhile be upbeat recent fda nod be expect expand company lumbar spacer portfolio include peek optima trabecular metal technology allograft note zimmer biomet have be gain strong uptake mobi cervical disc also company recently launch product avenue tlif cage well vitality vital spinal fixation system unite state market potentialper report market research future safely conclude latest development help zimmer biomet cash opportunity spinal implant market accord report global spinal implant market be expect see cagr roughly price performanceover past month zimmer biomet have be observed underperform industry stock have decline compare rise industry believe latest fda approval boost investor faith stock zack rank stock considerzimmer biomet currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina have expect long term earning growth rate amedisys have expect long term earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1633,ILMN,bristol myer squibb company bmy free report announce encourage datum phase iii checkmate study opdivo checkmate study be ongoing study evaluate immuno oncology combination opdivo nivolumab low dose mg kg yervoy ipilimumab compare pfizer pfe free report sutent sunitinib intermediate poor risk patient advanced renal cell carcinoma rcc year follow period treatment opdivo low dose yervoy lead statistically significant difference patient report outcome baseline versus sunitinib year follow study demonstrated patient show significant benefit disease related symptom improvement cancer related quality life well be benefit occur early opdivo low dose yervoy combination therapy be largely maintain treatment period opdivo maintenance therapy checkmate study patient advanced renal cell carcinoma have earlier show efficacy benefit opdivo low dose yervoy number measure include overall survival objective response rate progression free survival however result present now show patient treat immuno oncology combination also report significant improvement disease related symptom well positive change physical emotional functional well be additional analysis show similar result significant benefit see opdivo low dose yervoy relative sunitinib change baseline pre plan week landmark bristol myer share have decline year date compare industry decline note opdivo become first pd immune checkpoint inhibitor gain regulatory approval july be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy meanwhile company continue evaluate opdivo alone combination therapy yervoy other cancer agent label expansion drug additional indication give product access higher patient population increase commercial potential significantly however opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic squamous small cell lung cancer nsclc company be expect suffer further loss market share separate release bristol myer announce fda lift partial clinical hold place checkmate phase iii study evaluate addition opdivo pomalidomide dexamethasone patient relapse refractory multiple myeloma decision follow consultation fda agreement amendment study protocol fda put clinical hold study evaluate opdivo base combination relapse refractory multiple myeloma september fda precaution follow risk identify trial study pd agent keytruda patient multiple myeloma stock warrant lookbristol myer carry zack rank hold better rank stock same space be illumina inc ilmn free report sporting zack rank strong buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year bristol myer squibb company price bristol myer squibb company price bristol myer squibb company hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1634,ILMN,issue update research report boston scientific corporation bsx free report company be gain traction emerge market particularly bric zone however product recall issue continue impede growth stock carry zack rank hold past month share boston scientific have outperformed industry several issue stock have gain versus industry decline notably boston scientific post impressive first quarter back growth business line geography view also paint bright picture term boston scientific be leave stone unturned strengthen core business well invest new technology company achieve clinical milestone ranger drug coat balloon watchman left atrial appendage closure device also post suspension lotus valve europe acurate tavr valve platform continue build momentum company growth first quarter boston scientific announce several strategic acquisition include nxthera nvision urology pelvic health emcision endoscopy securus millipede structural heart inorganic expansion plan bode well stock operational efficiency also gradually improve foreign exchange scenario have start contribute company overall top line performance boston scientific be pull stop pump resource new technology global market accounting higher sale geographical region third quarter additionally be encourage company number approval gain product domestic well overseas market however be concern company recall prime product lotus range heart device fate lotus valve issue throw thro uncertainty more time boston scientific recently company announce delay earlier report timeline commercial return lotus edge aortic valve system europe well unite state follow product voluntary recall february latest update company expect launch lotus edge unite state european market not currently fear indefinite future company fast grow transcatheter aortic valve replacement tavr business interventional cardiology lotus valve line be prime product key picksa few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1635,ILMN,keep line company product expansion strategy bruker corporation brkr free report recently introduce broad line mass spectrometry product workflow asm american society mass spectrometry conference company claim product act breakthrough life science research clinical research large cohort validation phenomic proteomic biopharma application apply toxicology forensic market launchesthe mass spectrometry product launch company be follow company have introduce scimaxtm magnetic resonance mass spectrometer mrm come phenomic proteomic innovation product be design enable high throughput phenomic extreme resolution mrm also company have unveil spoton lc maldi spotter automate wizard base workflow phenomic proteomic innovation category life science translational mass spectrometry imaging company introduce scil lab version key addition quantitation module mass spectrometry imaging msi workflow life science translational research company introduce fourth generation software metabolomic lipidomic research metaboscape power mrm axelerate version support handle large study sample phenomic research apart bruker introduce solution target metabolomic profile call rex lc qtof apply toxicology forensic company launch enhance version targetscreener hr include more compound field veterinary drug new psychoactive substance pesticide result database exceed compound mass spec glancenotably bruker mass spectrometry business fall bruker calid group have demonstrated strong sale performance recent time have be fuelled robust performance microbiology business healthy result life science research mass spectrometry believe newly expand mass spectrometry portfolio focuse execution company primary target market microbiology diagnostic life science research bruker be go sustain strong momentum mass spectrometry share price performance past month share bruker have outperformed industry stock have gain industry decline zack rank other stock considerbruker currently carry zack rank buy few other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys hold zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1636,ILMN,abbott free report recently announce launch latest generation afinion test system afinion analyzer unite state system deliver accurate hemoglobin hba result minute albumin creatinine ratio acr result minute therefore product enable healthcare provider adhere american diabetes association ada testing guideline efficiently promptly be afinion analyzer rapid test system afinion analyzer be rapid compact multus assay platform be capable streamline simplify delivery actionable accurate measurement hba acr result point care afinion platform also provide connectivity laboratory hospital information system li enable healthcare provider use various patient setting ada regular measure hba acr level be effective long term management patient diagnosed diabetes give host benefit offer be upbeat launch afinion analyzer system be expect boost top line contribution diagnostic division glimpse diagnostic businessabbott diagnostic division market diagnostic system well test business line core laboratory molecular point care rapid diagnostic reflect sale alere be acquire oct division account total sale first quarter last report quarter diagnostic revenue grow year year comparable operational basis drive better expect performance company rapid diagnostic business strength flu season unite state notably rapid diagnostic record sale drive solid contribution infectious disease testing include flu strep testing further management project uptrend division continue back new product launch benefit alere acquisition strength alinity test platform market demographic be favor high incidence diabetes individual report mordor intelligence global market diabetes care device be expect attain value further abbott more person total population unite state be suffering diabetes thus such circumstance conclude developmental step undertake company seem be progressive be strategically align price have be gain investor optimism consistently positive result past month stock have outperformed industry share company have gain compare industry rise zack rank stock considerabbott currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1637,ILMN,abbott free report have be spotlight late favorable development medical device business include core structural heart division company recently announce encourage result global study tendyne transcatheter mitral valve replacement tmvr system datum be present europcr annual meeting european association percutaneous cardiovascular intervention eapci paris global study tendyne device expect register adult patient early result be base successful implantation tendyne device first patient patient enrolled study suffer symptomatic mitral regurgitation mr be not eligible open heart surgery repair replace mitral valve notably result end day demonstrated patient treat tendyne witness major reduction mitral regurgitation symptom low mortality rate further improvement symptom be assessed base new york heart association nyha grade severity kansa city cardiomyopathy questionnaire kccq tendyne device completely retrievable minimally invasive replacement option tendyne device be used treat functional degenerative mixed cause mr be treat minimally invasive valve repair open heart surgery notably tendyne device be currently clinical investigation approval europe further company plan enroll first patient pivotal trial same term glimpse structural heart businessabbott structural heart business maintain impressive top line performance last report quarter segment sale rise report basis notably structural heart business account total revenue broader medical device segment upside be lead continue double digit growth mitraclip company market lead device repair mr march company announce receipt national reimbursement japan same notably nearly country more person have be treat mitraclip ministry health labour welfare mhlw approve mitraclip system japan last november further company announce receipt fda approval world smallest rotatable bileaflet mechanical heart valve master hp mm approval company have expand master series portfolio structural heart business market prospectsabbott strategy gain traction structural heart segment seem be align datum provide ally market research datum provide company report tanscatheter mitral valve repair replacement market be estimate reach worth repair replacement valf cagr company almost person age suffer moderate severe mr share price have be gain investor confidence consistently positive result past month stock have outperformed industry stock have gain comparison industry gain zack rank stock considerabbott currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina have expect long term earning growth rate amedisys have expect long term earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1638,ILMN,astute investor always opt plan be likely yield high return irrespective market condition efficiency level measure company capability transform available input output be often consider important parameter used gauge company potential rake handsome return company favorable efficiency level be expect provide stellar return be believe be positively correlated price performance measure efficiency have consider popular ratio order find efficient company have potential provide impressive return inventory level be key indicator company business health high inventory level indicate company be go rough patch term sale dwindle level indicate run stock favorable sale condition be inventory turnover come play be ratio month cost good sell cog quarter average inventory thus high value ratio indicate low level inventory relative cog low ratio signal company have excess inventory receivables ratio be used measure company capability extend credit collect debt basis credit receivables turnover ratio account receivable turnover ratio debtor turnover ratio be calculate divide month sale quarter average receivables high ratio indicate company efficiently collect account receivables have quality customer low ratio signal company have inefficient collection procedure have low quality customer inefficient credit policy asset be widely used measure company efficiency asset utilization indicate company potential utilize asset be ratio total sale past month last quarter average total asset so higher ratio greater be chance company be utilize asset efficiently contrary low value ratio signal be fail use asset effectively operate marginanother popular efficiency ratio be operate margin operate profit margin be simply operate income past month divide sale same period indicate well company be control operate expense company have high operate profit margin relation competitor be do better job control operate expense ratio be consider effective measure compare different company particular sector industry be reason have consider only company have higher ratio respective industry average screening parametersin addition mentioned ratio have add favorable zack rank strong buy buy screen objective make strategy more profitable inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer use few criterium have narrow universe stock only here be stock make screen marine product corporation mpx free report design manufacture sell recreational fiberglas powerboat sportboat deckboat cruiser jet boat sport fishing market worldwide company have average quarter positive earning surprise stock have zack rank illumina inc ilmn free report provide sequence array base solution genetic analysis company have average quarter positive earning surprise stock sport zack rank see complete list today zack rank stock here cheme corporation che free report provide hospice palliative care service unite state company have average quarter positive earning surprise stock hold zack rank surmodic inc srdx free report provide medical device diagnostic technology healthcare industry unite state ireland company have average quarter positive earning surprise more stock have zack rank mam software group inc mam free report provide software information commerce related service business engage automotive aftermarket unite state canada unite kingdom ireland company have average quarter positive earning surprise stock have zack rank get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
1639,ILMN,abbvie abbv free report announce top line result phase iii illuminate pcyc study meet primary endpoint improvement progression free survival pfs study evaluate cancer drug imbruvica ibrutinib combination gazyva obinutuzumab previously untreated chronic lymphocytic leukemia small lymphocytic lymphoma cll sll patient compare chlorambucil obinutuzumab year date share abbvie have increase industry decline imbruvica be jointly develop market abbvie subsidiary pharmacyclic llc johnson johnson jnj free report subsidiary janssen biotech be currently approve unite state treat patient mantle cell lymphoma mcl have receive least therapy earlier cll patient deletion be also approve european union treatment mcl significantly january imbruvica be approve patient marginal zone lymphoma mzl require systemic therapy have receive least prior cd base therapy illuminate study meet primary endpoint clinically statistically significant difference pfs patient treat imbruvica obinutuzumab versus receive chlorambucil obinutuzumab assessed independent review committee irc pharmacyclic janssen be sharing primary analysis datum study regulatory authority plan present datum future publication medical congress base datum approve fda imbruvica obinutuzumab be first chemotherapy free cd combination first line cll treatment zack rank stock considerabbvie have zack rank hold better rank stock same space be illumina inc ilmn free report ligand pharmaceutical lgnd free report illumina sport zack rank strong buy ligand carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ligand earning share estimate have be revise upward past day company come positive earning surprise trail quarters average beat company share have rally year date abbvie inc price abbvie inc price abbvie inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1640,ILMN,pfizer inc pfe free report announce phase iii study evaluate epilepsy druglyrica pregabalin pediatric patient meet primary endpoint study be evaluate use lyrica oral solution cv adjunctive therapy partial onset seizure pediatric epilepsy patient month less year age indication lyrica be not yet approve top line result study show adjunctive treatment lyrica mg kg day result statistically significant reduction seizure frequency versus placebo be primary efficacy endpoint however treatment lyrica lower dose mg do not result statistically significant reduction seizure frequency versus placebo datum datum previous study be submit fda lyrica pediatric exclusivity determination lyrica have already lose patent exclusivity europe russia turkey israel central asia unite state favorable court decision july regard generic challenge protect lyrica genericization dec meanwhile pfizer be pursue month patent term extension fda pediatric exclusivity grant keep generic competition bay june believe positive datum pediatric study ease pfizer effort get pediatric exclusivity other epilepsy lyrica be indicated treat post herpetic neuralgia diabetic peripheral neuropathy fibromyalgia neuropathic pain due spinal cord injury unite state lyrica be also indicated treat partial onset seizure patient year age older sale lyrica decline first quarter share pfizer have lose year date compare industry decline zack rank stock considerpfizer have zack rank hold better rank stock same space worth consider be illumina inc ilmn free report ligand pharmaceutical lgnd free report enanta pharmaceutical inc enta free report illumina sport zack rank strong buy ligand enanta carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year stock have rally so far year ligand earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat company share have rally year date enanta earning share estimate have moved cent past day company deliver positive earning surprise trail quarters average beat stock have rally so far year pfizer inc price pfizer inc price pfizer inc quotemore stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1641,ILMN,look broad exposure healthcare biotech segment equity market consider powershare dynamic biotechnology genome portfolio pbe free report passively manage exchange trade fund launch excellent vehicle long term investor passively manage etfs be popular choice institutional retail investor due low cost transparency flexibility tax efficiency sector etfs be also fund convenience offer many way gain low risk diversify exposure broad group company particular sector healthcare biotech be broad zack sector zack industry classification be currently rank place bottom index fund be sponsored invesco powershare have amassed asset make average size etfs attempt match performance healthcare biotech segment equity market pbe seek match performance dynamic biotechnology genome intellidex index fee expense be comprise stock biotechnology genome company be company be principally engage research development manufacture marketing distribution various product service process company benefit significantly scientific technological advance biotechnology genetic engineering research costsexpense ratio be important factor return etf long term cheaper fund significantly outperform more expensive counterpart other thing remain same annual operate expense etf be make par most peer product space have month trail dividend yield sector exposure top holdingsit be important delve etf holding investing many upside kind fund diversify exposure minimize single stock risk most etfs be very transparent product disclose holding daily basis etf have heaviest allocation healthcare sector portfolio look individual holding illumina inc ilmn free report account total asset follow qiagen nv qgen free report biogen inc biib free report top holding account total asset management performance riskso far year pbe have gain approximately last year past week period fund have trade etf have beta standard deviation trail year period make high risk choice space holding have more concentrated exposure peer dynamic biotechnology genome portfolio hold zack etf rank buy be base expect asset class return expense ratio momentum other factor pbe be outstanding option investor seek exposure health care etfs segment market be other additional etfs space investor consider well spdr biotech etf xbi free report track biotechnology select industry index ishare nasdaq biotechnology etf ibb free report track nasdaq biotechnology index spdr biotech etf have asset ishare nasdaq biotechnology etf have xbi have expense ratio ibb charge bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
1642,ILMN,issue update research report illumina inc ilmn free report zack rank hold stock company market opportunity continue expand owing accelerate demand clinical translational customer recent strategic collaboration be also expect widen product portfolio share company have outperformed industry last month stock have rally industry decline notably illumina exit first quarter solid note better estimate earning well revenue moreover be encourage significant year year growth count huge upside be attribute strong rise consumable illumina sequence portfolio illumina inc price illumina inc price illumina inc quote additionally management be hopeful recently launch novaseq flow cell reagent kit company also receive product approval certificate nextseq dx instrument ministry food drug safety south korea field oncology illumina collaboration bristol myer squibb loxo oncology be likely garner positive result line meanwhile company raise guidance indicate deliver impressive performance quarters come san diego base illumina be tool integrate system provider analysis genetic variation function company focus product innovation research development evident recent launch iseq sequence system post promising first quarter expect illumina maintain growth momentum continue uptake sequence consumable instrument microarray portfolio flip side company face stiff competition sequence snp single nucleotide polymorphism genotyp gene expression molecular diagnostic market several bigwig already enjoy significant market share intellectual property portfolio well regulatory expertise also national institutes health funding issue raise concern key pickssome better rank stock broader medical sector be intuitive surgical isrg free report resm inc rmd free report amedisys inc am free report intuitive surgical sport zack rank strong buy resm amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate resm have long term historical earning growth amedisys project long term earning growth more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1643,ILMN,inovio pharmaceutical ino free report have initiate phase ii study evaluate efficacy pipeline candidate vgx adult man woman human papilloma virus hpv related anal dysplasia be third indication vgx be evaluate be already be evaluate treat hpv related vulvar anal precancer phase ii study vgx be administer intramuscular im injection system adult man woman be human virus hiv negative histologically confirm anal perianal high grade squamous intraepithelial lesion hsil associate hpv hpv study be expect enroll patient administer least dose vgx phase ii study cervical dysplasia vgx demonstrated systemic response versus localize surgery clearance cervical lesion eliminate underlie hpv infection many patient anal hsil dysplasia be precursor anal cancer be estimate cause more death unite state currently only treatment anal dysplasia be surgical excision electro cautery laser therapy however more treat current treatment experience recurrence disease vgx have potential be first approve treatment hpv infection cervix first surgical treatment precancerous cervical lesion year date share inovio have rally industry decline vgx dna base immunotherapy be most advanced candidate company pipeline be currently be evaluate phase iii study treatment cervical dysplasia cause hpv company be also conduct phase ii study examine efficacy vgx woman hpv related vulvar moreover company be evaluate medi combination vgx dna base il cytokine phase ii study combination astrazeneca azn free report pd checkpoint inhibitor imfinzi treatment hpv cause cervical head neck cancer zack rank stock considerinovio have zack rank sell better rank stock same space be illumina inc ilmn free report ligand pharmaceutical lgnd free report illumina sport zack rank strong buy ligand carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat stock have gain so far year ligand earning share estimate have be revise upward past day company come positive earning surprise last quarters average beat share company have surge year date inovio pharmaceutical inc price inovio pharmaceutical inc price inovio pharmaceutical inc hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1644,ILMN,issue update research report qiagen qgen free report be upbeat company progress testing menu expansion strategy however tough competitive landscape be concern stock carry zack rank hold netherlands base molecular diagnostic provider offer innovative technology product pre analytical sample preparation molecular diagnostic solution stock have be outperform industry past month latest stock movement have gain decline broader industry qiagen end first quarter solid note be impressed year year growth majority segment company have be proceed test menu expansion strategy regard april company announce receipt pre market approval fda partosure same month company launch qiastat dx europe follow closure recently announce stat dx acquisition completion defined development activity stat dx be also upbeat qiagen molecular diagnostic sale have be grow significantly first quarter company witness double digit cer growth revenue quantiferon latent tb test strength personalize healthcare follow rise sale infectious disease testing product also look forward implementation recently draw strategy boost top line contribution ngs portfolio meanwhile qiagen face stiff competition firm provide competitive pre analytical solution other product market company product be very competitive price sensitive add concern also strong reliance collaboration decline hpv sale unite state be other negative few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report cooper company inc coo free report intuitive surgical illumina sport zack rank strong buy cooper company carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate illumina have long term expect earning growth rate cooper company have long term expect earning growth rate make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1645,ILMN,medtronic plc mdt free report recently announce initiation clinical study bifurcation cohort evaluate efficiency safety standard drug eluting stent de treat bifurcation lesion study bifurcation cohort part resolute onyx post approval study cover patient bifurcation lesion site unite state europe be enrolling patient suffering coronary artery disease cad receive resolute onyx de diameter size vary mm notably resolute onyx de be not approve treat bifurcation lesion unite state further primary endpoint study be target vessel failure month medtronic datum study be submit fda expand indication approval include bifurcation lesion resolute onyx de further company state bifurcation lesion be responsible percutaneous coronary intervention thus believe positive datum provide impetus company effort achieve expand fda approval resolute onyx de accelerate business growth csh be consistently try enhance coronary structural heart csh segment be part cardiac vascular group cvg segment csh revenue third quarter fiscal be cer report low constant currency growth transcatheter aortic valf result strong customer uptake corevalve evolut pro platform expand fda approval include patient intermediate risk moreover continue uptake resolute onyx drug eluting stent unite state japan revive business encouragingly note medtronic recently receive fda nod launch resolute onyx mm drug eluting stent stent be smallest size market presently resolute onyx de be available use size unite state europe country recognize ce mark market strategy gain traction csh segment seem be align datum provide transparency market research report global coronary stent market be expect see cagr more specifically de market coronary stent market be expand fast be estimate witness cagr period market be likely expand unite state asia pacific europe well rest world stock performance past month medtronic have outperformed industry gain compare industry zack rank key picksmedtronic currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report cooper company inc coo free report intuitive surgical illumina sport zack rank strong buy cooper company carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate illumina have long term expect earning growth rate cooper company have long term expect earning growth rate make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1646,ILMN,issue update research report agio pharmaceutical inc agio free report agio only market drug be idhifa receive fda approval treatment patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation august however apart idhifa agio do not have approve product portfolio yet hence company top line mainly comprise collaboration revenue milestone payment year date share company have increase compare industry increase company have several interesting candidate pipeline lead cancer pipeline include tibsovo ivosidenib ag priority review unite state most advanced candidate target mutate isocitrate dehydrogenase idh december agio submit new drug application nda fda tibsovo ivosidenib have be develop treat patient aml idh mutation subsequently february fda accept nda priority review give indication fda have set action date aug regulatory filing candidate european union be expect fourth quarter same indication other candidate include ag target mutate idh mutate idh mutation be find wide range hematological malignancy solid tumor include aml chondrosarcoma treatment option prognosis patient be poor company lead rare genetic disease candidate ag be evaluation phase ii study adult transfusion independent patient pyruvate kinase pk deficiency first quarter company initiate activate single arm pivotal study ag adult pk deficiency patient receive regular blood transfusion fact company plan initiate study activate ag adult pk deficiency do not receive regular blood transfusion second quarter candidate ag first class methionine mat inhibitor be be evaluate phase dose escalation study patient phosphorylase mtap delete tumor potential approval pipeline candidate be huge boost company agio celgene celg free report announce new global strategic collaboration discovery development novel therapy utilize agio innovative cellular metabolism research platform term celgene deal be lucrative agio be eligible receive clinical regulatory commercial milestone payment royalty net sale product result collaboration however company depend heavily celgene revenue earn form collaboration revenue company also face stiff competition zack rank stock consideragiosha zack rank hold better rank stock same space be illumina inc ilmn free report ligand pharmaceutical lgnd free report illumina sport zack rank strong buy ligand carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ligand earning share estimate have be revise upward past day company come positive earning surprise trail quarters average beat company share have rally year date agio pharmaceutical inc price agio pharmaceutical inc price agio pharmaceutical inc quote wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1647,ILMN,earning season have reach tail end index market capitalization have report so far revenue growth beating ep estimate come ahead top line expectation earning revenue beat ratio be line prior quarter same group company growth rate be tracking historical period overall earning growth be pace be strongest year growth same period last year higher revenue read top flop etfs half way give several equity etfs have impressed performance generate handsome return trail month even be hit trade war worry geopolitical tension be winner many corner space be etfs buoy robust earning result addition have give chart month performance compare broad market fund spy free report broad sector powershare dwa healthcare momentum portfolio pth free report fund offer exposure healthcare stock be show relative strength momentum surge trail month period strong earning be stock price response earning announcement sector have be second highest gain total earning sector total market cap be higher revenue beating ep beating revenue estimate pth have zack etf rank hold high risk outlook powershare smallcap energy fund psce free report fund target small cap segment energy sector many energy etfs have perform exceptionally well earning season psce steal show gain month be primarily thank dual tailwind upbeat earning report jump oil price price performance response earning have be negative energy sector remain top contributor total earning earning growth additionally energy come earning beat ratio small cap space second highest trail transportation earning beat psce have zack etf rank high risk outlook read tap oil best energy etfs stock ytd purefund video game tech etf gamr free report fund target global video game industry technology sector include game developer console chip manufacturer game retailer have gain past month particular earning glu mobile gluu electronic art ea activision blizzard atvi take interactive software have be strong overall toy game hobby industry come earning beat ark innovation etf arkk free report be actively manage fund focuse company be expect benefit development new product service technological improvement advancement genomic revolution web industrial innovation strong earning company stratasys ssys free report intellium therapeutic ntla free report illimina ilmn free report edita medicine edit free report provide boost fund portfolio tesla tsla free report also add strength project become profitable second half stock be top holding make substantial asset lead rise arkk past month read etfs ride tesla growth story first trust nasdaq semiconductor etf ftxl free report fund offer exposure most liquid semiconductor security base volatility value growth string better expect result industry player such micron technology mu intel intc texas instrument txn mks instrument mksi free report lam research lrcx microchip technology mchp instilled optimism space see rough trading spate negative news just ahead earning stock account share basket overall semiconductor industry have be biggest driver technology earning contribute growth ftxl have gain month sport zack etf rank strong buy want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1648,ILMN,line product expansion strategy myriad genetic inc mygn free report have come new commercial coverage decision company market lead genomic test respect prostate cancer prolaris follow multiple reimbursement approval last few month molecular diagnostic personalize medicine major announce aggregate payer represent new cover life prolaris company payer include top commercial insurer unite state myriad note acceleration commercial insurer coverage prolaris have come close heel recently update national comprehensive cancer network nccn guideline support prolaris standard care make treatment decision patient suffering low favorable intermediate risk prostate cancer nccn guideline update nccn guideline release february revise medical rule prostate cancer treatment broadly include biomarker testing same indication state earlier change include new language back prolaris standard care take therapeutic decision patient low favorable intermediate risk prostate cancer rework nccn guideline accordingly instilled confidence myriad genetic receive expand reimbursement coverage certain test term company certain payer have already update policy base nccn rule include like medicaid state favorable prolaris medical policy decision several regional payer company first blue cross blue shield plan prospect development prolaris now provide insurance coverage prostate cancer patient unite state company grow prospect fast expand market prostate cancer test be also encourage report bcc research prostate cancer global market be estimate reach value worth cagr thus company clearly boast bountiful prospect market share price performanceover past day share myriad genetic have outperformed industry stock have rally compare industry increase zack rank key picksmyriad genetic currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina have expect long term earning growth rate amedisys have expect long term earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1649,ILMN,boston scientific corporation bsx free report have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have gain compare industry gain also company have outperformed gain developer manufacturer marketer medical device use interventional medical specialty have market cap company have earning growth rate next year solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction resultantly earning estimate rise let find recent positive trend be sustainable solid quarterly scientific exit first quarter solid note better expect earning revenue be upbeat company witness growth business line geography strategic buyout fortify ep businesswe be upbeat boston scientific recent acquisition apama medical deal boston scientific aim expand suite arrhythmia solution fall ep sub segment further gain traction ep market boston scientific announce plan acquire securus medical privately hold developer thermal monitoring system continuous measurement esophageal temperature geographic expansionan important part boston scientific growth strategy be continue pursue development opportunity outside unite state expand global presence inclusive emerge market boston scientific be gradually strengthen presence emerge market include brazil russia india china bric first quarter business emerge market register growth company be gain strong ground india well target emerge market additional emphasis boston scientific hope sustain strong overall international performance product launch be early stage rollout suspension medtech decision house senate suspend medical device tax year have come breather medical device bigwig boston scientific accord company temporary suspension allow continue plan invest innovative medical product company meanwhile have plan work full repeal medtech tax other stock considerother top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1650,ILMN,illumina inc ilmn free report recently announce acquisition edico genome strengthen next generation sequence ngs platform company edico genome dragen bio dragen platform pair well illumina sequence portfolio help deliver rapid streamline output ngs customer edico genome be eminent provider datum analysis acceleration solution ngs dragen be build field programmable gate array fpga technology help proprietary software algorithms help deliver result timely manner decrease datum footprint illumina edico genome have establish strong ngs customer base lead solid adoption dragen standard part sequence believe acquisition help illumina provide enhance datum analysis experience ngs user expand customer base ngs platform focusillumina be consistently work enhance ngs platform illumina recently introduce second fda regulate ce ivd marked ngs system nextseq dx company have also receive product approval nextseq dx instrument ministry food drug safety mfds south korea april company collaborate bristol myer squibb company bmy free report field oncology alliance utilize illumina ngs technology develop globally commercialize diagnostic ivd assay support bristol myer squibb oncology portfolio illumina also announce global strategic partnership wih loxo oncology develop commercialize multus gene panel broad tumor profile result distributable ngs base companion diagnostic cdx pan cancer indication market potentialaccord market market global next generation sequence market be estimate reach worth cagr show acquisition be line company strategy share price performanceover past year illumina have be outperform industry company have gain industry decline zack rank other key picksillumina currently sport zack rank strong buy other top rank stock broader medical sector be intuitive surgical isrg free report cooper company inc coo free report intuitive surgical sport zack rank cooper company carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate cooper company have long term expect earning growth rate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1651,ILMN,illumina inc ilmn free report have be gain investor confidence consistently positive result past year company share price have outperformed broader industry stock have gain comparison broader industry gain also company have outperformed gain renown sequence array base genetic analysis solution provider have market cap company have earning growth rate next year solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction resultantly earning estimate rise let find recent positive trend be sustainable illumina have be deliver solid quarterly result late post promising third quarter expect illumina maintain growth momentum continue uptake sequence consumable instrument microarray offering be upbeat illumina latest product launch last report quarter growth be fuel strong adoption veriseq nipt ce ivd marked ngs solution europe moreover novaseq platform continue drive growth close novaseq system be deliver launch january also order be ship third quarter november illumina introduce second fda regulate ce ivd marked next generation sequence ngs system nextseq dx company also announce intend use miseqdx instrument first fda regulate ngs sequencer have be extend include use dna library generate formalin fix paraffin embed ffpe tissue also october illumina announce availability novaseq flow cell reagent kit novaseq system moreover same month illumina announce availability nextera dna flex whole genome sequence wg library prep product management development boost demand novaseq platform illumina now have solid diagnostic ngs portfolio courtesy nextseq dx miseqdx product company be capable meeting clinical requirement ngs base diagnostic ivd product be also upbeat positive nipt reimbursement trend globally well unite state netherlands denmark have start cover veriseq nipt ce ivd test first quarter follow england france company continue see positive reimbursement trend europe well illumina effort drive growth internationally also buoy optimism apart north america company market distribute product directly customer europe latin america asia pacific region apac direct selling force distributor specialize life science product be also optimistic illumina expansion strategy enhancement portfolio sequence product development strategic partnership therapeutic diagnostic service provider august illumina partner telegraph hill partner set independent company verogen inc newly establish entity be expect strengthen illumina ngs business forensic genomic market other key picksother top rank medical stock be petm express inc pet free report align technology inc algn free report luminex corporation lmnx free report notably petm align technology sport zack rank strong buy luminex carry zack rank see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly year align technology have long term expect earning growth rate stock have gain year luminex have long term expect earning growth rate stock have gain past month investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1652,ILMN,illumina inc ilmn free report recently introduce second fda regulate ce ivd marked next generation sequence ngs system nextseq dx instrument have be design deliver power high throughput ngs clinical laboratory company announce intend use miseqdx instrument first fda regulate ngs sequencer have be extend include use dna library generate formalin fix paraffin embed ffpe tissue enable clinical lab use ffpe sample develop clinical test new application also allow development more diagnostic product service clinical lab clinician gain access information generate illumina ngs technology illumina now have solid diagnostic ngs portfolio courtesy nextseq dx miseqdx product portfolio be capable meeting clinical requirement ngs base diagnostic ivd product accord market market global next generation sequence market be estimate reach worth cagr illumina be strive expand ngs platform line company recently announce launch solution noninvasive prenatal testing nipt kit europe product veriseq nipt solution be ce ivd marked ngs base approach nipt meanwhile illumina telegraph hill partner announce plan set independent company verogen inc entity be expect strengthen illumina ngs business forensic genomic market also illumina announce extend ra panel fda approve ngs kit meet newly publish guideline evaluation colorectal cancer company have also launch bio rad single cell sequence solution first ngs single cell analysis collaboration bio rad laboratory inc last month illumina have gain broader industry decline estimate revision estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have rise share same period zack rank key picksillumina carry zack rank hold few better rank medical stock be petm express inc pet free report align technology inc algn free report myriad genetic inc mygn free report notably petm align technology myriad genetic sport zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly last year align technology have long term expect earning growth rate stock have gain last year myriad genetic have long term expect earning growth rate stock have gain last year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1653,ILMN,abbott free report provide impetus vascular business unite state recently announce receipt fda approval xience sierra notably xience sierra be latest family xience everolimus eluting coronary stent system xience sierra sierra be equip thinner profile enhance flexibility longer length small diameter further advanced stent delivery system effectively aids treat complex case involve multiple totally block vessel provide increase flexibility precision doctor management report case involve patient suffering complex blockage believe fda approval aid drive top line contribution abbott vascular business vascular business glancerecently abbott vascular business have continue deliver stable top line performance last report quarter segment sale improve report basis notably vascular business account total revenue broader medical device segment encouragingly note vascular business abbott have be slew development regard xience sierra coronary stent system company be award national reimbursement xience sierra japan ministry health labour welfare follow receipt regulatory approval april abbott have also be get positive response xience sierra coronary stent system post launch europe late last year market potentialper grand view research safely conclude development help abbott cash opportunity coronary stent market accord report global coronary stent market be expect witness cagr roughly share price movementover past month abbott have be outperform industry stock have gain compare industry increase zack rank stock considerabbott currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina have expect long term earning growth rate amedisys have expect long term earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1654,ILMN,month have go last earning report illumina inc ilmn free report share have add time frame recent positive trend continue lead next earning release be ilmn due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent report adjust earning share ep first quarter beating zack consensus estimate also bottom line exceed year number stupendous include time item company report ep compare year year figure include impact pre tax gain result grail repurchase share illumina revenuesin quarter review illumina revenue surge year year top line surpass zack consensus estimate huge upside be attribute strong consumable growth illumina sequence portfolio notable strength high throughput family moreover novaseq platform continue growth momentum exclude stocking order fourth quarter novaseq consumable soar approximately sequentially strong performance flow cell product revenue total revenue increase year year service other revenue be year year operational updateadjusted gross margin exclude amortization acquire intangible asset include stock base compensation expense come reflect expansion basis point bps year year owing favorable product mix sequence consumable also microarray contribute overall revenue report quarter compare year research development expense decline year year selling general administrative expense rise adjust operate margin expand bps year quarter financial updateillumina exit first quarter cash cash equivalent short term investment last year net cash provide operate activity mar be compare mar company project revenue growth gaap earning share attributable illumina stockholder gaap earning attributable illumina stockholder illumina have raise full year revenue compare earlier projection rise meanwhile zack consensus estimate metric be peg adjust certain net specify item full year ep be expect band raise earlier forecast consensus mark metric stand predict range have estimate be move then turn fresh estimate flatlined past month have be revision higher current quarter compare lower illumina inc price consensus illumina inc price consensus illumina inc quotevgm scoresat time ilmn have strong growth score be lag lot momentum front stock be also allocate grade value side putt bottom investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested company stock be suitable solely growth base style score outlookilmn have zack rank strong buy expect average return stock next few month
1655,ILMN,dr reddy laboratory ltd rdy free report report fourth quarter fiscal earning american depositary share ad cent cent earn year quarter moreover revenue decrease year year year date share company have decrease compare industry decline quarter detaildr reddy report revenue segment global generic pharmaceutical service active ingredient psai proprietary product other global generic revenue fall year year fourth quarter decline be due lower contribution north america generic market due higher price erosion unfavorable dollar conversion psai revenue be year quarter revenue proprietary product other segment come year quarter further research development expense be year year selling general administrative expense be year year mar dr reddy have generic filing abbreviated new drug application anda new drug application be pending fda approval anda be para iv filing have first file status result full fiscal year earning come cent fiscal revenue increase fiscal takein fourth quarter fiscal dr reddy bottom line suffer year year decline be mainly due continue headwind market temporary drop sale russia fourth quarter due shift channel purchasing pattern look ahead company plan continue work diligently resolve pending regulatory issue company also focus accelerate new product market improve approval process company first cycle nda approval high potency topical steroid impoyz treatment moderate severe plaque psoriasis patient year age older be significant milestone proprietary product pipeline zack rank stock considerdr reddy have zack rank hold better rank stock same space be illumina inc ilmn free report ligand pharmaceutical lgnd free report enanta pharmaceutical inc enta free report illumina sport zack rank strong buy ligand enanta carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ligand earning share estimate have be revise upward past day company come positive earning surprise trail quarters average beat company share have rally year date enanta earning share estimate have moved north cent past day company pull positive surprise last quarters average beat stock have soar so far year dr reddy laboratory ltd price consensus ep surprise dr reddy laboratory ltd price consensus ep surprise dr reddy laboratory ltd hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1656,ILMN,late medtronic plc mdt free report spine business have be register soft performance due challenge market scenario let see be possibility rebound time company be schedule report fourth quarter fiscal result open bell click here know company overall performance be likely be spine glancein last report quarter medtronic spine division be flat year year mid single digit growth bmp bone morphogenetic protein cer low single digit decline core spine hampered overall sale however company note growth be sluggish be line global spine market management combination advanced technology imaging navigation power instrument nerve monitoring have spur growth division company have also start demonstrate positive outcome related distribution relationship mazor robotic medtronic plc price ep surprise medtronic plc price ep surprise medtronic plc begin fiscal medtronic be suffering significant pricing pressure business offset strong procedural growth company believe price reduction basically stem consolidation hospital company state hospital be get more sophisticated buy pattern be consolidate vendor base result price decline medtronic expect competitive pricing pressure reduce next couple quarters lead net procedural growth company however look company outlook be uncertain term recovery company earlier note spine broader restorative therapy group rtg segment growth be mar impact slower spine market soon be report quarter zack rank stock currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate illumina have long term expect earning growth rate amedisys have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1657,ILMN,similar wise buy decision exit certain underperformer right time help maximize portfolio return selling loser be difficult share price estimate be fall be time get rid security more loss hit portfolio such stock want consider drop be chromadex corporation cdxc free report have witness significant price decline past week have see negative earning estimate revision current quarter current year zack rank sell further confirm weakness cdxc key reason move have be negative trend earning estimate revision full year have see estimate move past day compare upward revision trend have cause consensus estimate trend lower go loss cent share month current level loss cent also current quarter chromadex have see downward estimate revision versus revision opposite direction drag consensus estimate loss cent share loss cent cent past day stock also have see pretty dismal trading lately share price have drop past month chromadex corporation price consensus chromadex corporation price consensus chromadex corporation quote so not be good decision keep stock portfolio anymore least don have long time horizon be still interested medical biomedical genetic industry instead consider better rank stock illumina inc ilmn free report stock currently hold zack rank strong buy be better selection time see complete list today zack rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1658,ILMN,earning season have reach tail end index market capitalization have report so far revenue growth beating ep estimate come ahead top line expectation earning revenue growth rate be lower prior quarter same group company however total earning dollar term be track reach new quarterly time record index surpass previous record achieve fourth quarter revenue surprise be also tracking historical period give several equity etfs have impressed performance have generate handsome return trail month even be hit north korean tension be winner many corner space be etfs buoy robust earning result addition have give chart month performance compare broad market fund spy free report broad sector read etfs profit north korea tension ark innovation etf arkk free report be actively manage fund focuse company be expect benefit development new product service technological improvement advancement genomic revolution web industrial innovation amazing surge bitcoin price incredible earning company athenahealth athn free report illimina ilmn free report stratasys ssys free report provide boost fund portfolio tesla tsla free report also add strength increase production outlook stock make substantial asset lead rise arkk past month read bitcoin skyrocket race first cryptocurrency etf heat powershare smallcap utility portfolio pscu free report fund target small cap segment utility service sector total earning utility sector be higher revenue blended beat blended beat seem encourage price impact response earning be much better compare negative price reaction many other sector stock see modest rise only construction give psu be lead utility sector gain nearly read etfs focus utility result guggenheim solar etf tan free report etf offer exposure global company involved solar power industry have gain past month strong earning particular earning first solar fslr free report solaredge technology sedg canadian solar csiq have be strong stock be top holding fund overall solar industry come earning beat fidelity msci service etf fcom free report etf target telecom sector have gain month telecom kingpin verizon vz free report free report dominate fund return account share basket firm report strong result read etfs watch telecom earning want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1659,ILMN,aug issue update research report san diego base illumina inc ilmn free report company provide tool integrate system analysis genetic variation function illumina exit second quarter solid note earning revenue beating zack consensus estimate top line be strong new product launch include veriseq nipt solution europe strength novaseq more good news be rate nipt adoption be increase outside notably last month illumina have be trading broader industry stock have grow period compare gain broader industry company raise guidance be also encourage enough indicate bullish trend continue come period also demand novaseq surpass company expectation order beating forecast more novaseq instrument have be order launch january be also look forward grail illumina own develop company focuse cancer screening market clinical market demand customer undergo oncology testing remain robust be currently look forward performance extend ra panel slate launch third quarter significantly june company announce fda approval receipt extend ra companion diagnostic kit class iii pma flip side weak margin owing novaseq launch higher array service revenue product mix sequence consumable continue act deterrent also national institutes health nih funding issue tough competitive landscape be other few concern deal zack rank key picksillumina currently have zack rank hold better rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report sporting zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month insys therapeutic have expect long term earning growth rate stock have gain last month align technology have expect long term adjust earning growth almost stock have surge roughly last month today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1660,ILMN,roche hold ag rhhby free report subsidiary genentech announce fda have approvedan alternative delivery option itsrheumatoid arthritis drug actemra asubcutaneous sc formulation actemra tocilizumab treatment active polyarticular juvenile idiopathic arthritis pjia patient year older have be approve fda share company have lose year date compare industry decline note actemra be already approve pjia intravenous formulation be also approve several other arthritis indication adult well child approval be support datum jigsaw study determine appropriate dose regimen actemra sc base body weight child pjia study enrolled patient age year pjia previous inadequate response intolerance methotrexate be actemra naive be receive actemra iv adequate disease control safety observed actemra administer subcutaneously be consistent know safety profile actemra iv sale actemra be chf increase year year first quarter label expansion drug boost actemra sale zack rank stock considerroche currently carry zack rank hold few better rank stock same space worth consider be ligand pharmaceutical lgnd free report illumina ilmn free report enanta pharmaceutical enta free report ligand illumina sport zack rank strong buy enanta carry zack rank buy see complete list today zack rank stock here ligand earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat company share have rally year date illumina earning share estimate have moved plast day company deliver positive earning surprise trail quarters average beat stock have rally so far year stock have rally so far year enanta searning share estimate have moved cent past day company deliver positive earning surprise trail quarters average beat stock have rally so far year roche hold ag price roche hold ag price roche hold ag quote more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1661,ILMN,astute investor always opt plan be likely yield high return irrespective market condition efficiency level measure company capability transform available input output be often consider important parameter used gauge company potential rake handsome return company favorable efficiency level be expect provide stellar return be believe be positively correlated price performance key ratio identify become difficult measure efficiency level company be reason consider popular efficiency ratio select stock efficiency ratio be inventory turnover ratio month cost good sell cog quarter average inventory be consider most popular efficiency ratio indicate company ability maintain suitable inventory position high value indicate company have relatively low level inventory compare cog low value show company be face decline sale result excess inventory receivables turnover be ratio month sale quarter average receivables show company potential extend credit collect debt term credit high receivables turnover ratio account receivable turnover ratio debtor turnover ratio be desirable show company be capable collect account receivables have quality customer asset utilization ratio indicate company capability convert asset output be thus widely know measure efficiency level be calculate divide total sale past month last quarter average total asset ratio high asset utilization indicate company be efficient operate margin efficiency measure be ratio operate income past month sale same period measure company ability control operate expense hence high value ratio indicate company manage operate expense more efficiently peer screening parametersin addition mentioned ratio have add favorable zack rank strong buy buy screen objective make strategy more profitable see complete list today zack rank stock here inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer use few criterium have narrow universe stock only here be stock make screen marine product corporation mpx free report design manufacture sell recreational fiberglas powerboat sportboat deckboat cruiser jet boat sport fishing market worldwide company hold zack rank have average quarter positive earning surprise nutrisystem inc ntri free report provide weight management product service woman man unite state company zack rank have average quarter positive earning surprise exelixis inc exel free report engage discovery development new medicine enhance care outcome person cancer zack rank company have average quarter positive earning surprise see complete list today zack rank stock here illumina inc ilmn free report provide sequence array base solution genetic analysis company sport zack rank have average quarter positive earning surprise baxter international inc bax free report provide portfolio healthcare product company have zack rank have average quarter positive earning surprise get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
1662,ILMN,perrigo company plc prgo free report report first quarter adjust earning cent share miss zack consensus estimate bottom line however increase year figure cent net sale report quarter increase figure surpass zack consensus estimate company share have underperform industry year date stock have decline industry rally segment jan company report segment be consumer health care americas chca consumer health care international chci prescription pharmaceutical rx other segment chca chca net sale first quarter come year year upside be attribute strong performance infant nutrition analgesic cough cold category compare year quarter new product sale also contribute top line however upside be partially offset lower sale animal health category discontinue product chci chci segment report net sale decline constant currency basis year period exclude exit russian unprofitable distribution business favorable foreign currency movement net revenue grow drive new product sale however be partially offset lower net sale cough cold personal care analgesic category addition discontinue product rx segment net sale slip report basis constant currency basis new product sale be offset lower net revenue exist product primarily due price erosion be line expectation new product sale be lower expect due supply disruption key new product earning outlook perrigo reiterate revenue guidance expect be range company also reaffirm adjust earning guidance expect be band share corporate governance perrigo board director appoint rolf classon serve company board chairman effective zack rank stock considerperrigo be zack rank hold stock few better rank stock same space worth consider be ligand pharmaceutical lgnd free report protagonist therapeutic ptgx free report illumina inc ilmn free report sport zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat company share have rally year date protagonist loss estimate narrow cent last day company deliver positive earning surprise trail quarters average beat illumina earning share estimate have moved last day company come positive earning surprise precede quarters average beat stock have rally so far year perrigo company plc price consensus ep surprise perrigo company plc price consensus ep surprise perrigo company plc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1663,ILMN,share humana inc hum free report surge report second quarter operate earning share beating zack consensus estimate approximately share mondelez international inc mdlz free report gain report second quarter adjust earning share beat zack consensus estimate share time warner inc increase post second quarter adjust earning share surpass zack consensus estimate share ilumina inc ilmn free report rise report adjust earning share ep second quarter beat zack consensus estimate
1664,ILMN,be mystery investor hunt stock estimate beating potential ahead earning season be investor always try place ahead time look play stock be rich quality be positive earning surprise so important historically stock company solid quarterly earning nominal basis tank miss merely meet market expectation earning rise apparently look good doesn tell have be decelerate also seasonal fluctuation come play company be seasonally weak be strong be likely report sequential earning decline such case growth rate be mislead judge true health company other hand whole lot research analysis company financial initiative wall street analyst project earning also take company guidance consideration derive earning estimate thus outperform estimate be almost equivalent beating company own expectation well market perception margin earning surprise be big typically drife stock higher right release thus more anything else earning surprise push stock higher locate potential outperformer now find stock have potential beat bottom line be dream investor chase not always come true way fulfill be look earning surprise history company impressive track regard generally act driver send stock higher indicate company ability exceed estimate investor generally believe company have same trick sleeve deliver yet earn beat upcoming release winning strategyin order shortlist stock be likely come earning surprise choose followingas primary screening parameter last ep surprise greater equal stock deliver positive surprise last quarter tend surprise again average ep surprise last quarters greater lift bar outperformance slight higher set average earning surprise last quarters average ep surprise last quarters greater point more consistent surprise history make case surprise even stronger addition place few other criterium push chance positive surprise zack rank less equal only company zack rank strong buy buy rating get earning esp greater stock need have positive earning esp zack rank earning beat happen proven model order have long term growth potential high trading liquidity have add follow parameter too next year estimate ep growth year greater solid expect earning growth exhibit stock long term growth prospect average day volume greater high trading volume imply stock have adequate liquidity handful criterium have narrow universe stock here be stock caterpillar inc cat free report be manufacturer construction mining equipment diesel natural gas engine industrial gas turbine diesel electric locomotive have vgm value growth momentum score stock hail top rank top zack industry carry zack rank see complete list today zack rank stock here wellcare health plan inc wcg free report zack rank buy company focus exclusively provide government sponsored manage care service stock belong top rank top zack industry intuit inc intu free report zack rank company provide financial management compliance product service small business consumer self employ accounting professional stock hail top rank top zack industry cardtronic plc catm free report company provide atm service primarily north america europe stock belong top rank zack industry top sport zack rank illumina inc ilmn free report zack rank company be improve human health unlock power genome stock hail top rank zack industry top get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
1665,ILMN,agio pharmaceutical inc agio free report post first quarter loss share wider zack consensus estimate loss year loss total revenue report quarter amount lag zack consensus estimate revenue plunge year figure due adoption new revenue recognition standard stock have outperformed industry year date have surge compare industry rally research development expense be year year largely drive start cost ag pivotal program pk deficiency include initiation activate trial initiation phase dose escalation study ag first class mat inhibitor ind enable activity ag dhodh inhibitor general administrative expense increase year year due higher cost due growth company unite state commercial organization support expect launch tibs ivosidenib third quarter pipeline updatedure quarter fda accept priority review basis set action date aug new drug application nda tibsovo treatment patient aml isocitrate dehydrogenase idh mutation company plan submit marketing authorization application european medicine agency tibsovo aml idh mutation fourth quarter company also initiate phase dose escalation study ag first class methionine mat inhibitor patient phosphorylase mtap delete tumor also initiate activate single arm pivotal trial ag adult pyruvate kinase deficiency patient receive regular blood transfusion company plan submit investigational new drug application latest development candidate ag inhibitor metabolic enzyme dihydroorotate dehydrogenase treatment hematologic malignancy fourth quarter company also plan initiate phase ii proof concept trial ag thalassemia fourth quarter zack rank stock consideragio be zack rank hold stock few better rank stock same space worth consider be ligand pharmaceutical lgnd free report protagonist therapeutic ptgx free report illumina inc ilmn free report sport zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat company share have rally year date protagonist loss estimate narrow cent last day company deliver positive earning surprise trail quarters average beat illumina earning share estimate have moved last day company come positive earning surprise precede quarters average beat stock have rally so far year agio pharmaceutical inc price consensus ep surprise agio pharmaceutical inc price consensus ep surprise agio pharmaceutical inc quotemore stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1666,ILMN,smart investor always opt plan be likely yield high return irrespective market condition efficiency level measure company capability transform available input output be often consider important parameter used gauge company potential rake handsome return company favorable efficiency level be expect provide stellar return be believe be positively correlated price performance key ratio identify become difficult measure efficiency level company be reason consider popular efficiency ratio select stock efficiency ratio be inventory turnover ratio month cost good sell cog quarter average inventory be consider most popular efficiency ratio indicate company ability maintain suitable inventory position high value indicate company have relatively low level inventory compare cog low value show company be face decline sale result excess inventory receivables turnover be ratio month sale quarter average receivables show company potential extend credit collect debt term credit high receivables turnover ratio account receivable turnover ratio debtor turnover ratio be desirable show company be capable collect account receivables have quality customer asset utilization ratio indicate company capability convert asset output be thus widely know measure efficiency level be calculate divide total sale past month last quarter average total asset ratio high asset utilization indicate company be efficient operate margin efficiency measure be ratio operate income past month sale same period measure company ability control operate expense hence high value ratio indicate company manage operate expense more efficiently peer screening parametersin addition mentioned ratio have add favorable zack rank strong buy buy screen objective make strategy more profitable see complete list today zack rankstock here inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer use few criterium have narrow universe stock only here be stock make screen illumina inc ilmn free report provide sequence array base solution genetic analysis company have average quarter positive earning surprise stock have zack rank alarm com holding inc alrm free report provide cloud base software platform solution smart residential commercial property unite state internationally company have average quarter positive earning surprise stock sport zack rank copart inc cprt free report provide online auction vehicle remarketing service company have average quarter positive earning surprise stock sport zack rank vanda pharmaceutical inc vnda free report focus development product treatment central nervous system disorder company have average quarter positive earning surprise stock carry zack rank get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
1667,ILMN,illumina inc ilmn free report be big mover last session company see share rise day move come solid volume too far more share change hand normal session break recent trend company stock be now trading volatile price range past month time frame move come company report solid second quarter result company have see positive estimate revision past few week zack consensus estimate current quarter remain unchanged recent price action be encourage so make sure keep close watch firm future illumina currently have zack rank buy earning esp be negative illumina inc price consensus illumina inc price consensus illumina inc quoteanother stock worth consider medical biomedical genetic industry be innoviva inc carry zack rank strong buy see complete list today zack rank stock here be ilmn go predict see other think stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1668,ILMN,illumina inc ilmn free report report adjust earning share ep first quarter beating zack consensus estimate also bottom line exceed year number stupendous include time item company report ep compare year year figure include impact pre tax gain result grail repurchase share illumina revenuesin quarter review illumina revenue surge year year top line surpass zack consensus estimate huge upside be attribute strong consumable growth illumina sequence portfolio notable strength high throughput family moreover novaseq platform continue growth momentum exclude stocking order fourth quarter novaseq consumable soar approximately sequentially strong performance flow cell illumina inc price consensus ep surprise illumina inc price consensus ep surprise illumina inc quote product revenue total revenue increase year year service other revenue be year year operational updateadjusted gross margin exclude amortization acquire intangible asset include stock base compensation expense come reflect expansion basis point bps year year owing favorable product mix sequence consumable also microarray contribute overall revenue report quarter compare year research development expense decline year year selling general administrative expense rise adjust operate margin expand bps year quarter financial updateillumina exit first quarter cash cash equivalent short term investment last year net cash provide operate activity mar be compare mar company project revenue growth gaap earning share attributable illumina stockholder gaap earning attributable illumina stockholder illumina have raise full year revenue compare earlier projection rise meanwhile zack consensus estimate metric be peg adjust certain net specify item full year ep be expect band raise earlier forecast consensus mark metric stand predict range takeillumina exit first quarter solid note better expect earning well revenue be encourage year year increase count moreover management be hopeful recently launch novaseq flow cell reagent kit company also receive product approval certificate nextseq dx instrument ministry food drug safety mfds south korea field oncology illumina collaboration bristol myer squibb loxo oncology be expect garner positive result line additionally improve margin buoy optimism meanwhile company be operate tough competitive landscape be concern zack rank other key picksillumina have zack rank buy other top rank stock broader medical sector include abaxis inc abax free report bio rad laboratory inc bio free report resm inc rmd free report abaxis bio rad sport zack rank strong buy resm carry zack rank buy see complete list today zack rank stock here abaxis be expect release fourth quarter fiscal result apr zack consensus estimate adjust ep be cent revenue same be peg bio rad be expect report first quarter result zack consensus estimate adjust ep be cent revenue resm be slate release third quarter fiscal result apr consensus mark adjust ep be cent same revenue stand investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1669,ILMN,bristol myer squibb company bmy free report announce result phase iii trial checkmate trial blockbuster drug opdivo number person majority be china late stage multinational randomize study compare opdivo docetaxel treatment patient stage iiib iv small cell lung cancer nsclc disease have progressed platinum base doublet chemotherapy result show opdivo demonstrated statistically significant benefit versus docetaxel primary endpoint overall survival os os benefit be observed regardless pd expression tumor histology opdivo reduce risk death versus chemotherapy additionally secondary endpoint objective response rate median duration response demonstrated durability opdivo compare docetaxel objective response rate quadruple opdivo versus docetaxel median duration response not reach opdivo versus month docetaxel result be update immuno oncology trial session american association cancer research aacr annual meeting chicago abstract ct remind investor china food drug administration accept company biologic license application opdivo propose indication previously treat nsclc november tentative approval further boost geographic reach drug efficacy safety opdivo predominantly chinese patient population advanced nsclc be consistent result global checkmate study share company have rally past year outperform industry gain opdivo become first pd immune checkpoint inhibitor gain regulatory approval july be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy opdivo continue be launch globally approval label expansion drug have be perform impressively due demand result rapid commercial acceptance several indication include melanoma renal cell carcinoma second line nsclc fda also approve opdivo intravenous use patient hepatocellular carcinoma hcc have be previously treat nexavar opdivo have rapidly penetrate second line hcc market label expansion additional indication give product access higher patient population increase commercial potential drug significantly earlier company stop phase iii combination study checkmate earlier expect meet co primary endpoint phase iii study evaluate opdivo yervoy patient previously untreated advanced metastatic renal cell carcinoma meet co primary endpoint study show superior os compare current standard care sunitinib intermediate poor risk patient fda accept company sbla same take decision apr however opdivo face stiff competition merck mrk free report keytruda roche rhhby free report tecentriq concurrently bristol myer announce collaboration illumina inc ilmn free report use latter next generation sequence technology develop globally commercialize diagnostic assay support bristol myer squibb oncology portfolio zack rankbristol myer carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company re already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1670,ILMN,president donald trump successfully repeal replace obamacare healthcare bill affordable care act last year focus shift passage right try bill year president sign right try bill law law help patient suffering terminal disease undergo experimental treatment use drug be not yet approve food drug administration fda passage law be definitely good news patient be expect benefit biotech industry additionally world health organization be now assess quality biosimilar drug improve quality parameter drug same time ensure hassle free availability unite state be investing biotech stock significant exposure market be most suitable investment option present trump sign right try lawpresident trump say take long time drug get fda approval terminally ill patient don have abundance time address concern trump finally sign right try law help patient use experimental drug be not yet approve fda additionally scott gottlieb commissioner fda say right try act help patient family be face life threaten disease condition lot argument be make extent law actually benefit terminally ill patient fda job be assess certify drug quality safety do so fda sometimes block drug add so many regulation consumer fail afford sometimes company stop development altogether respect passage right try law be definitely patient give flexibility choose prefer mode medical treatment assess bio similar drugsdrug serious disease cancer leukemia aids be comparatively expensive however cheaper copy such drug know bio similar be now circulate global market accord emer cook head regulation medicine other health technology bio similar drug have become important part treatment armamentarium many country include low middle income country however lack proper regulation bio similar outside unite state european market be concern order address issue have decide invite drug make company june provide report various bio similar drug be essential check bio similar determine drug have same beneficial result original passage right try law be expect ease medical treatment patient suffering terminal disease additionally focus assess quality bio similar drug improve safety factor drug turn benefit biotech market context have select biotech stock be expect gain follow development stock also flaunt zack rank strong buy buy illumina inc ilmn free report be provider sequence array base solution genetic analysis san diego base company have expect earning growth current year zack consensus estimate current year have improve last day illumina have gain so far year stock sport zack rank see complete list today zack rank stock here athersys inc athx free report be biotechnology company focuse research development activity field regenerative medicine cleveland base company have zack rank expect earning growth rate current year be zack consensus estimate current year have improve last day athersys have gain year date eyepoint pharmaceutical inc eypt free report be specialty company engage develop commercialize ophthalmic product watertown base company have zack rank expect earning growth rate current year be zack consensus estimate current year have improve last day eyepoint pharmaceutical have gain so far year rhythm pharmaceutical inc rytm free report be company develop peptide therapeutic treatment rare genetic disorder obesity boston base company have zack rank expect earning growth rate current year be zack consensus estimate current year have improve last day rhythm pharmaceutical have gain year date ligand pharmaceutical incorporate lgnd free report be company focuse develop technology help pharmaceutical company develop medicine san diego base company have zack rank expect earning growth rate current year be zack consensus estimate current year have improve last day ligand pharmaceutical have gain so far year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1671,ILMN,share catalyst pharmaceutical inc cprx free report rise almost company announce fda have accept new drug application nda lead pipeline candidate firdapse grant priority review same fda have set action date nov firdapse have be develop symptomatic treatment lambert eaton myasthenic syndrome lem nda submission address issue raise refusal file letter previous firdapse nda submission include additional information request fda priority review designation fda be generally grant drug have potential provide significant improvement safety effectiveness treatment prevention diagnosis serious disease year date catalyst share have decline industry increase firdapse be currently approve european union eu symptomatic treatment lem adult however drug be not yet approve unite state january hold type meeting fda catalyst be advise base briefing document company propose nda be sufficient resubmission november company announce positive top line result second phase iii study firdapse patient lem catalyst also announce decision not include fda submission limit type congenital myasthenic syndrome cms be consider mechanistically similar lem catalyst decide not overcomplicate review nda submission lem second indication company be currently conduct phase iii study evaluate firdapse treatment cms expect complete enrollment end report top line result study first quarter result trial be successful company plan add cms indication labele firdapse catalyst have license right firdapse biomarin pharmaceutical inc bmrn free report development product unite state also firdapse enjoy orphan drug breakthrough therapy status unite state treatment lem firdapse receive orphan drug status unite state treatment congenital myasthenic syndrome cms myasthenia gravis mg lem be ultra rare disease even several drug treatment therapy steroid azathioprine other intravenous immunoglobulin be currently use guanidine hcl tablet be approve treatment lem however due significant side effect drug be not view effective treatment turn have create ample space introduce new therapy lem therefore approval firdapse indication be huge boost company give commercial potential target market stock warrant lookcatalyst carry zack rank hold better rank stock same space be illumina inc ilmn free report ligand pharmaceutical lgnd free report illumina sport zack rank strong buy ligand carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ligand earning share estimate have be revise upward past day company come positive earning surprise trail quarters average beat company share have rally year date catalyst pharmaceutical inc price catalyst pharmaceutical inc price catalyst pharmaceutical inc quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1672,ILMN,baxter international inc bax free report have be healthy growth trajectory late strategic acquisition product development bullish outlook have be provide company competitive edge medtech solid prospect zack rank buy stock be attractive pick moment past month share baxter have grow compare industry increase current level be also higher index rise stock have market cap company next year earning growth rate be also favorable compare industry rally company deliver positive earning surprise last quarters also have long term expect earning growth rate baxter have impressive growth score well growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine solid zack rank strong buy hold offer best investment opportunity let find recent positive trend be sustainable solid earningsbaxter end first quarter solid note beating consensus mark earning revenue adjust earning come cent share cent prior year quarter revenue be year year constant currency cc geographically sale inched year year meanwhile international sale increase year year company deliver strong result back solid performance core renaland pharmaceutical business renal unit sale increase year year basis pharmaceutical sale rise raise guidancebuoy solid first quarter earning result baxter lift financial outlook second quarter company expect sale growth approximately cc company expect adjust earning continue operation band cent also project sale growth cc anticipate adjust earning share continue operation range full year strategic buyout have be long help baxter gain market traction recently company complete consolidation thrombin topical preveleak surgical sealant product line mallinckrodt deal be expect widen baxter surgical portfolio hemostat sealant transaction have not be accretive first quarter earning company still estimate be so buyout india base claris injectable limit have provide baxter robust portfolio generic injectable molecule currently approve unite state upward estimate revision company estimate revision trend current year have be positive past couple month analyst moved north none opposite direction earning estimate have be raise same time frame other key picksother top rank stock broader medical sector include intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys project long term earning growth make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1673,ILMN,resm inc rmd free report recently announce definitive agreement buy healthcarefirst privately hold provider software solution service home health hospice agency meeting certain customary close condition receive regulatory approval deal be expect be finalize end first quarter fiscal resm calendar however financial detail deal have be keep wrapped further transaction be expect be immaterial resm consolidated financial result buyout integration synergiesper resm healthcarefirst solution comprise electronic health record ehr software bill coding service advanced analytic complement resm wholly own subsidiary line software solution integration healthcarefirst solution resm software service saas portfolio enhance latter efficacy manage grow population provide benefit patient family agency payer glimpse saas businessresm witness year year growth revenue saas business last report quarter notably company have be actively work chronic disease management algorithms include population health model health care analytic care co ordination saas model home health home nursing hospice area company introduce new offer oasis home health hospice market notably oasis stand outcome assessment information set resm be also expand range hospital software offering acquisition software service business home health home nursing other alternative care setting believe buyout help resm solidify saas portfolio market potential resm rapidly age population grow incidence chronic condition change trend higher inclination homecare other lower cost care setting continue provide impetus home health hospice segment go stratistic mrc report publish reuter global home healthcare market be expect reach worth cagr view state fact believe buyout be strategically align share price performanceover past month share resm have outperformed industry latest price movement stock have gain industry gain zack rank other stock considerresm currently carry zack rank buy other top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys project long term earning growth today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1674,ILMN,illumina inc ilmn free report report adjust earning share ep cent second quarter beat zack consensus estimate report figure also surpass company guide range cent adjust earning however lag year number include time item company report ep cent compare cent year revenuesin report quarter illumina revenue grow year year exceed company expectation approximately moreover top line beat zack consensus estimate management top line growth second quarter be attribute strong uptake sequence consumable microarray moreover novaseq platform continue drive growth more order launch jan product revenue total revenue increase year year service other revenue be year year illumina inc price consensus ep surprise illumina inc price consensus ep surprise illumina inc updateillumina adjust gross margin come reflect contraction basis point bps year year owing novaseq introduction higher array service revenue product mix sequence consumable exclude amortization acquire intangible asset include stock base compensation expense adjust gross margin be highlight contraction bps prior year period research development expense be year year selling general administrative expense rise consequently adjust operate margin reflect decline bps year period primarily due increase investment grail helix financial updateillumina exit second quarter cash cash equivalent short term investment first quarter year date net cash provide operate activity be compare year period guidancebanking solid second quarter performance illumina have raise full year revenue growth expectation earlier provide range meanwhile zack consensus estimate full year revenue be peg company continue expect adjust ep band unchanged earlier guidance current zack consensus estimate illumina bottom line stand low end guide range takeillumina exit second quarter solid note earning revenue beating zack consensus estimate top line be strong several product launch include veriseq nipt solution europe strength novaseq bottom line be impact margin pressure be currently look forward performance extend ra panel be slate launch third quarter notably company announce receipt fda approval test next generation sequence kit jun also illumina recently develop venture cancer screening market grail have start deliver positive news flip side weak margin owing novaseq launch higher array service revenue product mix sequence consumable continue act deterrent also tough competitive landscape be concern be also apprehensive issue pertain nih funding zack rank other key picksillumina currently have zack rank buy other top rank medical stock be mesa laboratory inc mlab free report insys therapeutic inc insy free report align technology inc algn free report notably insys therapeutic align technology sport zack rank strong buy mesa laboratory carry zack rank see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock have gain last month align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1675,ILMN,nordisk nvo free report announce headline result pioneer second phase iiia study oral formulation ozempic semaglutide treatment adult type ii diabetes study evaluate efficacy safety mg oral ozempic compare mg eli lilly lly free report boehringer ingelheim jardiance empagliflozin type ii diabetes inadequately controlled metformin week study achieve primary objective demonstrated statistically significant superior improvement blood glucose level hba oral ozempic compare jardiance week study show statistically significant improvement hba week week compare improvement hba mg empagliflozin week also demonstrated weight loss kg week kg week versus kg mg jardiance week week increase weight loss oral ozempic be also significant compare jardiance week time point remind investor december fda approve ozempic once daily pre filled pen improve glycaemic control type ii diabetes patient be also approve europe japan canda same indication share nordisk have decrease compare industry decline february nordisk successfully complete first phase iiia trial pioneer oral ozempic treatment adult type ii diabetes trial achieve primary objective demonstrate statistically significant superior improvement blood glucose level hba dose oral ozempic compare placebo mid company plan initiate cardiovascular outcome study call soul ozempic also company plan initiate phase iiia program call step explore potential once weekly ozempic treatment person obesity also include cardiovascular outcome trial select investigate impact ozempic incidence major adverse cardiovascular event compare placebo patient establish cardiovascular disease overweight obesity glp market lilly trulicity astrazeneca azn free report once weekly bydureon be competitor nordisk ozempic zack rank stock considernovo nordisk have zack rank hold better rank stock same space be illumina inc ilmn free report sporting zack rank strong buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year nordisk price nordisk price nordisk quotetoday stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1676,ILMN,medtronic plc mdt free report diabetes group have be solid growth trajectory late encourage contribution majority sub segment expect strength reflect fourth quarter fiscal result be schedule release open bell click here know company overall performance be likely be diabetes focusmedtronic diabetes group presently comprise intensive insulin management iim intensive diabetes therapy ndt diabetes service solution dss division diabetes segment develop manufacture market advanced integrate diabetes management solution include insulin pump therapy continuous glucose monitoring cgm system therapy management software note management expect double digit revenue growth diabetes group fourth quarter fiscal management consistently strong adoption minime system unite state enhance sensor supply capacity drive upside consequently zack consensus estimate diabetes group revenue indicate rise year quarter also estimate diabetes group revenue unite state reflect rise year medtronic plc price ep surprise medtronic plc price ep surprise medtronic plc quote last report quarter segment record improvement sale benefit increase uptake new sensor augment insulin pump system unite state well international market enhance production capacity same notably minime system have serve patient unite state apart management be optimistic uptick consumable revenue corporation johnson johnson diabetes care company user third quarter fiscal moreover have state company be progress well transition user expect trend continue yet be report quarter well fourth quarter fiscal medtronic proceed initiative boost performance minime portfolio february company expand product portfolio addition minime advance infusion set latest offer diabetes business be plan be make commercially available canada hong kong certain country europe fourth quarter fiscal same month company announce fda have approve new arm indication guardian sensor continuous glucose monitor cgm used minime insulin pump notably guardian sensor be company latest most accurate cgm medtronic be only sensor have receive fda nod control automate insulin delivery hybrid close loop system minime new arm indication guardian sensor offer more convenience flexibility patient be available unite state use minime system believe development be beneficial company diabetes group portfolio get reflect yet be report quarter result let see thing be shape sub segment fourth quarter release iim revenue rise high teen cer third quarter fiscal however company witness growth new patient count unite state growth be lead solid uptake minime system unite state guardian sensor cgm addition division deliver low digit constant currency growth international market account continue strength minime system give development regard minime system expect top line contribution continue uptake product rise get reflect soon be report quarter result dss grow mid single digit cer consumable benefit rise install base enhance patient utilization improvement business be expect continue zack rank stock currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate illumina have long term expect earning growth rate amedisys have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1677,ILMN,illumina inc ilmn free report be slate report first quarter result market close apr last quarter company deliver positive earning surprise average earning beat be trail quarters let see thing be shape prior announcement key prior quarter illumina be expect gain strong product revenue last few quarters company product revenue have be gain rise demand sequence consumable instrument well microarray range consumable novaseq platform continue see growth close novaseq system currently customer hand launch last january novaseq shipment be project range management be hopeful launch flow cell xp nextera dna flex library preparation kit drive novaseq demand term give transition illumina high throughput portfolio related novaseq introduction instrument revenue have also be rise illumina inc price ep surprise illumina inc price ep surprise illumina inc quote accordingly zack consensus estimate product revenue reflect increase year quarter total service other revenue include genotyp sequence service instrument maintenance contract revenue oncology agreement have also be strong upside be be drive strength genotyp service due sequence instrument maintenance contract increase consumer demand nipt illumina win dutch national contract previous quarter other encourage development management factor more double sale business moreover company be make progress nipt adoption courtesy continue uptake veriseq nipt solution include ce ivd marked library prep analysis software miniseq miseq shipment accounting roughly new sequence customer demand grow nextseq adoption commercial customer used platform production setting illumina benchtop portfolio have be encourage bullish trend be expect be reflect be report quarter result thus zack consensus estimate service other revenue show rise year quarter here be other factor influence illumina first quarter result january illumina announce launch iseq sequence system next generation sequence system deliver excellent datum accuracy low capital cost make illumina technology available virtually lab company begin shipping product january investor be watch difference make top line result quarter be report geographically illumina have be witness grow revenue europe middle east africa emea lead sequence instrument consumable solid performance asia pacific propel shipment growth greater china also encourage recently management have noticed uptick demand customer be attempt set nipt operation china believe development open channel illumina thereby enhance business growth immaterial be report quarter ongoing tension unite state china regard imposition tariff import have raise concern major medtech player adverse move mar sale china term total oncology testing be last report quarter management solid result be primarily lead continue growth translational liquid biopsy segment furthermore illumina continue expect robust demand oncology testing overall first quarter total revenue be project prior year quarter model zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp uncover best stock buy sell re report earning esp filter illumina have zack rank earning esp combination suggest company be likely beat estimate zack consensus estimate earning reflect rise year year basis other stock worth lookhere be few other medical stock worth consider have right combination element post earning beat quarter myriad genetic inc mygn free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank quest diagnostic incorporate dgx free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1678,ILMN,make debut smart beta exchange trade fund powershare dynamic biotechnology genome portfolio pbe free report provide investor broad exposure health care etfs category equity market be smart beta etfs market cap weight index be create reflect market specific segment market etf industry have traditionally be dominate product base strategy investor believe market efficiency consider market cap index replicate market return low cost convenient transparent way be investor rather invest smart beta fund fund track cap weight strategy be strong option prefer choose great stock order beat market index attempt select stock have better chance risk return performance base certain fundamental characteristic combination such characteristic even space provide many choice investor think simplest methodology equal weighting more complicate one fundamental volatility momentum base weighting not have be able deliver first rate result fund sponsor indexpbe be manage invesco powershare fund have amassed make average size etfs health care etfs pbe fee expense seek match performance dynamic biotechnology genome intellidex index be comprise stock biotechnology genome company be company be principally engage research development manufacture marketing distribution various product service process company benefit significantly scientific technological advance biotechnology genetic engineering research cost other expenseswhen consider etf total return expense ratio be important factor cheaper fund significantly outperform more expensive cousin long term other factor remain equal operate expense annual basis be pbe make par most peer product space fund have month trail dividend yield sector exposure top holdingseven etfs offer diversify exposure minimize single stock risk be still important look fund holding investing luckily most etfs be very transparent product disclose holding daily basis etf have heaviest allocation healthcare sector portfolio look individual holding illumina inc ilmn free report account fund total asset follow vertex pharmaceutical inc vrtx free report regeneron pharmaceutical inc regn free report top holding account approximately pbe total asset management performance etf have add roughly so far year be last year past week period have trade etf have beta standard deviation trail year period make high choice space holding have more concentrated exposure peer dynamic biotechnology genome portfolio be excellent option investor seek outperform health care etfs segment market be other etfs space investor consider well spdr biotech etf xbi free report track biotechnology select industry index ishare nasdaq biotechnology etf ibb free report track nasdaq biotechnology index spdr biotech etf have asset ishare nasdaq biotechnology etf have xbi have expense ratio ibb charge investor look cheaper lower risk option consider traditional market cap weight etfs aim match return health care etfs bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
1679,ILMN,mar issue update research report illumina inc ilmn free report zack rank hold stock share company have outperformed broader industry last month stock have gain higher broader industry rise illumina exit fourth quarter solid note earning revenue beating zack consensus estimate additionally metric improve year year basis apart progress margin scenario instilled investor confidence stock be also optimistic illumina expansion strategy enhancement portfolio sequence product development strategic partnership therapeutic diagnostic service provider regard illumina sign commercial agreement earlier january distribute thermo fisher scientific ion ampliseq technology researcher conduct study next generation sequence platform san diego base illumina be tool integrate system provider analysis genetic variation function company focus product innovation research development evident recent launch iseq sequence system post promising fourth quarter expect illumina maintain growth momentum continue uptake sequence consumable instrument microarray portfolio meanwhile company face stiff competition sequence snp single nucleotide polymorphism genotyp gene expression molecular diagnostic market several bigwig already enjoy significant market share intellectual property portfolio well regulatory expertise also national institutes health funding issue raise concern key pickssome better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report perkinelmer have long term expect earning growth rate stock carry zack rank buy bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1680,ILMN,feb issue update research report illumina inc ilmn free report zack rank hold stock last month san diego base company provide tool integrate system analysis genetic variation function have gain higher broader industry illumina exit fourth quarter solid note beating zack consensus estimate front additionally revenue earning improve year year basis apart improve margin scenario instilled investor confidence stock be also optimistic illumina expansion strategy enhancement portfolio sequence product development strategic partnership therapeutic diagnostic service provider regard january illumina sign commercial agreement distribute thermo fisher scientific ion ampliseq technology researcher conduct study illumina next generation sequence platform currently illumina be focuse product innovation research development well be evident recent launch iseq sequence system post promising fourth quarter expect illumina maintain growth momentum continue uptake sequence consumable instrument microarray portfolio meanwhile illumina face stiff competition sequence snp genotyp gene expression molecular diagnostic market several large player already enjoy significant market share intellectual property portfolio regulatory expertise also national institutes health nih funding issue raise concern key pickssome better rank stock broader medical sector be bio rad laboratory bio free report becton dickinson company bdx free report perkinelmer pki free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate becton dickinson company have zack rank company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1681,ILMN,illumina inc ilmn free report report adjust earning share ep fourth quarter beat zack consensus estimate adjust earning surpass year number include time item company report ep cent compare cent year include provisional estimate time transition tax impact tax reform full year adjust ep come beating zack consensus estimate moreover figure beat year number revenuesin quarter review illumina revenue grow year year top line beat zack consensus estimate net revenue totale outpace zack consensus estimate figure also improve year number management top line growth fourth quarter be attribute strong uptake sequence consumable instrument well microarray portfolio moreover novaseq platform continue drive growth close novaseq system currently customer hand launch january product revenue total revenue increase year year service other revenue be year year illumina inc price consensus ep surprise illumina inc price consensus ep surprise illumina inc updateadjusted gross margin come reflect expansion basis point bps year year owing favorable product mix sequence consumable exclude amortization acquire intangible asset include stock base compensation expense adjust gross margin be highlight expansion bps year research development expense be year year selling general administrative expense rise however adjust operate margin reflect rise bps year quarter financial updateillumina exit cash cash equivalent short term investment net cash provide operate activity be compare year project full year revenue growth range meanwhile zack consensus estimate revenue be peg adjust certain net specify item full year adjust earning share continue operation be expect band zack consensus estimate earning stand low end project range takeillumina exit fourth quarter solid note be encourage year year increase front management be hopeful product novaseq recently launch iseq broad clinical portfolio comprise veriseq nipt solution nextseqdx miseqdx drive top line moreover improve margin buoy optimism meanwhile company be operate tough competitive landscape be concern zack rank key picksillumina have zack rank hold few better rank stock broader medical sector be resm rmd free report perkinelmer pki free report accuray aray free report company carry zack rank buy see complete list today zack rank strong buy stock here resm post second quarter fiscal adjust earning prior year quarter revenue increase year year constant exchange rate cer perkinelmer report fourth quarter adjust earning cent company report adjust revenue approximately surpass year quarter accuray report loss cent second quarter fiscal cent narrower year figure total revenue increase year year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1682,ILMN,illumina inc ilmn free report lead provider tool integrate system analysis genetic variation function be schedule report second quarter result aug close bell last quarter company earning be line zack consensus estimate however illumina earning outpaced zack consensus estimate past quarters average let take look thing be shape prior announcement factor playin last report first quarter illumina witness robust revenue growth account consistent improvement sequence consumable strong demand microarray management be still emphasize portfolio sequence platform fortify market position expect company maintain top line growth second quarter management top line growth first quarter also be attribute strong uptake novaseq platform more order place period moreover active hiseq customer base roughly customer company expect replacement older generation instrument novaseq trend continue yet be report quarter illumina inc price ep surprise illumina inc price ep surprise illumina inc quotefurther company recently launch veriseq nipt solution europe ce ivd marked next generation sequence base approach noninvasive prenatal testing notably outside rate nipt adoption be increase netherlands denmark begin cover test first quarter same be expect shortly france company continue see positive reimbursement trend europe well also illumina have be forge ahead nipt expansion plan china believe development boost company top line upcoming quarter flip side weak margin owing introduction novaseq higher array service revenue product mix sequence consumable continue act deterrent company also tough competitive landscape challenge company be also apprehensive issue pertain nih funding illumina have be face quite time now overall second quarter illumina project revenue growth approximately current zack consensus estimate second quarter revenue be peg company expect adjust ep range cent however zack consensus estimate be stable cent guide range earning whispersour proven model do not conclusively show illumina be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp illumina have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank illumina zack rank increase predictive power esp however company earning esp make surprise prediction difficult meanwhile caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1683,ILMN,investor be always look stock be poise beat earning season illumina inc ilmn free report be such company firm have earning come pretty soon event be shape quite nicely report be illuminais see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface ilmn report fact most accurate estimate current quarter be currently share ilmn compare broader zack consensus estimate share suggest analyst have very recently bump estimate ilmn give stock zack earning esp head earning season illumina inc price ep surprise illumina inc price ep surprise illumina inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give ilmn have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead illumina beat be card upcoming report zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1684,ILMN,illumina inc ilmn free report be slate report fourth quarter fiscal result jan market close last quarter company deliver positive earning surprise let see thing be shape ahead announcement let take look illumina announcement preliminary fourth quarter result morgan healthcare conference hold san francisco announcement preliminary revenue fourth quarter be estimate year year figure be also higher zack consensus estimate preliminary figure revenue be drive adoption novaseq growth clinical consumer genomic figure be also zack consensus estimate illumina inc price ep surprise illumina inc price ep surprise illumina inc quote similar last quarter illumina be expect gain strong product well service other revenue last few quarters company product revenue increase primarily higher sequence consumable revenue total service other revenue demonstrate strong growth lead continue demand nextseq nipt customer partner company expect fourth quarter sequence consumable increase more year quarter back increase utilization high throughput system strong pull nextseq zack consensus estimate product revenue reflect increase year quarter also zack consensus estimate service other revenue indicate rise year quarter here be other factor influence illumina fourth quarter result november illumina introduce second fda regulate ce ivd marked next generation sequence ngs system nextseq dx illumina now have solid diagnostic ngs portfolio courtesy nextseq dx miseqdx product portfolio be capable meeting clinical requirement ngs base diagnostic ivd product be likely boost top line yet be report quarter last october illumina announce availability novaseq flow cell reagent kit novaseq system management expect witness strong novaseq uptake fourth quarter moreover same month illumina announce availability nextera dna flex whole genome sequence library prep product expect factor drive revenue well also encourage solid third quarter performance illumina raise adjust ep band earlier flip side tough competitive landscape challenge be also apprehensive issue pertain nih funding illumina have be face quite time now here be quantitative model predict illumina have right combination main ingredient positive earning esp zack rank hold better increase odd earning beat zack esp earning esp illumina be uncover best stock buy sell re report earning esp filter zack rank illumina carry zack rank zack consensus estimate earning cent reflect improvement year year basis other stock worth consideringhere be few medical other stock worth consider have right combination element post earning beat quarter bio rad laboratory inc bio free report have earning esp zack rank buy see complete list today zack rank stock here myriad genetic inc mygn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1685,ILMN,fourth quarter earning season be expect be strong earning growth likely pick continue accelerate dip precede quarter index be anticipate see earning growth revenue growth market be also record level scaling series high start year forecast compare favorably earning growth revenue growth revision trend have be favorable earning estimate hold better relative other comparable period earning estimate have moved percentage point start quarter additionally zack sector be likely be contributor earning growth suggest potential upside many corner market read etfs stock favorite sector earning give strong sentiment investor focus etfs large allocation stock have high chance surprising upcoming release result winning bet earning season find right etfs handpicking etfs portfolio stock be most likely beat earning be mean feat however proprietary methodology find earning esp stock calculate percentage difference most accurate estimate zack consensus estimate be solid build block uncover best stock buy sell re report earning esp filter bet etfs winning combination stock have positive earning esp favorable zack rank strong buy buy hold lead profit investor be especially true earning beat definitely draw investor attention propel stock price related etfs first run zack stock screener find stock positive earning esp favorable zack rank then narrow list select group stock higher positive earning esp accordingly choose etfs comprise few stock higher chance beating estimate particular industry see etf category here research show stock combination chance positive earning surprise be high result fund be excellent investor seek guarantee profit earning season vaneck vector biotech etf bbh free report fund offer exposure large biotechnology corporation tracking mvis list biotech index stock portfolio be expect beat earning quarter amgen amgn free report celgene celg free report illumina ilmn free report incyte incy be top holding have earning esp respectively firm have zack rank collectively account asset biomarin pharmaceutical bmrn free report account share basket also have zack rank earning esp bbh have amassed asset base charge bps fee year volume be moderate exchange share daily average have zack etf rank high risk outlook read value biotech etfs buy now powershare dynamic retail portfolio pmr free report fund follow dynamic retail intellidex index measure performance company engage operate general merchandise store such department store discount store warehouse club superstore specialty store include apparel electronic accessory footwear store home improvement home furnishing store total product hold security stock portfolio expect come earning beat suggest solid upside etf particular best buy bby dollar tree dltr home depot hd free report walgreen boot alliance wba be top holding account share have earning esp respectively fund have accumulate just asset base charge bps fee year average daily volume be paltry share etf carry zack etf rank medium risk outlook read holiday sale year high best consumer etfs stock powershare dynamic energy exploration production portfolio pxe free report product follow dynamic energy exploration production intellidex index thoroughly evaluate company base variety investment merit criterium include price momentum earning momentum quality management action value hold stock basket have higher chance beating estimate quarter firm continental resource clr conocophillip cop eog resource eog occidental petroleum corp oxy have earning esp respectively eog have zack rank rest have zack rank pxe be expensive choice energy space expense ratio fund have aum trade volume share day average have zack etf rank high risk outlook read energy etfs stock soar start ishare home construction etf itb free report fund provide pure play home construction stock tracking dow jone select home construction index asset basket be expect surprise quarter top firm dr horton dhi free report have zack rank esp dhi account nearly share basket other firm toll brother tol free report home depot hd free report lowes company low free report have earning esp respectively have zack rank product have amassed asset base trade robust volume more share day average charge bps annual fee have zack etf rank high risk outlook read top rank etfs stock crushed market want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1686,ILMN,illumina inc ilmn free report have sign commercial agreement distribute thermo fisher scientific inc tmo free report ion ampliseq technology researcher conduct study illumina next generation sequence ngs platform term agreement thermo fisher provide illumina ion ampliseq technology research use notably amplicon technology be highly effective capture dna rna very limit amount sample application range research area ion ampliseq technology be develop facilitate amplicon sequence ion torrent ngs system illumina now distribute product directly customer brand ampliseq meanwhile thermo fisher continue sell ion ampliseq chemistry ivd ruo application ion torrent ngs customer furthermore thermo fisher retain right make technology available other next generation sequence platform next generation sequence platform focusillumina be consistently work enhance next generation sequence platform illumina recently introduce second fda regulate ce ivd marked next generation sequence system nextseq dx august illumina partner telegraph hill partner set independent company verogen inc entity be expect strengthen illumina ngs business forensic genomic market accord market market global next generation sequence market be estimate reach worth cagr last month illumina have gain broader industry decline estimate revision current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have rise share same period zack rank key picksillumina carry zack rank hold couple better rank stock broader medical sector be amedisys inc am free report bio rad laboratory inc bio free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank buy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1687,ILMN,jan issue update research report pacific bioscience california inc pacb free report solid contribution instrument consumable revenue platform have be boost pacific bioscience growth trajectory however cutthroat competition niche space have be hamper pacific bioscience revenue stock have zack rank sell pacific bioscience be lead player dna sequence market however niche space be highly competitive owing presence establish player illumina ilmn free report thermo fisher scientific inc tmo free report low cost sequence product illumina continue gain traction be headwind company moreover pacific bioscience be relatively small company compare second generation sequence technology firm moreover product launch like oxford nanopore dovetail genomic be expect intensify competition genome assembly market increase pricing pressure pacific bioscience long term other major concern pacific bioscience sale europe have decline substantially year year basis lag company target number customer europe have be slow initiate usage sequel system result company product witness poor adoption european market recent past further management forecast rise operate expense full year year year basis operate expense third quarter totale compare year quarter cash investment end third quarter be compare end second quarter positive note pacific bioscience flagship platform sequel system have be fortify company footprint worldwide sequel system be nucleic acid sequence platform base smrt technology be develop partnership roche however pacific bioscience agreement roche terminate earlier sequel system have be persistent contributor pacific bioscience top line price price movement pacific bioscience have be unfavorable last month notably stock have lose almost compare unfavorably industry rally roughly further current level compare unfavorably index return ongoing sluggishness european market be principal cause dismal price performance further company terminate year long agreement roche diagnostic collaboration provide way generate million long single molecule barcode dna fragment average kilobasis originated much longer fragment kilobasis key picka better rank stock broader medical sector be bio rad laboratory inc bio free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1688,ILMN,illumina inc ilmn free report be big mover last session company see share rise more day move come solid volume too far more share change hand normal session break recent trend company stock be now trading volatile price range past month time frame move come company announce latest gene sequence machine well issue earning guidance outpaced analyst projection company have see upward estimate revision past month zack consensus estimate current quarter remain unchanged so make sure keep eye stock go forward see recent jump turn more strength road illumina currently have zack rank hold earning esp be positive illumina inc price illumina inc price illumina inc quotea better rank stock medical biomedical genetic industry be emergent biosolution inc ebs free report currently sport zack rank strong buy see complete list today zack rank stock here be ilmn go predict see other think downlooking stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1689,ILMN,dec issue update research report illumina inc ilmn free report stock carry zack rank hold last month share san diego base company have be trading broader industry stock have rally versus broader industry decline period be encourage note company third quarter performance be quite promising top line be drive solid uptake sequence consumable instrument well microarray portfolio meanwhile company raise guidance indicate bullish trend be here stay management be hopeful recent launch company product portfolio include novaseq flow cell reagent kit novaseq system drive demand novaseq also look forward introduction novaseqxp company launch nextera dna flex buoy optimism moreover have recently partner telegraph hill partner set independent entity be also curious grail prospect illumina venture cancer screening market importantly company have start detailed plan embark large scale clinical trial illumina be currently keep pace goal strengthen foothold multus gene sequence market highly competitive product exist portfolio pipeline market expansion company primary focus be reproductive genetic health space illumina seek widen portfolio provide verifi laboratory develop invasive prenatal test nipt market be rapidly develop global scale allow company witness consistent growth number nipt sample good news be positive nipt reimbursement trend have be observed unite state third quarter incidentally rate nipt adoption be equally high country periphery be particularly upbeat strong uptake veriseq nipt ce ivd solution third quarter positive note country netherlands denmark too have start cover test first quarter follow england france hence company continue see positive reimbursement trend europe well flip side weak margin due novaseq launch higher array service revenue product mix sequence consumable continue raise concern also national institutes health funding issue tough competitive landscape be few more challenge deal key pickssome top rank medical stock be bio rad laboratory bio free report baxter international inc bax free report icu medical inc icui free report notably bio rad laboratory sport zack rank strong buy baxter international inc icu medical inc carry zack rank buy see complete list zack rank stock here bio rad have long term earning growth rate stock have rally roughly year baxter international have earning growth rate next quarter stock have surge roughly year icu medical have long term growth rate stock have soar roughly year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1690,ILMN,shire plc shpg free report report third quarter earning american depositary share ad beat zack consensus estimate be year quarter figure however revenue year year slightly miss zack consensus estimate year year increase be aid strong growth immunology franchise partially offset loss sale cinryze lialda shire share close higher friday presumably earning beat strong immunology franchise growth however company share have underperform industry so far year stock fall time compare industry decline quarter detailproduct sale increase year year drive immunology franchise royalty other revenue be primarily due increase royalty acquire dyax sensipar company ophthalmology franchise contribute total product sale sequentially drive strong demand xiidra immunology franchise register sale year year neuroscience franchise sale come drive strong demand adderall xr generic competition moreover mydayis be approve june attention deficit hyperactivity disorder adhd have be available prescription late august unite state bring sale vyvanse sale increase genetic disease portfolio sale be primarily due lower sale cinryze decline result supply shortage arise manufacturing interruption however sale firazyr be elaprase sale increase company have lose hereditary angioedema hae patient rival product due shortage however avoid supply shortage future company be plan manufacture cinryze application house manufacturing facility have be file unite state lialda sale be due entry generic competition company have launch authorize generic version own counter competition however gattex natpara show impressive performance sale increase respectively oncology sale add total revenue research development cost be selling general administrative sg expense decrease primarily due synergy related baxalta integration company be process divest manufacturing facility have excess facility follow baxalta acquisition shire have already divest facility divestment hayward biotechnology site outlook reiteratedshire maintain earning ad guidance range product sale projection range company re state forecast royalty other revenue gross margin be estimate regulatory updatein august shire submit marketing authorization application europe seek approval lifitegrast approve xiidra unite state treat dry eye disease september fda grant fast track designation chronic lung disease candidate shp ongoing phase ii study be evaluate candidate extremely premature infant subsequent quarter october european commission approve label expansion firazyr include paediatric patient adolescent child age year older acute hae meanwhile committee medicinal product human use have recommend approval marketing authorization application lyophilize oncaspar new dry formulation shire hemophilia candidate shp be grant orphan drug designation fda company be plan file biologic license application hae candidate shp march new drug application chronic constipation candidate shp end year pipeline updateshire continue progress pipeline candidate september angioedema candidate shp demonstrated significant reduction hae monthly attack rate versus placebo pivotal sahara study patient year age older meanwhile intuniv demonstrated superiority placebo improve clinically administer adhd rating scale compare baseline phase iii study takeshire third quarter result be encourage company beating bottom line estimate drive sale immunology sale approval label expansion firazyr europe be expect boost sale go ahead potential approval lyophilize oncaspar provide further boost top line availability mydayis boost company immunology space uptake have be strong physician prescribe patient oct manufacturing issue related cinryze be also address product ship customer early october shipment be expect have significant impact fourth quarter sale however generic competition lialda be expect continue further impact sale unfavorably fourth quarter shire plc price ep surprise shire plc price ep surprise shire plc quotezack rank key picksshire carry zack rank sell better rank stock pharma sector include illumina inc ilmn free report exact science corporation exas free report exelixis inc exel free report stock carry zack rank buy see complete list today zack rank strong buy stock here illumina earning estimate increase last day company deliver positive earning surprise trail quarters average beat share price be so far year exact science loss estimate narrow cent cent last day company come positive earning surprise trail quarters average beat share price be so far year company be schedule release third quarter result today exelixis earning share estimate remain flat cent increase cent cent last day company deliver positive surprise trail quarters average beat stock be so far year company be schedule release third quarter result nov zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1691,ILMN,omnicell inc omcl free report report earning share cent third quarter beating zack consensus estimate penny earning improve year figure cent welll revenue detailrevenue third quarter increase year year miss zack consensus estimate year year upside be drive product sensation related ramp xt series launch revenue also lag company guide range owing impact harvey irma hurricane segmental basis omnicell automation analytic revenue inched year year third quarter however revenue medication adherence segment rise year year omnicell inc price consensus ep surprise omnicell inc price consensus ep surprise omnicell inc quote operational updateomnicell gross profit report quarter increase gross margin contract basis point bps accord company adjust gross margin third quarter be reflect contraction bps year year sg expense third quarter decline year year research development expense rise year year operate expense be third quarter year year accord company adjust operate expense quarter totale year quarter financial updateomnicell exit third quarter cash cash equivalent compare end second quarter full year omnicell expect product booking range unchanged earlier forecast company have slash high end earlier guidance adjust revenue band moreover company now expect adjust earning band sharea compare project earlier zack consensus estimate full year earning share be peg zack consensus estimate full year revenue stand company also issue fourth quarter guidance management expect adjust revenue band omnicell project fourth quarter adjust earning cent cent zack consensus estimate fourth quarter revenue be peg earning share cent takeomnicell third quarter performance be impressive year year increase earning revenue further company segment witness year year growth be encourage note company be work product innovation also omnicell be expect gain recent launch strategic partnership third quarter company launch xt series automate supply dispense system be encourage development however weak margin be matter concern zack rank key picksomnicellha zack rank hold few better rank stock broader medical sector be petm express inc pet free report illumina inc ilmn free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy illumina intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter illumina report adjust earning share third quarter year year also illumina revenue grow year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1692,ILMN,illumina inc ilmn free report report adjust earning share ep third quarter beat zack consensus estimate cent adjust earning also surpass year number include time item company report ep compare cent year revenuesin report quarter illumina revenue grow year year moreover top line beat zack consensus estimate illumina inc price consensus ep surprise illumina inc price consensus ep surprise illumina inc quote management top line growth third quarter be attribute strong uptake sequence consumable instrument well microarray portfolio moreover novaseq platform continue drive growth close novaseq system currently customer hand launch january management be also hopeful recent launch flow cell xp nextera dna flex library preparation kit drive novaseq demand product revenue total revenue increase year year service other revenue be year year operational updateillumina adjust gross margin come reflect contraction basis point bps year year owing novaseq introduction higher array service revenue product mix sequence consumable exclude amortization acquire intangible asset include stock base compensation expense adjust gross margin be highlight contraction bps year research development expense be year year selling general administrative expense rise consequently adjust operate margin reflect decline bps year period financial updateillumina exit third quarter cash cash equivalent short term investment third quarter year date net cash provide operate activity be compare year period guidancebanking solid third quarter performance illumina have raise full year revenue growth expectation earlier provide range meanwhile zack consensus estimate full year revenue be peg company raise adjust ep band earlier zack consensus estimate illumina bottom line stand far low end guide range takeillumina exit third quarter solid note be also encourage year year increase front company have also raise full year revenue guidance adjust ep range be look forward performance novaseq flow cell reagent kit novaseq xp novaseq system flip side weak margin owing lower instrument margin associate novaseq launch higher array service mix continue act deterrent also tough competitive landscape be concern zack rank key pickscurrently illumina have zack rank hold better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1693,ILMN,illumina inc ilmn free report be slate report third quarter fiscal result market close oct last quarter company deliver positive earning surprise average earning beat trail quarters let see thing be shape announcement key prior quarter illumina be expect gain strong performance product revenue well service other revenue segment last few quarters company product revenue increase primarily onrising sequence consumable revenue total service other revenue be demonstrate strong growth lead continue demand nextseq nipt customer partner expect factor drive yet be report quarter performance well zack consensus estimate product revenue reflect increase year quarter also zack consensus estimate service other revenue indicate rise year quarter overall third quarter total revenue be project prior year quarter illumina inc price ep surprise illumina inc price ep surprise illumina inc quote here be other factor influence illumina third quarter result illumina earlier announce fda approve next generation sequence ngs extend ra panel have meet current colorectal cancer guideline new kit fulfill most date guidance ra testing determine eligibility epidermal growth factor receptor egfr inhibitor metastatic colorectal cancer management expect shipment kit start third quarter hence expect drive top line second quarter illumina witness growth asia pacific region propel rise china emerge market china currently offer most favorable space illumina business growth recent time management have noticed considerable rise demand customer look set nipt operation china china currently be fourth largest develop nation term nominal gdp believe progress country open channel illumina thereby drive top line yet be report quarter also encourage solid second quarter performance illumina have raise full year revenue growth expectation earlier provide range flip side tough competitive landscape challenge company be also apprehensive issue pertain nih funding illumina have be face quite time now here be quantitative model predict illumina do not have right combination main ingredient positive earning esp zack rank hold better increase odd earning beat zack esp earning esp illumina be uncover best stock buy sell re report earning esp filter zack rank illumina carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise nonetheless zack consensus estimate earning cent reflect improvement year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter abbott free report have earning esp zack rank buy see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1694,ILMN,oct issue update research report illumina inc ilmn free report stock currently carry zack rank hold last month san diego base company provide tool integrate system analysis genetic variation function have be trading broader industry stock have gain period higher broader industry gain past few quarters company have deliver promising top line performance primarily banking strong product launch latest list include launch veriseq nipt solution europe also overall strong uptake novaseq be encourage moreover rate nipt adoption be rise outside unite state be also upbeat illumina partnership telegraph hill partner set independent company verogen inc independent company be expect boost illumina next generation sequence ngs business forensic genomic market have global commercial right product illumina be only provider miseq fgx forensic genomic system include miseq fgx sequencer forenseq dna signature prep kit forenseq universal analysis software be encourage development clinical market demand customer undergo oncology test remain robust moreover investor be await response extend ra panel be slate launch third quarter june company announce receipt fda approval extend ra companion diagnostic kit class iii pma be also look forward grail illumina own develop company focuse cancer screening market flip side weak margin due novaseq launch higher array service revenue product mix sequence consumable continue raise concern also national institutes health nih funding issue tough competitive landscape be few challenge deal key picksa few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report zack rank buy see complete list today zack strong buy rank stock here abbott have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1695,ILMN,global leader field dna sequence array base technology illumina inc ilmn free report telegraph hill partner thp announce plan set independent company verogen inc thp be life science focuse venture capital growth equity firm base san francisco verogen headquarter san diego area have right provide illumina forensic sequence technology forensic customer include criminal casework other human nonhuman forensic application independent company be expect strengthen illumina next generation sequence ngs business forensic genomic market be sole provider miseq fgx forensic genomic system include miseq fgx sequencer forenseq dna signature prep kit forenseq universal analysis software also have global commercial right product miseq fgx forensic genomic system be used operational crime laboratory private service lab forensic research institutes worldwide company also be offer other illumina product forensic lab operationalize ngs routine forensic genomic illumina continue manufacture miseq fgx instrument core sequence consumable management believe miseq fgx forensic genomic system continue lead transition ngs genomic forensic market improve justice public safety remove barrier adopt ngs crime laboratory company be hopeful illumina ngs technology together thp forensic expert help verogen provide long term success customer kirk malloy have be name ceo verogen cydne holt serve general manager chief scientific officer accord bcc research report major forensic product service market reach worth nearly cagr period thus company clearly have bountiful opportunity space illumina be strive expand ngs technology base line illumina have announce launch solution noninvasive prenatal testing nipt kit europe product veriseq nipt solution be ce ivd marked next generation sequence ngs base approach nipt also illumina announce extend ra panel fda approve next generation sequence ngs kit meet newly publish guideline evaluation colorectal cancer company have also launch bio rad single cell sequence solution first next generation sequence ngs single cell analysis collaboration bio rad laboratory inc bio free report last month illumina have be trading broader industry stock have gain past month compare broader industry zack rank key picksillumina carry zack rank hold few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank strong bu stock here lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have rally last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
